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I. Abstract 
To rationally design therapeutic human papillomavirus (HPV) vaccines, it is important to know which 
T cell epitopes are present on HPV-transformed cells. HPV affects the cellular antigen processing 
machinery, thus not every epitope derived from viral proteins is necessarily presented by human 
leukocyte antigen (HLA) molecules on the cancer cell surface. 
HPV16 has been identified as the causative agent in 50% of all cervical cancer cases and in 
approximately 95% of all extra-cervical mucosal HPV-induced tumors. The transforming potential of 
high-risk HPVs is mediated by two consistently expressed viral oncoproteins, E6 and E7. As the 
induction and maintenance of the malignant phenotype depend on these two proteins, they are ideal 
targets for immunotherapy. A therapeutic vaccine that is applicable to everyone without prior HLA 
typing needs to contain epitopes for the major HLA types. To date, HPV T cell epitopes have mostly 
been determined for the most prevalent HLA type, HLA-A2. We now aim to identify HPV16 E6 and 
E7 T cell epitopes for the HLA-A3, HLA-A11 and HLA-A24 supertypes. 
Different in silico prediction algorithms were used to predict prospective epitopes from the E6 and E7 
proteins derived from the HPV16 reference sequence for the mentioned HLA supertypes. In total, 74 
epitopes, comprised of 8 to 11mer peptides, were predicted for HLA-A3, 96 epitopes for HLA-A11 
and 95 epitopes for HLA-A24. In competition-based cellular binding assays, 22 previously known 
binding peptides were confirmed and 78 novel binding peptides were identified. Additionally, HPV16 
variants harbored in our HPV16-positive cell line collection were determined and peptide binding to 
HLA-A24 was shown for seven out of 20 tested HPV16 variant peptides. 
Evaluation of prediction server performance based on the generated data suggested different optimal 
prediction servers depending on peptide length and on the HLA type. NetMHC and NetMHCcons 
were shown to be the best predictors overall.  
Immunogenicity of identified binding peptides was investigated by screening long-term memory 
responses in healthy donors. To this end, peptide-specific short-term T cell lines were generated from 
peripheral blood mononuclear cells, which were HLA typed, stimulated with HLA-matching peptides 
and cultured for twelve days. Several peptides were identified to be immunogenic. Immunogenicity of 
the four most promising candidate peptides for HLA-A24 could be further confirmed by generation of 
peptide-specific long-term T cell lines from healthy HLA-A24-positive donors and subsequent co-
culture with autologous B cells pulsed with the respective peptide. Functional assays, such as IFNγ 
ELISpot assays and cytotoxicity assays, determined the best vaccine candidates.  
In conclusion, several novel HPV16 E6 and E7 CD8
+
 T cell epitopes were identified. Verified epitopes 
are the basis of rational therapeutic vaccine design and are also important for immunomonitoring 
purposes. In addition, they can be employed as a tool for the development of other immunotherapies 
such as adoptive T cell transfer with transgenic T cell receptors. 
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II. Zusammenfassung  
Für die Entwicklung eines effizienten therapeutischen Impfstoffs gegen humane Papillomviren 
(HPVs) ist es wichtig zu wissen, welche T Zell Epitope auf HPV-transformierten Zellen präsentiert 
werden. HPV beeinflusst die zelluläre Prozessierung von Antigenen und deshalb wird nicht jedes 
Epitop der viralen Proteine zwangsweise auch von humanen Leukozytenantigen (HLA)-Molekülen auf 
der Oberfläche von Krebszellen präsentiert.  
HPV16 wurde als kausal in 50% aller Gebärmutterhalskrebsfälle und in ungefähr 95% aller anderen 
mukosalen HPV-induzierten Tumoren identifiziert. Das transformierende Potential von Hochrisiko-
HPV-Typen ist durch die beiden konstitutiv exprimierten Onkoproteine E6 und E7 gegeben. Da die 
Induktion und das Aufrechterhalten des malignen Phänotyps auf diesen beiden Proteinen beruht, sind 
sie ideale Ziele für Immuntherapien. Ein therapeutischer Impfstoff, der ohne eine vorherige HLA-
Typisierung für jeden verwendbar ist, muss Epitope für mehrere HLA-Typen beinhalten. Allerdings 
wurden bisher hauptsächlich HPV T-Zell-Epitope für den häufigsten HLA-Typ, HLA-A2, bestimmt. 
Das Ziel dieser Studie war die Identifizierung von HPV16 E6 und E7 T-Zell-Epitopen für die HLA-
Supertypen HLA-A3, HLA-A11 und HLA-A24. 
Verschiedene in silico Algorithmen wurden verwendet um potentielle 8- bis 11mer Epitope der E6 und 
E7 Proteine der HPV16 Referenzsequenz für die obengenannten HLA-Supertypen vorherzusagen. 
Insgesamt wurden 74 Epitope für HLA-A3 vorhergesagt, sowie 96 Epitope für HLA-A11 und 95 
Epitope für HLA-A24. In kompetitiven Peptid-Bindungs-Tests konnten 22 bekannte bindende Peptide 
bestätigt und 78 neue bindende Peptide identifiziert werden. Zusätzlich wurden HPV16-Varianten, die 
in unserer HPV16 positiven Zellkultursammlung vorkommen, bestimmt. Die Peptidbindung an HLA-
A24 konnte in sieben von zwanzig getesteten HPV16-Variantpeptiden gezeigt werden. 
Basierend auf den generierten Daten von bindenden und nicht bindenden Peptiden wurde eine 
Evaluation der Leistung der Vorhersageserver wurde durchgeführt. Hierbei stellten sich verschiedene 
Vorhersageserver als führend bei unterschiedlichen Peptidlängen und bei verschiedenen HLA-Typen 
heraus. Generell konnten NetMHC und NetMHCcons in dieser Studie als die beste Vorhersageserver 
bestimmt werden.  
Um die Immunogenität der identifizierten bindenden Peptide zu untersuchen, wurden Langzeit-
Gedächtniszellantworten in gesunden Spendern überprüft. Zu diesem Zweck wurden Peptid-
spezifische Kurzzeit-T-Zelllinien aus mononukleären Zellen des peripheren Blutes generiert und die 
HLA-Typen der Spender bestimmt. Daraufhin wurden die Zellen mit HLA-passenden Peptiden 
stimuliert und für zwölf Tage kultiviert. Etliche Peptide waren immunogen. Die Immunogenität der 
vier vielversprechendsten Peptidkandidaten wurde durch Peptid-spezifische Langzeit-T-Zelllinien 
bestätigt, welche zu diesem Zweck mit autologen B Zellen co-kultiviert wurden, die zuvor mit den 
selben Peptiden gepulst worden waren. Funktionelle Tests, wie IFNγ-ELISpot-Assays oder 
Zytotoxizitäts-Experimente, wurden verwendet um die besten Impfstoffkandidaten zu bestimmen. 
Zusamenfassung 
IV 
 
In der vorliegenden Studie konnten neue HPV16 E6 und E7 T-Zell-Epitope identifiziert werden. 
Verifizierte Epitope sind die Basis für die rationale Entwicklung von therapeutischen Impfstoffen und 
zudem wichtig für Immunomonitoring-Ansätze. Zusätzlich können sie genutzt werden, um andere 
Immuntherapien, wie zum Beispiel adoptiven T-Zelltransfer mit transgenen T-Zellrezeptoren, zu 
entwickeln.
  Acknowledgements 
V 
 
III. Acknowledgements 
An dieser Stelle möchte ich mich bei allen Personen bedanken, die bei der Umsetzung dieser 
Doktorarbeit durch fachliche und persönliche Hilfestellung mitgewirkt haben. 
Zu allererst möchte ich mich bei PD Dr.Dr. Angelika Riemer bedanken, die mir die Möglichkeit 
gegeben hat, meine Doktorarbeit in ihrer Arbeitsgruppe anfertigen zu können. Besonders möchte ich 
mich für das Vertrauen und den großen wissenschaftlichen Freiraum bedanken, den ich während 
meiner Promotion hatte. Sie hat mich über das Projekt hinaus voll unterstützt und mir die Chance 
gegeben mich sowohl menschlich als auch wissenschaftlich weiterzuentwickeln. 
Bei Prof. Dr. Martin Müller möchte ich mich herzlich für die Übernahme des Erstgutachtens 
bedanken und dafür, mir als TAC Mitglied zur Seite zu stehen. Zudem möchte mich mich bei PD Dr. 
Suat Ötzbeck und Dr. Steeve Boulant dafür bedanken, dass sie meine Prüfer in meiner Disputation 
waren. Ein weiteres Dankeschön geht an Dr. Volker Lohman, der mich als TAC Mitglied unterstützt 
hat. 
Ein ganz besonderer Dank geht an unser gesamtes Labor mit der alten und etwas neueren 
Stammbesetztung aus Renata Blatnik, Dr. Aginieszka Grabowska, Dr. Hadeel Khallouf, Alina 
Steinbach, Martin Wühl und Alexandra Klevenz. Danke für die vielen Ratschläge, Meinungen, 
Diskussionen, die Offenheit und Direktheit, die Hilfe im Labor und vor allem für die fantastische 
Atmosphäre. Egal was war, wir hatten so viel Spass und ihr wart immer für mich da. 
Renatka möchte ich hvala sagen dafür, dass wir das Abenteur PhD von Anfang an gemeinsam 
durchgestanden haben. Vielen Dank für alles über das Labor hinaus, dafür dass Du mir deine Heimat 
gezeigt hast, für unseren letzten genialen Skiurlaub und und und... Bei Hadeel möchte ich mich 
speziell für die wissenschaftlichen Diskussionen, die Hilfe im Labor und für deinen Input zu dieser 
Arbeit bedanken, zudem für unsere ganzen gemeinsamen Konferenzen, vor allem unser Trauma 
Mickey Mouse. Außerdem für deine motivierende Art und dein Verständnis und dafür, dass Du ein 
treuer Spinning- und Unisportpartner bist, اركش. Ein ganz dickes Dankeschön an Alina, dafür dass Du 
einfach du bist. Wenn man dich sieht, geht die Sonne auf. Vielen Dank für die ganze theoretische und 
praktische Hilfe bei den T und B cells und fürs Korrekturlesen. Bei Martin möchte ich mich für die 
ganze Unterstützung in der Zellkutur bedanken, dafür dass ich mit allem zu Dir kommen konnte und 
Du immer ein offenes Ohr hattest. Alex möchte ich für die wertvollen Tipps, tatkräftige Unterstützung 
und Ideen im letzten Jahr ganz speziell danken. Im Besonderen auch dafür, dass Du selbst in 
stressigsten Situationen und sonst auch immer gut gelaunt bist. Bei Agi möchte ich mich für die Hilfe 
und Tipps im Labor bedanken. Dziękujemy, für deine einmalige Art und auch für all unsere Labtrips 
nach Stuttgart bzw Bad Cannstatt. Ein weiteres Dankeschön geht an Jan Winter für die ganzen Ideen 
und Unterstützung in puncto Bioinformatik bei den T cell predictions und für deine beruhigende Art.  
 
Acknowledgements 
VI 
 
Vielen Dank auch an all unsere Praktikanten und Studenten die über die Jahre bei uns waren, Marc 
Pfeil, Aakanksha Jain, Victoria Hentschke, David Kranz, Fanny Georgi, Johannes Stortz, Kinga 
Grabowska, Sina Knapp, Jasmin Mangei, Miriam Bertrant und Sebastian Utz und ganz speziell 
an meine Bachelor und Master Studenten: Vielen Dank an Johanna Dickmann, die meine erste 
Bachelorette war und mir bei der Story um die HPV16 Varianten sehr geholfen hat. Danke an Marius 
Küpper, der es fast ein ganzes Jahr mit mir und seiner Masterarbeit bei uns ausghalten hat. Ein dickes 
Dankeschön an Julia Schessner und Lisa Dreßler, die mir im letzten Sommer bei den ELISpots 
geholfen haben. Danke, dass ihr euch mit mir die Nächte vorm FACS und in der Zellkultur um die 
Ohren geschlagen habt.  
Für die Unterstützung bei allem Bürokratischen möchte ich mich bei Angelika Schmidt-Zitouni und 
Monika Bock herzlich bedanken.  
Auch unseren alten und neuen Labornachbarn, den Hoppe Seylers und den de Villiers, möchte ich 
sehr für die Unterstützung und tolle Nachbarschaft danken. Zudem vielen Dank an die Krammers, die 
uns in ihren Journal Club aufgenommen haben und für die ganzen Antikörper und Co. Zudem möchte 
ich mich bei all meinen Blutspendern bedanken, ohne die diese Arbeit nie zustande gekommen. 
Vielen Dank an Prof. Michael Pawlita für die unzähligen Male Blut abnehmen. 
Vielen Dank auch an Hans-Henning Schmidt und Jasmin Quandt von den Beckhoves dafür, mich 
jahrelang an das FACS mit dem 96-well plate reader gelassen zu haben. 
Ausserdem möchte ich meinen Freunden, die mir das Leben nebem dem Labor versüßt haben danken.  
Ein dickes Dankeschön geht an Lisa Thill dafür dass, wenn Du auch im weit, weit entfernten 
Amsterdam, Trier, Köln oder auf irgendwelchen thüringischen Wiesen warst, trotzdem immer in 
Kontakt geblieben bist und für dein spontanes Korrekturlesen. Ganz speziell möchte ich mich bei 
Bettina Fiege bedanken, für unsere letzten gemeinsamen Jahre in Heidelberg. 1000 Dank dafür, dass 
Du mich immer wieder daran erinnert hast, dass es auch ein Leben ausserhalb des Labs gibt, für unsere 
ganzen Kaffeepausen und Wein-, Koch- und Partyabende. Danke auch fürs Korrekturlesen. Ein ganz 
spezieller Dank geht an Nadine Hertrich. Vielen, vielen Dank, dass Du Tag und Nacht für mich da 
warst. Ohne die tausenden Kilometer die wir zusammen gelaufen sind, wären wir wohl beide noch 
mehr abgedreht, als wir es eh schon sind. Danke fürs Zuhören, Ertragen und die ganzen Dinge die wir 
in den letzten fast sieben Jahren erlebt haben. Außerdem natürlich fürs Korrekturlesen und die 
Fernunterstützung in den letzten 4 Monaten. 
Abschließend danke ich meiner Familie, Nils, Gabi und Günter Hoppe, die mich während des 
gesamten Studiums und während meiner Promotion bedingungslos unterstützt haben. Vielen, vielen 
Dank für eure Geduld mit mir, fürs Zuhören und eure Ratschläge in allen Lebenslagen. Danke dafür, 
dass ihr einfach immer für mich da seid. 
  Table of Contents 
VII 
 
IV. Table of Contents 
I. Abstract ................................................................................................................................................. I 
II. Zusammenfassung ............................................................................................................................ III 
III. Acknowledgements .......................................................................................................................... V 
IV. Table of Contents ........................................................................................................................... VII 
V. List of Figures................................................................................................................................... XI 
VI. List of Tables................................................................................................................................ XIII 
1. Introduction ......................................................................................................................................... 1 
1.1 Human papillomavirus and associated diseases ............................................................................ 1 
1.1.1 HPV classification and distribution ........................................................................................ 4 
1.1.2 The HPV genome and its organization ................................................................................... 6 
1.1.3 Viral life cycle and viral proteins ........................................................................................... 7 
1.1.3.1 The early proteins E1, E2, E4, E5 and the oncoproteins E6 and E7 ............................. 10 
1.1.3.2 The late proteins L1 and L2 ........................................................................................... 12 
1.2 The immune system ..................................................................................................................... 12 
1.2.1 The innate and adaptive immune system .............................................................................. 13 
1.2.2 The major histocompatibility complex ................................................................................. 14 
1.2.3 Dendritic cells ....................................................................................................................... 18 
1.2.4 T lymphocytes ...................................................................................................................... 19 
1.2.4.1 The T cell response and T cell subsets .......................................................................... 20 
1.2.5 Tumor immunology .............................................................................................................. 22 
1.2.6 HPV and immune evasion .................................................................................................... 25 
1.3 Cancer immunotherapy ............................................................................................................... 27 
1.3.1 T cell epitope predictions ..................................................................................................... 32 
1.3.2 HPV vaccines ....................................................................................................................... 34 
1.3.2.1 Prophylactic vaccines .................................................................................................... 34 
1.3.2.2 Therapeutic Vaccines .................................................................................................... 36 
1.4 Objectives of this study ............................................................................................................... 41 
2. Material and Methods ........................................................................................................................ 43 
2.1 Materials ...................................................................................................................................... 43 
2.1.1 Chemicals and biological reagents ....................................................................................... 43 
2.1.2 Buffers and solutions ............................................................................................................ 44 
2.1.3 Consumables ........................................................................................................................ 45 
2.1.4 Kits ....................................................................................................................................... 47 
2.1.5 Markers and ladders ............................................................................................................. 47 
Table of Contents 
VIII 
 
2.1.6 Enzymes ............................................................................................................................... 47 
2.1.7 Equipment ............................................................................................................................ 47 
2.1.8 Eukaryotic cell lines ............................................................................................................. 49 
2.1.9 Cell culture basal media and supplements ............................................................................ 52 
2.1.10 Cell culture media............................................................................................................... 53 
2.1.11 Antibodies .......................................................................................................................... 54 
2.1.11.1 Primary antibodies ....................................................................................................... 54 
2.1.11.2 Secondary antibodies ................................................................................................... 55 
2.1.12 Peptides .............................................................................................................................. 56 
2.1.12.1 Control peptides........................................................................................................... 56 
2.1.12.2 HPV16 E6 and E7 peptides ......................................................................................... 56 
2.1.13 Oligonucleotides ................................................................................................................. 62 
2.1.13.1 Oligonucleotides for HPV16 E6 and E7 sequencing ................................................... 63 
2.1.13.2 Oligonucleotides for HLA genotyping ........................................................................ 63 
2.1.14 Blood samples and buffy coats ........................................................................................... 63 
2.1.15 Software .............................................................................................................................. 64 
2.2 Methods ....................................................................................................................................... 64 
2.2.1 In silico methods .................................................................................................................. 64 
2.2.1.1 T cell epitope predictions .............................................................................................. 64 
2.2.1.2 MHCcombine ................................................................................................................ 67 
2.2.1.3 Evaluation of prediction servers .................................................................................... 67 
2.2.1.4 Peptide motif analysis.................................................................................................... 67 
2.2.2 Molecular biological methods .............................................................................................. 70 
2.2.2.1 DNA extraction ............................................................................................................. 70 
2.2.2.2 Polymerase Chain Reaction (PCR) ............................................................................... 70 
2.2.2.3 Agarose gel electrophoresis ........................................................................................... 72 
2.2.2.4 Determination of DNA concentration ........................................................................... 73 
2.2.2.5 Sequencing of HPV 16 E6 and E7 genes ...................................................................... 73 
2.2.2.6 Analysis of HPV 16 E6 and E7 sequences .................................................................... 73 
2.2.3 Biochemical Methods ........................................................................................................... 74 
2.2.3.1 Competition-based binding assays ................................................................................ 74 
2.2.3.2 Immunoprecipitation ..................................................................................................... 75 
2.2.3.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) .............. 76 
2.2.3.4 Coomassie stain ............................................................................................................. 76 
2.2.3.5 Oriole stain .................................................................................................................... 77 
2.2.3.6 Western Blot .................................................................................................................. 77 
  Table of Contents 
IX 
 
2.2.4 Cell culture methods ............................................................................................................. 78 
2.2.4.1 Thawing and freezing of cells ....................................................................................... 78 
2.2.4.2 Culturing and passaging of cells .................................................................................... 78 
2.2.4.3 Counting of cells............................................................................................................ 79 
2.2.4.4 Flow cytometry .............................................................................................................. 79 
2.2.4.5 Peripheral blood mononuclear cell (PBMC) isolation .................................................. 81 
2.2.4.6 Magnetic-activated cell sorting (MACS) ...................................................................... 82 
2.2.5 T cell assays .......................................................................................................................... 83 
2.2.5.1 Generation of peptide-specific T cell lines .................................................................... 83 
2.2.5.2 T cell receptor sequencing ............................................................................................. 89 
2.2.5.3 Interferon (IFN) ELISpot assays .................................................................................. 89 
2.2.5.4 IL-2 Enzyme Linked Immunosorbent Assay (ELISA) .................................................. 91 
2.2.5.5 Cytotoxicity assay ......................................................................................................... 91 
3. Results ............................................................................................................................................... 93 
3.1 In silico predictions and in vitro binding affinity of HPV16 E6 and E7 peptides to HLA-A3, 
HLA-A11 and HLA-A24 molecules ................................................................................................. 94 
3.1.1 T cell epitope predictions reveal numerous potential HLA binding HPV16-derived peptides
 ....................................................................................................................................................... 95 
3.1.2 Competition-based cellular binding assays verify binding of HPV16 E6 and E7 peptides to 
designated HLA types ................................................................................................................... 97 
3.1.3 Motif analysis identifies additional binding peptides ......................................................... 100 
3.1.4 Evaluation of prediction servers ......................................................................................... 102 
3.2 HPV16 variants and their HLA-binding E6 and E7 peptides .................................................... 106 
3.3 Immunoprecipitation of HLA/peptide complexes from HPV16-transformed cells .................. 110 
3.3.1 HLA expression levels ....................................................................................................... 110 
3.3.2 Immunoprecipitation .......................................................................................................... 111 
3.4 Evaluation of peptide immunogenicity by establishing short-term T cell lines ........................ 113 
3.4.1 HLA typing of buffy coat cells ........................................................................................... 114 
3.4.2 IFN ELISpot assays .......................................................................................................... 115 
3.5 Functional analysis of peptide candidates using peptide-specific HLA-A24-positive T cell lines
 ......................................................................................................................................................... 118 
3.5.1 IL-2 secretion upon peptide stimulation ............................................................................. 118 
3.5.2 Clonality of T cell receptors of peptide-specific long-term CD8
+
 T cell lines ................... 119 
3.5.3 IFN secretion by peptide-specific long-term CD8+ T cells upon co-culture with autologous 
peptide-pulsed B cells ................................................................................................................. 121 
3.5.4 Cytotolytic activity of E6/56-65-specific T cells ............................................................... 122 
 
Table of Contents 
X 
 
4. Discussion ....................................................................................................................................... 125 
4.1 Identification of HLA-A3, HLA-A11 and HLA-A24-binding HPV16 E6 and E7 peptides ..... 127 
4.2 Performance evaluation of prediction servers ........................................................................... 130 
4.3 Direct identification of CD8
+ 
T cell epitopes ............................................................................ 132 
4.4 Immunogenicity of candidate peptides in short-term T cell lines ............................................. 133 
4.5 Functional analysis of peptide candidates ................................................................................. 135 
4.6 Conclusions and future perspectives ......................................................................................... 137 
5. References ....................................................................................................................................... 141 
6. Abbreviations .................................................................................................................................. 167 
7. Appendix ......................................................................................................................................... 169 
  List of Figures 
XI 
 
V. List of Figures 
Figure 1 I Global cervical cancer distribution in 2008. ........................................................................... 4 
Figure 2 I HPV classification demonstrated by HPV16. ......................................................................... 5 
Figure 3 I Structure of the papillomavirus capsid. .................................................................................. 6 
Figure 4 I Genomic organization of HPV16.. ......................................................................................... 7 
Figure 5 I HPV viral life cycle from infection of basal keratinocytes to virion release. ......................... 8 
Figure 6 I Schematic structure of MHC class I and MHC class II molecules. ...................................... 15 
Figure 7 I Antigen presentation via the classical MHC class I pathway.. ............................................. 16 
Figure 8 I Antigen presentation via the classical MHC class II pathway. ............................................. 17 
Figure 9 I Mechanism of classical cross-priming and its role in anti-tumor immunity. ....................... 19 
Figure 10 I The three E’s of cancer immunoediting. ............................................................................. 23 
Figure 11 I Timeline of the most important breakthroughs in cancer immunotherapy. ........................ 28 
Figure 12 I Generation of an effective anti-tumor immune response and its multiple steps. ................ 32 
Figure 13 I ScanProsite result.pl output for one peptide. ...................................................................... 70 
Figure 14 I Schematic presentation of the assembly of a Western Blot.. .............................................. 77 
Figure 15 I Schematic work flow of generation of peptide-specific short-term T cell lines. ................ 86 
Figure 16 I Schematic work flow of generation of peptide-specific long-term T cell lines. ................. 88 
Figure 17 I Schematic work flow of generation of peptide-specific semi long-term T cell lines. ........ 89 
Figure 18 I Plate loading scheme of IFN ELISpot. ............................................................................. 90 
Figure 19 I Plate loading scheme for cytotoxicity assays. .................................................................... 92 
Figure 20 I Schematic overview of the experimental set up.. ............................................................... 94 
Figure 21 I Peptide binding affinity to HLA-A3, HLA-A11 and HLA-A24. ....................................... 99 
Figure 22 I Sequence logos of HPV16 E6 and E7 peptides binding to HLA-A24. ............................ 100 
Figure 23 I Sequence logos of HPV16 E6 and E7 peptides not binding to HLA-A24. ...................... 101 
Figure 24 I Peptide binding affinity to HLA-A24 of peptides predicted by motif analysis. ............... 102 
Figure 25 I Evaluation of prediction server performance for peptide predictions of 8mers, 9mers, 
10mers and 11mers binding to HLA-A24 by ROC analysis. .............................................................. 103 
Figure 26 I Evaluation of prediction server performance for peptide predictions for HLA-A3, HLA-
A11 and HLA-A24 by ROC analysis.. ................................................................................................ 104 
Figure 27 I Peptide binding affinity of predicted HPV16 variant peptides to HLA-A24. .................. 109 
Figure 28 I HLA expression levels determined for HPV16 positive cell lines.. ................................. 111 
Figure 29 I Immunoprecipitation of HLA/peptide complexes from SiHa and CaSki cells. ................ 113 
Figure 30 I Immunogenicity screening of HPV16 E6 and E7 epitopes by IFNγ ELISpot assay. ....... 116 
Figure 31 I Immunogenicity testing results of HPV16 E6 and E7 peptides in twelve donors. ........... 117 
Figure 32 I IL-2 secretion of PBMCs after stimulation with HPV16 E6 and E7 peptides. ................. 119 
Figure 33 I CDR3 sequencing of peptide-specific CD8
+
 T cells indicates poly- and monoclonal 
cultures. ............................................................................................................................................... 120 
Figure 34 I IFNγ secretion of peptide-specific CD8+ T cells upon co-culture with autologous B cells 
presenting the respective peptide......................................................................................................... 122 
Figure 35 I HPV16 E7/56-65-specific cytolytic activity. .................................................................... 123 
Figure 36 I Evaluation of prediction server performance for peptide predictions of 8mers, 9mers, 
10mers and 11mers binding to HLA-A3 by ROC analysis. ................................................................ 173 
Figure 37 I Evaluation of prediction server performance for peptide predictions of 8mers, 9mers, 
10mers and 11mers binding to HLA-A11 by ROC analysis. .............................................................. 173 
 
 
 XII 
 
 
  List of Tables 
XIII 
 
VI. List of Tables 
Table 1 I Prediction servers used to predict binding peptides to designated HLA alleles. ................... 65 
Table 2 I Amino acid sequences of HPV16 E6 and E7 proteins. .......................................................... 65 
Table 3 I Naming system and specifies of output from prediction servers. .......................................... 66 
Table 4 I Final output of combined results from all peptide prediction servers. ................................... 66 
Table 5 I Tab-separated text file input for the PERL script AAcount.pl. .............................................. 68 
Table 6 I I FASTA format of predicted peptides used for creation of sequence logos with Weblogo3 
and for ScanProsite. ............................................................................................................................... 68 
Table 7 I Settings applied for the creation of sequence logos with Weblogo 3 (Crooks et al., 2004)... 69 
Table 8 I Components for HPV16 E6 and E7 sequencing PCR. ........................................................... 71 
Table 9 I PCR cycles for HPV16 E6 and E7 sequencing PCR. ............................................................ 71 
Table 10 I Components for HLA genotyping PCR. .............................................................................. 71 
Table 11 PCR cycles for HLA genotyping PCR. .................................................................................. 71 
Table 12 I Overview of primer pairs for HLA genotyping PCR. .......................................................... 72 
Table 13 I Schedule for culturing of PBMCs/CD40-B cells and preparation of tCD40L plates. ......... 85 
Table 14 I Predicted and experimental binding affinities to HLA-A24 for HPV16 E6 peptides. ......... 96 
Table 15 I Predicted and experimental binding affinities to HLA-A24 for HPV16 E7 peptides. ......... 97 
Table 16 I Predictor assessment for classification of binders and non-binders using the AROC. ......... 106 
Table 17 I HPV16 variants present in cell lines with their amino acid exchanges compared to the 
HPV16 reference sequence. ................................................................................................................ 107 
Table 18 I HPV16 E6 and E7 variant peptides predicted to bind to HLA-A24.. ................................ 108 
Table 19 I Predicted and tested HPV16 E6 and E7 peptides and their binding status to their respective 
HLA type. ............................................................................................................................................ 110 
Table 20 I HLA typing for twelve buffy coats by FACS staining and HLA genotyping PCR. .......... 115 
Table 21 I TCR sequencing of peptide-specific T cell lines. .............................................................. 120 
Table 22 I Predicted and experimental binding affinities to HLA-A3 for HPV16 E6 peptides. ......... 169 
Table 23 I Predicted and experimental binding affinities to HLA-A3 for HPV16 E7 peptides. ......... 170 
Table 24 I Predicted and experimental binding affinities to HLA-A11 for HPV16 E6 peptides. ....... 170 
Table 25 I Predicted and experimental binding affinities to HLA-A11 for HPV16 E7 peptides. ....... 172 
Table 26 I Classification of 62 HPV16 whole genome sequences to distinct HPV16 variants. ......... 174  
Table 27 I Cell lines with their HLA type and designated HPV16 variant including nucleotide and 
amino acid exchanges in comparison to the HPV16 reference sequence... ......................................... 175   
Table 28 I Blood donor characteristics and HLA types. ..................................................................... 176   
 
 XIV 
 
 
 
  Introduction 
1 
 
1. Introduction 
In 3000 BC, cancer was first described as a disease (Hajdu, 2011) and despite of considerable progress 
in development of therapy, cancer still remains the second-leading cause of death in the industrialized 
world today (WHO, 2008). After cardiovascular diseases, cancer is also the second most common 
cause of death for women and men in Germany (DKFZ, 2012). In 2012, cancer globally accounted for 
8.2 million deaths (Ferlay et al., 2012; WHO, 2014) and it is estimated that annual cancer cases will 
increase further from 14 million in 2012 to 22 million cases within the next two decades. Moreover, 
the WHO indicates that 60% of the global new annual cases will occur in less developed countries. 
Incidences of most cancer entities increase with age and thus, cancer is often referred to as a disease of 
the advanced age. Taking into consideration that medical progress also accounts for a steadily 
increasing life expectancy, cancer has been becoming a growing major public health problem (Jemal et 
al., 2011; Soerjomataram et al., 2012). 
Cancer can be described as a large group of diseases comprising the formation of neoplasms or 
malignant tumors in any part of the body (Ferlay et al., 2012). Abnormal cells grow unlimited beyond 
their normal boundaries and thus form tumors. If they invade adjacent tissue and spread to other 
organs, this process is called metastasis and is actually the major cause of death from cancer. The 
origin of cancer is multifaceted, including inherited genetic causes as well as environmental factors 
such as tobacco smoking, diet, obesity and infections (Ferlay et al., 2012). Infectious agents causing 
cancer include bacteria and viruses such as the human papillomaviruses (HPV), the hepatitis B and C 
viruses (HBV and HCV), human herpes virus 8 (HHV8) and Epstein-Barr virus (EBV) (Parkin, 2006).  
Since cancer cells are altered cells of one’s own body, treatment is difficult. For successful treatment, 
it is crucial to distinguish cancerous cells from nonmalignant cells and elucidate the underlying 
mechanisms that lead to the development of cancer. During the last decades, genetic alterations were 
discovered to be the cause for cancer on the molecular level. In 2000, Hanahan and Weinberg 
formulated the hallmarks of cancer (Hanahan and Weinberg, 2000), which describe the six major 
capabilities that cells acquire during the malignant transformation process. Those hallmarks include 
sustaining proliferative signaling, evading growth suppressors, enabling replicative immortality, 
activating invasion and metastasis, inducing angiogenesis and resisting cell death. In 2011, 
deregulation of cellular energetics and avoiding immune destruction were added as two new emerging 
hallmarks and tumor-promoting inflammation and genome instability and mutation were added as two 
‘enabling characteristics’ (Hanahan and Weinberg, 2011).  
1.1 Human papillomavirus and associated diseases 
Papillomaviruses (PVs) cause epithelial infections in most mammals and birds, and are highly species-
specific (de Villiers et al., 2004). PVs were first identified in warts of cottontail rabbits (Shope and 
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Hurst, 1933) and in 1935, Francis Peyton Rous discovered that the cottontail rabbit papillomavirus 
(CRPV) induces malignant transformation and tumors in the skin of infected rabbits (Rous and Beard, 
1935). In the 1970s, the first connection between cervical cancer and HPV was postulated by Harald 
zur Hausen (zur Hausen et al., 1975; zur Hausen, 1977), which could be later confirmed biologically 
(Gissmann and zur Hausen, 1980; Gissmann et al., 1982a; Gissmann et al., 1982b) and 
epidemiologically (Munoz et al., 2006). Since the first isolation of HPV16 in 1983 (Durst et al., 1983), 
HPV has been investigated intensively finally leading to the development of prophylactic vaccines that 
have been introduced in more than 40 national vaccination programs worldwide (Poljak, 2012).  
HPV types can be subdivided into low-risk and high-risk types. Low-risk HPV types mainly cause 
benign ano-genital and skin warts whereas high-risk types are associated with ano-genital cancer, such 
as cervical, vaginal, penile and anal cancers (Chow et al., 2010), and head and neck cancers including 
their precursor lesions (Pim and Banks, 2010). HPV-associated squamous cell carcinomas (SCCs) of 
the head and neck (HNSCC) are mainly found in the oropharynx, especially at the base of the tongue 
and the tonsils (Gillison et al., 2000; Chow et al., 2010; Lajer and von Buchwald, 2010). Other sites in 
the head and neck region can also be infected by HPVs, e.g. the eye conjunctiva, the nasal sinuses and 
ear canals.  
The high-risk types HPV16, 18, 31, 33, 35, 45, 52 and 58 account for most of all ano-genital cancers 
and especially cervical carcinomas. HPV16 and 18 together cause approximately 70% of all cervical 
cancers, and in virtually all other cervical cancers DNA from other high-risk HPV types can be 
detected (Munoz et al., 2006).  
Depending on the site of infection, cervical, vulval, vaginal and anal intraepithelial neoplasias are 
distinguished (CIN, VIN, VAIN and AIN, respectively). Persisting infection with high-risk HPV can 
progress to intraepithelial neoplasia grade I, such as CIN1 in the cervix. Most squamous intraepithelial 
lesions are cleared within 6 to 12 months after infection, however a small number of lesions persist 
(2% over 5 years) and can develop to moderate dysplasia (CIN2) or severe dysplasia (CIN3), which is 
the immediate precursor of cervical cancer (zur Hausen, 2002; Longworth and Laimins, 2004). It has 
been shown that even CIN3 lesions can regress spontaneously in some cases and are thus considered 
to be a dynamic disease (Zehbe et al., 1998). However, a high viral load of especially HPV16 and 18 
has been shown to elevate the risk to develop CIN3 (Schlecht et al., 2001). 
The general time frame between the initial HPV infection and CIN3 development was estimated to be 
7 to 15 years. If the primary infection has occurred in the late teens or early twenties, as seen mostly, 
CIN3 diagnosis peaks around 25-30 years of age (Bosch and de Sanjose, 2003). For some cohort 
studies it was documented, however, that there is a much faster development of CIN2-3 among 
women infected with HPV16 or 18 (Winer et al., 2005). 
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HPV is the most common sexually transmitted agent worldwide and the associated risk of cancer 
development is a major health burden. The virus is strictly tissue-tropic, infecting only squamous 
epithelia of cutaneous and mucosal surfaces in humans. At highest risk for malignant transformation 
are the so-called transformation zones between the squamous and columnar epithelium. Such zones 
are found in the larynx, nasal sinuses, urethra, cervix and anal/rectal junctions. HPV is mainly 
transmitted during sexual intercourse or other contact of affected surfaces. Therefore, the majority of 
the sexually active population, up to 95%, are or will become infected once in their lifetime (Evander 
et al., 1995; Woodman et al., 2007). Of all the women who acquire a genital HPV infection, half of 
them are infected within three years of their first sexual contact (Collins et al., 2002). The infection is 
usually transient and resolves spontaneously within 6 to 18 months in 95% of all cases (Crosbie et al., 
2013). Thus, HPV infections are very common amongst young women at ages 20 to 24, and the 
prevalence in this age group ranges from 20 and 40% depending on the geographical region 
(Richardson et al., 2003; Cuschieri et al., 2004; Dunne et al., 2007). The incidence of HPV infections 
declines with age because infections are often cleared and controlled by the host’s immune system 
(Doorbar, 2006; Stanley, 2008). Despite the high prevalence and the transforming potential of HPV 
infections, only a minority of women infected with oncogenic HPV types develop cervical 
intraepithelial neoplasia (CIN) and cervical cancer (Doorbar, 2006). Cervical cancer is mainly slow-
growing and symptoms are not always present, but premalignant and malignant stages can be detected 
with a regular Papanicolau test (Pap test, a gynecological screening test).  
Globally, HPVs accounted for approximately 528,000 new cases and more than 265,000 death cases in 
women in 2012 (WHO, 2014) and it is estimated that about 5.2% of all cancers worldwide are 
associated with HPV infection (Parkin, 2006; Frazer et al., 2011). In developing countries, where more 
than 90% of cases occur, cervical cancer is still the second leading cause of death among women (van 
Bogaert, 2013) (Fig.1).  
In different studies, the prevalence of HPV in cervical cancer varies between 87 and 99%. 
Additionally, HPVs have already been associated with 85% of anal squamous cell cancers (Daling et 
al., 2004), 40-50% of penile cancers (Parkin, 2006), 33-60% of oropharyngeal cancers and 23% of oral 
cancers (Mork et al., 2001; Kreimer et al., 2005). Genital HPV types are also accountable for a number 
of benign clinical conditions, such as genital warts, which are important health burdens as well.  
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Figure 1 I Global cervical cancer distribution in 2008. Age-standardized mortality rates are depicted in blue. The highest 
mortality rates occur in less developed countries. This figure is adapted from (Frazer et al., 2011). 
 
1.1.1 HPV classification and distribution 
To date, 170 to 180 different HPV genotypes were identified based on the coding sequence of the 
major capsid protein L1 (de Villiers, 2013). By comparing the L1 gene, the family of 
Papillomaviridae has been classified into genera, species (clades) and types. The genera, which are 
described by Greek letters, include species that are phylogenetically related but often biologically 
quite diverse. There are five different genera including the α, β, γ, µ and ν genus (de Villiers et al., 
2004; Bernard, 2005). The latter four primarily infect cutaneous sites. The clinically most significant 
and largest genus is that of the alpha papillomaviruses, which can be further subdivided into mucosal 
and cutaneous species according to the site of infection. Mucosal species are divided into high-risk and 
low-risk types depending on their capacity of causing malignant transformation of cells. Critical 
determinants distinguishing these two groups of viruses are biological and biochemical differences 
between the E7 proteins (Munger et al., 1991). Alpha papillomaviruses are grouped into 15 species, 
which are named α1 to α15 (Doorbar, 2006). HPV16, for example, belongs to the α9 species and 
HPV18 to the α7 species. Those two are the most common representatives of their species. Within 
each species, different types are differentiated based on the most conserved gene L1. A type is defined 
by a minimal difference of 10% in the open reading frame (ORF) of its L1 gene compared to any other 
characterized HPV type of the same species (Burk et al., 2009). Furthermore, types are classified into 
subtypes and variants and are subdivided into variant lineages and sublineages (Burk et al., 2011; 
Smith et al., 2011; Burk et al., 2013). If the nucleotide sequence of the L1 gene differs less than 10% 
but more than 2% from that of a described HPV type, a subtype is defined. Only a few HPV types 
(HPV34, 44, 54, 68, 82) comprise subtypes, and it is questionable if “subtype” is a useful designation, 
because so far no differences of biological importance have been described for subtypes (Burk et al., 
2009).  
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A variant of a respective HPV type is defined by showing less than 2% differences in the nucleotide 
sequence of the L1 open reading frame. To classify further, whole genome sequences are compared. 
By this, variant lineages and sublineages can be distinguished, where variant lineages are defined by 
whole genome sequences with a nucleotide difference of 1 to 10% compared to other sequences of the 
same type (Burk et al., 2011). In case of HPV16, a maximum pair wise difference of 2.3% was 
confirmed (Smith et al., 2011) and thus this type can be divided into lineages. Here, the four major 
intratypic variant lineages are called European (E), Asian-American (AA), African-1 (Af-1) and 
African-2 (Af-2). Within such variant lineages, sublineages are defined by 0.5 to 1% nucleotide 
difference in whole genomes. For HPV16, the European variant lineage is comprised of the 
sublineages European Prototype 1 and 2 (E-1, E-2) and European Asian (E-A). Asian-American 1 and 
2 (AA1, AA2) and North American (NA1) are sublineages of the Asian-American variant lineage. The 
HPV16 reference sequence (NC_001526) belongs to the European Prototype 1 sublineage (Burk et al., 
2011; Smith et al., 2011).  
The distinct classification system of papillomaviruses is presented exemplarily for HPV16 in Figure 2.  
 
Figure 2 I HPV classification demonstrated by HPV16. HPVs are classified into genera, species, types and variants. The 
latter can be further subdivided into variant lineages and sublineages depending on their whole genome differences. All five 
genera (α-ν) are listed. At lower levels of the classification, only HPV16 relevant groups are listed. E: European, AA: Asian-
American, Af-1: African-1, Af-2: African-2, E-1: European Prototype 1, E-2: European Prototype 1, E-A: European Asian, 
AA1: Asian-American 1, AA2: Asian-American 2, NA1: North American. This figure is taken from (Dickmann, 2012). 
Variants are described by specifying the exchanged nucleotide and its position in comparison to the 
closest related variant lineage (Burk et al., 2011). The variant lineage to which the variant belongs is 
stated, followed by the initial nucleotide, the position of exchange and new base. For example, a 
variant with a nucleotide sequence that is identical to the European Prototype 1 apart from nucleotide 
350 (T in the European Prototype 1) that is exchanged by a G, would thus be called E-1-T350G. 
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Variants can also be described by the amino acid changes that are caused by the nucleotide exchange. 
In this case, the position within the respective protein is designated. The T350G nucleotide exchange 
results in an amino acid exchange from leucine to valine at position 83 of the Early (E)-6 protein and 
is referred to as L83V. 
Related variants often correlate with the distribution of major ethic groups, which might explain the 
endemic nature of HPV variants due to adaption of variants to respective hosts over time (Tabora et 
al., 2010). The variants are distributed all over the world, despite clustering in specific regions. Thus, 
the European variant lineage is for example not restricted to Europe (Tu et al., 2006). 
1.1.2 The HPV genome and its organization 
PVs contain double-stranded circular DNA, are non-enveloped and have a conserved icosahedral 
capsid structure. The capsid is composed of 72 capsomers consisting of the structural proteins, which 
are named late (L)-1 and L2 protein (Modis et al., 2002). L1 represents approximately 80% of the 
capsid and is thus called the major structural protein of the virus, whereas the minor L2 protein 
accounts for the remainder and is found mostly internally (Frazer et al., 2011). A model of the virus 
capsid structure is depicted in Figure 3.  
 
Figure 3 I Structure of the papillomavirus capsid. The capsid is assembled from 72 pentamers of the L1 protein in a 
icosahedral symmetry. Genotypic variations are depicted in pink and mostly affect the external surface whereas the internal 
structure (blue) is largely conserved. This figure is adapted from (Frazer et al., 2011). 
The virus measures about 55nm in diameter (Hagensee et al., 1993). It has a genome of between 7400 
and 8200 base pairs (bp), in case of HPV16 7908 bps, which encode for eight ORFs (Chen et al., 
2005; Doorbar, 2006). The HPV genes are divided into early (E) and late (L) genes depending on their 
time point of expression during the viral life cycle as shown in Figure 4. 
The whole HPV16 genome can be divided into three regions. The smallest region is the noncoding 
upstream regulatory region (URR) that contains binding sites for cellular and viral transcription and 
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replication factors (e.g. AP1, E1 and E2). The second largest segment are the two late ORFs that 
comprise the genetic sequence of the major capsid protein L1 and the minor capsid protein L2 and 
thus are transcribed in the latest phase of the viral life cycle. The largest region are the early ORFs that 
code for the six early proteins E6, E7, E1, E2, E4 and E5, which are transcribed throughout the course 
of infection. To fit all relevant information into the relatively small genome of approximately 8 kb, the 
sequences of some gene products overlap (Fig. 4). They are separated after transcription by mRNA 
splicing. For instance, the E2 sequence also contains the genetic information for the E4 protein 
(Doorbar, 2006).  
 
Figure 4 I Genomic organization of HPV16. The circular genome with eight open reading frames (ORFs) marked in blue 
and green encodes for six early proteins which are involved in viral replication and transcription (E1 and E2), release and 
immune evasion (E4 and E5) and transformation (E6 and E7). The two late proteins L1 and L2 form the viral capsid. Control 
of early gene transcription and replication is conferred by the upstream regulatory region (URR). It contains the viral origin 
of replication (ORI) and the late polyadenylation signal (AL). The corresponding polyadenylation signal for early genes is 
located between E5 and L2. This figure is taken from (Stanley, 2012). 
1.1.3 Viral life cycle and viral proteins 
In general, PVs are adapted perfectly to their natural host tissues, the squamous epithelia of mucosa 
and skin, where the rapidly cycling and dividing, nondifferentiated basal keratinocytes set the stage for 
the viral life cycle (Doorbar, 2005). High-risk HPVs show a special tropism for the so called 
transformation zone, which consists of the basal cell layers at the metaplastic epithelial site of the 
cervix. This area is a ring of mucosa where squamous epithelium of the ectocervix replaces the 
glandular epithelium of the endocervix (Schiffman et al., 2007). Cells close to this area have a higher 
susceptibility for persistent infections (Chow et al., 2010; Doorbar et al., 2012). Other sites of the body 
that are prone to HPV associated cancers show strong similarities in terms of intersecting epithelium, 
like the uneven reticulated epithelium lining the base of the tongue and the crypts of the palatine 
tonsils (Boscolo-Rizzo et al., 2013). These sites are susceptible to HPV-mediated HNSCCs.  
Initially, virions infect cells of the basal layer of the epithelium as displayed in Figure 5. This requires 
(micro-) trauma or epithelial wounding in the stratified epithelium to permit access to basal cells. The 
subsequent healing processes have also been suggested to play a role as active cell division is 
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necessary for establishing an infection (Pyeon et al., 2009; Schiller et al., 2010). Binding of HPV to 
the surface of the epithelium or the basement membrane occurs by interaction of the major capsid 
protein L1 of the virion with heparan sulfate proteoglycans (Johnson et al., 2009; Kines et al., 2009; 
Abban and Meneses, 2010; Horvath et al., 2010). The internalization of the virus and transfer of its 
genome to the nucleus is propagated by changes in the capsid structure (Doorbar, 2005; Horvath et al., 
2010; Schiller et al., 2010). To date, many different studies tried to elucidate the mechanism of 
infection, however the exact details of endocytosis still remain elusive. Endocytosis of HPV16 viruses 
has been shown not to depend on clathrin, caveolin, or dynamin. It might occur via a so far 
uncharacterized endocytotic pathway that could be supported by tetraspanins and actin (Spoden et al., 
2008; Schelhaas et al., 2012). Moreover, it is possible that various internalization and entry pathways 
exist that might use different cell surface molecules (Raff et al., 2013) and that this process is also 
dependent on the virus type (Doorbar et al., 2012). In contrast to other virions, for HPV the process 
takes several hours (Horvath et al., 2010).  
 
Figure 5 I HPV viral life cycle from infection of basal keratinocytes to virion release. After infection, the virus replicates 
and maintains its genome in dividing cells. Upon cell differentiation into mature keratinocytes, viral gene amplification is 
increased. Finally, virions assemble and are released via shedding. Proteins are depicted in pink. This figure is taken from 
(Stanley, 2012). 
After internalization, the virus is trafficked across early and late endosomal compartments, is uncoated 
and final entry of the viral genome to the nucleus is achieved by a complex of the L2 protein and DNA 
(Sapp and Bienkowska-Haba, 2009; Bergant Marusic et al., 2012; Schelhaas et al., 2012). The HPV 
genome is maintained as an episome, a closed DNA element, which is able to replicate 
extrachromosomally within the host cell. Soon after infection, the virus replicates up to 50 to 100 
copies separate from the cell cycle but dependent on the cellular DNA synthesis machinery, as well as 
the viral helicase E1 and the transcription factor E2 (Doorbar et al., 2012). Specifically, E2 is a DNA 
binding protein that forms a complex with E1 to initiate episome replication in the S-phase (Doorbar, 
2006). The E5 protein helps to create a favorable environment by e.g. enhancement of epidermal 
growth factor (EGF)-signaling and mitogen-activated protein (MAP)-kinase activity. Upon host cell 
  Introduction 
9 
 
division, viral episomes are distributed to daughter cells. The initially infected cell in the basal cell 
layer maintains the viral episome in a low copy number. The cells expand laterally, daughter cells 
move towards the surface and start to differentiate. Since viral replication depends on the host cell’s 
DNA replication machinery, no replication would occur once the cell enters cell cycle arrest. In 
uninfected keratinocytes, this takes place as the cell undergoes terminal differentiation. In infected 
cells however, this step is prevented by expression of the E6 and E7 genes. The E7 protein associates 
with the retinoblastoma protein (pRB) and thus disrupts the binding of pRB to the transcription factor 
E2F. This way, S-phase entry is blocked, because E2F induces the activation of several genes, like 
cyclin A and E that promote S-phase (zur Hausen, 2002; Doorbar, 2006; Lehoux et al., 2009). 
However, cell cycle promotion by E7 also leads to increased p53 levels that would result in apoptosis. 
To suppress apoptosis, the E6 protein binds to an ubiquitin ligase, which then marks p53 for 
proteasomal degradation (Ganguly and Parihar, 2009). Their potential to stimulate cell cycle 
progression and block tumor suppressors makes these two oncoproteins essential for the malignant 
phenotype. Viral replication is kept active throughout the whole differentiation process at a low level. 
When reaching the late stage of keratinocyte development, L1, L2 and E4 proteins are expressed. 
Here, in terminally differentiated cells, viral genomes are packed into self-assembling capsids 
consisting of  L1 proteins  and interspersed L2. Mature keratinocytes undergo their natural shedding 
process and meanwhile, with the help of the E4 protein, virions are released (Narisawa-Saito and 
Kiyono, 2007; Stanley et al., 2007; Stanley, 2008). These virions can infect more exposed basal 
keratinocytes of the same individual or can be transmitted to a naïve host. The whole viral life cycle 
takes up to 6 to 12 weeks which is remarkably long for a virus (Stanley, 2012). A detailed description 
of functions of all HPV proteins is given in section 1.1.3.1 and section 1.1.3.2. 
In case of HPV high-risk types, the viral genome eventually can integrate into the host cell’s DNA. In 
contrast to benign and low-grade lesions, where HPV DNA is mostly found extrachromosomally, in 
premalignant lesions (CIN 2/3) HPV DNA is integrated into the chromosome. Therefore, lesions can 
progress to microinvasive and invasive cancer (Doorbar, 2006). In case of integration, the episome is 
mostly opened within the E2 ORF and thereby functional expression of E2 is prevented. Since E2 
represses expression of both oncogenes E6 and E7, loss of E2 leads to a deregulated expression of E6 
and E7 and increases the proliferative capacity (zur Hausen, 2002; IARC, 2007). Preferential sites of 
integration have been described including the region in and around the human telomerase reverse 
transcriptase gene (hTERT). Increased hTERT expression induces telomerase activity which finally 
leads to the immortalization of infected cells. Hence, is has been suggested that changed expression of 
genes adjacent to the integration site may contribute to cancer development as well (Doorbar, 2006; 
IARC, 2007). 
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1.1.3.1 The early proteins E1, E2, E4, E5 and the oncoproteins E6 and E7  
As outlined above, after infection of dividing basal cells, the viral genome is established as a stable 
episome with a low copy number. The viral proteins E1 and E2 are responsible for regulating early 
transcription and additionally serve for maintenance of the viral episome in the basal layer. The E1 
protein is a DNA helicase. The E2 protein plays a crucial role in the beginning of the viral life cycle, 
as it initiates viral DNA replication directly after entry into the host cell (Zheng and Baker, 2006). E2 
recognizes four palindromic motifs in the non-coding region of the viral genome (Dell et al., 2003). 
Upon E2 binding, E1 binds to the viral origin of replication (Amador-Molina et al., 2013). E2 
eventually dissociates, letting E1 form a hexameric ring. E2 binds to the viral DNA via multiple 
binding sites in the long control region (LCR), which on the one hand leads to gene replication as 
described above and on the other hand might also activate expression of the late genes (Johansson et 
al., 2012). Moreover, E2 is controlling the expression of the two oncogenes E6 and E7 in lower 
epithelial layers. While high levels of E2 repress the expression of E6 and E7, lower levels enhance 
their transcription. An additional function of E2 is to cause cell cycle arrest at the G2 phase and thus 
inhibition of cell proliferation. E2 is also important for correct segregation during mitosis as it anchors 
the viral episomes to cellular chromosomes. Besides, E2 is thought to be involved in virus assembly 
during productive infection in upper epithelial layers. During viral DNA integration into the host cell’s 
genome, the E2 gene is often disrupted leading to loss of E2, which causes increased expression of E6 
and E7 as already metioned above (Doorbar, 2006).  
The E4 protein is expressed in terminally differentiated keratinocytes (Zheng and Baker, 2006). It 
accumulates at the epithelial surface and is believed to support viral release by disrupting the keratin 
network (Doorbar, 2006).  
The transmembrane E5 protein is mostly found in the endoplasmic reticulum (ER) and plays an 
important role in maintaining the environment in favor of cellular replication in the upper epithelial 
layers. E5 binds to vacuolar proton ATPases leading to delayed endosomal acidification, which in turn 
causes recycling of growth factor receptors to the cell surface rather than their being degraded by the 
endosome (Doorbar, 2006). By this, E5 is enhancing EGF receptor activity. The subsequent increase 
in EGF-mediated receptor signaling promotes cellular replication (Frazer et al., 2011). E5 also 
prevents apoptosis due to DNA damage but is not considered of special importance in late stages of 
HPV-mediated carcinogenesis because it may be lost during integration of viral DNA (Doorbar, 
2006). 
The two oncoproteins E6 and E7 are mainly responsible for the malignant transformation of infected 
cells in high-risk HPV types, such as HPV16 (zur Hausen, 2002; Ganguly and Parihar, 2009). As 
mentioned above, the virus is in need of the cellular replication machinery in cells that stopped 
dividing. To solve this problem, the E6 and E7 proteins reactivate cellular DNA synthesis, inhibit 
apoptosis and delay differentiation. Thus, cell growth becomes largely uncontrolled, which leads to the 
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development of neoplasias and eventually cancer. The p97 promoter directs the expression of the E6 
and E7 proteins (Kammer et al., 2000), which consist of 158 and 98aa, and have a weight of 
approximately 19 and 11kDa, respectively. The E7 protein keeps the cell in a proliferating state to 
ensure viral replication as mentioned before. To this end, E7 binds to pRb which in turn releases and 
thereby activates the transcription factor E2F. E2F is enhancing gene transcription that is needed for 
G1/S-phase transition. In uninfected cells, pRb is associated with E2F and regulates cell cycle arrest 
and G1/S-phase transition depending on its phosphorylation status. Cyclin dependent kinases (CDK) 
such as cyclinD/Cdk4/6 phosphorylate pRb, E2F dissociates and gene expression to promote G1/S-
phase transition is activated. In infected cells, E7 binds directly to pRb and thus leads to the same 
events (reviewed in (Longworth and Laimins, 2004; Doorbar, 2006). In addition, this process is further 
regulated by a negative feedback loop as E2F mediates transcription of p16 and p14
Arf
. While p16 
regulates the levels of active cyclin kinases, which are absent in infected cells (McLaughlin-Drubin et 
al., 2011), p14
Arf
 increases the levels of p53. More specifically, p14
Arf
 is encoded by the alternative 
reading frame of the CDKN2A gene and usually regulates the activity of the MDM (murine double 
minute) ubiquitin ligase. This ligase maintains p53 at a low level that is not sufficient to trigger cell 
cycle arrest and/or apoptosis. An increased level of p14
Arf
 leads to the inhibition of MDM function and 
thus elevates the level of p53 (Piette et al., 1997; Busch et al., 2010). E7 also supports proteasome-
mediated degradation of pRb. The different potentials of low and high-risk E7 to immortalize seem to 
depend rather on their ability to degrade pRb than to bind to pRb (Doorbar, 2006). Additionally, E7 
also associates with other proteins involved in cell proliferation, it activates cyclin A and E genes, 
which are required for S-phase progression. Moreover, it blocks CDK inhibitors p21 (WAF1) and p27 
(KIP1), interacts with the AP1 transcription complex and with enzymes that mediate histone 
acetylation (Antinore et al., 1996; Doorbar, 2006). Finally, E7 promotes genomic instability by 
activation of the ataxia telangiectasia mutated (ATM)- ataxia telangiectasia and Rad3-related (ATR) 
pathway and induction of abnormal centrosome synthesis by interaction with CDK2 and γ-tubulin 
(Moody and Laimins, 2010).  
The function of the E7 protein is complemented by the E6 protein. E6 counteracts apoptosis by 
interaction with p53 and other pro-apoptotic proteins. p53 is polyubiquinated and degraded by the 
proteasome upon interaction with the cellular E3-ubiquitin E6-associated protein (E6-AP). This 
prevents apoptosis in response to E7-mediated cell cycle entry in the upper epithelial layers (Doorbar, 
2006). External and internal apoptotic signaling is inhibited through interaction with tumor necrosis 
factor α (TNFα), Fas-associated protein with Death Domain (FADD), caspase 8 and the pro-apoptotic 
proteins Bak and Bax. Moreover, E6 is activating transcription of hTERT, which is the catalytic 
subunit of the telomerase. Telomerase activity prevents cells from becoming senescent due to telomere 
shortening, and is thus an essential step for immortalization (Kiyono et al., 1998). The presence of E6 
and E7 alone is not sufficient to cause the multi-step process of carcinogenesis, but in synergy they 
allow for secondary mutations, centrosome amplification and aneuploidy (Narisawa-Saito and Kiyono, 
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2007). These events can lead to accidental integration of HPV episomal DNA, which in turn is 
increasing expression of the E6 and E7 proteins and thus also increases cell growth. All those factors 
and the fact that E7-mediated apoptosis is prevented by E6 account for their synergistic effect (zur 
Hausen, 2002). Besides these well known functions of the two oncoproteins E6 and E7, a variety of 
other binding partners have been identified that have many different functions (Klingelhutz and 
Roman, 2012). Detailed mechanisms behind these functions still remain greatly elusive (Narisawa-
Saito and Kiyono, 2007; Ganguly and Parihar, 2009; Klingelhutz and Roman, 2012). 
1.1.3.2 The late proteins L1 and L2  
The capsid of HPV is composed of the two structural late proteins, L1 and L2, which are key players 
in mediating infectivity. The primary structural element of the capsid is the major capsid protein L1, 
which can form pentamers (Hagensee et al., 1993). These pentamers have the ability to self-assemble 
into capsids as depicted in Figure 3. In case of HPV16, the L1 protein consists of 503aa and has a 
molecular weight of 56kDa. The minor capsid protein L2 has a size of 473aa and a molecular weight 
of 51kDa. It was found to be located in the central internal cavity of the L1 pentamer (Buck et al., 
2008). Moreover, it was shown to interact with the viral genome and is essential for the encapsidation 
process of the viral genome (Stauffer et al., 1998). The L2 protein has furthermore been suggested to 
play a role in infection and immune escape mechanisms of HPV (Fahey et al., 2009). Natural virus 
capsids consist of 72 L1 pentamers that comprise 360 L1 molecules and approximately 30 L2 
molecules (Baker et al., 1991). The rim of the L1 pocket is variable whereas the L1 side chains lining 
the axial cavity are highly conserved between different HPV types (Chen et al., 2000). The capsomers 
are stabilized by formation of intercapsomeric disulfide bridges between neighboring capsomers (Sapp 
et al., 1998; Sapp and Bienkowska-Haba, 2009). The non-covalent interaction of L2 with the L1 
capsomers is based on a hydrophobic C-terminal L1 binding domain of L2 and an additional L1 
binding domain at the N-terminus of the L2 sequence (Volpers et al., 1995; Okun et al., 2001; Finnen 
et al., 2003). L2 incorporation enhances the formation of infectious viruses. Moreover, it has been 
postulated that there exists an L2 network within the viral capsid (Buck et al., 2008). 
 
1.2 The immune system 
The human body is constantly exposed to numerous different pathogens, including viruses, bacteria, 
parasites and fungi. To be able to prevent or combat infections of the body, a system of organs, 
cellular and soluble components, has evolved – the immune system. In 1796, Edward Jenner, an 
English physician, tested his hypothesis that healthy individuals inoculated with cowpox could be 
protected from severe infections with smallpox and proved this to be true. Thus the term 
“vaccination”, coming from Variolae Vacciniae (cow pox), was born and today, Edward Jenner is 
regarded to be the ‘father of immunology’ (Murphy, 2007).  
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The bone marrow, spleen, thymus, lymph nodes, tonsils and the mucosa- and gut-associated lymphoid 
tissues are organs of the immune system, which are classified into primary and secondary lymphoid 
organs. All cells of the immune system develop from specialized hematopoietic stem cells in the bone 
marrow, a primary lymphoid organ. T cells further develop in the thymus. These cells migrate towards 
secondary lymphoid tissue for further maturation or circulate in the blood or lymph for detection of 
pathogenic or malignant threats to the body. To be able to discriminate self and non-self or malignant 
tissues, immune cells possess a distinct set of receptors (Murphy, 2007). 
1.2.1 The innate and adaptive immune system 
The human immune system is classically subdivided into the innate and adaptive arm. However, the 
innate and adaptive immune system branches are in close contact through signaling mechanisms. They 
differ in response kinetics, their cellular subsets and the mechanisms of pathogen recognition.  
Innate immunity shows an array of first line defense mechanisms against invading pathogens that are 
immediately available and display low specificity. Cells of the innate immune system express 
germline encoded receptors that are non-clonally distributed, and are specific for surface repeating 
structural patterns that are shared by many microorganisms. Thereby, upon recognition of bacteria or 
viruses, for instance, an immune reaction is instantly initiated without the need for prior sensitization. 
These functions are carried out by the most important cell types of the innate branch: macrophages, 
monocytes, dendritic cells (DCs), granulocytes and natural killer (NK) cells.  
Patterns that are recognized by innate immune cell receptors, are called pathogen-associated molecular 
patterns (PAMPs) and are recognized by pattern recognition receptors (PRR). For example. Toll-like 
receptors (TLRs), initiate different signaling pathways that lead to the transcription of genes for 
inflammatory cytokines like type I interferons (IFNs). PAMPs, which are promiscuously expressed on 
many pathogens, confer self/non-self discrimination capabilities. For instance, double-stranded RNA, 
that is often exposed upon viral infection, is recognized by TLR3, bacterial lipopolysaccharide (LPS) 
by TLR4, flagellin by TLR5 and unmethylated CpG by TLR9. 
DCs are specialized in capturing antigens by phagocytosis and macropinocytosis and subsequent 
presentation of these antigens to T cells. Therefore, DCs act as a link between the innate and adaptive 
sides of the immune system. The adaptive immune system is composed of B and T lymphocytes. 
These cells express non-germline receptors with unique specificity and are able to recognize virtually 
every foreign antigen. During their development, B and T cells recombine their receptor genes 
randomly, a process known as V(D)J recombination. The whole process of expression of one single 
functional receptor can create up to 10
14
-10
18
 specificities on the way, which get depleted of self-
reactive receptors, a process known as clonal deletion, leading to central tolerance.  
Upon recognition of their specific antigen, naïve B and T lymphocytes differentiate to effector cells 
and undergo clonal expansion and massive proliferation. B cells differentiate into plasma cells that 
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produce antibodies and thus mediate humoral immunity. T cells mediate adaptive immunity by 
developing into different subsets of effector cells that produce cytokines and display cytotoxic effector 
functions. CD4
+
 T cells recognize antigens originating from extracellular proteins that are presented by 
major histocompatibility complex (MHC) II molecules and can differentiate into T helper (TH) cells, 
e.g. TH1 or TH2 depending on the cytokine milieu during activation. CD8
+
 T cells are specialized in 
recognition of antigens that are presented on MHC I molecules. They play a pivotal role in anti-tumor 
immunity. Upon elimination of a pathogen, most effector cells are eliminated, but some lymphocytes 
persist and constitute a pool of immunological memory cells. Upon a subsequent encounter with the 
same antigen, these cells mount a more rapid and effective immune response and  can provide their 
host with life-long protection (Murphy, 2007).  
Since the field of immunology is extremely complex and this work is focused on the investigation of T 
cell epitopes for therapeutic vaccine development, only components of the immune system that are 
involved in generation of antigen-specific immune responses are described in greater detail.  
1.2.2 The major histocompatibility complex  
Major histocompatibility complex (MHC) molecules were first discovered as the major determinants 
of histocompatibility in transplantation. In humans MHC molecules are called human leukocyte 
antigen (HLA) molecules. MHC molecules are surface proteins that form complexes with peptides 
inside the cell and are then transported to the cell surface for antigen presentation, where they can be 
recognized by T cells. There exist two major classes of MHC molecules, class I proteins are presenting 
peptides from the cytosol, mainly with a length of 8 to 11aa, while class II proteins present peptides 
from intracellular vesicles of variable length between 9 and 25aa. While MHC class I molecules 
(MHC I) are found on virtually all nucleated cells, MHC class II molecules (MHC II) are mainly 
expressed on specialized antigen-presenting cells (APCs) such as B lymphocytes, macrophages and 
DCs (Rammensee, 1995; Villadangos, 2001; Gromme and Neefjes, 2002).  
Peptide presentation by MHC I is crucial for the detection of intracellular pathogens, including 
viruses, by cytotoxic T lymphocytes (CTLs) that can subsequently kill these cells. MHC I complexes 
consist of a transmembrane α-chain with three extracellular Ig domains (α1-α3) that have a mass of 
approximately 44kDa and a soluble β2-microglobulin chain, which weights 13kDa and is non-
covalently associated (Fig. 6). The interface of the α1 and α2 domains forms a closed peptide binding 
cleft in which the peptide ligand is bound in an elongated conformation (Fremont et al., 1992; Madden 
et al., 1993). The binding is stabilized on both ends of the peptide via intermolecular interactions by 
H-bonds and ionic interactions, which are independent of the peptide’s sequence. These interactions 
limit the length of bound peptides to 8 to 11aa. 
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Figure 6 I Schematic structure of MHC class I and MHC class II molecules. A The MHC class I molecule consists of an 
α-chain with three extracellular domains and a non-covalently associated polypeptide chain, β2-microglobulin. The β2-
microglobulin chain is invariant, while especially α1 and α2 are highly polymorphic (blue shading). B In MHC class II 
molecules both chains are polymorph, mainly in the α1 and β1 domains (blue shading). Both proteins possess peptide binding 
sites that present peptides to T cells. This figure is taken from (Alberts, 2007). 
The generation of MHC I peptides involves a complex process starting in the cytosol, followed by 
translocation of peptide intermediates into the endoplasmatic reticulum (ER), and trimming of the 
peptides that will be subsequently transported as a MHC/peptide complex via the Golgi apperatus to 
the cell surface (Fig. 7). Cytoplasmic proteins are degraded by the proteasome into peptides (Yewdell 
and Bennink, 2001). C‐terminal cleavage of peptide bonds is facilitated by the three catalytical beta 
subunits 5-7 (Tanaka, 2009). Proteasomal products have usually a size of 2 to 25aa (Nussbaum et al., 
1998; Kisselev et al., 1999) and therefore, the majority are too long or short for MHC I binding. 
Longer peptides are digested at the N‐terminus by various cytosolic aminopeptidases (Stoltze et al., 
2000; Reits et al., 2004). Subsequently, these peptides are translocated into the ER by the transporter 
associated with antigen processing (TAP) complex. The TAP heterodimer consist of TAP1 and TAP2 
that actively translocate peptides (Momburg et al., 1994; Koopmann et al., 1996). Within the peptide-
loading complex (PLC) which consists of the transporter TAP, the chaperones tapasin, thiol 
oxidoreductase ERp57, calreticulin and the MHC I molecule, a peptide is loaded into the binding 
pocket of the MHC I molecule. In detail, tapasin binds to TAP and is linked to a cysteine residue at the 
active site of ERp57 (Peaper et al., 2005), leading to recruitment of MHC class I molecules and 
calreticulin to the PLC (Wearsch and Cresswell, 2007). The PLC receives the peptides translocated by 
TAP and induces MHC loading. Final trimming of peptides is mediated by endoplasmatic reticulum-
associated aminopeptidase/endoplasmatic reticulum aminopeptidase 1 (ERAAP/ERAP1) and ERAP2 
(Wearsch and Cresswell, 2008). Components, which are involved in these processes are named 
together the antigen-processing machinery (APM). Eventually, the peptide/MHC I complex is 
transported via the Golgi apparatus to finally reach the cell surface where it is exposed to the T cell 
receptor (TCR) of CD8
+
 T cells (Neefjes et al., 2011). 
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Of note is the so‐called immunoproteasome that has a different composition of subunits, which are 
formed under the influence of IFNγ or TNF (Kloetzel and Ossendorp, 2004). Here, three catalytic 
subunits are replaced, which leads to an increased proteolytic activity and throughput (Sorokin et al., 
2009; Kruger and Kloetzel, 2012). Moreover, it results in a change of the epitope repertoire presented, 
suggesting an altered cleavage specificity (Van den Eynde and Morel, 2001; Kloetzel and Ossendorp, 
2004).  
 
Figure 7 I Antigen presentation via the classical MHC class I pathway. Proteins are degraded into smaller peptide 
fragments via the proteasome and translocated into the endoplasmatic reticulum (ER) by the transporter associated with 
antigen processing (TAP). The peptide loading complex is formed and peptides are loaded onto MHC class I molecules. The 
MHC I/peptide complex is transported via the Golgi apperatus to the cell surface, where peptides are presented to CD8+ T 
cells. This figure is taken from (Neefjes et al., 2011). 
Besides the classical MHC I pathway, some APCs can also present peptides from exogenous antigens 
on their MHC I molecules. Since in the canonical model, these peptides would be expected to be 
presented by MHC II, the process has been named ‘cross-presentation’ (Bevan, 2006; Kurts et al., 
2010). Antigens escape from early endosomes into the cytosol through the Sec61b transporter and are 
then processed in the same way as intracellular antigens (Amigorena and Savina, 2010). 
The MHC II complex consists of two transmembrane chains, α and β, of approximately 30kDa with 
two Ig domains each with the peptide binding site in between α1 and β1 as depicted in Figure 6 
(Dessen et al., 1997). In comparison to MHC I, the binding cleft of MHC II is open and can 
accommodate peptides of various lengths up to 25aa. Peptides that are presented by MHC II are 
usually derived from phago- or pinocytosed extracellular proteins that are digested in the 
phagolysosome by acidic proteases and cathepsins. Peptides can also be derived from pathogens that 
replicate within intracellular vesicles. The MHC class II complex reaches the endosomal compartment 
from the ER together with the invariant chain (Ii), which is blocking the peptide binding cleft 
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(Weenink and Gautam, 1997). Ii is degraded and the left over fragment class II-associated Ii peptide 
(CLIP), now occupying the binding groove. Consecutively, MHC II molecules like HLA-DM and 
HLA-DO (Dengjel et al., 2005), bind and stabilize the MHC II/CLIP complex and catalyze the 
exchange of CLIP with peptides. At the plasma membrane, MHC II presents these peptides to CD4
+
 T 
cells (Fig. 8). 
 
Figure 8 I Antigen presentation via the classical MHC class II pathway. MHC class II complexes including the invariant 
chain (Ii) arrive from the ER via the Golgi complex to the endosomal compartment termed the MHC class II compartment  
(MIIC) where Ii is degraded to CLIP, which occupies the MHC class II peptide cleft. CLIP is exchanged for an antigenic 
peptide from exogenous proteins, the MHC class II/peptide complex is eventually transported to the plasma membrane and 
recognized by CD4+ T cells. This figure is taken from (Neefjes et al., 2011). 
The MHC complex is a large gene cluster, which is located on chromosome 6 in humans and contains 
more than 200 genes coding for HLA molecules. The genes encoding for the β2-microglobluin and the 
invariant chain, however, are located outside the MHC locus on chromosome 15. MHC molecules 
need to bind and present a multitude of different peptides, ideally all possible ones. In contrast to 
TCRs, the required variability is not achieved by somatic recombination, but by polygeny and 
polymorphism of the MHC genes. There are three loci for the MHC I heavy chain in the human 
genome, HLA-A, HLA-B and HLA-C, with approximately 9,500 alleles being known. To date (March 
2015), these alleles include 2,995 for HLA‐A, 3,760 for HLA‐B, 2,553 for HLA‐C (EMBL-EBI). The 
gene encoding for β2-microglobulin is nonpolymorphic. For MHC II molecules there are also at least 
three functional loci each for the α- and the β-chains, with in total 3,104 known functional alleles 
(EMBL-EBI). The facts that each individual is heterozygous for the whole MHC locus and that the 
MHC haplotypes are codominant, increase the diversity between individuals of the same species as 
well. 
Introduction 
18 
 
The peptide binding cleft of each allele is different and has a unique specificity for certain amino acids 
in defined positions. There are so-called key-peptide interaction sites inside the MHC molecule’s 
binding groove which preferentially bind to certain amino acid residues inside the peptide. Thus, they 
determine parts of the amino acid sequence of peptides which are presented by the respective MHCI 
molecule. Since these interactions also strengthen the binding of the peptide to the peptide binding 
pocket, the peptide residues involved are referred to as anchor residues. Considering anchor positions 
and length preferences of certain HLA alleles, peptide motifs were described by Rammensee and 
colleagues for different alleles (Falk et al., 1991; Rammensee et al., 1993). By eluting peptides from 
MHC complexes, sequences of these peptides were consequently identified via mass spectrometry. On 
the basis of these gathered sequence findings, Rammensee and colleagues developed an algorithm for 
the prediction of short peptides derived from protein sequences that are potentially presented by a 
given MHC molecule. This algorithm is called SYFPEITHI (Rammensee et al., 1999) and will be 
described in the context of other T cell epitope prediction servers in section 1.3.1 in greater detail. 
1.2.3 Dendritic cells 
Dendritic cells (DCs) are APCs, which can prime naïve T lymphocytes. Myeloid and lymphoid 
progenitors in the bone marrow give rise to DCs that migrate via the blood stream to secondary lymph 
organs and other tissues throughout the body. DCs can be subdivided into plasmocytoid DCs and 
conventional DCs, which are differentiating into further subsets. 
Immature DCs ingest antigens by receptor mediated phagocytosis and micropinocytosis, leading to the 
uptake of surrounding fluids. Phagocytosis is mediated by receptors such as Fc receptors, C-type 
lectins and dectin-1. DCs also express TLRs which recognize PAMPs and other danger signals. 
Through extensive antigen sampling, DCs can present virtually all kinds of antigens derived from 
various sources such as parasites, fungi, bacteria, viruses and tumors. The antigen-presenting 
pathways, described in section 1.2.2, are initiated. Upon TLR-triggering, antigens are more efficiently 
processed and chemokine receptor expression patterns are altered, leading to migration of DCs to 
lymphoid tissues. They migrate via the CCR7-CCL21-axis to lymph nodes and mature meanwhile. 
Maturation terminates the uptake of antigens and increases the expression of high levels of MHC class 
I and II molecules that present epitopes from processed pathogens. Moreover, mature DCs attract 
naïve T lymphocytes by secretion of chemokines and express the costimulatory molecules CD70, 
CD80 and CD86 (Murphy, 2007).  
In virus-infected and tumor cells, the antigens need to be cross-presented to prime naïve CD8
+
 T cells 
to become fully activated cytotoxic T lymphocytes (CTLs). Cross-priming describes the initiation of a 
CD8
+
 T cell response which is not produced solely by the APC itself and is depicted in Figure 9 (Kurts 
et al., 2010). Here, conventional tissue DCs transmit antigens from the affected peripheral tissue to 
resident (CD8α+) DCs in lymph nodes and other secondary lymphoid organs (Allan et al., 2006). TLRs 
of DCs are required to receive signals from PAMPs to enable cross-presentation. Antigen-specific 
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CD4
+
 TH cells are recruited and alter the DCs into a transient phase that leads to programming CTLs 
for effector functions and memory formation. This process is accomplished by interaction of CD40 on 
the DC and CD40L on the TH cell (Smith et al., 2004). The so-called licensed, cross-presenting DCs 
start to program naïve CD8
+
 T cells which have been shown to be attracted to the DCs likely by 
CCR5-ligands. Besides TCR-MHC I binding and CD28-CD80/CD86 interaction, CD27 on the T cell 
side and CD70 on the DC side need to interact (Keller et al., 2009). Interleukin 2 (IL-2) has been 
reported to be essential during priming for CTL survival (Williams et al., 2006b). In humans, CD141 
positive DCs seem to cross-present most efficiently (Haniffa et al., 2012). 
In conclusion, DCs are crucial for anti-tumor immune responses as they can cross-present antigens and 
prime CTLs. Melief and colleagues have suggested that this process also takes place after anti-cancer 
vaccination with synthetic peptides. Subcutaneously injected antigens are engulfed by tissue resident 
DCs, that migrate to draining lymph nodes of the vaccination site, where the antigen is cross-presented 
(Melief and van der Burg, 2008).  
 
Figure 9 I Mechanism of classical cross-priming and its role in anti-tumor immunity. A Dendritic cells (DCs) present 
antigens via MHC class II to CD4+ T helper cells (TH) and cross-present antigens via MHC class I to CD8
+ cytotoxic T cells 
(CTLs). DCs upregulate costimulatory molecules like CD70, CD80 and CD86 while downregulating inhibitory molecules 
like programmed cell death ligand 1 (PD-L1). B Tumor-antigens are released either by the tumor or introduced through 
vaccination and are cross-presented by DCs to CTLs. This process requires costimulation (e.g. by CD40) or danger signals 
(e.g. by TLRs). This figure is adapted from (Kurts et al., 2010).  
 
1.2.4 T lymphocytes 
T lymphocytes are mediators of cellular immunity. They express highly variable TCRs on their 
surface, which are able to recognize specific non‐self peptides presented on MHC class I or II 
molecules. While most T cells have α:β receptors, consisting of an α- and β-chain, a minority with 
greatly reduced receptor variability carries γ:δ receptors (Chien and Konigshofer, 2007). The α:β T 
cell subset express either CD4 or CD8 on their surface. These two proteins act as coreceptors 
mediating the recognition of MHC class I (CD8) or MHC class II (CD4) molecules (Bierer et al., 
1989). CD8
+
 T cells are also referred to as cytotoxic T lymphocytes (CTLs), due to their task to kill 
infected cells which are presenting peptides that are non-self on their surface. CD4
+
 T cells can be 
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further subdivided (see section 1.2.4.1). When CD4
+ 
T cells are activated, they are responsible for 
activating macrophages and trigger antibody secretion by B cells. Moreover, TH cells can also help to 
activate CTLs. 
1.2.4.1 The T cell response and T cell subsets 
After leaving the thymus, naïve T cells circulate through the blood and lymphoid system, entering the 
latter via the lymph nodes by high endothelial venules. High endothelial venules express ligands, CC 
chemokine 21 and peripheral node addressin (PNAd), that interact with CC chemokine receptor 7 
(CCR7) and L-selectin CD62L on T cells and mediate migration (von Andrian and Mackay, 2000). In 
the lymph node, T cells encounter APCs, e.g. DCs, and T cells bind transiently to DCs via adhesion 
molecule interaction of LFA-1 and CD2 on the T cells side and ICAM-1, ICAM-2 and CD58 on the 
DC side, and screen for their cognate antigen (Grakoui et al., 1999). The fate of a T cell is determined 
as soon as they meet their cognate antigen-MHC complex on a DC. If such an interaction is not given, 
T cells remain naïve, leave the lymph node and reenter the blood stream via the thoracic duct. Apart 
from signaling through the TCR, further costimulatory signals are necessary for the T cell to be 
activated, undergo clonal proliferation and differentiate into effector cells. However, signaling through 
the TCR alone indicates recognition of a self‐antigen and induces anergy or apoptosis (Guerder et al., 
1994). The secondary signal is provided by the interaction between the costimulatory molecules CD28 
and CD27 on T cells and CD80 and CD70 on activated DCs. Signaling through CD28 leads to the 
secretion of IL‐2, which is an autocrine proliferation factor for T cells (Appleman et al., 2000; Zhou et 
al., 2002). Simultaneously, expression of the α-chain of the IL‐2 receptor is induced, leading to the 
formation of the high affinity trimeric αβγ receptor, which increases the effect of IL‐2. Additionally, 
other costimulatory signals are transmitted through the two TNF receptor family members 4‐1BB 
(CD137) and OX40 (CD134) on T cells and their ligands 4‐1BBL and OX40L (OX40 ligand or TNF 
receptor-associated factor 2 (TRAF2)) on the APC (Croft, 2003), or ICOS (CD278) and its ligand 
ICOSL (ICOS ligand (B7-H2)) (Dong et al., 2001; Carreno and Collins, 2002). Physical contact 
between the APC and the T cell is also reinforced by several cell adhesion molecule pairs like ICAM‐
1/LFA‐1 or DC‐SIGN/ICAM‐3, thus forming a so‐called ‘immunological synapse’ (Grakoui et al., 
1999; Bromley et al., 2001). Next to the activating costimulatory signals, several inhibitory receptors 
are expressed on T cells as well, which can downmodulate or inhibit complete activation. The two 
most prominent representatives are cytotoxic T lymphocyte antigen 4 (CTLA-4, CD125) and 
programmed cell death 1 (PD-1). Negative costimulatory signals have been shown to be important to 
prevent excessive immune responses and maintain self-tolerance (Greenwald et al., 2005). 
CD4
+
 T cells differentiate into three major classes of TH cells, TH1, TH2 or the more recently identified 
TH17 T cells. All subsets differ in their cytokine secretion pattern and by this also in the target cells 
that they activate. TH1 cells produce mostly IFN and control cell-mediated immunity by activating 
macrophages and CTLs (Stout and Bottomly, 1989; Andreasen et al., 2000). TH2 cells produce IL-4, 
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IL-5 and IL-13 and direct the immune response towards humoral immunity by activation of B cells 
and their antibody production (Croft and Swain, 1991b; Croft and Swain, 1991a; Parker, 1993). TH17 
cells secrete IL-17A, IL-17F, IL-21, IL-22 and IL-23 (Tato and O'Shea, 2006), which are important in 
activation of neutrophils and immunity against parasites (Fallon et al., 2006). Naïve CD4
+
 T cells 
differentiate into the respective subtype depending on the cytokine milieu prevailing during their 
priming. While development of the TH1 phenotype is induced by IL‐12 and IFNγ, IL-4 leads to 
development of TH2 CD4
+
 T cells (Mosmann and Coffman, 1989; O'Garra and Arai, 2000). Of note, 
TH1 and TH2 cells have been shown to inhibit the activation of each other, therefore committing the 
local immune response to either one of the two pathways (Jankovic et al., 2001). TH17 cells are 
induced early during an immune response in the presence of transforming growth factor β (TGF-β) 
and IL-6 (Veldhoen et al., 2006)  
Moreover, other suppressive and regulatory CD4
+
 T cell populations are known. Amongst those are 
regulatory T cells (Treg). While natural Tregs develop in the thymus in between positive and negative 
selection (Klein et al., 2014), induced Tregs develop in the periphery. Both Treg types can suppress 
CD4
+
 as well as CD8
+
 T cells, and are crucial for the maintenance of self‐tolerance (Sakaguchi et al., 
1995). Expression of CD25 and especially the master transcription factor forkhead box P3 (FoxP3) are 
characteristic markers for Tregs (Fontenot and Rudensky, 2005). 
After priming, naïve CD8
+
 T cells differentiate into effector cytotoxic T cells, produce IFN, TNFα 
and lytic granules containing enzymes such as perforin and granzymes. Effector T cells leave 
secondary lymphoid organs and migrate into tissues to kill infected and altered cells. Of note, effector 
CTLs can kill cells expressing the MHC/peptide complex they recognize without further stimulatory 
signals being needed. CTLs express CD95L, which is capable of inducing apoptosis by binding to its 
receptor on target cells (Russell and Ley, 2002). Upon activation, CTLs produce effector molecules 
and store them in modified lysosomes, so-called cytotoxic granules (Henkart, 1994), from which they 
can be quickly released after contact with the cognate epitope. The glycoprotein CD107a (LAMP-1: 
lysosomal associated membrane protein-1) in the membranes of these granules is a marker for 
degranulation and can give information about the cytolytic activity of CTLs (Aktas et al., 2009). 
Cytotoxic granules include the aforementioned perforin, which disintegrates the plasma membrane of 
a target cell (Tschopp et al., 1986), and granzymes, which are serine proteases. These can enter target 
cells and induce an apoptotic cascade through activation of caspase 3 (Heusel et al., 1994). 
Additionally, cytokines like IFN and TNFα are secreted, which increase for example the density of 
MHC molecules on target cells (Slifka and Whitton, 2000).  
After the ‘effector phase’ and clearance of an infection, a contraction phase occurs and approximately 
90 to 95% of the effector T cells undergo apoptosis, while the remaining activated T cells constitute 
the immunological memory T cell pool (Murali-Krishna et al., 1998). Upon reinfection with the same 
pathogen, memory T cells show a higher sensitivity to antigen stimulation, are less dependent on 
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costimulatory signals and display effector functions more efficiently and rapidly than naïve T cells 
(Veiga-Fernandes et al., 2000). These memory T cells show a differential expression of cell surface 
markers namely no CD45RA expression in comparison to naïve T cells which are positive for 
CD45RA. The expression of CCR7 in combination with the CD45RO tyrosine phosphatase, another 
isoform of CD45RA, allows to subdivide central memory T cells (TCM) (CD45RO
-
CCR7
+
) and 
effector memory T cells (TEM) (CD45RO
-
CCR7
-
). TCM cells show a similar homing behavior as naïve 
T cells and circulate in the blood and lymphoid system, while TEM are found in the periphery more 
frequently (Sallusto et al., 1999). The latter ones display more rapid effector functions, have cytolytic 
abilities and produce IFN. TCM, however, produce IL-2, have a higher proliferative capacity and 
undergo less cell divisions. Furthermore, they are also able to differentiate into effector cells upon 
secondary stimulation (Masopust et al., 2001). Another subset is referred to as TSCM (stem cell 
memory), which are similar to TEM but express CD45RA (Faint et al., 2001; Gattinoni et al., 2011). 
TSCM express large amounts of perforin (Sallusto et al., 1999) and it has been suggested that they are 
derived from TCM cells upon homeostatic proliferation in the absence of antigens (Geginat et al., 
2003). TSCM have self-renewing potential and are highly proliferative. Besides, they are considered to 
be multipotent, being able to further differentiate into other (memory) T cell subsets. Of note, this 
subset is discussed as a valuable new tool for adoptive T cell therapies in the field of cancer 
immunotherapy (Gattinoni et al., 2012).  
The expression of other cell surface markers such as the homing receptor CD62L, costimulatory 
receptors CD28 and CD27 and the IL-7 receptor α-chain (CD127) are also used to differentiate T cell 
subsets. In most tissues, a prominent population of long-lived CD8
+
 T cells, tissue-resident memory 
cells (TRM), which is distinct from the TEM cell populations and does not recirculate, exist. They are 
residing in tissues of potential reinfection, such as the intestinal, genital and respiratory mucosa and 
the skin. Here, TRMs coordinate the initial response to pathogens, providing an important function by 
directly recognizing antigen, recruiting circulating memory cells and reducing the amount of infected 
cells (Schenkel et al., 2013). 
It has been suggested that determination of differentiation into memory T cells occurs early during 
infection (Marzo et al., 2005). For the generation of CD8
+
 memory T cells, CD4
+
 T cell help has been 
shown to be essential (Shedlock and Shen, 2003). Later on, however, CD8
+
 memory T cells, do not 
require help of CD4
+
 T cells for a recall response. 
1.2.5 Tumor immunology 
Besides fighting pathogenic invaders, the immune system has also evolved strategies to distinguish 
altered self from normal self and is thus able to initiate an immune reaction against tumor cells. 
However, tumor immunity is regarded as a double-edged sword, because on the one hand, 
inflammation can serve as the driving force to develop cancer and on the other hand, immune effector 
functions are crucial for tumor control (Schreiber et al., 2011). This ambivalence was recently also 
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integrated into the hallmarks of cancer by Weinberg and Hanahan as described in section 1. While one 
emerging hallmark is the avoidance of immune destruction, one of the enabling characteristic of 
cancer is promotion through inflammation (Hanahan and Weinberg, 2011).  
In 1909, more than 100 years ago, Paul Ehrlich introduced the idea of immune cells that control cancer 
growth. About 50 years later in 1957, Burnet and Thomas proved this hypothesis to be true by 
observations in mice, giving rise to the concept of immunosurveillance (Burnet, 1957). Another 50 
years later, Schreiber and colleagues summarized all these findings by formulating the immunoediting 
hypothesis (Dunn et al., 2004; Schreiber et al., 2011). In this hypothesis, they describe the cancer-
immune cell crosstalk through several phases, that explain how immune cells can either benefit or 
harm patients with tumors (Dunn et al., 2002; Ikeda et al., 2002). This is illustrated in Figure 10. 
 
Figure 10 I The three E’s of cancer immunoediting. This scheme displays the interplay between the immune system and 
tumor cells at various stages of tumor development. During the elimination and equilibrium stage, the immune system can 
eliminate and control tumor outgrowth. Entering the escape phase, the tumor has acquired strategies for immune escape and 
actively suppresses immune effector functions. This figure is taken from (Schreiber et al., 2011) 
Transformation of normal cells to malignant cancer cells can be caused by multiple factors, such as 
exposure to carcinogens or viral infections resulting in mutations. Even after overcoming intrinsic 
tumor suppression, such as DNA repair, cellular senescence and apoptosis, transformed cells can still 
be detected by the immune system. Developing tumor tissue presents tumor antigens, expresses 
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danger-associated molecular patterns (DAMPs) and sends danger signals by secretion of cytokines, 
such as e.g. type I IFNs. 
During cancer immunoediting the immune system recognizes and eliminates malignant cells. 
However, tumor cells can escape the immune system and sustain a pool of malignant cells. Cancer 
immunoediting is divided into three distinct phases, which are named the three capital “E”s, being 
comprised of an elimination, equilibrium and escape phase. In the first phase, the elimination phase, 
innate and adaptive immunity try to prevent tumor outgrowth by detection and elimination of 
transformed cells. T cells recognize the presentation of tumor-antigens by MHC molecules. Especially 
CTLs kill tumor cells by exploiting cytotoxic capabilities such as the secretion of cytotoxic granules 
and CD95L expression. Expression of markers by the tumor cell, such as the natural-killer group 2, 
member D (NKG2D) ligand can lead to activation of NK and  T cells (Cerwenka and Lanier, 2001). 
NK and T cells in turn secrete IFN, which can inhibit tumor cell proliferation and angiogenesis and 
induce apoptosis (Bromberg et al., 1996; Kumar et al., 1997; Qin and Blankenstein, 2000). On NK 
cells, TNF-related apoptosis-inducing ligand (TRAIL) is expressed on the cell surface and perforin 
dependent mechanisms are used to eliminate cells (Smyth et al., 2001). In addition, activated 
macrophages can kill tumor cells via reactive oxygen species (ROS) (Liou and Storz, 2010). Danger 
signals, like type I IFN, IL-1, TNFα, high mobility group box 1 (HMGB1) or hyaluronan fragments 
from damaged tissue contribute to recruitment of immune cells. Tissue resident sentinel DCs get 
activated by cytokines such as IFNγ or by tumor-infiltrating NK cells themselves (Sims et al., 2010). 
Additionally, the micromilieu is enriched for heat shock proteins (Hsps) and apoptotic cell fragments 
that constitute an large pool of tumor antigens (Haug et al., 2005; Berg et al., 2006). DCs that have 
engulfed tumor antigens migrate to the draining lymph node to induce specific anti-tumor T cell 
responses. In addition to an initial CD8
+
 T cell response, CD4
+
 TH cells are also induced which 
subsequently help to activate CTLs via cross-presentation (Kurts et al., 2010).  
However, rare tumor cells manage to survive the elimination phase, enter the equilibrium phase. 
Herein, CD4
+
 and CD8
+
 cells as well as the cytokines IFN and IL-12 seem to counterbalance 
immunosuppressive mechanisms and keep tumor cells in dormancy (Aguirre-Ghiso, 2007; Koebel et 
al., 2007). Immunoediting of the tumor cells takes place in the equilibrium phase, possibly due to the 
selection pressure of the immune system that enables survival of tumor cells with immunoevasive 
features. These variants of the tumor cells are more aggressive compared to the original tumor. 
Eventually, they cannot be killed by immune cells anymore and form new colonies of cancer cells.  
In the last phase of immunoediting, tumor cells escape from immune control leading to tumor 
progression and clinical manifestation. The intrinsic mechanisms and mutations that finally lead to the 
escape stage are loss of immunodominant antigens, loss of MHC I and II molecules and defects in the 
APM (Khong and Restifo, 2002). Furthermore, tumor cells take advantage of various possibilities to 
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keep the microenvironment in an immunosuppressive state. Secretion of immunosuppressive 
cytokines leads to strong tumor-protective functions. These include IL-10, vascular endothelial growth 
factor (VEGF), TGF-β and indoleamine 2,3-dioxygenase (IDO) (Gabrilovich et al., 1996; Gorelik and 
Flavell, 2002; Uyttenhove et al., 2003). Moreover, tumor cells specifically recruit immunosuppressive 
immune cells such as Tregs and myeloid-derived suppressor cells (MDSCs). Tregs produce 
immunosuppressive cytokines such as TGF-β or IL-10 upon stimulation with their respective cognate 
peptide. High expression levels of CD25 are proposed to consume the IL-2 from the environment and 
by this limit effector T cell proliferation (Pandiyan et al., 2007). Further, Tregs express inhibitory 
molecules such as CTLA-4 and PD-1 (Vignali et al., 2008). MDSCs are a heterogeneous population of 
immature myeloid cells and exhibit various functions that suppress the functions of immune cells 
(Schlecker et al., 2012). Special mechanisms that lead to the immune escape of HPV-transformed cells 
are discussed in the next subchapter.  
1.2.6 HPV and immune evasion  
More than 95% of incident infections with HPV are cleared by the immune system within 6 to 18 
months (Crosbie et al., 2013). For clearance, the HPV-infected cells need to be recognized by the 
host’s immune cells. Regressing warts, for example, show a marked infiltration of macrophages and 
CD4
+
 and CD8
+
 T cells to the site of infection (Nicholls et al., 2001). CD8
+
 T cell-mediated immune 
responses have been reported to be crucial for clearance of HPV16 (Stanley, 2012). Protective HPV 
immunity against reinfection is achieved by neutralizing antibodies in the serum, which are mainly 
directed against the viral capsid protein L1. However, antibody titers were found to be rather low after 
natural HPV infection and only occur in some patients (Stanley, 2006a). 
In general, HPVs are very successful pathogens because they are able to cause chronic infections but 
rarely kill their host. Through this strategy, HPV is able to produce large amounts of infectious virions 
for transmission to naïve new hosts (Stanley, 2008). Comparable to other infections, in HPV-infected 
cells, both innate and adaptive immunity are invoked to eliminate the infected cell by various 
mechanisms. However, HPV and many other viruses have evolved numerous strategies to escape from 
host immune responses (O'Brien and Saveria Campo, 2002; Doorbar, 2006; Grabowska and Riemer, 
2012). First of all, the HPV life cycle itself is an immune evasion mechanism, which delays virus 
detection by the host’s immune system. The life cycle is non-lytic, neither tissue nor cell damage 
occurs and no pro-inflammatory signals are induced that could activate innate or adaptive immunity. 
Another strategy that HPV has evolved to avoid detection, is to stay outside the basement membrane 
and thereby maintain a very low profile. The virus is directly infecting basal skin cells from the 
outside, at a very low viral copy number and without a blood born infection phase. The expression of 
the oncogenes E6 and E7 is highly controlled by the repressor function of E2. Thus the viral early 
proteins are expressed at levels below those required for an effective host immune response (Doorbar, 
2006; Kanodia et al., 2007; Stanley, 2008). Higher expression levels of viral proteins only occur in 
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upper layers of the epithelium. At this stage, also immunogenic particles like the capsid proteins 
L1and L2 are expressed. However, the keratinocytes are already in the last differentiation 
compartment and are soon shed from the surface of the epithelium (Stanley, 2012).  
Regarding innate immune responses to viral infection, many mechanisms are affected by HPV. 
Usually, cells express TLRs which sense PAMPs and then elicit a response against the infection. 
TLR9, that senses CpG DNA patterns, has been shown to be downregulated in HPV-positive 
carcinomas (Hansen and Bouvier, 2009). Moreover, the two oncoproteins E6 and E7 counteract TLR 
signaling by directly interacting with different components of the IFN signaling pathways and these 
inhibit IFN synthesis (Kanodia et al., 2007; Stanley, 2008). The E7 protein of high-risk HPVs inhibits 
the activation of the IFNβ promotor by blocking the transcription factor interferon regulatory factor 1 
(IRF-1), thereby inhibiting the transcription of the chemotactic ligand CCL2 and TAP1. Besides, E7 
also interferes with IFNα signaling by preventing the translocation of IRF-9 to the nucleus. Hence, it 
inhibits the formation of the interferon-stimulated gene factor 3 (ISGF-3) complex, that binds to 
interferon-specific response elements (ISREs) which leads to activation of interferon-responsive 
genes. High-risk HPV E6 proteins are preventing transcriptional activation of IFNα by binding to the 
transcription activator IRF-3. The E6 protein additionally interferes with IFNα signaling by preventing 
the tyrosine kinase 2 (TYK2) to bind to the cytoplasmic side of the IFN receptor. This impairs 
phosphorylation of several signal transducers and activators of transcription (STATs) leading to 
impaired janus kinase (JAK)-STAT signaling (reviewed in Grabowska and Riemer, 2012).  
In addition to TLRs, the innate immune system also includes nucleotide binding domain, leucine-rich 
repeat gene family receptors (NLR-receptors) which are expressed on keratinocytes. These receptors 
sense PAMPs, as well as DAMPs, and induce secretion of IL-1β and IL-18 and proinflammatory 
signaling. IL-1β and IL-18 activate macrophages and resident APCs and attract effector T cells, 
forming a bridge to the adaptive side of the immune system. IL-6 is also constitutively expressed by 
keratinocytes (Stanley, 2012). High-risk HPVs seem to be able to counteract expression and secretion 
of this cytokine. It has been reported that in HPV16 infected cells, many proinflammatory and 
chemotactic cytokines are downregulated, including IL-1β and IL-6. In case of IL-1β, this might be 
mediated by proteasomal degradation of pro-IL-1β through E6-AP and p53 (Niebler et al., 2013).  
HPVs have also evolved to successfully escape from adaptive immune responses. Upon viral 
infection, APCs usually sense the virus in the periphery. Since HPV exclusively infects stratified 
squamous epithelia, Langerhans cells  specialized epithelial DCs  , act as APCs (Drijkoningen et al., 
1988) (Miyagi et al., 2001). Langerhans cells have been reported to be decreased in low-grade HPV 
lesions and are even more markedly absent in high-grade lesions. Thus, the number of cells 
recognizing infection and presenting antigens is reduced, which may facilitate the establishment and 
persistence of local HPV infection (Leong et al., 2010). Langerhans cells normally take up antigens 
and mature during migration to the lymph node where they eventually prime naïve T cells (Mota et al., 
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1999). However, in high-grade lesions, Langerhans cells were shown to exhibit an early failure of 
activation compared to normal tissue and low-grade lesions. Being not fully activated when presenting 
antigens to naïve T cells, Langerhans cells are believed to induce tolerance rather than the 
inflammatory response needed to induce a cytotoxic CD8
+ 
T cell response (Stanley, 2012).  
On the keratinocyte side, HPV-positive cells have a downregulated MHC I surface expression in 
comparison to uninfected cells (Ashrafi et al., 2005; Kanodia et al., 2007). The downregulation of 
MHC molecules on the surface is mainly attributed to the E5 protein, which interferes with the 
trafficking of MHC I/peptide complexes via the Golgi network. E5 influences the pH of the Golgi 
network and thus reduces MHC I stability. Moreover, it directly interacts with the MHC I/peptide 
complex, leading to accumulation of the MHC I/peptide complex within the Golgi network (Ashrafi et 
al., 2005; Campo et al., 2010). In addition, reduced protein levels of various components of the APM 
were reported in cervical cancer lesions and HPV-positive cell lines (Seliger et al., 2000; Manning et 
al., 2008; Hasim et al., 2012). Dysregulation of the APM results in downregulation of MHC I/peptide 
complexes and protects infected cells from immune attack. 
Taken together, in more than 95% of HPV infections the immune system successfully clears the virus, 
particularly via local antigen-specific CD8
+
 and CD4
+
 T cell responses (Stanley, 2012). However, if 
the immune system fails to clear the infection, the described immune evasion mechanisms allow 
establishment of a persistent infection, which might lead to CIN2/CIN3 and eventually cancer. The 
expression of cytokines, chemokines and signaling receptors that are necessary for proficient cytotoxic 
T cell responses are more and more reduced during progressing neoplastic transformation and 
associated genetic instability. This leads to a balance shift from an effective cytotoxic T cell response 
to increased immune suppression that is mediated by regulatory T cells (Stanley, 2012).  
 
1.3 Cancer immunotherapy 
At the end of 2013, the journal Science announced ‘Cancer Immunotherapy’ as the breakthrough of 
the year. The ability of immune cells and immune-modulatory drugs to substantially help in 
controlling tumor growth in cancer patients, which was shown in convincing clinical trials, were 
recognized by the scientific community. In Figure 11, several important milestones of cancer 
immunotherapy are displayed that include the translation of basic scientific findings from “bench to 
bedside”. 
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Figure 11 I Timeline of the most important breakthroughs in cancer immunotherapy. Important immunological 
discoveries and clinical trials that form the basis of today’s cancer immunotherapy are displayed. This figure is taken from 
(Lesterhuis et al., 2011). 
The overall concept of cancer immunotherapy is based on the aforementioned immunosurveillance 
mechanisms, which are hypothesized to prevent development of tumors from transformed cells on the 
one side, and immune escape of transformed cells on the other side. Thus, immunotherapy aims to 
manipulate the patient’s immune system to enhance anti-tumor immunity and disable immune escape 
by the tumor (Fig. 12). First hints towards natural tumor immunity were observed after transplantation, 
that is accompanied by therapeutic immunosuppression, leading to an increased risk for patients to 
develop tumors (Vial and Descotes, 2003).  
Direct evidence for the immune system controlling tumor growth was provided in the 1990s with 
IFNγ-/- or IFNγ receptor (IFN-γR)-/- mice that showed defective tumor rejection compared to 
immunocompetent wild type (wt) mice upon carcinogen challenge or injection of tumor cell lines. 
Additionally, tumors of immunodeficient mice that were implanted to immunocompetent wt mice, 
were completely rejected, implying that the immune system is not only capable of preventing tumor 
growth but also of eliminating established tumors, which were not grown under immunosurveillance. 
(Vesely et al., 2011). 
Cancer immunotherapy comprises two different strategies to support the immune system for targeted 
cancer treatment. While passive immunotherapies specifically target tumor cells and perform anti-
tumor effects on their own, active immunotherapy stimulates the host’s immune system to generate 
anti-tumor cellular and humoral responses. In both cases, treatment can be directed at tumor antigens, 
which can be subdivided into highly tumor specific antigens (TSAs) and tumor associated antigens 
(TAA). The first class comprises for instance peptides of oncoviral proteins like HPV16 E6 and E7. 
The subset of cancer testis antigens is not strictly tumor specific, as those are also expressed on male 
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germline cells and trophoblastic cells. However, these cells do not express MHC molecules and 
therefore cannot present antigens. Cancer testis antigenes include the melanoma antigen (MAGE) 
family and the New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) (van der Bruggen et 
al., 1991; Ressing et al., 1995; Gnjatic et al., 2006). TAAs show a lower tumor specificity and include 
for example the overexpressed growth factor HER2/neu in breast and other epithelial tumors (Fisk et 
al., 1995) and the unglycosylated mucin. MUC-1, which is expressed on most adenocarcinomas, like 
breast and pancreatic cancers (Vlad et al., 2004). These antigens, however are also expressed in some 
normal tissues. 
Antibody therapies belong to the most successful treatments of cancer by passive immunotherapy. The 
Her2/neu blocking antibody transtuzumab (Herceptin) was already approved in the 1990s for 
treatment of Her2/neu overexpressing breast cancer in combination with standard chemotherapy and 
significantly improved survival of patients (Piccart-Gebhart et al., 2005; Romond et al., 2005). 
Checkpoint inhibitors build the newest group of immunotherapy strategies. The most famous 
examples include blocking of the inhibitory receptors CTLA-4 and PD-1 on T cells. Blocking these 
two receptors with antibodies can efficiently activate the whole T cell pool. Importantly, 
impilimumab, a CTLA-4 blocking antibody, has been shown in a large randomised trial to prolong 
overall survival of metastatic melanoma patients (Hodi et al., 2010) and was subsequently approved 
for treatment of melanoma by the US Food and Drug Administration (FDA) in 2011.  
Infiltration of lymphocytes into the tumor was shown to be associated with a better prognosis in many 
different tumor entities, including HPV-driven tumors (Vanky et al., 1986; Zhang et al., 2003; Ward et 
al., 2014). During adoptive T cell transfer (ACT), autologous or allogenic effector T cells are activated 
in vitro and transferred to the patient. Various approaches have been developed through the last two 
decades and most of them employ T cells that are partly genetically engineered (Restifo et al., 2012). 
One of the first studies, published in 2002, showed that isolated and reinfused tumor infiltrating 
lymphocytes (TILs) of melanoma patients result in cancer regression (Dudley et al., 2002). Based on 
these findings, more targeted strategies were developed such as an ACT therapy with engineered T 
cells expressing tumor-antigen specific high affinity TCRs (Rosenberg, 2011). Moreover, genetically 
engineered T cells can express chimeric antigen receptors (CARs) (reviewed in Tey, 2014), which are 
not restricted to MHC molecules as they contain antigen-recognition domains of antibodies combined 
with intracellular signaling moieties of T cells. A CD19 B cell antigen CAR approach developed by 
June and colleagues led to complete remission of chronic lymphocytic leukemia (CLL) (Porter et al., 
2011) and pediatric acute lymphoid leukemia (ALL) (Grupp et al., 2013). However, off target toxicity, 
which represents a problem when tumor-antigens are also expressed in normal tissue, has been shown 
to be fatal in ACT therapy. Cancer patients that were treated with an anti-MAGE-A3 TCR showed 
fatal neurologic toxicity attributed to cross-reactivity of the TCR with MAGE-12 (Morgan et al., 
2013).  
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Cytokines such as IL-2, IFNα and GM-CSF have also been used in cancer immunotherapy. IL-2 was 
approved for treatment of renal cancer and metastatic melanoma despite low response rates 
(Rosenberg et al., 1985; Atkins et al., 1999; Smith et al., 2008). Toxic side effects, however, were 
severe, even leading to organ failure (Rosenberg et al., 1989). Importantly, besides the desired 
unspecific activation of T cells, IL-2 can induce Tregs when being injected systemically. Local 
administration of IL-2 and TNFα were reported to be beneficial in sarcoma and melanoma (Grunhagen 
et al., 2006; Weide et al., 2010).  
Vaccination approaches, belonging to the active cancer immunotherapy strategies, are generally 
considered to be safe and cost-efficient. However, initially they are far less effective than passive 
immunotherapy approches. For a robust immune response, APCs, mostly DCs, need to take up tumor 
antigens, process them and present them by HLA molecules to naïve CD4
+
 and CD8
+
 T cells. These 
need to differentiate into effector T cells as described in detail in section 1.2.4.1. Antigen presentation 
can be achieved through DC-, protein- and peptide-based vaccines.  
The DC-based vaccine Sipuleucel-T (Provenge™) was the first active cancer vaccine to be approved 
by the FDA. It induces T cell responses against the prostate carcinoma antigen prostatic acid 
phosphatase (PAP) (Kantoff et al., 2010). Protein vaccines include numerous CD8
+ 
and CD4
+
 T cell 
epitopes. Vaccination with such a vaccine induce weak, variable antigen-specific CD8
+
 T cells 
responses and mainly CD4
+
 T cell responses, which are mainly immunodominant. The poor efficiency 
of vaccine antigen uptake, processing and presentation by APCs limits the magnitude of resulting 
immune responses. Peptide vaccines, on the other hand, induce more specific T cell responses in 
comparison. The NY-ESO-1 antigen was targeted by both, protein and peptide vaccines in various 
studies (Karbach et al., 2011; Sabbatini et al., 2012). More clinical studies, including protein and 
peptide vaccination for HPV treatment, will be discussed in section 1.3.2.  
Possible options for the peptide vaccination approach are long and short synthetic peptides. Long 
synthetic peptides, presenting a defined sequence of a protein, may contain several CD8
+
 and CD4
+
 T 
cell epitopes. As proteins, these long peptides also require optimal uptake, processing and HLA 
loading of T cell epitopes by APCs to give rise to effective immune responses. Long synthetic peptide 
vaccines mainly result in good CD4
+
 T cell responses and rather poor CD8
+
 T cell responses, 
suggesting a failure of efficient processing and cross-presentation. Short synthetic peptides generally 
contain one exact, immunodominant CD8
+
 T cell epitope that binds directly to a HLA molecule on 
APCs. Phagocytosis, processing and entry into the cross-presentation pathway is not required. Hence, 
short peptide vaccines induce very robust specific CD8
+
 T cell responses but lack the ability to trigger 
a CD4
+
 TH cell response. Moreover, short specific peptides are HLA-restricted, combination of various 
different HLA-specific precise CD8
+
 T cell epitopes into one vaccine can solve this shortcoming. 
Long peptides are not HLA-restricted. Thus, prior HLA typing of patients is not required. 
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Van der Burg and van Hall have published “Seven hallmarks of peptide vaccination” in analogy to 
Hanahan’s and Weinberg’s hallmarks of cancer (van Hall and van der Burg, 2012) that include factors 
which need to be considered for peptide vaccination. These include peptide length, APC targeting, 
CD4
+
 T cell help, epitope breadth, peptide dose, bio distribution and supply of danger signals.  
As described in section 1.2.5, CD4
+
 T cell help (TH1) is important for the priming of naïve CD8
+
 T 
cells by DCs. Indeed, the addition of TH cell epitopes to peptide vaccines improves protective T cell 
responses (Zwaveling et al., 2002; Bijker et al., 2007). Moreover, it was observed, that TH cells also 
seem to provide help to CTLs in the tumor microenvironment and thus enhance CTL recruitment and 
their cytolytic functions (Bos and Sherman, 2010). Consequently, the inclusion of TH cell epitopes 
increases a vaccine’s efficiency. This can be achieved by either adding common agonistic sequences to 
the peptide vaccine, such as as known sequence, the pan HLA-DR-binding epitope (PADRE), or 
specific antigen-derived peptides (van Hall and van der Burg, 2012). 
Equally important as the antigen is the mode of delivery. Especially for peptide vaccines, appropriate 
adjuvants are crucial. These are compounds that enhance the magnitude, breadth, quality and longevity 
of specific immune responses to antigens. Since the 1920s, adjuvants are commonly used for 
vaccinations. At that time an aluminium salt, also known as alum, was discovered and shown to 
improve diphtheria vaccination results (Park and Schroder, 1932). Adjuvants can be categorized into 
two main subsets, delivery systems and immune potentiators (Brito et al., 2013). While immune 
potentiators directly activate the immune system, delivery systems target the vaccine to immune cells, 
prolong their activity and enhance antigen uptake (Pashine et al., 2005). An example for immune 
potentiators are synthetic TLR ligands, such as polyinosinic-polycytidylic acid (poly I:C) and 
monophosphoryl lipid A (MPLA), which is e.g. a component of the prophylactic vaccine Cervarix™ 
together with aluminium hydroxide (Keam and Harper, 2008). Commonly used delivery systems for 
peptide-vaccines are water-in-oil emulsions such as Montanide (Brito et al., 2013). Especially 
Montanide ISA 51 (Aucouturier et al., 2002) has been widely used for clinical trials. It forms depots 
from which antigens are slowly released, which is thought to improve antigen uptake by DCs (Bijker 
et al., 2007).  
Apart from activating the immune system, additional hurdles need to be overcome in cancer 
immunotherapy. These are the local immunosuppressive milieu at the tumor site and targeting of 
activated T cells to the tumor. Immunosupressive cell populations such as Tregs should be inhibited, 
leading to elevated antigen-specific responses. This was achieved in colorectal cancer patients by Treg 
depletion (Clarke et al., 2006). This strategy, however, brought along the risk of autoreactive immune 
responses (Kim et al., 2007).  
In summary, cancer immunotherapy has the aim to generate potent anti-tumor immune responses. To 
this end, DC priming for efficient antigen-presentation to T cells is very important, in addition to 
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enhancement of T cell functions, migration to the tumor site and inhibition of immunosuppression 
(Fig. 12). 
 
Figure 12 I Generation of an effective anti-tumor immune response and its multiple steps. a Priming of DCs with 
tumor-antigens can be accomplished by various means, including injection of whole irradiated tumor cells, or reinfusion of ex 
vivo antigen-loaded autologous DCs. Chemotherapy and targeted therapy can kill tumor cells which are then phagocytosed 
by DCs. b T cell function can be improved by costimulation or blocking of inhibitory signals with respective antibodies. c 
Immunosuppressive Tregs and myeloid-derived suppressor cells (MDSCs) have an inhibitory effect of immune responses by 
secretion of cytokines. Depletion of immunosuppressive cell or inhibition of cytokine secretion can increase effective anti-
tumor T cell responses. This figure is adapted from (Vanneman and Dranoff, 2012). 
 
1.3.1 T cell epitope predictions 
Identification of the precise tumor-derived T cell epitopes is crucial for development of a short peptide 
vaccine to evoke efficient T cell immune responses. Since the experimental testing of binding affinity 
of peptides to MHC molecules in general is not economical in terms of time and cost, various 
computational approaches have been developed. These computational predictions of MHC I binding 
capacities have been used for many years now and are permanently updated (De Groot et al., 2001; 
Sylvester-Hvid et al., 2004; Sette and Rappuoli, 2010; Lund et al., 2011). For this study, different 
prediction servers were chosen to exploit the individual strengths of each server since they are based 
on different algorithms and training data sets.  
In 1994, Parker and his group developed the first HLA peptide prediction server Bioinformatics and 
Molecular Analysis Section (BIMAS) (Parker et al., 1994), which is based on the predicted half-time 
of dissociation from HLA I molecules and some mouse MHC I. A few years later, Rammensee and 
colleagues developed a prediction server called SYFPEITHI (Rammensee et al., 1999), which is based 
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on allele-specific amino acid motifs and includes peptide predictions for MHC I as well as MHC II. 
The name SYFPEITHI is taken from the first MHC-eluted peptide that was directly sequenced (Falk et 
al., 1991).  
A more recent group of servers, the NetMHC servers are hosted by the Center for Biological Sequence 
Analysis by the Technical University of Denmark and were developed by groups around Lund and 
Nielsen. These servers are based on different methods, such as artificial neural networks (ann) 
(NetMHC, (Nielsen et al., 2003)) that can be pan-specific (NetMHCpan, (Lundegaard et al., 2008a; 
Lundegaard et al., 2008b; Stranzl et al., 2010)) or matrix-based relying on receptor-pocket similarities 
between MHC molecules (PickPocket). They were also combined in one single server, NetMHCcons 
(Karosiene et al., 2012). Moreover, they developed a specific CTL prediction server, NetCTL, which 
integrates prediction of peptide MHC class I binding, proteasomal C-terminal cleavage and TAP 
transport efficiency (Larsen et al., 2005; Larsen et al., 2007). The MHC peptide binding is predicted 
using neural networks trained as described for the NetMHC server (Nielsen et al., 2003), TAP 
transport efficiency prediction uses a weight matrix based method (Peters et al., 2003) and proteasome 
cleavage events are predicted by NetChop neural networks trained on C-terminals of known CTL 
epitopes (Nielsen et al., 2005). 
The Immune Epitope Database Analysis Resource (IEDB) website provides a collection of 
computational tools for the prediction and analysis of immune epitopes. Here, the tool for peptide 
binding to MHC class I molecules offers various prediction methods to the user, including some of the 
already described NetMHC methods, NetMHCpan, NetMHCcons and PickPocket. Besides, an 
artificial neural network-based algorithm (IEDBann) (Nielsen et al., 2003) and three matrix-based 
algorithms, average relative binding (IEDBarb) (Bui et al., 2005), the stabilized matrix method 
(IEDBsmm) (Peters and Sette, 2005) and SMM with a Peptide:MHC Binding Energy Covariance 
matrix (IEDBsmmpmbec) (Sidney et al., 2008) are available. CombLib, another method, stands for 
Scoring Matrices derived from Combinatorial Peptide Libraries (Sidney et al., 2008). 
IEDBrecommended combines the results of the Consensus method consisting of ANN, SMM, and 
CombLib if any corresponding predictor is available for the MHC molecule. Otherwise, NetMHCpan 
is used. Some of these mentioned algorithms, however, are only included in older versions of available 
tools. 
Most prediction servers offer predictions for various MHC alleles, sometimes also including other 
species than human and mouse, and often allow for predictions for HLA supertypes. HLA supertypes 
consist of different HLA class I molecule types which share high similarities in binding peptides and 
were thus grouped into nine HLA supertype families (Sette and Sidney, 1999). Each supertype can be 
described by a supermotif reflecting the general main anchor motif recognized by molecules within the 
corresponding supertype. For instance, alleles of the HLA-A2 supertype share specificity for peptides 
with aliphatic hydrophobic residues at the C-terminus and at position 2 of the peptide. HLA-A3 
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supertype molecules, on the other hand, bind peptides with small or aliphatic residues in position 2 and 
basic residues at the C-terminus. Later on, the supertype concept was adapted and three more family 
clusters were added, resulting in twelve HLA supertypes (Lund et al., 2004). Moreover, HLA 
supertypes each have representative HLA alleles, presenting the most common ones of the respective 
supertype. The three HLA supertypes, which are investigated in this study, are HLA-A3 with the 
major allele HLA-A*03:01, HLA-A11 with the major allele HLA-A*11:01 and HLA-A24 with HLA-
A*24:02 as the representative allele. While HLA-A24 is widely spread amongst Asian populations, 
reaching 58.6% in the Japanese population, up to 37.5% in Caucasians harbor HLA-A3 and HLA-A11 
alleles (Sette and Sidney, 1999). In Germany, 28.6% carry the HLA-A*03:01 allele, while 10% are 
positive for HLA-A*11:01 and 18.1% for HLA-A*24:02. All three together thus cover a high 
percentage of the world’s population (Gonzalez-Galarza et al., 2015). 
1.3.2 HPV vaccines 
In spite of relatively low serum antibody titers, it has been reported that HPV-seropositive animals are 
protected against further viral challenge (Kreider and Bartlett, 1981). A few years later, it was shown 
that passively transferred serum immunoglobulins from immunized to naïve animals conferred 
protection from infection (Suzich et al., 1995). HPV L1 virus-like particle (VLP) vaccines are subunit 
vaccines consisting only of the major viral capsid protein L1, which self-assemble into VLPs, which 
have been shown to be highly immunogenic. They induce circulating, neutralizing antibodies that 
offer protection against infection with HPV and were reported to have a good safety profile (Stanley, 
2006b). These studies were the basis to develop prophylactic vaccines against several human high-risk 
HPV types based on L1 VLPs, of which the first two were approved in 2006.  
Various vaccination strategies, including prophylactic and therapeutic approaches, are utilized to 
combat HPV-mediated malignancies. Currently used prophylactic HPV vaccines are administered to 
prevent uninfected individuals from acquiring a HPV infection. Therapeutic vaccination, in contrast, 
aims to support the patient’s immune system to clear persistent HPV infection. Various stages of 
disease progression need to be taken into consideration, starting with low-grade lesions via high-grade 
lesions up to invasive cancer (Kanodia et al., 2008). 
1.3.2.1 Prophylactic vaccines 
To date, three prophylactic HPV vaccines have been licensed in the US by the FDA and two in Europe 
by the European Medicines Agency (EMA). All three vaccines are based on recombinant L1 proteins 
that spontaneously self-assemble into pentameric capsomeres congregating to form non-infectious 
VLPs. One single VLP consists of the repeated structure of 72 capsomers (360xL1) making it highly 
immunogenic and resembling native viruses (Frazer et al., 2011). Strong humoral and cell-mediated 
responses are induced by VLPs. Intramuscular injection ensures that VLPs quickly reach the lymph 
nodes. Here, they are recognized by the immune system by binding to the cell surface of monocytes, 
macrophages and DCs, which results in their acute activation and production of inflammatory 
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cytokines (Lenz et al., 2003). Those DCs initiate an immune cascade that results in T cell dependent B 
cell responses. These events are followed by generation of high levels of L1-specific neutralizing 
antibodies and immune memory (Stanley, 2008). Systemic vaccination was shown to induce markedly 
higher antibody titers against L1 of the respective HPV type than a natural local infection (Stanley et 
al., 2012). 
The vaccines are HPV type-specific, since the genotypic variances between HPV types originate from 
the surface-exposed parts of the L1 capsid protein. The neutralizing antibodies generated by HPV L1 
VLP vaccines thus only mediate protection against the corresponding virus type. Hence, to confer 
protection against multiple HPV types, respective type-specific L1 VLPs need to be included into the 
vaccine. Nonetheless, some evidence for cross-protection against HPV types other than those 
incorporated in the vaccines was reported (Frazer, 2010). However, it is not completely clear how and 
to what extent cross-protection against other types exist. In some immunized individuals, cross-
protection against HPV31, 33, 45, 51 and 58 was reported (Malagon et al., 2012; Szarewski, 2012). 
The bivalent vaccine Cervarix™ is produced by GlaxoSmithKline and combines VLPs of HPV16 and 
HPV18. VLPs are produced in a recombinant baculovirus expression vector system, that uses 
Trichoplusia ni Hi-5 insect cells. The formulation of the vaccine includes the AS04 adjuvant, 
consisting of 500μg aluminium hydroxide and 50μg 3-desacylatedmonophosphoryl lipid A (MPLA) 
(Harper et al., 2004). 
The quadrivalent vaccine Gardasil™ was developed by Merck and includes HPV16 and 18 VLPs, but 
also additional VLPs from the low-risk HPV types 6 and 11, protecting against genital warts. It is 
produced in Saccharomyces cerevisiae by using recombinant DNA techniques. Aluminium 
hydroxyphosphate sulphate is used as an adjuvant here (Villa et al., 2005). 
Both vaccines were found to be safe, immunogenic and efficient in various randomized controlled 
trials and confer protection against CIN induced by the respective HPV types (Stanley, 2006a). 
Various studies have been conducted to follow up Cervarix™ vaccination. High and sustained 
immune responses were detected in women aged 15-55 years. Antibody levels were several-fold 
higher than following natural infection, for at least 4 years after the first vaccine dose (Schwarz et al., 
2011). In young girls and boys aged 10-14 or 12-15 years, the antibody levels were reported to be even 
higher for HPV16 and HPV18 antibodies (Medina et al., 2010). In the age group of 15-25 year old 
women, antibody levels remain high up to 8.4 years. Efficacy against incident infections was also 
sustained (95-97%), as well as against infections persisting for 12 months (100%), cytological 
abnormalities and histopathological lesions (CIN2+ 100%) that are caused by HPV 16 and/or 18 
(GlaxoSmithKline Vaccine HPV Study Group et al., 2009). In a final report of the large PATRICIA 
(PApilloma TRIal against Cancer In young Adults) trial, immunogenicity and high efficacy against 
persistent infection and high-grade CIN were confirmed (Apter et al., 2015).  
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Gardasil™ was demonstrated to be highly immunogenic by inducing antibody levels that are 27-145-
fold higher than HPV antibody levels detected in naturally HPV infected women. All vaccinated 
individuals seroconverted after the third dose (Villa et al., 2005). Combined final data from the 
FUTURE (Females United to Unilaterally Reduce Endo/Ectocervical Disease) I and FUTURE II 
studies included 17,622 women in the age group of 15-26 years. The vaccine efficacy against lesions 
related to HPV6, 11, 16 and 18 was 96% for CIN1, 100% for both VIN1 and VAIN1, and 99% for 
condylomata acuminata (Future I/II Study Group et al., 2010). 
Recently, in December 2014, a new nonavalent prophylactic HPV vaccine from Merck was approved 
by the FDA. Gardasil™9 is an enhancement of the quadrivalent Gardasil and includes VLPs of nine 
HPV types, HPV6, 11, 16, 18, 31, 33, 45, 52 and 58. Thus it covers a broader range of high-risk HPV 
types than the original Gardasil. The new vaccine has been evaluated in five clinical studies including 
14,204 16-26 year old females and was shown to be safe and add additional value regarding efficacy 
against HPV types 31, 33, 45, 52, and 58 in comparison to the first-generation vaccine (Joura et al., 
2015). The EMA is currently assessing Gardasil™ 9 for European approval and Merck confirmed 
applications in other jurisdictions such as Australia.  
The full impact of all prophylactic HPV vaccinations on cervical cancer prevention is not assessable 
yet, because routine vaccination is conducted for less than nine years and the development of cervical 
cancer can take much longer.  
Vaccination programs are not completely successful everywhere, since not all people receive the 
recommended booster doses and vaccination coverage in populations in the US and Europe are lower 
than for other vaccinations (Bonanni et al., 2015). In Australia however, the national HPV 
immunization program started in 2007 and has resulted in high coverage with more than 70% for three 
doses (Garland, 2014). In contrast to developed countries, in developing countries, vaccination is often 
not accessible due to high cost and other social factors, which leads to a low percentage of vaccination 
in the population (van Bogaert, 2013). 
The available described HPV vaccines, Cervarix™ and both Gardasil™ types, are strictly prophylactic 
und thus do not treat pre-existing infections or prevent progression of existing HPV-induced lesions 
(Kanodia et al., 2008). Hence, novel therapeutic strategies to control and treat existing HPV infections 
and associated malignancies are still needed. 
1.3.2.2 Therapeutic Vaccines  
A therapeutic vaccine against HPV that can support the immune system to clear a persistent HPV-
infection would be an attractive option. Additionally it would need to overcome the viral evasion 
mechanisms and immunosuppressed situation at the site of infection (Frazer et al., 2011). Thus, HPV 
therapeutic vaccines should aim to evoke strong cellular immune responses, especially T cell-mediated 
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immune responses, against naturally processed and presented HPV antigens in HPV-infected cells 
(Kanodia et al., 2008).  
HPV-associated tumors represent an ideal scenario for cancer vaccine development. In contrast to 
most other tumor entities, one can target immunologically foreign viral antigens and thus does not 
need to worry about breaking tolerance and potential subsequent autoimmunity. Furthermore, 
approximately 95% of HPV-infected people clear the infection (Crosbie et al., 2013), proving that 
elimination of HPV by the immune system is possible. Moreover a sufficient time window is given as 
it takes approximately 7 to 15 years from initial HPV infection to development of invasive cancer 
(Bosch and de Sanjose, 2003). Despite the availability of the prophylactic vaccines, development of a 
therapeutic vaccine is still desirable as a large proportion of the worldwide population is already 
infected and cannot be protected with prophylactic vaccination anymore (Frazer et al., 2011). 
Especially in developing countries, there is insufficient vaccine coverage due to economical and socio-
cultural factors. The situation is worsend by the fact that in these countries screening and detection of 
pre-cancerous lesions is also limited. If detected in time, HPV-induced premalignant lesions are 
commonly removed surgically, which can lead to impaired function of the affected tissue, possibly 
resulting in premature births in case of the cervix. In conclusion, therapeutic HPV vaccination as a 
non-invasive treatment strategy is a goal worth pursuing.  
The aim of therapeutic tumor vaccination is to stimulate the patient’s own immune response to be able 
to recognize and eliminate cancer cells that express the targeted tumor antigens (Kanodia et al., 2008). 
All cells of HPV-induced lesions and tumors constantly express the two oncoproteins E6 and E7, as 
they are crucial for induction and maintenance of the malignant phenotype. Besides, E6 and E7 are 
viral proteins and therefore result in presentation of foreign viral epitopes on infected cells. Moreover, 
as HPV is replicating using the host’s cellular replication machinery, mutation rates are extremely low 
in HPV proteins. This renders it unlikely that HPV16 escapes an immune response by mutating 
(Frazer et al., 2011). As T cell-mediated immunity is one of the most important factors to clear HPV 
infections and HPV-associated lesions, effective therapeutic vaccines should generate strong E6/E7-
specific T cell-mediated immune responses to the early proteins E6 and E7 (zur Hausen, 2002; Tan et 
al., 2012). To reduce potential oncogenicity, the E6 and E7 oncogenes have been mutated in many 
studies to abrogate p53 and pRb binding. Next to E6 and E7, some attempts have also been made in 
targeting E2 and E5, as those two proteins are essential for immune escape and carcinogenic 
progression (Ganguly, 2012; Xue et al., 2012). Most HPV therapeutic vaccine studies have been 
designed with antigens from the most abundant HPV type, HPV16. 
In the past two decades, major efforts have been made in terms of development of therapeutic HPV 
vaccines. A multitude of approaches was tested, including DNA-based, live vector-based, cell-based 
and protein- and peptide-based vaccines (Stern et al., 2012; Khallouf et al., 2014).  
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DNA-based vaccines are considered to be an attractive therapeutic approach, because they are safe, 
easily produced, show stable expression of the encoded antigen and can include adjuvant functions 
(Hemmi et al., 2000; Shirota and Klinman, 2014). A DNA vaccine based on the HLA-A2-restricted 
HPV16 E7/83-95 peptide called ZYC101 (Klencke et al., 2002) was tested in phase I and II trials with 
15 patient with CIN2 and CIN3 lesions, and induced HPV-specific T cell responses in eleven and 
complete histological regression in five patients (Sheets et al., 2003). This DNA plasmid was 
formulated within biodegradable polymer microparticles. The next generation of this vaccine, 
including HPV16 and HPV18 E6 and E7-derived CTL epitopes, achieved regression of lesions in an 
even higher number of subjects, however the effect was not statistically significant (Garcia et al., 
2004). An DNA vaccine targeting the HPV16 E7 oncoprotein, pNGVL4a-Sig/E7(detox)-HSP70, 
encodes a mutated form of HPV16 E7 with an abolished pRb binding site, denoted E7 (detox) in 
combination with a viral vector and has shown immune responses as well as clinical regression in 
CIN2/3 patients (Maldonado et al., 2014). More clinical trials taking advantage of the very same 
plasmid accompanied with other factors are ongoing for CIN1/3 and HNSCC (Bagarazzi et al., 2012) 
(NIH, NCT01493154 and NCT00988559).  
Bacterial and viral vectors are also used as therapeutic strategies. A live-attenuated vaccine based on 
E7-secreting Listeria monocytogenes (Lovaxin-C, Lm-LLO-E7) was shown to reduce tumor load in 
some patients, however with severe adverse events in 40% of patients (Radulovic et al., 2009). Viral 
vectors show advantage as they can be attenuated easily and especially recombinant ones are fast to be 
developed and induce strong immune responses (Rollier et al., 2011). A disadvantage is, however, 
potential pre-existing immunity. This can be overcome by using viruses that infect other species. 
Preclinical studies have been conducted with recombinant adenoviral vectors, based on adenovirus 
type 5 and expressing HPV16 E6 and E7 (Lee et al., 2008). The first viral based HPV vaccine is called 
TA-HPV and based on recombinant vaccinia virus, encoding E6 and E7 fusion proteins of HPV16 and 
18, where E7 is mutated (Borysiewicz et al., 1996). It has been used in various studies (Borysiewicz et 
al., 1996; Kaufmann et al., 2002; Baldwin et al., 2003) and was reported to lead to HPV16-specific 
immune responses and partial regression in some high-grade VIN patients (Davidson et al., 2003). 
TA-HPV was also applied in DNA prime/viral vector boost regimes as described above (Maldonado et 
al., 2014) and protein prime/viral vector boost regimes (Davidson et al., 2004; Smyth et al., 2004; 
Fiander et al., 2006), where vaccination with TA-CIN, a fusion protein of HPV16 E6, E7 and L2, and 
the TLR-agonist imiquimod resulted in complete histological regression of VIN2/3 in 63% of patients 
(Frazer et al., 2004).  
Treatment with autologous DCs, was investigated with DCs being loaded with recombinant HPV16 
E7 protein, and partial CD4
+
 and CD8
+ 
T cell responses were seen in some patients with cervical 
cancer (Santin et al., 2006; Santin et al., 2008). 
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In comparison to whole protein formulations and other vaccination strategies, synthetic peptides show 
advantages concerning safety and production. The synthetic peptides can be subdivided into two 
categories, epitope-specific short peptides and synthetic long peptide (SLP) (Kanodia et al., 2008; Su 
et al., 2010). Short peptides only consist of a single CTL epitope, while SLPs combine CTL and CD4
+
 
TH epitopes. Taking specific T cell epitopes as targets for a HPV peptide vaccine has the potential to 
precisely trigger epitope-specific T cell-mediated immune responses. However, to this end, short 
synthetic peptide needs to be administered in combination with adjuvants, which are described below.  
Past preclinical studies have shown significant success for a peptide vaccination using 15-25aa long, 
overlapping E6/E7-derived peptides that cover the whole sequence of these two proteins(Melief and 
van der Burg, 2008). These peptides are processed by APCs for epitope presentation on HLA I and II 
molecules, and hence, prior HLA typing of patients is not required. Based on promising preclinical 
results, various clinical studies were initiated by Melief and colleagues which showed induction of 
HPV-specific CD4
+
 and CD8
+
 T cell responses (Bouvard et al., 2009). Moreover, complete regression 
was observed in 43% of VIN3 patients that received the HPV16 SLP vaccine (Kenter et al., 2009). A 
subsequent clinical trial with cervical cancer patients however did not succeed in tumor regression 
(van Poelgeest et al., 2013). In order to enhance the effect of the safe and highly immunogenic HPV16 
SLP vaccines, different strategies are pursued, including combination with for instance chemotherapy 
to overcome local immunosuppression and other regulatory mechanisms (Van de Wall et al., 2014; 
van der Sluis et al., 2015). 
In preclinical studies in mice, a mixture of HPV16 peptides E7/11-20, E7/82-90, E7/86-93 and E6/29-
38 and a new adjuvant system (VacciMax® liposomes) has been reported to induce robust CTL 
responses and eradication of TC-1 tumors, which are HPV16 E6 and E7 positive. An E7-derived 
peptide with Hsp110 was also shown to evoke broad anti-TC-1 responses (Steller et al., 1998; Ressing 
et al., 2000). Various epitope-specific peptides, including E7/11-20, E7/12-20 and E7/86-93, were also 
tested in clinical trials either alone or together with different adjuvants. These studies ultimately 
reported partial responses in 50% of high-grade CIN and VIN patients (Muderspach et al., 2000). 
Promising clinical responses in CIN2/3 patients were achieved by vaccination with the HPV16 E7/86-
93 peptide delivered by proteoliposomes (Solares et al., 2011). Ongoing phase I studies are combining 
HPV16 peptides with GM-CSF and Montanide ISA 51 (NIH, NCT00257738) or are taking advantage 
of novel  adjuvants like Candin® (NIH, NCT01653249). 
Linear short peptides representing precise epitopes with a length of 8-11aa have been shown to 
incduce strong cytotoxic responses, however, these peptides are HLA-restricted and necessitate HLA 
typing of patients. A therapeutic vaccine that is applicable to everyone without prior HLA typing 
needs to contain epitopes for all HLA-types. This issue is facilitated by the exploitation of HLA 
supertypes, that include groups of HLA molecules that share peptide-binding specificity (Sette and 
Sidney, 1999). Definition of epitopes for the five major HLA class I supertypes allows > 95% 
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population coverage (Sette and Sidney, 1999; Middleton et al., 2003; Lund et al., 2004). Nonetheless, 
slight variations even between closely related alleles might occur, leading to exclusion of some 
peptides or HLA types (Macdonald et al., 2003; Peters et al., 2006; Zhang et al., 2007).  
These matters are addressed in this study by determining T cell epitopes for specific HLA molecules 
and supertypes. To this end, HPV16 E6 and E7 epitopes were assessed by a broad bioinformatics 
approach, which included the application of various T cell epitope prediction servers and algorithms 
which are described in detail in section 1.3.1. Actual HLA-peptide binding was verified in vitro.  
In silico predictions and in vitro HLA-peptide binding assays can successfully narrow down the 
number of vaccine candidates but do not verify that those peptides are naturally processed and 
presented on infected kerationcytes of patients. Thus, direct identification of physically present 
epitopes needs to be conducted. Mass spectrometry (MS) techniques have been shown to be feasible to 
identify such epitopes on tumors (reviewed in Haen and Rammensee, 2013) and these techniques have 
been established and are refined in our laboratory. This approach was explored in studies by Riemer 
and colleagues (Riemer et al., 2010) for HLA-A*02:01-restricted peptides and led to the detection of 
HPV16 E7/11-19 as a naturally processed and presented peptide.  
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1.4 Objectives of this study  
As outlined above, despite the introduction of prophylactic vaccines, HPV-mediated malignancies are 
still a major global health problem. Existing treatment options rely mainly on early detection and can 
have serious sequelae, such as premature births. Thus, a non-invasive treatment, harnessing the 
patient’s own immune system, is an attractive option. 
Moreover, HPV-mediated cancers represent an ideal scenario to develop a therapeutic cancer vaccine. 
Most people infected with HPV clear the infection, or even intraepithelial precursor lesions of cancer, 
proving that immune-mediated elimination of the virus is possible. HPV-mediated tumors also pose 
the opportunity to target immunologically foreign tumor-specific antigens. The viral oncoproteins E6 
and E7 are expressed in all stages of HPV-mediated carcinogenesis and are essential for induction and 
maintenance of the malignant phenotype. Therefore, they are ideal targets for immunotherapeutic 
approaches.  
For development of therapeutic vaccines, but also for other immunotherapies such as adoptive transfer 
of T cells with transgenic T cell receptors or chimeric antigen receptors (CARs), the precise 
identification of the viral epitopes that are naturally processed and presented on the target cell surface 
is crucial. Validated epitopes can also facilitate immunomonitoring, as only immune responses 
targeted against these epitopes need to be analyzed. 
The aim of this study was, therefore, to identify and immunologically validate HPV16 E6 and E7-
derived T cell epitopes. To date, HPV T cell epitopes have mostly been determined for the most 
prevalent HLA-type HLA-A2. The objective of this thesis was to describe epitopes for the highly 
prevalent HLA supertypes HLA-A3, HLA-A11 and HLA-A24. 
To do so, the following experiments and analyses were performed: 
1) Prospective T cell epitopes from the HPV16 E6 and E7 proteins for the above mentioned HLA 
supertypes were predicted in silico. 
2) The actual peptide-HLA binding was tested in in vitro cellular binding assays.  
3) Immunogenicity of identified peptides was assessed by screening memory responses and 
establishing T cell lines from healthy donors. 
4) Functional assays, such as ELISpot and cytotoxicity assays, were conducted to determine the 
best vaccine candidates. 
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2. Material and Methods 
2.1 Materials 
2.1.1 Chemicals and biological reagents 
Product Company 
1-Step™ NBT/BCIP Thermo Scientific, Rockfort, 
IL, USA 
2-Mercaptoethanol Roth, Karlsruhe 
51-Chromium radionuclide (Na2
51
CrO4-solution (5 mCi, 185 MBq)) Perkin Elmer, Waltham, 
MA, USA 
6x Orange DNA Loading Dye  Thermo Fisher Scientific 
Ldt., Loughborogh, UK 
Acetic acid (100%) Merck Millipore, Billerica, 
MA, USA 
Agarose NEEO Ultra-Qualität Roti®garose Roth, Karlsruhe 
Albumin, from bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen 
Ammonium chloride (NH4Cl) Roth, Karlsruhe 
Avidin-Horseradish Peroxidase BioLegend, San Diego, CA, 
USA 
Beta2-(ß2) microglobulin MP Biomedicals, Illkirch, 
France 
BD Biosciences, Franklin 
Lakes, NJ, USA 
Brilliant Blue G Sigma-Aldrich, Taufkirchen 
Calcium chloride (CaCl2) Sigma-Aldrich, Taufkirchen 
CEF-Class I Peptide Pool “Classic” Cellular Technology 
Limited, Shaker Heights, 
OH, USA 
CHAPS AppliChem, Darmstadt 
Citric acid AppliChem, Darmstadt 
cOmplete Mini Protease Inhibitor Cocktail Roche, Basel, Switzerland 
Concanavalin A (ConA) from C.ensiformis Sigma-Aldrich, Steinheim 
Deoxynucleoside Triphosphate Roche, Mannheim 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen 
Deoxynucleoside Triphosphate Roche, Mannheim 
Distilled water DNase/RNase free Life Technologies, Brown 
Deer, WI, USA 
Ethanol (absolute) Sigma-Aldrich, Taufkirchen 
Ethidium bromide Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Taufkirchen 
Gelatine Roth, Karlsruhe 
Glycine Sigma-Aldrich, Taufkirchen 
Hydrogen chloride (HCl) VWR International, 
Fontenay-sous-Bois, France  
Isopropanol  Sigma-Aldrich, Taufkirchen 
Laemmli sample buffer (2x) Biorad, Hercules, CA, USA 
Magnesium chloride (MgCl2) Roche, Branchburg, NJ, 
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USA 
Methanol Sigma-Aldrich, Taufkirchen 
Milk powder Roth, Karlsruhe 
OneComp eBeads eBioscience, San Diego, CA, 
USA 
Oriole™ Fluorescent Gel Stain Biorad, Hercules, CA, USA 
Phenylmethanesulfonyl uoride (PMSF) Roth, Karlsruhe 
Phytohemagglutinin (PHA) from Ph. vulgaris Sigma-Aldrich, Steinheim 
Pierce ECL Western Blotting Substrate Thermo Fisher Scientific, 
Waltham, MA, USA 
Ponceau red solution Serva, Heidelberg 
Potassium bicarbonate (KHCO3) Roth, Karlsruhe 
Potassium chloride (KCl) Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) Roth, Karlsruhe 
Protease inhibitor cocktail, cOmplete mini Roche, Mannheim 
Recombinant human IL-2 standard BioLegend, San Diego, CA, 
USA 
Sodium acetate (C2H3NaO2) Roth, Karlsruhe 
Sodium azide (NaN3) AppliChem, Darmstadt 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, Taufkirchen  
Sodium chloride (NaCl) Sigma-Aldrich, Taufkirchen 
Sodium dihydrogen dibasic phosphate (NaH2PO4 2 H2O) Sigma-Aldrich, Taufkirchen 
Sodium dodecyl sulfate (SDS) ultrapure Roth, Karlsruhe 
Sodium hydroxide (NaOH) Sigma-Aldrich, Taufkirchen 
Streptavidin-Alkaline Phosphatase Mabtech, Nacka Strand, 
Sweden 
TMB Substrate Set BioLegend, San Diego, CA, 
USA 
TMB Stop Solution BioLegend, San Diego, CA, 
USA 
Trizmabase Sigma-Aldrich, Taufkirchen 
Triton-x100 AppliChem, Darmstadt 
Tween20 (=Polysorbat 20) MP Biomedicals, Illkirch, 
France 
 
2.1.2 Buffers and solutions 
Name Ingredients 
10x PBS  1.37M NaCl 
27mM KCl 
100mM Na2PO4
 
(anhydrous) 
20mM KH2PO4
 
pH 7.2 adjusted with NaOH or HCl 
10x SDS-PAGE running buffer 30.3g Tris  
144g Glycine 
10g SDS 
ad. 1L ddH2O 
2x CHAPS buffer 1.2% (w/v) CHAPS 
dissolved in 1xPBS 
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2x CHAPS lysis buffer 5.25mL 2xCHAPS buffer 
100mM PMSF 
1 cOmplete Mini PIC tablet 
50x TAE 484g Tris  
41g C2H3NaO2 
37g EDTA 
pH 7.8 adjusted with acetic acid 
ad. 2L ddH2O 
ACK lysis buffer 0.829g NH4Cl 
0.1g KHCO3 
0.38mg EDTA  
pH 7.2-7.4 adjusted with NaOH or HCl 
ad. 100mL ddH2O  
Blocking buffer (WB) 1x PBS 
5% (w/v)milk powder  
Blocking buffer (FACS) 1x PBS 
10% (v/v) FCS  
Carbonate Coating buffer (ELISA) 8.4g NaHCO3 
3.56g Na2CO3 
pH 9.5 adjusted with NaOH or HCl 
ad. 1L ddH2O 
Coomassie Briliant Blue 25mL CH3COOH 
125mL MeOH 
0.25g Brilliant blue G 
ad. 250ml ddH2O 
Coomassie destain CH3COOH:MeOH:ddH2O (1:2:8) 
dNTP mix 10mM each dATP, dCTP, dGTP, dTTP 
Elution buffer 50% 0.263M (v/v)citric acid  
50% 0.123M (v/v) Na2HPO4  
pH 2.9 or 2.1: adjusted with HCl 
FACS buffer 1x PBS 
2% FCS  
0.1% (v/v)NaN3
  
MACS buffer 1x PBS 
0.5% (v/v)FCS  
2mM EDTA  
PMSF stock 100mM PMSF 
dissolved in 100% ethanol 
Transfer buffer 9g Tris 
43.2g Glycine 
20% (v/v) Methanol 
ad. 3L ddH2O 
Tween PBS (TPBS) 1xPBS 
0.05% (v/v)Tween20 or 
0.1% (v/v)Tween20  
 
2.1.3 Consumables 
Product Company 
Aluminium foil CeDo GmbH, Mönchengladbach 
Any kD™ Precast Gel Biorad, Hercules, CA, USA 
Blood collection tubes (NH, 170 I.U.) BD, Plymouth, UK 
Material and Methods 
46 
 
Blood collection set (Safty-lok™) BD, Franklin Lakes, NJ, USA 
Cell culture dish (100mm x 20mm ) TPP, Trasadingen, Switzerland 
Cell culture flask (25cm
2
) TPP, Trasadingen, Switzerland 
Cell culture flask (75cm
2
) TPP, Trasadingen, Switzerland 
Cell culture plate “CytoOne” (6-well) Starlab, Hamburg 
Cell culture plate (12-well) Corning, Corning, NY, USA 
Cell culture plate (24-well) Corning, Corning, NY, USA 
Cell culture plate (96-well) 
- U bottom (Microtest) 
- V bottom 
- Flat bottom, black (OptiPlate™) 
 
BD, Franklin Lakes, NJ, USA 
Greiner Bio-One, Frieckenhausen 
Perkin Elmer, Maltham, MA, USA 
Cell scraper Sarstedt, Newton, NC, USA 
Cell strainer (40µM, 70µM) BD, Corning, NY, USA 
Cling film  CeDo GmbH, Mönchengladbach 
Costar™, high binding plates Thermo Fisher Scientific, 
Rochester, NY, USA 
Cryogenic vials (Nalgene) Thermo Fisher Scientific, 
Rochester, NY, USA 
FACS tubes (5mL Polystrene round-bottom tube) BD, Franklin Lakes, NJ, USA 
Falcon tube (15mL and 50mL) Nerbe Plus, Winsen 
Leucosep™ Greiner Bio-One, Frieckenhausen 
Filter (Millex®-GS, pore size 0.22µm) Merck Milipore, Cork, Ireland 
GammaBind™ Plus Sepharose™ beads GE Healthcare, München 
Gloves  Microflex, Reno, NV, USA 
Kimwipes lite 200 Kimberly-Clark, Irving, TX, USA 
Luma plate ™-96 Perkin Elmer, Waltham, MA, USA 
MACS Seperation Column LS Miltenyi Biotec, Bergisch Gladbach 
MultiScreen®-HA, 96-well filtration plate Merck Milipore, Cork, Ireland 
Mini-PROTEAN®TGX™ gels, Any kD™, various combs Biorad, Hercules, CA, USA 
Parafilm Bemis, Neeah, WI, USA 
PVDF Transfer Membrane Thermo Scientific, Rockford, IL, 
USA 
Pipette tips, with and without filter Starlab, Hamburg 
Reaction tubes (0.2mL, 0.5mL, 1.5mL and 2mL)  Starlab, Hamburg 
Scalpel  Feather, Osaka, Japan 
Serological pipette (2mL) BD, Franklin Lakes, NJ, USA 
Syringe (20mL BD Plastipak Luer-Lok™) BD, Drogheda, Ireland 
Syringe (2mL Injekt®)  Braun, Melsungen  
Vacuum filter (bottle top, pore size 0.22µM) Corning, Corning, NY, USA 
Western Blotting Filter Paper Thermo Scientific, Rockford, IL, 
USA 
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2.1.4 Kits 
Name Company 
CD8
+
 T Cell Isolation Kit, human Miltenyi Biotec, Bergisch Gladbach 
CD14
+
mircobeads, human Miltenyi Biotec, Bergisch Gladbach 
QIAamp DNA Mini Kit Qiagen, Hilden 
 
2.1.5 Markers and ladders 
Name Company 
GeneRuler™ Ladder Mix, 100 bp -10000 bp Thermo Fisher Scientific Ldt., 
Loughborogh, UK  
Precision Plus Protein™ Standards Kaleidoscope ™, 10-
250kDa 
Biorad, Hercules, CA, USA 
Precision Plus Protein™ Unstained Standards, 10-250kDa Biorad, Hercules, CA, USA 
 
2.1.6 Enzymes 
Enzyme Company 
AmpliTaq Gold®DNA Polymerase Roche, Branchburg, NJ, USA  
REDTaq® ReadyMix™ PCR Reaction Mix Sigma-Aldrich, Steinheim  
 
2.1.7 Equipment 
Equipment Name Company 
Analytical balance  Ohaus, Nänikon, 
Switzerland 
Cell counter Countess® Automated Cell 
Counter 
Invitrogen, Carlsbad, CA, 
USA 
Cell freezing device Mr. Frosty Bel-Art Products, Wayne, 
NJ, USA 
Centrifuge Biofuge Pico, Fresco 
Centrifuge 5417R, 5418 
Multifuge
®
 16R 
Heraeus, Hanau 
Eppendorf, Hamburg 
Heraeus, Hanau 
Centrifuge rotor TX-400 
M-20 
Heraeus, Hanau 
Heraeus, Hanau 
Chemiluminescence camera Fusion-SL chemiluminescence-
camera  
Vilber Lourmat, 
Eberhardzell 
Documentation agarose gels Gel Jet Imager 2006 
Printer P39D 
Intas, Göttingen 
Mitsubishi, Electric, Tokio 
Documentation gels Gel Doc ™ EZ Imager Biorad, Hercules, CA, USA 
Electrophoresis chamber for 
agarose gels 
Owl Easycast B2 Owl Seperation Systems, 
Portsmouth, NH, USA 
Electrophoresis chamber for 
SDS-PAGE  
Mini-PROTEAN® Tetra Cell Biorad, Hercules, CA, USA 
ELISpot plate reader AID ELISpot reader Autoimmun Diagnostika, 
Strassberg 
Flow cytometer FACS Canto II™ BD Biosciences, Franklin 
Lakes, NJ, USA 
Freezer (-20° C) Medline  
 
Liebherr, Biberach an der 
Riss 
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 Bosch, Stuttgart 
Freezer (-80° C) U725 Innova New Brunswick, Nürtingen 
Glasware Duran 
Fisherbrand 
Schott, Mainz 
Thermo Fisher Scientific, 
Waltham, MA, USA  
Ice machine Hoshizaki Cube Star Hoshizaki, Tokio, Japan 
Incubator Heracell 150i 
 
C200 
Thermo Fisher Scientific, 
Waltham, MA, USA 
Labotec Göttingen,  
Irradiator Gammacell 1000 Atomic Energy of Canada 
Limited, Ottawa, Canada 
Laminar flow hood SterilGard® Class II laminar 
flow hood  
The Baker Company, 
Sanford, USA 
Light microscope Wilovert Standard 30 
microscope 
Hund Wetzlar, Wetzlar 
Liquid nitrogen tank Locator 8 plus Barnstead/Thermolyne, 
Dubuque, IA, USA 
Luma plate reader TopCount NXT™ Perkin Elmer, Waltham, 
MA, USA 
Magnet for MACS Quadro MACS Miltenyi Biotec, Bergisch 
Gladbach 
Magnetic stirrer Combimag RCO  
MR-Hei-Standard 
IKA-Werke GmbH, Staufen 
Heidolph Instruments, 
Schwabach 
Microwave  Sharp, Osaka, Japan 
Multilable plate reader Victor
3
 Perkin Elmer, Waltham, 
MA, USA 
Nano Drop ND-1000 peqLab Biotechnologies, 
Erlangen 
Neubauer cell counting chamber Profondeur Brand, Wertheim  
PCR cycler C1000 Touch™ Thermal Cycler  Biorad, Hercules, CA, USA 
pH Meter 766 Knick, Berlin 
Pipette-Boy pipetus
®
-akku 
 
Hirschmann Labortechnik, 
Eberstadt 
Pipettes Pipetman
®
 Gilson P2, P20, 
P200, P1000 
FinnPipette F2 
Gilson, Bad Camberg 
 
Thermo Scientific, 
Rockford, IL, USA 
Pipettes glass  Hirschmann Labortechnik, 
Eberstadt 
Power supply EPS500-400, EPS3500 
MP 250V 
Pharmacia, Uppsala, Sweden 
MS Major Science, Saratoga, 
CA, USA 
Pump N86KT.18 KNF Neuberger, Freiburg 
Refrigerator (4°C) Medline  
 
 
Liebherr, Biberach an der 
Riss 
Bosch, Stuttgart 
Rolling shaker CATMR5 Zipperer, Staufen 
Rotator  NeoLab, Heidelberg 
Scale Kern EG 4200-2NM Kern & Sohn, Balingen 
Surgical tweezer and scissors  Dimeda, Tuttlingen 
Thermomixer Thermomixer compact Eppendorf, Hamburg 
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Vortexer Vortex-Genie 2 Scientific Industries, 
Bohemia, NY, USA 
Water bath  GFL, Burgwedel 
WB transfer chamber Mini Trans-Blot® Cell Biorad, Hercules, CA, USA 
 
2.1.8 Eukaryotic cell lines 
Name Description HPV-status Source Culture 
medium 
Reference 
866 human, cervical, 
adherent  
HPV16 positive Kindly provided 
by Peter L Stern, 
University of 
Manchester, 
Manchester, UK 
F-medium (Brady et al., 
2000) 
879 human, cervical, 
adherent 
HPV16 positive Kindly provided 
by Peter L Stern, 
University of 
Manchester, 
Manchester, UK 
F-medium (Brady et al., 
2000) 
915 human, cervical, 
adherent 
HPV16 positive Kindly provided 
by Peter L Stern, 
University of 
Manchester, 
Manchester, UK 
F-medium (Brady et al., 
2000) 
93VU147T human, HNSCC, 
adherent 
HPV16 positive Kindly provided 
by Renske 
Steenbergen, 
University 
Medical Center 
Amsterdam, 
Netherlands 
complete 
DMEM 
(Steenbergen 
et al., 1995) 
C66#3 human, cervical, 
HPV-transfected,  
adherent 
HPV16 positive Kindly provided 
by John H Lee, 
Sanford Health 
Center, Sioux 
Falls, SD, USA 
E-medium (Lee et al., 
2004) 
C66#7 human, cervical, 
HPV-transfected,  
adherent 
HPV16 positive Kindly provided 
by John H Lee, 
Sanford Health 
Center, Sioux 
Falls, SD, USA 
E-medium (Lee et al., 
2004) 
CaSki human, cervical,  
adherent 
HPV16 positive Kindly provided 
by Felix Hoppe-
Seyler, F065, 
DKFZ 
complete 
DMEM 
(Pattillo et 
al., 1977) 
FK16A human, foreskin 
keratinocytes,  
adherent 
HPV16 positive Kindly provided 
by Renske 
Steenbergen, 
University 
Medical Center 
Amsterdam, 
Netherlands 
complete K-
SFM 
(de Wilde et 
al., 2008) 
Goercke human, cervical,  
adherent 
HPV16 positive Kindly provided 
by Andreas 
Kaufmann, 
M10 
medium 
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Charité, Berlin 
HPK 1A human, foreskin 
keratinocytes,  
adherent 
HPV16 positive Kindly provided 
by Elisabeth 
Schwarz, F030, 
DKFZ 
complete 
DMEM 
(Henderson 
et al., 1991) 
Marqu  human, cervical,  
adherent 
HPV16 positive Kindly provided 
by Andreas 
Kaufmann, 
Charité, Berlin 
DMEM +  
15% (v/v) 
FCS + 1% 
(v/v) HEPES  
 
MRI-H-
196 
human, cervical,  
adherent 
HPV16 positive Kindly provided 
by Elisabeth 
Schwarz, F030, 
DKFZ 
complete 
DMEM 
(Schmitt and 
Pawlita, 
2011) 
SCC090 human, HNSCC, 
adherent 
HPV16 positive Kindly provided 
by Susanne 
Gollins, 
University of 
Pittsburgh, 
Pittsburgh, PA, 
USA  
M10 
medium 
(Ragin et al., 
2004) 
SCC152 human, HNSCC, 
metastasis of 
SCC90, adherent 
HPV16 positive Kindly provided 
by Susanne 
Gollins, 
University of 
Pittsburgh, 
Pittsburgh, PA, 
USA 
M10 
medium 
(Ragin et al., 
2004) 
SCC154 human, HNSCC,  HPV16 positive Kindly provided 
by Susanne 
Gollins, 
University of 
Pittsburgh, 
Pittsburgh , PA, 
USA 
M10 
medium 
(White et al., 
2007) 
SiHa human, cervical,  
adherent 
HPV16 positive Kindly provided 
by Felix Hoppe-
Seyler, F065, 
DKFZ 
complete 
DMEM 
(Friedl et al., 
1970) 
SNU 1000 human, cervical,  
adherent 
HPV16 positive Korean Cell 
Line Bank, 
Seoul, South 
Korea 
complete 
RPMI-H 
(Ku et al., 
1997) 
SNU 1005 human, cervical,  
adherent 
HPV16 positive Korean Cell 
Line Bank, 
Seoul, South 
Korea 
complete 
RPMI-H 
(Ku et al., 
1997) 
SNU 1299 human, cervical,  
adherent 
HPV16 positive Korean Cell 
Line Bank, 
Seoul, South 
Korea 
complete 
RPMI-H 
(Ku et al., 
1997) 
SNU 17 human, cervical,  
adherent 
HPV16 positive Korean Cell 
Line Bank, 
Seoul, South 
Korea 
complete 
RPMI-H 
(Ku et al., 
1997) 
SNU 703 human, cervical,  
adherent 
HPV16 positive Korean Cell 
Line Bank, 
complete 
RPMI-H 
(Ku et al., 
1997) 
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Seoul, South 
Korea 
UD-SCC2 human, HNSCC, 
adherent 
HPV16 positive Kindly provided 
by Thomas 
Hoffmann, 
Uniklinikum 
Essen, Essen 
complete 
RPMI-P + 
1% (v/v) P/S 
(Hoffmann et 
al., 2008) 
UM-SCC-
47 
human, HNSCC, 
adherent 
HPV16 positive Kindly provided 
by Tom Carey, 
University of 
Michigan, Ann 
Arbor, MI, USA 
complete 
DMEM 
(Virolainen 
et al., 1984) 
W12 
20861 
human, cervical,  
adherent 
HPV16 positive Kindly provided 
by Paul 
Lambert, 
University of 
Wisconsin, 
Madison, WI, 
USA 
F-medium (Jeon et al., 
1995) 
W12 
20863 
human, cervical,  
adherent 
HPV16 positive Kindly provided 
by Paul 
Lambert, 
University of 
Wisconsin, 
Madison, WI, 
USA 
F-medium (Jeon et al., 
1995) 
BSM human, B-LCL, 
suspension 
negative IHWG Cell 
Bank, Seattle, 
WA, USA 
complete 
RPMI-P  
 
EA human, B-LCL, 
suspension 
negative IHWG Cell 
Bank, Seattle, 
WA, USA 
complete 
RPMI-P  
 
FH8 human, B-LCL, 
suspension 
negative IHWG Cell 
Bank, Seattle, 
WA, USA 
complete 
RPMI-P  
 
LKT3 human, B-LCL, 
suspension 
negative IHWG Cell 
Bank, Seattle, 
WA, USA 
complete 
RPMI-P  
 
RiSH human, B-LCL, 
EBV-
immortalized, 
suspension 
negative generated in this 
studyfrom a 
healthy blood 
donor 
RPMI + 10-
20% (v/v) 
FCS 
 
WT100BIS human, B-LCL, 
suspension 
negative IHWG Cell 
Bank, Seattle, 
WA, USA 
complete 
RPMI-P  
 
3T3  mouse, fibroblasts, 
adherent  
negative Kindly provided 
by Paul 
Lambert, 
University of 
Wisconsin, 
Madison, WI, 
USA 
complete 
DMEM 
(Jainchill et 
al., 1969) 
tCD40L 
NIH3T3 
mouse, fibroblasts, 
transduced with 
human tCD40L 
negative Kindly provided 
by Derin 
Keskin, Harvard 
tCD40L NIH 
3T3 
tCD40L WT 
(Schultze et 
al., 1995) 
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Medical School, 
Boston, MA, 
USA 
 
2.1.9 Cell culture basal media and supplements 
Product Company 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Sigma-Aldrich, Taufkirchen 
Eagle’s minimum essential medium 
(EMEM) 
Sigma-Aldrich, Taufkirchen 
Iscove's Modified Dulbecco's Medium 
(IMDM) 
Life Technologies, Brown Deer, WI, USA 
Ham’s F12 Nutrient Mix Invitrogen, Carlsbad, CA, USA 
Keratinocyte serum-free medium (KSFM) Invitrogen, Carlsbad, CA, USA 
Minimum Essential Medium (MEM) SAFC Biosciences, Nantes, France 
RPMI 1640 (1x) with L-Glutamine  Sigma-Aldrich, Taufkirchen 
2-mercaptoethanol Life Technologies, Grand Island, NY, USA 
Adenine PAA Laboratories, Cölbe 
Bovine pituitary extract (BPE) Invitrogen, Carlsbad, CA, USA 
Calcium chloride (CaCl2) Sigma-Aldrich, Steinheim 
Cholera toxin Sigma-Aldrich, Taufkirchen 
Cyclosporin A Sigma, St. Louis, MO, USA 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Steinheim 
Epidermal growth factor (EGF)  Invitrogen, Carlsbad, CA, USA 
Fetal Calf Serum (FCS) Biowest, Nuaillé, France 
Sigma-Aldrich, Taufkirchen 
Ficoll-Paque™ PLUS GE Healthcare Bio-Sciences, Uppsala, Sweden  
G-418 Sulfate  Cayman Chemical, Ann Arbor, MI, USA 
Gentamycin BioConcept, Allschwil, Switzerland 
GM-CSF, recombinant human R & D Systems, Minneapolis, MN,  USA 
Human serum, type AB Life Technologies, Brown Deer, WI, USA 
HEPES Life Technologies, Grand Island, NY, USA 
Hydrocortizone Sigma-Aldrich, Taufkirchen 
IL-1β, recombinant human R & D Systems, Minneapolis, MN,  USA 
IL-2, recombinant human PeproTech, Rocky Hill, NJ, USA 
IL-4, recombinant human R & D Systems, Minneapolis, MN,  USA 
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IL-6, recombinant human R & D Systems, Minneapolis, MN,  USA 
IL-7, recombinant human R & D Systems, Minneapolis, MN,  USA 
Insulin, recombinant human Sigma-Aldrich, Taufkirchen 
Ionomycin Sigma-Aldrich, Taufkirchen 
L-Glutamine Sigma-Aldrich, Taufkirchen 
Lipopolysaccharide (LPS) Invivogen, Toulouse, France 
MEM Non-essential amino acid solution 
(MEM NEAA) 
Invitrogen, Carlsbad, CA, USA 
Paraformaldehyde (PFA) Sigma-Aldrich, Taufkirchen 
Penicillin/Streptomycin-Solution (P/S) Sigma-Aldrich, Taufkirchen 
Prostaglandin E2 (PGE2) Cayman Chemical, Ann Arbor, MI, USA 
Phorbol 12-myristate 13-acetate (PMA)  Sigma-Aldrich, Taufkirchen 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, Taufkirchen 
Sodium pyruvate (C3H3NaO3) PAA Laboratories, Cölbe 
TNFα, recombinant human R & D Systems, Minneapolis, MN, USA 
Transferrin, recombinant human Sigma-Aldrich, Taufkirchen 
Tri-iodo-thyronine Sigma-Aldrich, Taufkirchen 
Trypsin-EDTA Solution Sigma-Aldrich, Taufkirchen 
Trypan Blue  Sigma-Aldrich, Taufkirchen 
 
2.1.10 Cell culture media 
All media were sterile filtered and stored at 4°C. 
Name Ingredients 
B cell medium  IMDM 
10% (v/v) human serum, AB,  2mM L-Glutamine,  
50µg/mL human transferrin, 5µg/ mL human insulin, 
15µg/mL Gentamycin 
B-LCL medium RPMI-1640 
10%-20% (v/v) FCS 
complete DMEM DMEM 
1% (v/v) P/S, 10% (v/v) FCS, 2mM L-Glutamine 
complete K-SFM K-SFM 
1% (v/v) P/S, 10% (v/v) FCS, 5ng/mL EGF, 50µg/mL 
BPE 
complete RPMI-P RPMI-1640 
15% (v/v) FCS, 1% 100mM sodium pyruvate 
complete RPMI-H RPMI-1640 
1% (v/v) P/S, 10% (v/v) FCS, 25mM HEPES, 25mM 
NaHCO3 
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DC medium DMEM 
1% (v/v) P/S, 10% (v/v) human serum, AB,  2mM L-
Glutamine,  10mM HEPES 
E-medium DMEM 
22.5% (v/v) Ham's F12. 10% (v/v) FCS. 1% (v/v) P/S, 
0.5µg/mL hydrocortisone, 8.4ng/mL cholera toxin, 
5µg/mL transferrin, 5µg/µL insulin, 1.36ng/mL tri-
iodo-L-thyronine, 5µg/mL EGF 
F-medium Ham's F12  
25% (v/v) DMEM, 5% (v/v) FCS, 1 % (v/v) P/S, 
0.4mg/mL hydrocortisone, 0.5µg/mL cholera toxin, 
5µg/mL insulin, 24.2µg/mL adenine, 0.1µg/mL EGF 
M10 medium EMEM 
10 % (v/v) FCS, 1% (v/v) P/S, 2mM L-Glutamine, 1% 
(v/v) MEM NEAA 
T cell medium  DMEM 
1% (v/v) P/S. 10% (v/v) human serum, AB, 2mM L-
Glutamine, 10mM HEPES, 0.1mM 2-mercaptoethanol 
tCD40L NIH3T3 medium Ham's F12/DMEM 
10% (v/v) FCS, 2mM L-Glutamine, 10mM HEPES, 
15µg/mL Gentamycin, 500µg/mL G418 
tCD40L WT medium Ham's F12/DMEM 
10% (v/v) FCS, 2 mM L-Glutamine, 10mM HEPES, 
15µg/mL Gentamycin 
R10 RPMI-1640 
1% (v/v) P/S, 10% (v/v) FCS, 2mM L-Glutamine, 
10mM HEPES 
 
2.1.11 Antibodies 
2.1.11.1 Primary antibodies  
Name Clone Description Dilution Company 
anti-human 
CD4-PE 
RPA-T4 Monoclonal, mouse IgG, PE-
conjugated 
FACS 1:20 BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
CD8-FITC 
RPA-T8 Monoclonal, mouse 
IgG,FITC-conjugated 
FACS 1:20 BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
CD14-FITC 
M5E2 Monoclonal, mouse 
IgG,FITC-conjugated 
FACS 1:20 BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
CD19-PE 
 
 
 
anti-human 
CD19-Pacific 
blue 
LT19 
 
 
 
 
HIB19 
Monoclonal, mouse IgG, PE-
conjugated 
 
 
 
Monoclonal, mouse IgG, 
Pacific blue-conjugated 
FACS 1:20 
 
 
 
 
FACS: 1:20 
Immunotools, 
Friesoythe 
Kindly provided by 
Alexandra Kurz, 
D030, DKFZ 
BioLegend, San 
Diego, CA, USA 
anti-human 
CD80-PE 
L307.4 Monoclonal, mouse IgG, PE-
conjugated 
FACS  1:20 BD Biosciences, 
San Diego, CA, 
USA 
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anti-human 
CD83-PE-
Cy™7 
HB15e Monoclonal, mouse IgG, PE-
Cy™7conjugated 
FACS 1:20 BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
CD86-APC 
2331 Monoclonal, mouse IgG, 
APC-conjugated 
FACS 1:20 BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
HLA-DR-
PerCP-Cy™5.5 
G46-6 Monoclonal, mouse IgG, 
PerCP-Cy™5.5-conjugated 
FACS 1:20 BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
HLA-A2 
BB7.2 monoclonal, mouse IgG WB 1:1000 
FACS 1:100 
 
BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
HLA-A2 FITC 
BB7.2 monoclonal, mouse IgG, 
FITC-conjugated 
FACS 1:20 
 
BD Biosciences, 
San Diego, CA, 
USA 
anti-human 
HLA-A3 
GAP A3  monoclonal, mouse IgG WB 1:1000 
FACS 1:688 
 
Kindly provided by 
Stefan Stevanović, 
University of 
Tübingen 
anti-human 
HLA-A11 
4i93 monoclonal, mouse IgG WB 1:1000 
FACS 1:100 
 
Abcam, Cambridge, 
UK 
anti-human 
HLA-A24 
22E10 monoclonal, mouse IgG WB 1:1000 
FACS 1:200 
 
MBL, Nagano, 
Japan 
anti-human 
HLA-B7 
BB7.1 monoclonal, mouse IgG WB 1:1000 
FACS 1:268 
 
Abcam, Cambridge, 
UK 
anti-human 
HLA-B13, 
B62, B15  
4i109 monoclonal, mouse IgG WB 1:1000 
FACS 1:200 
 
Abcam, Cambridge, 
UK 
anti-human 
IFN-γ 
1-D1K  monoclonal, mouse IgG, 
capture antibody 
ELISpot 
1:500 
Mabtech, Nacka 
Strand, Sweden 
anti-human 
IFN-γ biotin 
7-B6-1  monoclonal, mouse IgG, 
biotinylated 
ELISpot 
1:2000 
Mabtech, Nacka 
Strand, Sweden 
anti-human IL-
2  
MQ1-
17H12 
monoclonal, rat IgG, LEAF™ 
purified, capture antibody 
ELISA 
4µg/mL 
BioLegend, San 
Diego, CA, USA 
anti-human IL-
2 biotin  
Poly5176 polyclonal, goat IgG, 
biotinylated 
ELISA 
1:2000 
BioLegend, San 
Diego, CA, USA 
anti-human 
MHC class I 
EPR1394Y monoclonal, rabbit IgG WB 1:1500 
 
Epitomics, 
Burlingame, CA, 
USA 
 
2.1.11.2 Secondary antibodies 
Name Dilution Company 
goat-anti-rabbit IgG (H&L) Ab 
Peroxidase 
WB 1:5000 
 
Rockland, Gilbertsville, PA, 
USA 
rabbit-anti-mouse IgG FITC FACS 1:1500 DAKO, Glostrup, Denmark 
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2.1.12 Peptides 
Peptides were synthesized with a purity of >95% and purchased from PSL GmbH (Heidelberg), 
SynBioSci (San Francisco, CA, USA) and the DKFZ Peptide Core Facility (Dr. Rüdiger Pipkorn, Dr. 
Stefan Eichmüller). Lyophilized peptides were dissolved in DMSO at 10mg/mL and stocked in small 
aliquots at -80°C. 
2.1.12.1 Control peptides  
HLA alleles for (potential) binding are indicated. FL: fluorescein 
Name Source Region  aa sequence HLA allele Reference 
HLA-A3 fl consensus 
sequence 
 KVFPC(fl)ALINK HLA-A3 (Sette et al., 
1994) 
HLA-A11 fl consensus 
sequence 
 KVFPC(fl)ALINK HLA-A11 (Sette et al., 
1994) 
HLA-A24 fl HIV-1 Env 
gp41 
583-591 RYLKC(fl)QQLL HLA-A24 (Dai et al., 
1992) 
HLA-A2 control HIV-1 Nef 137-145 LTFGWCFKL HLA-A2 (Vaslin et 
al., 1994) 
HLA-A3 control consensus 
sequence 
 KVFPYALINK HLA-A3 (Sette et al., 
1994) 
HLA-A11 control HIV-1 Nef 73-82 QVPLRPMTYK HLA-A11 (Koenig et 
al., 1990) 
HLA-A24 control HIV-1 Env 
gp41 
583-591 RYLKDQQLL HLA-A24 (Dai et al., 
1992) 
HLA-A24 EBV 
control 
EBV BRLF1 28-37 DYCNVLNKEF HLA-A24 (Pepperl et 
al., 1998) 
 
2.1.12.2 HPV16 E6 and E7 peptides 
Name Origin Region  aa sequence HLA allele 
HPV16 E6/18-26 HPV16 E6  18-26 KLPQLCTEL HLA-A2 
HPV16 E6/18-28 HPV16 E6  18-28 KLPQLCTELQT HLA-A2 
HPV16 E6/25-33 HPV16 E6  25-33 ELQTTIHDI HLA-A2 
HPV16 E6/28-38 HPV16 E6  28-38 TTIHDIILECV HLA-A2 
HPV16 E6/29-38 HPV16 E6  29-38 TIHDIILECV HLA-A2 
HPV16 E6/34-44 HPV16 E6  34-44 ILECVYCKQQL HLA-A2 
HPV16 E6/52-60 HPV16 E6  52-60 FAFRDLCIV HLA-A2 
HPV16 E7/7-15 HPV16 E7  7-15 TLHEYMLDL HLA-A2 
HPV16 E7/11-20 HPV16 E7  11-20 YMLDLQPETT HLA-A2 
HPV16 E7/11-19 HPV16 E7  11-19 YMLDLQPET HLA-A2 
HPV16 E7/11-21 HPV16 E7  11-21 YMLDLQPETTD HLA-A2 
HPV16 E7/11-18 HPV16 E7  11-18 YMLDLQPE HLA-A2 
HPV16 E7/12-20 HPV16 E7  12-20 MLDLQPETT HLA-A2 
HPV16 E7/12-19 HPV16 E7  12-19 MLDLQPET HLA-A2 
HPV16 E7/66-74 HPV16 E7  66-74 RLCVQSTHV HLA-A2 
HPV16 E7/76-86 HPV16 E7  76-86 IRTLEDLLMGT HLA-A2 
HPV16 E7/77-87 HPV16 E7  77-87 RTLEDLLMGTL HLA-A2 
HPV16 E7/77-86 HPV16 E7  77-86 RTLEDLLMGT HLA-A2 
HPV16 E7/78-86 HPV16 E7  78-86 TLEDLLMGT HLA-A2 
HPV16 E7/80-90 HPV16 E7  80-90 EDLLMGTLGIV HLA-A2 
HPV16 E7/81-90 HPV16 E7  81-90 DLLMGTLGIV HLA-A2 
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HPV16 E7/81-91 HPV16 E7  81-91 DLLMGTLGIVC HLA-A2 
HPV16 E7/82-91 HPV16 E7  82-91 LLMGTLGIVC HLA-A2 
HPV16 E7/82-90 HPV16 E7  82-90 LLMGTLGIV HLA-A2 
HPV16 E7/82-92 HPV16 E7  82-92 LLMGTLGIVCP HLA-A2 
HPV16 E7/83-93 HPV16 E7  83-93 LMGTLGIVCPI HLA-A2 
HPV16 E7/84-93 HPV16 E7  84-93 MGTLGIVCPI HLA-A2 
HPV16 E7/85-93 HPV16 E7  85-93 GTLGIVCPI HLA-A2 
HPV16 E7/86-93 HPV16 E7  86-93 TLGIVCPI HLA-A2 
HPV16 E6/8-18 HPV16 E6  8-18 MFQDPQERPRK HLA-A3 
HPV16 E6/29-39 HPV16 E6  29-39 TIHDIILECVY HLA-A3 
HPV16 E6/32-41 HPV16 E6  32-41 DIILECVYCK HLA-A3 
HPV16 E6/33-41 HPV16 E6  33-41 IILECVYCK HLA-A3 
HPV16 E6/34-41 HPV16 E6  34-41 ILECVYCK HLA-A3 
HPV16 E6/37-46 HPV16 E6  37-46 CVYCKQQLLR HLA-A3 
HPV16 E6/37-47 HPV16 E6  37-47 CVYCKQQLLRR HLA-A3 
HPV16 E6/38-46 HPV16 E6  38-46 VYCKQQLLR HLA-A3 
HPV16 E6/43-50 HPV16 E6  43-50 QLRREVY HLA-A3 
HPV16 E6/43-52 HPV16 E6  43-52 QLLRREVYDF HLA-A3 
HPV16 E6/44-52 HPV16 E6  44-52 LLRREVYDF HLA-A3 
HPV16 E6/48-55 HPV16 E6  48-55 EVYDFAFR HLA-A3 
HPV16 E6/52-61 HPV16 E6  52-61 FAFRDLCIVY HLA-A3 
HPV16 E6/52-62 HPV16 E6  52-62 FAFRDLCIVYR HLA-A3 
HPV16 E6/53-62 HPV16 E6  53-62 AFRDLCIVYR HLA-A3 
HPV16 E6/58-67 HPV16 E6  58-67 CIVYRDGNPY HLA-A3 
HPV16 E6/59-67 HPV16 E6  59-67 IVYRDGNPY HLA-A3 
HPV16 E6/67-75 HPV16 E6  67-75 YAVCDKCLK HLA-A3 
HPV16 E6/68-75 HPV16 E6  68-75 AVCDKCLK HLA-A3 
HPV16 E6/68-76 HPV16 E6  68-76 AVCDKCLKF HLA-A3 
HPV16 E6/68-77 HPV16 E6  68-77 AVCDKCLKFY HLA-A3 
HPV16 E6/70-79 HPV16 E6  70-79 CDKCLKFYSK HLA-A3 
HPV16 E6/72-79 HPV16 E6  72-79 KCLKFYSK HLA-A3 
HPV16 E6/73-83 HPV16 E6  73-83 CLKFYSKISEY HLA-A3 
HPV16 E6/74-83 HPV16 E6  74-83 LKFYSKISEY HLA-A3 
HPV16 E6/75-83 HPV16 E6  75-83 KFYSKISEY HLA-A3 
HPV16 E6/75-84 HPV16 E6  75-84 KFYSKISEYR HLA-A3 
HPV16 E6/75-85 HPV16 E6  75-85 KFYSKISEYRH HLA-A3 
HPV16 E6/79-86 HPV16 E6  79-86 KISEYRHY HLA-A3 
HPV16 E6/79-88 HPV16 E6  79-88 KISEYRHYCY HLA-A3 
HPV16 E6/81-91 HPV16 E6  81-91 SEYRHYCYSLY HLA-A3 
HPV16 E6/84-91 HPV16 E6  84-91 RHYCYSLY HLA-A3 
HPV16 E6/89-97 HPV16 E6  89-97 SLYGTTLEQ HLA-A3 
HPV16 E6/89-98 HPV16 E6  89-98 SLYGTTLEQQ HLA-A3 
HPV16 E6/89-99 HPV16 E6  89-99 SLYGTTLEQQY HLA-A3 
HPV16 E6/92-101 HPV16 E6  92-101 GTTLEQQYNK HLA-A3 
HPV16 E6/93-101 HPV16 E6  93-101 TTLEQQYNK HLA-A3 
HPV16 E6/94-101 HPV16 E6  94-101 TLEQQYNK HLA-A3 
HPV16 E6/105-115 HPV16 E6  105-115 DLLIRCINCQK HLA-A3 
HPV16 E6/106-115 HPV16 E6  106-115 LLIRCINCQK HLA-A3 
HPV16 E6/107-115 HPV16 E6  107-115 LIRCINCQK HLA-A3 
HPV16 E6/113-122 HPV16 E6  113-122 CQKPLCPEEK HLA-A3 
HPV16 E6/116-124 HPV16 E6  116-124 PLCPEEKQR HLA-A3 
HPV16 E6/122-129 HPV16 E6  122-129 KQRHLDKK HLA-A3 
HPV16 E6/125-133 HPV16 E6  125-133 HLDKKQRFH HLA-A3 
HPV16 E6/129-136 HPV16 E6  129-136 KQRFHNIR HLA-A3 
HPV16 E6/129-138 HPV16 E6  129-138 KQRFHNIRGR HLA-A3 
HPV16 E6/134-142 HPV16 E6  134-142 NIRGRWTGR HLA-A3 
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HPV16 E6/139-148 HPV16 E6  139-148 WTGRCMSCCR HLA-A3 
HPV16 E6/142-151 HPV16 E6  142-151 RCMSCCRSSR HLA-A3 
HPV16 E6/143-151 HPV16 E6  143-151 CMSCCRSSR HLA-A3 
HPV16 E6/143-153 HPV16 E6  143-153 CMSCCRSSRTR HLA-A3 
HPV16 E6/144-151 HPV16 E6  144-151 MSCCRSSR HLA-A3 
HPV16 E6/144-152 HPV16 E6  144-152 MSCCRSSRT HLA-A3 
HPV16 E6/144-153 HPV16 E6  144-153 MSCCRSSRTR HLA-A3 
HPV16 E6/144-154 HPV16 E6  144-154 MSCCRSSRTRR HLA-A3 
HPV16 E7/7-15 HPV16 E7  7-15 TLHEYMLDL HLA-A3 
HPV16 E7/49-57 HPV16 E7  49-57 RAHYNIVTF HLA-A3 
HPV16 E7/50-60 HPV16 E7  50-60 AHYNIVTFCCK HLA-A3 
HPV16 E7/51-60 HPV16 E7  51-60 HYNIVTFCCK HLA-A3 
HPV16 E7/52-60 HPV16 E7  53-60 YNIVTFCCK HLA-A3 
HPV16 E7/53-60 HPV16 E7  53-60 NIVTFCCK HLA-A3 
HPV16 E7/63-73 HPV16 E7  63-73 STLRLCVQSTH HLA-A3 
HPV16 E7/65-74 HPV16 E7  65-74 LRLCVQSTHV HLA-A3 
HPV16 E7/66-73 HPV16 E7  66-73 RLCVQSTH HLA-A3 
HPV16 E7/66-74 HPV16 E7  66-74 RLCVQSTHV HLA-A3 
HPV16 E7/82-91 HPV16 E7  82-91 LLMGTLGIVC HLA-A3 
HPV16 E7/87-97 HPV16 E7  87-97 LGIVCPICSQK HLA-A3 
HPV16 E7/88-97 HPV16 E7  88-97 GIVCPICSQK HLA-A3 
HPV16 E7/89-97 HPV16 E7  89-97 IVCPICSQK HLA-A3 
HPV16 E6/8-18 HPV16 E6  8-18 MFQDPQERPRK HLA-A11 
HPV16 E6/9-18 HPV16 E6  9-18 FQDPQERPRK HLA-A11 
HPV16 E6/18-25 HPV16 E6  18-25 KLPQLCTE HLA-A11 
HPV16 E6/27-36 HPV16 E6  27-36 QTTIHDIILE HLA-A11 
HPV16 E6/28-36 HPV16 E6  28-36 TTIHDIILE HLA-A11 
HPV16 E6/28-37 HPV16 E6  28-37 TTIHDIILEC HLA-A11 
HPV16 E6/29-37 HPV16 E6  29-37 TIHDIILEC HLA-A11 
HPV16 E6/29-39 HPV16 E6  29-39 TIHDIILECVY HLA-A11 
HPV16 E6/32-41 HPV16 E6  32-41 DIILECVYCK HLA-A11 
HPV16 E6/33-41 HPV16 E6  33-41 IILECVYCK HLA-A11 
HPV16 E6/34-41 HPV16 E6  34-41 ILECVYCK HLA-A11 
HPV16 E6/37-46 HPV16 E6  37-46 CVYCKQQLLR HLA-A11 
HPV16 E6/37-47 HPV16 E6  37-47 CVYCKQQLLRR HLA-A11 
HPV16 E6/38-46 HPV16 E6  38-46 VYCKQQLLR HLA-A11 
HPV16 E6/48-55 HPV16 E6  48-55 EVYDFAFR HLA-A11 
HPV16 E6/48-56 HPV16 E6  48-56 EVYDFAFRD HLA-A11 
HPV16 E6/52-62 HPV16 E6  52-62 FAFRDLCIVY HLA-A11 
HPV16 E6/52-62 HPV16 E6  52-62 FAFRDLCIVYR HLA-A11 
HPV16 E6/53-62 HPV16 E6  53-62 AFRDLCIVYR HLA-A11 
HPV16 E6/59-67 HPV16 E6  59-67 IVYRDGNPY HLA-A11 
HPV16 E6/63-73 HPV16 E6  63-73 DGNPYAVCDKC HLA-A11 
HPV16 E6/64-72 HPV16 E6  64-72 GNPYAVCDK HLA-A11 
HPV16 E6/67-75 HPV16 E6  67-75 YAVCDKCLK HLA-A11 
HPV16 E6/68-75 HPV16 E6  68-75 AVCDKCLK HLA-A11 
HPV16 E6/68-76 HPV16 E6  68-76 AVCDKCLKF HLA-A11 
HPV16 E6/68-77 HPV16 E6  68-77 AVCDKCLKFY HLA-A11 
HPV16 E6/68-78 HPV16 E6  68-78 AVCDKCLKFYS HLA-A11 
HPV16 E6/69-79 HPV16 E6  69-79 VCDKCLKFYSK HLA-A11 
HPV16 E6/70-79 HPV16 E6  70-79 CDKCLKFYSK HLA-A11 
HPV16 E6/71-79 HPV16 E6  71-79 DKCLKFYSK HLA-A11 
HPV16 E6/72-79 HPV16 E6  72-79 KCLKFYSK HLA-A11 
HPV16 E6/73-83 HPV16 E6  73-83 CLKFYSKISEY HLA-A11 
HPV16 E6/75-83 HPV16 E6  75-83 KFYSKISEY HLA-A11 
HPV16 E6/75-84 HPV16 E6  75-84 KFYSKISEYR HLA-A11 
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HPV16 E6/75-85 HPV16 E6  75-85 KFYSKISEYRH HLA-A11 
HPV16 E6/77-84 HPV16 E6  77-84 YSKISEYR HLA-A11 
HPV16 E6/79-86 HPV16 E6  79-86 KISEYRHY HLA-A11 
HPV16 E6/79-88 HPV16 E6  79-88 KISEYRHYCY HLA-A11 
HPV16 E6/80-88 HPV16 E6  80-88 ISEYRHYCY HLA-A11 
HPV16 E6/81-89 HPV16 E6  81-89 SEYRHYCYS HLA-A11 
HPV16 E6/81-91 HPV16 E6  81-91 SEYRHYCYSLY HLA-A11 
HPV16 E6/84-91 HPV16 E6  84-91 RHYCYSLY HLA-A11 
HPV16 E6/88-97 HPV16 E6  88-97 YSLYGTTLEQ HLA-A11 
HPV16 E6/89-97 HPV16 E6  89-97 SLYGTTLEQ HLA-A11 
HPV16 E6/89-99 HPV16 E6  89-99 SLYGTTLEQQY HLA-A11 
HPV16 E6/91-101 HPV16 E6  91-101 YGTTLEQQYNK HLA-A11 
HPV16 E6/92-99 HPV16 E6  92-99 GTTLEQQY HLA-A11 
HPV16 E6/92-101 HPV16 E6  92-101 GTTLEQQYNK HLA-A11 
HPV16 E6/93-101 HPV16 E6  93-101 TTLEQQYNK HLA-A11 
HPV16 E6/94-101 HPV16 E6 94-101 TLEQQYNK HLA-A11 
HPV16 E6/101-109 HPV16 E6  101-109 KPLCDLLIR HLA-A11 
HPV16 E6/105-115 HPV16 E6  105-115 DLLIRCINCQK HLA-A11 
HPV16 E6/106-115 HPV16 E6 106-115 LLIRCINCQK HLA-A11 
HPV16 E6/107-115 HPV16 E6 107-115 LIRCINCQK HLA-A11 
HPV16 E6/113-122 HPV16 E6  113-122 CQKPLCPEEK HLA-A11 
HPV16 E6/116-124 HPV16 E6 116-124 PLCPEEKQR HLA-A11 
HPV16 E6/122-129 HPV16 E6 122-129 KQRHLDKK HLA-A11 
HPV16 E6/129-136 HPV16 E6 129-136 KQRFHNIR HLA-A11 
HPV16 E6/129-138 HPV16 E6  129-138 KQRFHNIRGR HLA-A11 
HPV16 E6/134-142 HPV16 E6  134-142 NIRGRWTGR HLA-A11 
HPV16 E6/139-148 HPV16 E6 139-148 WTGRCMSCCR HLA-A11 
HPV16 E6/140-148 HPV16 E6  140-148 TGRCMSCCR HLA-A11 
HPV16 E6/143-151 HPV16 E6  143-151 CMSCCRSSR HLA-A11 
HPV16 E6/143-153 HPV16 E6  143-153 CMSCCRSSRTR HLA-A11 
HPV16 E6/144-151 HPV16 E6 144-151 MSCCRSSR HLA-A11 
HPV16 E6/144-152 HPV16 E6 144-152 MSCCRSSRT HLA-A11 
HPV16 E6/144-153 HPV16 E6 144-153 MSCCRSSRTR HLA-A11 
HPV16 E6/144-154 HPV16 E6  144-154 MSCCRSSRTRR HLA-A11 
HPV16 E6/145-153 HPV16 E6 145-153 SCCRSSRTR HLA-A11 
HPV16 E7/18-25 HPV16 E7  18-26 ETTDLYCY HLA-A11 
HPV16 E7/18-26 HPV16 E7  18-26 ETTDLYCYE HLA-A11 
HPV16 E7/19-27 HPV16 E7  19-27 TTDLYCYEQ HLA-A11 
HPV16 E7/31-40 HPV16 E7  31-40 SSEEEDEIDG HLA-A11 
HPV16 E7/50-60 HPV16 E7  50-60 AHYNIVTFCCK HLA-A11 
HPV16 E7/51-60 HPV16 E7  51-60 HYNIVTFCCK HLA-A11 
HPV16 E7/52-60 HPV16 E7  52-60 YNIVTFCCK HLA-A11 
HPV16 E7/53-60 HPV16 E7  53-60 NIVTFCCK HLA-A11 
HPV16 E7/55-63 HPV16 E7  55-63 VTFCCKCDS HLA-A11 
HPV16 E7/63-71 HPV16 E7  63-71 STLRLCVQS HLA-A11 
HPV16 E7/63-73 HPV16 E7  63-73 STLRLCVQSTH HLA-A11 
HPV16 E7/68-77 HPV16 E7  68-77 CVQSTHVDIR HLA-A11 
HPV16 E7/71-80 HPV16 E7  71-80 STHVDIRTLE HLA-A11 
HPV16 E7/77-84 HPV16 E7  77-84 RTLEDLLM HLA-A11 
HPV16 E7/85-93 HPV16 E7  85-93 GTLGIVCPI HLA-A11 
HPV16 E7/87-97 HPV16 E7  87-97 LGIVCPICSQK HLA-A11 
HPV16 E7/88-97 HPV16 E7  88-97 GIVCPICSQK HLA-A11 
HPV16 E7/89-97 HPV16 E7  89-97 IVCPICSQK HLA-A11 
HPV16 E6/11-19 HPV16 E6  11-19 DPQERPRKL HLA-A24 
HPV16 E6/18-26 HPV16 E6  18-26 KLPQLCTEL HLA-A24 
HPV16 E6/26-34 HPV16 E6  26-34 LQTTIHDII HLA-A24 
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HPV16 E6/35-44 HPV16 E6  35-44 LECVYCKQQL HLA-A24 
HPV16 E6/36-46 HPV16 E6  36-46 ECVYCKQQLLR HLA-A24 
HPV16 E6/38-45 HPV16 E6  38-45 VYCKQQLL HLA-A24 
HPV16 E6/38-46 HPV16 E6  38-46 VYCKQQLLR HLA-A24 
HPV16 E6/38-47 HPV16 E6  38-47 VYCKQQLLRR HLA-A24 
HPV16 E6/42-52 HPV16 E6  42-52 QQLLRREVYDF HLA-A24 
HPV16 E6/43-52 HPV16 E6  43-52 QLLRREVYDF HLA-A24 
HPV16 E6/44-52 HPV16 E6  44-52 LLRREVYDF HLA-A24 
HPV16 E6/44-54 HPV16 E6  44-54 LLRREVYDFAF HLA-A24 
HPV16 E6/45-54 HPV16 E6  45-54 LRREVYDFAF HLA-A24 
HPV16 E6/47-54 HPV16 E6 47-54 REVYDFAF HLA-A24 
HPV16 E6/47-57 HPV16 E6  47-57 REVYDFAFRDL HLA-A24 
HPV16 E6/48-57 HPV16 E6  48-57 EVYDFAFRDL HLA-A24 
HPV16 E6/48-58 HPV16 E6  48-58 EVYDFAFRDLC HLA-A24 
HPV16 E6/49-57 HPV16 E6  49-57 VYDFAFRDL HLA-A24 
HPV16 E6/49-59 HPV16 E6  49-59 VYDFAFRDLCI HLA-A24 
HPV16 E6/49-58 HPV16 E6  49-58 VYDFAFRDLC HLA-A24 
HPV16 E6/50-59 HPV16 E6  50-59 YDFAFRDLCI HLA-A24 
HPV16 E6/50-60 HPV16 E6 50-60 YDFAFRDLCIV HLA-A24 
HPV16 E6/51-59 HPV16 E6  51-59 DFAFRDLCI HLA-A24 
HPV16 E6/51-60 HPV16 E6  51-60 DFAFRDLCIV HLA-A24 
HPV16 E6/59-68 HPV16 E6  59-68 IVYRDGNPYA HLA-A24 
HPV16 E6/60-69 HPV16 E6  60-69 VYRDGNPYAV HLA-A24 
HPV16 E6/64-74 HPV16 E6  64-74 GNPYAVCDKCL HLA-A24 
HPV16 E6/65-74 HPV16 E6  65-74 NPYAVCDKCL HLA-A24 
HPV16 E6/66-74 HPV16 E6  66-74 PYAVCDKCL HLA-A24 
HPV16 E6/66-75 HPV16 E6  66-75 PYAVCDKCLK HLA-A24 
HPV16 E6/66-76 HPV16 E6  66-76 PYAVCDKCLKF HLA-A24 
HPV16 E6/67-76 HPV16 E6  67-76 YAVCDKCLKF HLA-A24 
HPV16 E6/72-80 HPV16 E6  72-80 KCLKFYSKI HLA-A24 
HPV16 E6/73-83 HPV16 E6 73-83 CLKFYSKISEY HLA-A24 
HPV16 E6/75-83 HPV16 E6 75-83 KFYSKISEY HLA-A24 
HPV16 E6/75-85 HPV16 E6  75-85 KFYSKISEYRH HLA-A24 
HPV16 E6/76-83 HPV16 E6  76-83 FYSKISEY HLA-A24 
HPV16 E6/76-84 HPV16 E6  76-84 FYSKISEYR HLA-A24 
HPV16 E6/76-85 HPV16 E6  76-85 FYSKISEYRH HLA-A24 
HPV16 E6/76-86 HPV16 E6  76-86 FYSKISEYRHY HLA-A24 
HPV16 E6/80-90 HPV16 E6  80-90 ISEYRHYCYSL HLA-A24 
HPV16 E6/81-90 HPV16 E6  81-90 SEYRHYCYSL HLA-A24 
HPV16 E6/81-91 HPV16 E6  81-91 SEYRHYCYSLY HLA-A24 
HPV16 E6/82-90 HPV16 E6  82-90 EYRHYCYSL HLA-A24 
HPV16 E6/82-91 HPV16 E6  82-91 EYRHYCYSLY HLA-A24 
HPV16 E6/85-94 HPV16 E6  85-94 HYCYSLYGTT HLA-A24 
HPV16 E6/85-95 HPV16 E6  85-95 HYCYSLYGTTL HLA-A24 
HPV16 E6/86-95 HPV16 E6  86-95 YCYSLYGTTL HLA-A24 
HPV16 E6/86-96 HPV16 E6  86-96 YCYSLYGTTLE HLA-A24 
HPV16 E6/87-94 HPV16 E6  87-94 CYSLYGTT HLA-A24 
HPV16 E6/87-95 HPV16 E6  87-95 CYSLYGTTL HLA-A24 
HPV16 E6/87-96 HPV16 E6  87-96 CYSLYGTTLE HLA-A24 
HPV16 E6/88-95 HPV16 E6  88-95 YSLYGTTL HLA-A24 
HPV16 E6/90-98 HPV16 E6  90-98 LYGTTLEQQ HLA-A24 
HPV16 E6/90-99 HPV16 E6  90-99 LYGTTLEQQY HLA-A24 
HPV16 E6/96-106 HPV16 E6  96-106 EQQYNKPLCDL HLA-A24 
HPV16 E6/97-106 HPV16 E6  97-106 QQYNKPLCDL HLA-A24 
HPV16 E6/98-106 HPV16 E6  98-106 QYNKPLCDL HLA-A24 
HPV16 E6/98-107 HPV16 E6  98-107 QYNKPLCDLL HLA-A24 
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HPV16 E6/98-108 HPV16 E6  98-108 QYNKPLCDLLI HLA-A24 
HPV16 E6/109-117 HPV16 E6  109-117 RCINCQKPL HLA-A24 
HPV16 E6/124-132 HPV16 E6  124-132 RHLDKKQRF HLA-A24 
HPV16 E6/125-135 HPV16 E6  125-135 HLDKKQRFHNI HLA-A24 
HPV16 E6/126-135 HPV16 E6  126-135 LDKKQRFHNI HLA-A24 
HPV16 E6/127-135 HPV16 E6  127-135 DKKQRFHNI HLA-A24 
HPV16 E6/128-135 HPV16 E6  128-135 KKQRFHNI HLA-A24 
HPV16 E6/128-136 HPV16 E6  128-136 KKQRFHNIR HLA-A24 
HPV16 E6/128-137 HPV16 E6  128-137 KKQRFHNIRG HLA-A24 
HPV16 E6/128-138 HPV16 E6  128-138 KKQRFHNIRGR HLA-A24 
HPV16 E6/131-139 HPV16 E6 131-139 RFHNIRGRW HLA-A24 
HPV16 E6/138-146 HPV16 E6  138-146 RWTGRCMSC HLA-A24 
HPV16 E6/138-147 HPV16 E6  138-147 RWTGRCMSCC HLA-A24 
HPV16 E6/26-34var HPV16 E6  26-34var LQTTIHEII HLA-A24 
HPV16 E6/81-90var HPV16 E6  81-90var SEYRHYCYSV HLA-A24 
HPV16 E6/82-90var HPV16 E6  82-90var EYRHYCYSV HLA-A24 
HPV16 E6/82-91var HPV16 E6  82-91var EYRHYCYSVY HLA-A24 
HPV16 E6/85-93var HPV16 E6  85-93var HYCYSVYGT HLA-A24 
HPV16 E6/85-94var HPV16 E6  85-94var HYCYSVYGTT HLA-A24 
HPV16 E6/85-95var HPV16 E6  85-95var HYCYSVYGTTL HLA-A24 
HPV16 E6/87-94var HPV16 E7 87-94var CYSVYGTT HLA-A24 
HPV16 E6/87-95var HPV16 E6  87-95var CYSVYGTTL HLA-A24 
HPV16 E6/87-96var HPV16 E6  87-96var CYSVYGTTLE HLA-A24 
HPV16 E6/88-95var HPV16 E6  88-95var YSVYGTTL HLA-A24 
HPV16 E6/90-98var HPV16 E6  90-98var VYGTTLEQQ HLA-A24 
HPV16 E6/90-99var HPV16 E6  90-99var VYGTTLEQQY HLA-A24 
HPV16 E7/10-18 HPV16 E7 10-18 EYMLDLQPE HLA-A24 
HPV16 E7/10-19 HPV16 E7 10-19 EYMLDLQPET HLA-A24 
HPV16 E7/10-20 HPV16 E7 10-20 EYMLDLQPETT HLA-A24 
HPV16 E7/22-31 HPV16 E7 22-31 LYCYEQLNDS HLA-A24 
HPV16 E7/24-32 HPV16 E7 24-32 CYEQLNDSS HLA-A24 
HPV16 E7/24-33 HPV16 E7 24-33 CYEQLNDSSE HLA-A24 
HPV16 E7/48-57 HPV16 E7 48-57 DRAHYNIVTF HLA-A24 
HPV16 E7/49-57 HPV16 E7 49-57 RAHYNIVTF HLA-A24 
HPV16 E7/50-57 HPV16 E7 50-57 AHYNIVTF HLA-A24 
HPV16 E7/51-58 HPV16 E7 51-58 HYNIVTFC HLA-A24 
HPV16 E7/51-59 HPV16 E7 51-59 HYNIVTFCC HLA-A24 
HPV16 E7/51-60 HPV16 E7 51-60 HYNIVTFCCK HLA-A24 
HPV16 E7/56-65 HPV16 E7 56-65 TFCCKCDSTL HLA-A24 
HPV16 E7/56-66 HPV16 E7 56-66 TFCCKCDSTLR HLA-A24 
HPV16 E7/61-69 HPV16 E7 61-69 CDSTLRLCV HLA-A24 
HPV16 E7/67-76 HPV16 E7 67-76 LCVQSTHVDI HLA-A24 
HPV16 E7/67-77 HPV16 E7 67-77 LCVQSTHVDIR HLA-A24 
HPV16 E7/69-76 HPV16 E7 69-76 VQSTHVDI HLA-A24 
HPV16 E7/74-82 HPV16 E7 74-82 VDIRTLEDL HLA-A24 
HPV16 E7/74-83 HPV16 E7 74-83 VDIRTLEDLL HLA-A24 
HPV16 E7/77-87 HPV16 E7 77-87 RTLEDLLMGTL HLA-A24 
HPV16 E7/78-87 HPV16 E7 78-87 TLEDLLMGTL HLA-A24 
HPV16 E7/82-91 HPV16 E7 82-91 LLMGTLGIVC HLA-A24 
HPV16 E7/19-28var HPV16 E7 19-28var TTDLYCYEQF HLA-A24 
HPV16 E7/20-28var HPV16 E7 20-28var TDLYCYEQF HLA-A24 
HPV16 E7/21-28var HPV16 E7 21-28var DLYCYEQF HLA-A24 
HPV16 E7/22-30var HPV16 E7 22-30var LYCYEQFSD HLA-A24 
HPV16 E7/22-31var HPV16 E7 22-31var LYCYEQFSDS HLA-A24 
HPV16 E7/24-33var HPV16 E7 24-33var CYEQFSDSSE HLA-A24 
HPV16 E7/24-32var HPV16 E7 24-32var CYEQFSDSS HLA-A24 
Material and Methods 
62 
 
HPV16 E6/15-23 HPV16 E6  15-23 RPRKLPQLC HLA-B7 
HPV16 E6/15-24 HPV16 E6  15-24 RPRKLPQLCT HLA-B7 
HPV16 E6/15-25 HPV16 E6  15-25 RPRKLPQLCTE HLA-B7 
HPV16 E6/19-26 HPV16 E6  19-26 LPQLCTEL HLA-B7 
HPV16 E6/44-54 HPV16 E6  44-54 LLRREVYDFAF HLA-B7 
HPV16 E6/59-69 HPV16 E6  59-69 IVYRDGNPYAV HLA-B7 
HPV16 E6/95-103 HPV16 E6  95-103 LEQQYNKPL HLA-B7 
HPV16 E6/101-108 HPV16 E6  101-108 KPLCDLLI HLA-B7 
HPV16 E6/101-111 HPV16 E6  101-111 KPLCDLLIRCI HLA-B7 
HPV16 E6/107-117 HPV16 E6  107-117 LIRCINCQKPL HLA-B7 
HPV16 E6/118-126 HPV16 E6  118-126 CPEEKQRHL HLA-B7 
HPV16 E6/134-144 HPV16 E6  134-144 NIRGRWTGRCM HLA-B7 
HPV16 E6/136-144 HPV16 E6  136-144 RGRWTGRCM HLA-B7 
HPV16 E6/148-158 HPV16 E6  148-158 RSSRTRRETQL HLA-B7 
HPV16 E6/149-158 HPV16 E6  149-158 SSRTRRETQL HLA-B7 
HPV16 E6/151-158 HPV16 E6  151-158 RTRRETQL HLA-B7 
HPV16 E7/5-12 HPV16 E7 5-12 TPTLHEYM HLA-B7 
HPV16 E7/5-13 HPV16 E7 5-13 TPTLHEYML HLA-B7 
HPV16 E7/49-57 HPV16 E7 49-57 RAHYNIVTF HLA-B7 
HPV16 E7/46-55 HPV16 E7 46-55 EPDRAHYNIV HLA-B7 
HPV16 E6/18-26 HPV16 E6 18-26 KLPQLCTEL HLA-B15 
HPV16 E6/41-50 HPV16 E6 41-50 KQQLLRREVY HLA-B15 
HPV16 E6/42-50 HPV16 E6 42-50 QQLLRREVY HLA-B15 
HPV16 E6/44-52 HPV16 E6 44-52 LLRREVYDF HLA-B15 
HPV16 E6/44-54 HPV16 E6 44-54 LLRREVYDFAF HLA-B15 
HPV16 E6/52-61 HPV16 E6 52-61 FAFRDLCIVY HLA-B15 
HPV16 E6/53-61 HPV16 E6 53-61 AFRDLCIVY HLA-B15 
HPV16 E6/57-67 HPV16 E6 57-67 LCIVYRDGNPY HLA-B15 
HPV16 E6/58-67 HPV16 E6 58-67 CIVYRDGNPY HLA-B15 
HPV16 E6/59-67 HPV16 E6 59-67 IVYRDGNPY HLA-B15 
HPV16 E6/68-77 HPV16 E6 68-77 AVCDKCLKFY HLA-B15 
HPV16 E6/73-83 HPV16 E6 73-83 CLKFYSKISEY HLA-B15 
HPV16 E6/74-83 HPV16 E6 74-83 LKFYSKISEY HLA-B15 
HPV16 E6/75-83 HPV16 E6 75-83 KFYSKISEY HLA-B15 
HPV16 E6/79-88 HPV16 E6 79-88 KISEYRHYCY HLA-B15 
HPV16 E6/81-91 HPV16 E6 81-91 SEYRHYCYSLY HLA-B15 
HPV16 E6/83-91 HPV16 E6 83-91 YRHYCYSLY HLA-B15 
HPV16 E6/84-91 HPV16 E6 84-91 RHYCYSLY HLA-B15 
HPV16 E6/89-99 HPV16 E6 89-99 SLYGTTLEQQY HLA-B15 
HPV16 E6/97-106 HPV16 E6 97-106 QQYNKPLCDL HLA-B15 
HPV16 E7/7-15 HPV16 E7 7-15 TLHEYMLDL HLA-B15 
HPV16 E7/15-23 HPV16 E7 15-23 LQPETTDLY HLA-B15 
HPV16 E7/15-25 HPV16 E7 15-25 LQPETTDLYCY HLA-B15 
HPV16 E7/42-52 HPV16 E7 42-52 AGQAEPDRAHY HLA-B15 
HPV16 E7/43-51 HPV16 E7 43-51 GQAEPDRAH HLA-B15 
HPV16 E7/43-52 HPV16 E7 43-52 GQAEPDRAHY HLA-B15 
HPV16 E7/49-57 HPV16 E7 49-57 RAHYNIVTF HLA-B15 
HPV16 E7/82-89 HPV16 E7 82-89 LLMGTLGI HLA-B15 
HPV16 E7/82-90 HPV16 E7 82-90 LLMGTLGIV HLA-B15 
2.1.13 Oligonucleotides 
All oligonucleotides were used for sequencing and synthesized by Sigma-Aldrich, Steinbach. 
Lyophilized oligonucleotides were dissolved in ddH2O at 100µM and stored in aliquots at -20°C. 
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2.1.13.1 Oligonucleotides for HPV16 E6 and E7 sequencing 
Nucleotides in italics indicate T7 (forward) and T3 (reverse) sequencing primer sequences, 
respectively. Nucleotides in bold stand for actual PCR primer sequences. 
Name Sequence 5’-3’ Tm [C°] 
E6_T7_for TAATACGACTCACTATAGGGCGAAACCGGTTAGTATAA 72.2 
E6_T3_rev ATTAACCCTCACTAAAGGGAGTATCTCCATGCATGATT 74.6 
E7_T7_for TAATACGACTCACTATAGGGATAATATAAGGGGTCGGTGG 73.8 
E7_T3_rev ATTAACCCTCACTAAAGGGACATTTTCGTTCTCGTCATCTG 77.8 
 
2.1.13.2 Oligonucleotides for HLA genotyping  
Oligonucleotide sequences were taken from (Bunce, 2003). 
Name Sequence 5’-3’ Tm [C°] 
HLA-f-402 AGGCCCACTCACAGACTC 60.5 
HLA-r-249 CCTCCAGGTAGGCTCTCAA 62.0 
HLA-f-296 GTGGATAGAGCAGGAGGGT 60.7 
HLA-r-302 CCAAGAGCGCAGGTCCTCT 67.0 
HLA-f-291 AGCGACGCCGCGAGCCA 76.6 
HLA-r-299 CACTCCACGCACGTGCCA 71.4 
HLA-f-290 ACGGAATGTGAAGGCCCAG 67.3 
HLA-r-145 GAGCCACTCCACGCACTC 65.0 
HLA-f-239 GGGTACCAGCAGGACGCT 65.4 
HLA-r-167 GAGCCACTCCACGCACCG 70.8 
HLA-f-208 ACCGAGAGAACCTGCGGAT 66.1 
HLA-r-146 CCCTCCAGGTAGGCTCTCT 62.4 
HLA-f-292 GGCCGGAGTATTGGGACGA 69,3 
HLA-r-170 CCTCCAGGTAGGCTCTCTG 61.6 
HLA-f-193 GGAGTATTGGGACCGGAAC 63.1 
HLA-r-221 TACCAGCGCGCTCCAGCT 69.7 
HLA-f-243 CGCGAGTCCGAGGATGGC 71.8 
HLA-r-250 GCAGGTTCCGCAGGCTCT 68.1 
HLA-f-280 CTACGTGGACGACACGCT 69.7 
HLA-r-281 CTCGGTCAGTCTGTGCCTT 63.2 
HLA-r-282 TCTCGGTAAGTCTGTGCCTT 61.5 
 
2.1.14 Blood samples and buffy coats 
Blood samples were taken from healthy donors after their written informed consent. Sampling and use 
of blood samples were in accordance with the Institutional Review Board at the Geramn Cancer 
Research Center (DKFZ) and the University of Heidelberg, Heidelberg, Germany. Blood buffy coats 
of anonymous, healthy donors were obtained from the German Red Cross (DRK) blood transfusion 
service Mannheim through the blood bank Institut für Klinische Transfusionsmedizin und Zelltherapie 
(IKTZ) Heidelberg. 
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2.1.15 Software 
Name Company/Source  
AAcount.pl Jan Winter, F130 
Adobe Photoshop CS4 Adobe, San José, CA, USA 
Adobe Illustrator CS4 Adobe, San José, CA, USA 
AID EliSpot Evaluation System 5 Autoimmun Diagnostika, Strassberg 
BD FACS Diva Software BD Biosciences, San José, CA, USA 
ExPASy ScanProsite http://http://prosite.expasy.org/scanprosite/ 
access date: 20121025 
EndNote X7.2 Thomas Reuters, Philadelphia, PA, USA 
FlowJo 6.5 TreeStar, Ashland, OR, USA 
Fusion Vilber Lourmat, Eberhardzell 
GENTle Magnus Manske, University of Cologne, 
Cologne 
Image Lab 3.0 Biorad, Hercules, CA, USA 
MS Office 2010 (German version) Microsoft Corperation, Redmond, WA, USA 
Notepad++ 6.3 http://notepad-plus-plus.org/  
PeptidePrediction.pI Jan Winter, F130 
PRISM® 5 GraphPad, La Jolla, CA, USA 
ScanProsite_result.pI Jan Winter, F130 
SigmaPlot 12 Systat Software, San José, CA, USA 
WebLogo 3 (Crooks et al., 2004) http://weblogo.threeplusone.com/create.cgi 
access date: 20121024 
 
2.2 Methods 
2.2.1 In silico methods 
As the experimental testing of binding affinity of peptides to MHC molecules is rather expensive and 
time-consuming, various computational approaches have been developed to predict MHC binding 
peptides. In theory, 941 peptides of the HPV16 E6 and E7 proteins with a length of 8-11 amino acids 
(aa) can be generated for each HLA allele and thus might be identified as potential T cell epitopes 
presented by HPV16-transformed cells. To cut down this number, different prediction servers were 
used to predict the binding affinities of all possible HPV16 E6 and E7 peptides to HLA-A3 (HLA-
A*03:01), HLA-A11 (HLA-A*11:01) and HLA-A24 (HLA-A*24:02).  
2.2.1.1 T cell epitope predictions 
Peptide epitope prediction was performed using six prediction servers with ten algorithms in total. The 
NetMHC server is based on artificial neural networks and includes NetMHC 3.2 (Lundegaard et al., 
2008a), NetMHCpan 2.4 (Nielsen et al., 2007) and NetMHCcons 1.0 (Karosiene et al., 2012), that 
combines the former two and a third algorithm, PickPocket. The Immune Epitope Database (IEDB) 
server includes two artificial neural network-based algorithms, IEDBann (Nielsen et al., 2003) and 
IEDBpan-specific ann (Hoof et al., 2009), as well as three matrix-based algorithms; IEDBarb (Bui et 
al., 2005), IEDBsmm (Peters and Sette, 2005) and IEDBsmmpmbec (Sidney et al., 2008). Those eight 
prediction methods all calculate a putative binding affinity given as IC50 [nM]. Two additional matrix-
based servers, BIMAS (Parker et al., 1994) and SYFPEITHI (Rammensee et al., 1999), which display 
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the predicted peptide affinity as a score, were included as well. Since all prediction servers use 
different algorithms, are not trained with the same training databases and therefore yield different 
results, we took advantage of the high number of available servers and combined the results of the ten 
different prediction algorithms (Tab. 1). 
 
Table 1 I Prediction servers used to predict binding peptides to designated HLA alleles. Algorithms: ANN: Artificial 
Neural Network, ARB: Average Relative Binding, SMM: Stabilized Matrix Method, SMMPMBEC: SMM with energy 
covariance matrix, AU: arbitrary units 
Server Algorithm Scoring 
method  
Peptide lengths 
predicted 
Reference 
netMHC 3.2 ANN  IC50 8-11 (Lundegaard et al., 
2008a) 
NetMHCpan 2.4 pan-specific 
ANN 
IC50 8-11 (Nielsen et al., 
2007) 
NetMHCcons 1.0 NetMHC, 
PickPocket, 
NetMHCpan 
IC50 8-11 (Karosiene et al., 
2012) 
IEDB  ANN IC50 9+10 (Nielsen et al., 
2003) 
IEDB ARB (Matrix) IC50 8-11 (Bui et al., 2005) 
IEDB SMM (Matrix) IC50 8-11 (Peters and Sette, 
2005) 
IEDB SMMPMBEC 
(Matrix) 
IC50 8-11 (Sidney et al., 
2008) 
IEDB Pan-specific 
ANN 
IC50 8-11 (Hoof et al., 2009) 
SYFPEITHI Matrix Score (AU) 9+10 (Parker et al., 
1994) 
BIMAS Matrix Score (AU) 9+10 (Rammensee et al., 
1999) 
 
Whenever possible, the option to predict binding affinities for all possible peptides with 8, 9, 10 and 
11 amino acids (8-11mers) was selected and standard settings recommended by the respective 
developers were chosen. HLA-A3 (HLA-A*03:01), HLA-A11 (HLA-A*11:01) and HLA-A24 (HLA-
A*24:02) were selected as alleles individually. The protein sequences, HPV16 E6 and E7 
(NC_001526), which were applied are shown in Table 2.  
Table 2 I Amino acid sequences of HPV16 E6 and E7 proteins. Sequences were derived from the HPV16 reference 
sequence (NC_001526) and belong to the HPV16 variant European Prototype 1. The E6 protein is translated starting from the 
second methionine (M) at position 8. 
Protein 
name 
Amino acid sequence 
HPV16 
E6 
MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFR
DLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCI
NCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL 
HPV16 
E7 
MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNI
VTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP 
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The output lists were combined into one file with binding affinities given as a score in arbitrary units 
(BIMAS and SYFPEITHI) or as IC50 values [nM] (all other servers). To this end, the PERL script 
PeptidePrediction.pl, which automatically combines all output files into one sortable file, was used 
(written by Jan Winter). The script only accepts tab-separated text files of the different prediction 
server results and all files had to be put into one folder. For NetMHC, NetMHCpan and NetMHCcons, 
the option “Save prediction to .xls file” had to be selected and the corresponding XLS files were 
renamed according to e.g. “netmhc%.txt”. The script assumes certain standard values like the file 
name and the binding affinity threshold that is used by the prediction server. File name and binding 
affinity threshold for the respective server could be changed. For the other prediction servers, the 
results were copied directly from the website into Notepad++ and saved.  
Depending on the number of peptide lengths that were available for one server, several files were 
created that were distinguishable by an additional number within the name, e.g. “netmhc1.txt”, 
“netmhc2.txt” etc. The standard number of files and specifics are described in Table 3. 
Table 3 I Naming system and specifies of output from prediction servers. Results of predictions were saved in tab-
separated text files indicating the server name and number. % stands for the number (1, 2, 3 etc.) that describes the different 
outputs for various amino acid lengths for the same HLA allele and server. 
Server Standard file name Standard # files Standard threshold 
NetMHC netmhc%.txt  4 40000 
NetMHCpan netmhcpan%.txt 1 40000 
NetMHCcons netmhccons%.txt 1 40000 
IEDB (all) iedb%.txt 5 40000 
SYFPEITHI syf%.txt 1 0 
BIMAS bimas%.txt 2 0 
 
Merging of data is achieved through comparing the information about the amino acid sequence, the 
starting position and the threshold for each predicted peptide and prediction server. This results in a 
tab-separated text file “PeptidePrediction.txt”. The content of this file was then copied into a provided 
excel file “Peptide Prediction XX HLA.xlsx” to create a sortable excel sheet as shown in Table 4. 
Here, the peptides were sorted then by the average predicted IC50-value calculated from all servers 
except BIMAS and SYFPEITHI. The in vitro binding affinities of all peptides with an average IC50 
below 5000 or 7000nM were then tested in competition-based binding assay (section 2.2.3.1). 
Table 4 I Final output of combined results from all peptide prediction servers. Results were combined by the 
PeptidePrediction.txt PERL script and pasted into a sortable excel sheet. A clipping of predictions of HPV16 E6 peptides 
binding to HLA-A*24:02 is shown exemplarily. 
 
 
id Position Start Region Length Sequenz NetMHC Score NetMHC Pan Score NetMHC cons Score IEDB - ann IEDB - smm IEDB - arb IEDB - smmpmbec IEDB - netmhcpanSYFPEITHI BIMAS
233 87 87 - 95 9 CYSLYGTTL 452,000 220,045 506,120 452,421 941,670 815,380 955,615 995,27 20,00 200,000
228 82 82 - 90 9 EYRHYCYSL 485,000 176,188 681,520 485,942 944,587 171,733 786,267 482,07 19,00 200,000
693 98 98 - 107 10 QYNKPLCDLL 641,000 320,498 1249,170 641,425 1843,395 320,666 966,079 1619,56 23,00 360,000
195 49 49 - 57 9 VYDFAFRDL 918,000 260,234 1242,430 918,266 1212,345 1477,972 1379,054 984,56 23,00 240,000
147 1 1 - 9 9 MHQKRTAMF 1302,000 452,602 628,400 1302,388 1435,462 627,973 1194,406 1550,96 12,00
677 82 82 - 91 10 EYRHYCYSLY 1461,000 4160,745 4856,710 1461,167 1628,276 8155,474 1199,989 6262,79 11,00 5,000
655 60 60 - 69 10 VYRDGNPYAV 1524,000 1426,974 2403,860 1524,160 826,249 1845,831 636,616 2607,06 13,00 6,000
277 131 131 - 139 9 RFHNIRGRW 2617,000 287,708 1864,160 2617,660 1540,828 186,645 1763,666 598,54 6,00
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2.2.1.2 MHCcombine 
Since it is very laborious to combine all different results even with the help of the PERL script 
PeptidePrediction.pl, we developed a web-based tool, MHCcombine, which combines the results of ten 
prediction servers directly into one file that can be opened in a sortable MS Excel® format. 
MHCcombine processes data directly from the respective servers and combines the outputs in the same 
manner as the PERL script. However, none of manual steps descriped above have to be performed by 
the user. This web-based tool was developed in context of this PhD thesis with the kind help of Jan 
Winter and Christine Zeller who programmed the tool.  
2.2.1.3 Evaluation of prediction servers 
By taking the reference sequence of HPV16 E6 and E7 proteins (NC_001526) and HLA-A3 (HLA-
A*03:01), HLA-A11 (HLA-A*11:01), HLA-A24 (HLA-A*24:02) as examples, evaluation of the 
performance of the servers described in Table 1 was performed with in vitro data retrieved from 
competition-based binding assays (section 2.2.3.1). By this, we wanted to measure the ability of 
prediction servers to correctly classify our experimental results into binders or non-binders. Sensitivity 
is the proportion of experimentally measured binders, which were predicted as binders and is defined 
as true positive rate. The false positive rate describes the proportion of experimentally measured non-
binders that were incorrectly predicted as binders. To this end, receiver operating characteristic (ROC) 
curves (Swets, 1988) were created. Plotting the rates of true positive predictions as a function of the 
rate of false positive predictions results in a ROC curve. The area under the curve (AROC) gives a 
measure of the prediction quality. The AROC of a prediction server is equivalent to the probability that 
the prediction server will rank a randomly chosen positive instance higher than a randomly chosen 
negative instance and is also equivalent to the Wilcoxon test of ranks (Hanley and McNeil, 1982). 
All chosen NetMHC and IEDB prediction algorithms were included into this evaluation. The two 
servers BIMAS and SYFPEITHI were omitted due to unclear definition and discrimination of 
predicted binders and non-binders.  
2.2.1.4 Peptide motif analysis  
In order to identify HPV16 E6 and E7 peptides that were predicted with an average IC50 above a 
certain cutoff, but do bind to the desired HLA type nevertheless, amino acid distribution motifs were 
generated from the peptides identified as binders (positive motifs) and non-binders (negative motifs). 
By this, it was possible to screen peptides for potential motifs that either suggest binding due to 
defined positions of amino acids or exclude possible binding.  
Generation of amino acid distribution motifs 
Binding assay results (sections 3.1.2, 3.1.3 and 3.2) were processed with the AAcount.pl PERL script 
(written by Jan Winter) that creates matrices by counting the occurrence of amino acids at each 
position within a group of peptides. Those matrices can then be visualized with additional tools. To 
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this end, all HPV16 E6 and E7 peptides that were tested as binders (IC50 < 100µM) and non-binders 
(IC50 > 100µM) were combined into two tab-separated text-files containing the protein name, the 
amino acid position, the sequence and the experimental IC50 of the peptides (Tab. 5). AAcount.pl was 
applied on both files, creating a text-file output including a FASTA format summary of the peptides 
sorted by peptide length.  
Table 5 I Tab-separated text file input for the PERL script AAcount.pl. Binding assay results were converted into a tab-
separated format, starting with the protein, region, sequence and the IC50 value if applicable. A clipping of the file from tested 
HPV16 E6 peptides binding to HLA-A*24:02 is shown exemplarily.  
Protein Region Sequence IC50 (optinal)[µM] 
E6 85-95 HYCYSLYGTTL 0,09536667 
E6 49-57 VYDFAFRDL 0,10343333 
E6 87-95 CYSLYGTTL 0,1191 
E6 49-59 VYDFAFRDLCI 0,25856667 
E6 66-76 PYAVCDKCLKF 0,2817 
… … … … 
 
The FASTA output (Tab. 6) was then used to create sequence logos which visualize the amino acid 
occurrence at each position in a given set of peptides. To do so, the FASTA outputs for the different 
peptide lengths were copied to the input mask of the Weblogo 3 web service (Crooks et al., 2004), 
individually. Sequence logos (examples are displayed in section 3.1.3 Fig. 22 and 23), were created 
applying the settings listed in Table 7 and saved as .pdf files. 
Table 6 I I FASTA format of predicted peptides used for creation of sequence logos with Weblogo3 and for 
ScanProsite. Peptides are written in the format: >region_length_protein_sequence. A clipping from the file for motif search 
of HPV16 E6 peptides binding to HLA-A*24:02 is shown exemplarily. 
FASTA  
region    length       protein  
 x 
>85-95_11_E6  
HYCYSLYGTTL        sequence 
>49-57_9_E6 
VYDFAFRDL 
>87-95_9_E6 
CYSLYGTTL 
>49-59_11_E6 
VYDFAFRDLCI 
>66-76_11_E6 
PYAVCDKCLKF 
… 
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Table 7 I Settings applied for the creation of sequence logos with Weblogo 3 (Crooks et al., 2004). 
Option Input Option Input 
Output format PDV (vector) Error bars checked 
Logo size large Title Logo title 
Stacks per line 40 Figure label empty 
Sequence type protein X-axis position 
Ignore lower case checked Y-axis auto 
Units bits Y-axis scale auto 
First position number 1 Y-axis tix spacing 1 
Logo range empty Sequence end labels unchecked 
Composition No adjustment Version fineprint checked 
Scale stack widths checked Color scheme Hydrophobicity 
 
Motif search 
To investigate possible additional binding peptides for HLA-A3 (HLA-A*03:01), HLA-A11 (HLA-
A*11:01) and HLA-A24 (HLA-A*24:02), amino acid distribution results were used to search for 
motifs within the predicted peptide list that was created before. By searching for similar amino acid 
motifs, additional peptides might be found within the predicted list that were not considered due to 
thresholds that were applied before the selection peptides to be tested was made. The amino acid 
distribution was used to search for similar motifs with the ExPASy ScanProsite tool. To this end, 
binding motifs, that were compatible with the ScanProsite format, were created out of the amino acid 
distribution sequence logos and enriched by residue information described before by (Sette and 
Sidney, 1999) and (Rammensee et al., 1999). 
For each peptide length, three positive and three negative motifs were generated. With the positive 
motifs, ScanProsite searches for existence of the amino acids at the defined positions, since they were 
found to facilitate binding to the respective HLA-type as proven by in vitro binding assays. With the 
negative motifs, in contrast, it searches for the absence of these amino acids at the defined positions in 
the peptides, since they were contained in peptides determined to not bind to the respective HLA-
molecule. For each positive and negative motif, three sequences were created that account for a C- and 
N-terminal match or a C- or N-terminal match of the scanned peptide with the motif. The sequences 
inducing a C- and N-terminal match will only match with peptides of the same length as the motif. 
The C- or N-terminal sequences in contrast, allow longer or shorter peptides to match with this motif. 
In addition to these motifs, ScanProsite requires a FASTA-formatted list of all peptides to be scanned 
for matches. Thus, the lists of predicted HPV16 E6 and E7 peptides were combined in a FASTA text-
file and converted to the format shown in Tab. 6 using Notepad++. 
Both, the motifs (section 3.1.3, Fig. 22 and 23) and the FASTA-formatted predicted peptide list (Tab. 
6), were then copied to the web interface of ScanProsite. Here, all options were unticked and the 
output format was selected to ‘plain text tabular’. The results were copied and pasted to a new 
Notepad++ text-file. Since the tool handled a maximum of 30 peptides and eight motifs in one run at 
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the time of access, this step was repeated until all peptides were scanned for all motifs. The results 
were copied to the same text-file. Using the PERL Script ScanProsite_result.pl (written by Jan 
Winter), the file was then converted to an Excel file combining the motif matches of each peptide (Fig. 
13). Results were analyzed for peptides matching with at least two positive motifs or with one positive 
and no matching with any negative motif. The binding affinities of these peptides were tested 
experimentally in competition-based binding assays (section 2.2.3.1). 
Protein Region Length Pattern Sequence Length 
E6 85-95 11 2 
 
11 
   
6 CYSLYGTTL 
 
   
3 YSLYGTTL 
       
Figure 13 I ScanProsite result.pl output for one peptide. ScanProsite result.pl creates a list view and combines all matched 
motifs for one peptide. Within the result, the input information of the peptide is given (yellow), the matched motifs (blue), the 
matched sequence (green) and the peptide length (orange). 
 
2.2.2 Molecular biological methods 
2.2.2.1 DNA extraction 
DNA extraction was conducted using the QIAamp DNA Mini Kit (Qiagen, Hilden). DNA binds 
specifically to the QIAamp silica-gel membrane while contaminants pass through and PCR inhibitors, 
such as divalent cations and proteins, are completely removed in wash steps. Pure DNA is then eluted 
in water. DNA extraction was performed according to the manufacturer’s instruction. Briefly, cells 
were harvested as described under section 2.2.4, counted and up to 5x10
6
 cells were used. After 
isolation, the DNA concentration was measured by Nano Drop (section 2.2.2.4). 
2.2.2.2 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction allows the amplification of DNA starting with a low concentrated 
template (Saiki et al., 1985; Mullis et al., 1986). As starter molecules, short synthetic oligonucleotides 
(primers) are used that bind specifically to the flanking 3’ regions of the desired DNA-fragment. Using 
a heat stable polymerase, synthesis of the strand occurs in 5’ to 3’ direction. In this study, PCR was 
used on the one hand to amplify HPV16 E6 and E7 genes from cell lines for subsequent sequencing to 
determine their HPV16 variant and on the other hand to HLA genotype buffy coats that were used to 
generate peptide-specific short-term T cell lines (section 2.2.5.1). 
The PCR reaction starts by heating up the DNA template to 95°C or 92°C, depending on the PCR 
program used, which denatures the double strands into single strands. Often an initial denaturation step 
is conducted before the first denaturation step. The sample is then cooled to a specific temperature, 
which allows the primers to anneal to the template. The melting temperature for primers was 
determined by software analysis and the PCR program adjusted accordingly. When the sample is 
heated up again to 72°C, the polymerase uses the primers as starting points to synthesize a new DNA 
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strand complementary to the DNA template strand. This cycle is repeated several times. After 
finishing the last cycle, a final elongation step follows in some cases, to ensure that all left single DNA 
strands are fully extended. Tables 8 and 10 show the compositions of the used PCR reactions for 
HPV16 variant sequencing and HLA genotyping, and Tables 9 and 11 the corresponding PCR 
programs. 
Table 8 I Components for HPV16 E6 and E7 sequencing PCR. 
Component Stock concentration  Final concentration Volume/sample [µL] 
10x PCR buffer 10x 1x 5 
dNTPs 10mM 200µM 4 
MgCl2 solution 25mM 2.5mM 5 
Forward Primer  10µM 1µM 5 
Reverse Primer 10µM 1µM 5 
Template-DNA  40ng/µL 400ng 10 
AmpliTaq Gold DNA 
Polymerase 
5 U/µL 1.25 U/reaction 0.25 
PCR grade ddH2O - - ad. up to 50µL 
Vtotal   50 
 
Table 9 I PCR cycles for HPV16 E6 and E7 sequencing PCR. 
Step Time [min] Temperature [°C] 
Initial denaturation  15 95 
Denaturation 1 94 
Annealing 1 55            40x 
Extension 2 72 
Final extension  10 72 
Final hold ∞ 4 
 
Table 10 I Components for HLA genotyping PCR. 
Component Stock concentration  Final concentration Volume/sample [µL] 
REDTaq® 
ReadyMix™ PCR 
Reaction Mix 
2x 1.08x 1.5 
Forward Primer  10µM 1µM 2.5 
Reverse Primer 10µM 1µM 2.5 
Template-DNA  50µg/µL 50ng 1 
PCR grade ddH2O - - ad. up to 25µL 
Vtotal   25 
 
Table 11 PCR cycles for HLA genotyping PCR. 
Step Time [min] Temperature [°C] 
Initial denaturation  5 92 
Denaturation 1 92 
Annealing 2 65            30x 
Extension 3 72 
Final hold ∞ 4 
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Denaturation, annealing and extension were repeated for 30 or 40 times, respectively. All PCR 
reactions were prepared on ice, mixed and put into the pre-heated PCR cycler (C1000 Touch™ 
Thermal Cycler; Biorad, Hercules, CA, USA). Primers were purchased from Sigma-Aldrich and 
primer sequences are listed in section 2.1.13.2. The exact used primer pairs for HLA-genotyping are 
displayed in Table 12. For controls, either DNA template or primers were substituted by PCR grade 
ddH2O. DNA from cells with known HLA-type was used as a reference for HLA genotyping PCR. 
Optimized PCR conditions for HPV16 E6 and E7 sequencing were kindly provided by Tarik Gheit 
(WHO/IARC, Lyon). Successful PCR was verified by gel electrophoresis (section 2.2.2.3). 
Table 12 I Overview of primer pairs for HLA genotyping PCR. Primers, the HLA types that are covered by the primer 
and the resulting product size are indicated (Bunce, 2003). 
Primer 
names 
Pair HLA types Product 
size  
HLA-f-402 
HLA-r-249 
A2-1 A*0201, *0204, *0206, *0207, *0209, *0210, *0214, *0215N, 
*0216, *0217, *0218,*0220, *0221, *0224, *0225 
521 bp 
HLA-f-296 
HLA-r-302 
A2-2 A*0201, *0202, *0203, *0204, *0205, *0206, *0207, *0208, *0209, 
*0210, *0211,*0212, *0213, *0214, *0215N, *0216, *0217, *02172, 
*0218, *0219, *0220, *0221,*0222, *0225, *0226 
489 bp 
HLA-f-291 
HLA-r-299 
A3 A*0301, *0302, *0303N, *0304 628 bp 
HLA-f-290 
HLA-r-145 
A11-
1 
A*1101, *1102, *1103, *2502, *6601 552 bp 
HLA-f-239 
HLA-r-167 
A11-
2 
A*2501, *2502, *2601, *2603, *2605, *2607, *2608, *4301, *6601, 
*6602, *6603 (control for A11-1 and A11-3) 
170 bp 
HLA-f-290 
HLA-r-167 
A11-
3 
A*2501, *2502, *2601, *2603, *2605, *2607, *2608, *4301, *6601, 
*6602, *6603 
552 bp 
HLA-f-208 
HLA-r-146 
A24-
1 
A*2402, *2403, *2405, *2407, *2408, *2409N, *2410, *2411N, 
*2414 
504 bp 
HLA-f-292 
HLA-r-170 
A24-
2 
*2402, *2402102L, *2403, *2404, *2405, *2407, *2409N, *2410, 
*2411N, *2414 
557 bp 
HLA-f-193 
HLA-r-221 
B7 B*07021, *07022, *07023, *0703, *0704, *0705, *0706, *0707, 
*0708, *8101 
1207 bp 
HLA-f-243 
HLA-r-250 
B15 B*1501, *1502, *1504, *1505, *1506, *1507, *1508, *1511, *1512, 
*1514, *1515,*1519, *1520, *1521, *1525, *1526N, *1527, *1528, 
*1530, *1531, *1532, *1533,*1534, *1535, *1538, *1539 
124 bp 
HLA-f-280 
HLA-r-281 
B27-
1 
B*2701, *2702, *2703, *2704, *27052, *27053, *2706, *2707, 
*2708, *2709, *2710, *2711 
149 bp 
HLA-f-280 
HLA-r-282 
B27-
2 
B*2701, *2702, *2703, *2704, *27052, *27053, *2706, *2707, 
*2708, *2709, *2710, *2711 
150 bp 
 
2.2.2.3 Agarose gel electrophoresis 
As nucleic acids are charged negatively due to their phosphate residues, they can be separated by 
agarose gel electrophoresis using an electric field (Sambrook and Gething, 1989). Shorter DNA 
fragments migrate faster and further than larger ones and therefore the DNA fragments undergo a 
characteristic separation. Detection is performed with the help of ethidium bromide, which interacts 
with nucleic acids and can be visualized by UV light. A 1% agarose gel was used which was 
supplemented with 0.5μg/mL ethidium bromide. Samples were mixed with 6x Orange DNA Loading 
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Dye (Thermo Fisher Scientific Ldt., Loughborogh, UK) before they were applied to the gel. 
GeneRuler
TM
 DNA Ladder (Thermo Fisher Scientific Ldt., Loughborogh, UK) was used as a reference 
for the size of the DNA strands. Running of gels in 1x TAE buffer was conducted at 125V until bands 
were sufficiently separated. Afterwards, gels were documented using the INTAS UV System, Gel Jet 
Imager 2006.  
2.2.2.4 Determination of DNA concentration 
1µl of DNA sample was applied to the Nano Drop to measure the concentration and purity of the 
sample. Nucleic acids absorb light at different wavelengths. By using the Lambert-Beer law: 
A = ε x c x d 
(A: absorbance, ε: extinction coefficient; c: concentration; d: distance), 
the absorbance can be related to the concentration of a sample. At a wavelength of 260nm, the 
extinction coefficient for ds DNA is 0.02 (µg/mL)
-1
 cm
-1
. Hence, an optical density (OD) of 1 
corresponds to a concentration of 50µg/mL. In contrast, proteins show a maximum light absorption at 
280nm. Thus the purity of nucleic acids can be determined by measuring the ratio of 260nm and 
280nm with an optimal value between 1.8 and 1.95. 
2.2.2.5 Sequencing of HPV 16 E6 and E7 genes 
PCR products were sequenced by GATC Biotech, Konstanz. To this end, 20µL of unpurified PCR 
sample with a concentration of 100ng/µL DNA were sent for sequencing. 
2.2.2.6 Analysis of HPV 16 E6 and E7 sequences 
In order to characterize the HPV16 variants present in our cell line collection, 62 HPV16 whole 
genome sequences, representative of all known variants, provided by Robert D. Burk (Albert Einstein 
College of Medicine, New York, NY, USA) (Burk et al., 2011; Smith et al., 2011), were used as 
references. The sequences were grouped beforehand according to the variant lineages and sublineages 
they represent (European Prototype 1, European Prototype 2, European Asian, African-1, African-2, 
North American-1, Asian American-1, Asian American-2). Multiple sequence alignments within the 
groups were conducted by using the Clustal-W algorithm (match: 2, gap penalty: -2, gap extension 
penalty: -1) implemented in GENtle. By this, sequence differences within the E6 and E7 open reading 
frames (nucleotides 83-559 and 562-858, respectively) for each group were identified. The DNA 
sequences were then translated into protein sequences to reveal silent and non-silent mutations in 
comparison to the HPV16 reference sequence (NC_001526).  
Sequences of the HPV16 E6 and E7 PCR samples obtained from GATC Biotech were aligned to the 
HPV16 reference sequence as described above. All nucleotide changes were listed and compared with 
variant lists to see if nucleotide exchanges would result in exchanges on protein level. In cases where 
novel nucleotide exchanges were detected, the sequence was translated into the protein sequence and 
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the respective codon was checked for silent and non-silent mutations. All HPV16-positive cell lines 
from our cell culture could be assigned to a specific HPV16 variant. 
2.2.3 Biochemical Methods 
2.2.3.1 Competition-based binding assays 
Peptide binding affinity to selected HLA class I molecules was tested in competition-based cellular 
binding assays (Kessler et al., 2003; Kessler et al., 2004) based on the competition of HLA class I 
binding between a test peptide of interest and a fluorescein-labeled HLA class I binding reference 
peptide, which is a known strong binder to the HLA meolecule of interest. The binding affinity of the 
test peptide was determined by non-linear regression analysis as the concentration that inhibits 50% 
binding of the fluorescein-labeled reference peptide (IC50). 
Briefly, a 96-well plate was prepared containing serial dilutions in 1xPBS of a peptide with a high 
binding affinity (positive controls: HLA-A3: consensus sequence KVFPALINK (Sette et al., 1994); 
HLA-A11: HIV-1 Nef 73-82 QVPLRPMTYK (Koenig et al., 1990); HLA-A24: HIV-1 env pg41 583-
591 RYLKDQQLL (Dai et al., 1992)), a peptide with a low binding affinity (negative control: HLA-
A3/11: HPV16 E6/85-94 HYCYSLYGTTL; HLA-A24: HPV16 E6/93-101 TTLEQQYNK), a DMSO-
only control (peptide diluent) and test peptides (dilutions from 600 – 4.6875µM in 1:2 steps in 1xPBS, 
50µL per well). 25µL of each well were transferred to the same well of a second 96-well plate 
containing 25µL 900nM fluorescent reference peptide (HLA-A3/11: KVFP(fluorescein)ALINK; 
HLA-A24: RYLK(fluorescein)QQLL), in each well except for those of the DMSO-only control (25µL 
1xPBS instead). 
B-LCL cells with the desired HLA class I molecule were washed twice with 1xPBS and then stripped 
from natural bound peptides and β2-microglobulin by using ice cold citric acid buffer (HLA-A3: pH 
2.9; HLA-A11: pH 3.1; HLA-A24: pH 3.1) for 90sec. After stripping, the cells were instantly washed 
twice with ice-cold culture medium before they were finally dissolved in culture medium which 
contained 4µL/mL β2-microglobulin (MP Biomedicals, Illkirch, France; BD Biosciences, Franklin 
Lakes, NJ, USA) to reconstitute the HLA class I complex. 100µL of the cell suspension containing 
6x10
4 
cells were pipetted to each well of the 96-well plate resulting in a final concentration of control 
and test peptides from 100-0.78µM. The concentration of fluorescent reference peptide was 150nM. 
Plates were incubated o/n at 4°C in the dark, washed twice with 0.5% BSA in 1x PBS, resuspended in 
80µL/well 1% PFA in 1xPBS and stored at 4°C in the dark until flow cytometric analysis.  
Fluorescence was measured by flow cytometry (FACS Canto II™; BD Biosciences, Franklin Lakes, 
NJ, USA) and data processed as described in section 2.2.4.4. The binding of each test and positive-
control peptide was calculated as the percent inhibition of Fl peptide binding relative to the minimal 
response (without Fl peptide; MFbackground) and the maximal response (Fl peptide only; MFFl) using the 
following equation: 
  Material and Methods 
75 
 
100 x )
MF - MF
MF - MF
-(1  (%)  Inhibition
backgroundFl
background
  
 
Percent inhibition was plotted against the peptide concentration and a logistic 4-parametric non-linear 
regression curve was fitted to the data points using SigmaPlot software. From this regression analysis, 
the peptide concentration that inhibited binding of the fluorescent reference peptide by 50% (IC50) was 
calculated for each peptide using the following equation: 
d)
c
x
(  1
b
  a y 

  
(a-d: constants in equation), 
where x represents the peptide concentration and y the corresponding inhibition (%). Peptides were 
ranked as strong binders (IC50 < 5µM), intermediate binders (IC50 5-15µM) or weak binders (IC50 15-
100µM), as recommended for the used reference peptides (Kessler et al., 2003; Kessler et al., 2004). 
Peptides with an IC50 above 100µM were defined as non-binders. For confirmation and statistical 
significance, the assay was performed three times for binders and twice for non-binders. 
2.2.3.2 Immunoprecipitation 
To assess that the candidate peptides are truly presented on the surface of HPV16-transformed cells, 
HLA class I molecule/peptide complexes were isolated from these cells. Immunoprecipitations of 
various HLA-class I molecule/peptide complexes from different HPV16-transformed cells was carried 
out and analyzed for purity and enrichment by Oriole staining (section 2.2.3.5) and Western blot 
(section 2.2.3.6). 
GammaBind™ Plus Sepharose™ beads (GE Healthcare, Munich) were prepared by taking 1mL of dry 
beads (equal to 2mL of beads in suspension) into a 2ml tube and centrifugation at 5000rpm for 3min at 
RT with a swinging rotor. The supernatant (SNT) was removed and 1mL of 10% acetic acid (pH 3.0) 
added, the beads were vortexed and centrifuged at 5000rpm for 3min at RT with a swinging rotor. The 
SNT was removed and the beads were washed five times with 1mL 1xPBS. Eventually, the SNT was 
removed and the beads were resuspended in 1mL 1xPBS with 0.02% sodium azide and stored at 4˚C.  
Depending on growth properties, cells were seeded four to two days prior immunoprecipiation in 
10cm Ø cell culture dishes. 50µL sepharose beads were washed three times with 500µL 1xCHAPS 
buffer and then coupled with 20µg of specific antibody directed against the desired HLA class I type 
in 500µL 1x CHAPS buffer for two to three hours at RT on a rotator. In the meantime, cells were 
washed twice with ice-cold 1xPBS, detached with a cell scraper and lysed in 1mL 2x CHAPS buffer. 
Cell lysates were pooled of different numbers of confluent 10cm Ø cell culture dishes, by transferring 
the lysate from one to the next dish without adding new CHAPS buffer. The lysate pools were then 
incubated for 10min on ice and vortexed every 3min before they were centrifuged for 30min at 
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14000rpm at 4°C. After centrifugation, an aliquot of the cleared lysate was taken for analysis. After 
incubation of beads with antibody, beads were centrifuged at 5000rpm for 3min with a swinging-rotor. 
The SNT was removed and beads were washed twice with 500µL 1xCHAPS buffer. Cleared lysate 
was incubated with the respective anti-HLA-class-I-antibody-coupled sepharose beads on a rotator at 
4°C for 3hrs. As negative controls, CHAPS buffer was incubated with beads alone or beads coupled 
with antibody.  
After incubation with cleared lysate, beads were washed twice with 500µL of ice-cold 1:1 diluted 2x 
CHAPS lysis buffer, once with ice-cold 1x CHAPS buffer and three times with ice-cold 10mM Tris-
HCl (pH 8.0). Aliquots of the flow through and of the SNTs of all washing step were collected for 
analysis. HLA/peptide complexes on washed beads were then used for biochemical analysis or mass 
spectrometry (MS) analysis. Samples for MS were stored at -80°C. For SDS-PAGE, the beads were 
mixed with 20µL 10mM Tris-HCl (pH 8.0) and 20µL 2x Laemmli sample buffer (Biorad, Hercules, 
CA, USA). 
2.2.3.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE (Laemmli, 1970) is a method for separating denatured proteins according to their 
molecular weight. In the process, one uses the negatively charged detergent SDS which is able to mask 
the different charges of the amino acid residues. All proteins are thus stretched, and these negatively 
charged polypeptides can be separated by an electric field in a polyacrylamide matrix. As proteins 
have a constant negative charge per mass unit, separation occurs exclusively by their molecular 
weight. Moreover, disulfide bridge formation is inhibited by adding 2-mercaptoethanol. The samples 
are commonly boiled at 95°C for 10min in 2x Laemmli buffer to enhance the denaturing effect of 
SDS.  
The desired volume of sample was loaded onto an Any kD™ Precast Gel (Biorad, Hercules, CA, 
USA) that was put into an electrophoresis chamber for SDS-PAGE (Mini-PROTEAN® Tetra Cell; 
Biorad, Hercules, CA, USA). As a marker either Precision Plus Protein™ Standards Kaleidoscope ™, 
10-250kDa (Biorad, Hercules, CA, USA) for Coomassie staining and Western blot or Precision Plus 
Protein™ Unstained Standards ™, 10-250kDa (Biorad, Hercules, CA, USA) for Oriole staining were 
used. The protein samples were run at 100V until loading pockets were empty and were subsequently 
run at 150V. Afterwards, the gels were either stained (sections 2.2.3.4 and 2.2.3.5) or used for Western 
blot analysis (section 2.2.3.6). 
2.2.3.4 Coomassie stain 
Protein gels were Coomassie-stained after electrophoresis (section 2.2.3.3) using Coomassie Brilliant 
Blue solution gently shaking o/n at RT. To reduce background staining, gels were destained for 30 to 
60min in Coomassie destaining solution and subsequently washed with Milipore water. Gels were 
scanned for documentation. 
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2.2.3.5 Oriole stain 
Oriole staining of protein gels was performed according to the manufacturer’s instructions using 
Oriole™ Fluorescent Gel Stain (Biorad, Hercules, CA, USA). Briefly, gels were incubated for 90min 
in Oriole™ Fluorescent Gel Stain and put into Milipore water for documentation with the Gel Doc™ 
EZ Imager (Biorad, Hercules, CA, USA). 
2.2.3.6 Western Blot 
Western blot analysis is based on the principle that proteins bind to nitrocellulose or polyvinylidene 
fluoride (PDFV) membranes and can be detected by antibodies (Thorpe and Kricka, 1986). The 
electrical transfer of the proteins onto a PVDF membrane was performed using the tank transfer 
method. After SDS-PAGE (section 2.2.3.3), the PVDF Transfer Membrane (Thermo Scientific, 
Rockford, IL, USA) was activated shortly in 100% methanol and subsequently equilibrated together 
with the polyacrylamide gel and two Western Blotting Filter Papers (Thermo Scientific, Rockford, IL, 
USA) in transfer buffer for 1min. Western Blotting Filter Papers, the gel and the PVDF Transfer 
Membrane were assembled, occurring air bubbles removed, and the package placed into the transfer 
chamber (Mini Trans-Blot® Cell; Biorad, Hercules, CA, USA) according to the schematic diagram 
shown in Figure 14. Protein transfer was performed for 1.5hrs at 30V and 4°C. Successful transfer of 
proteins to the PVDF Transfer Membrane was monitored by Ponceau Red (Serva, Heidelberg) 
staining. To this end, the PVDF membrane was incubated for 30-60sec with Ponceau S solution. 
Afterwards the membrane was washed with ddH2O to visualize red protein bands. For subsequent 
processing of the blot membranes, the Ponceau S stain was removed by incubation of the membrane in 
1xPBS for several minutes.The blot was then blocked for 45min in 5% milk powder (blotting grade; 
Roth, Karlsruhe) in 1xPBS at RT.  
 
Figure 14 I Schematic presentation of the assembly of a Western Blot. The gel and PVDF membrane are placed into the 
cassette between two filter papers followed by a sponge on each side. 
After blocking, the blot was incubated with the desired first antibody (diluted in 1.5% milk powder in 
1xPBS) either o/n at 4°C or for 1hr at RT on a shaker. The antibody solution was then poured off and 
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the blot was washed three times for 5min with 1xTPBS with continuous shaking. Afterwards, the blot 
was incubated with the corresponding secondary antibody (diluted in 1.5% milk powder in 1xPBS) at 
RT for 45min. After incubation with the secondary antibody the blot was washed three times for 5min 
with 1xTPBS, covered with 750µL Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, 
Waltham, MA, USA) for 3min at RT and luminescence signals were recorded using a Fusion-SL 
chemiluminescence-camera (Vilber Lourmat, Eberhardzell). 
2.2.4 Cell culture methods 
Cell culture work was conducted under sterile conditions in a laminar flow hood. Prior to usage, 
equipment, material and solutions were sterilized or disinfected. Mycoplasma testing and cell 
authentification was performed upon arrival of newly acquired cell lines and at regular intervals to 
ensure mycoplasma negativity and cell authentiticy.  
2.2.4.1 Thawing and freezing of cells  
Frozen cells were stored in liquid nitrogen. In order to reduce extended exposure of cells to toxic 
concentrations of DMSO, handling of cells was done fast during freezing and thawing of cells. 
50mL tubes were filled with 20mL of pre-warmed medium. Cryo vials were taken from the liquid 
nitrogen tank and thawed immediately at 37°C in a water bath. Cells were then directly transferred 
into the prepared tubes and resuspended. Cells were centrifuged at 1400rpm for 5min at RT and the 
SNT decanted. A second washing step was conducted and cells were resuspended in 7mL medium and 
seeded into a 25cm
2
 flask. The next day or at least 12hrs after thawing, the medium was exchanged. 
For freezing, the cell suspension was centrifuged at 1400rpm for 5min at 4°C, the SNT removed and 
the cell pellet was resuspended in the appropriate volume of freezing medium. Freezing medium was 
always freshly prepared by taking the pre-cooled usual medium of the respective cell line and adding 
10% DMSO and 10% serum, either FCS or HS. Aliquots of 1mL with a cell concentration of up to 
1x10
7
 cells/mL were quickly transferred to 2mL cryo vials. Those were placed into a pre-cooled cell 
freezing device (Mr. Frosty; Bel-Art Products, Wayne, NJ, USA), which allows a consistent cool 
down of 1°C/min after being put into the -80°C freezer. Three days later, cryo vials were transferred to 
the liquid nitrogen tank for permanent storage. 
2.2.4.2 Culturing and passaging of cells 
All cell lines were cultured in an incubator at 37°C, 95% relative humidity and 5% CO2 in either 
25cm
2
, 75cm
2 
or 150cm
2
 tissue culture flasks or cell culture plates from 6- up to 96-wells. Adherent 
cell  flasks were kept horizontal while flasks for suspension cell lines were kept upright. Every second 
week at the latest, the cell culture flasks were exchanged.  
In order to passage adherent confluent cells, medium was removed and cells were washed with 
1xPBS. Cells were detached by incubation with trypsin-EDTA at 37°C until all cells detached upon 
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rocking of the flask. Trypsin-EDTA was inactivated by adding fresh, pre-warmed, serum-containing 
medium and cells separated by pipetting up and down. Cells were then transferred to 50mL tubes that 
were filled up with medium and centrifuged at 1400rpm for 5min at RT. The SNT was removed from 
the pellet by decanting and the cells were resuspended in fresh medium. They were either split at 
appropriate ratios (between 1:1 to 1:30) into fresh cell culture flasks or used for experiments. Cells 
were split whenever flasks reached between 80 to 100% confluency.  
Suspension cells (e.g. B-LCLs) were resuspended every day by shaking to isolate cells from 
accumulations. The desired volume of cell suspension for splitting was transferred to 15 or 50mL 
tubes that were filled up with medium and centrifuged at 1400rpm for 5min at RT. Cells were then 
resuspended in the appropriate volume of medium. 
W12 20861 and 20863 cells were grown on irradiated 3T3 fibroblast cells, serving as feeder cells. To 
this end, 3T3 cells were grown confluent, harvested by trypsination, washed with 1xPBS, irradiated at 
50Gy (Gammacell 1000; Atomic Energy of Canada Limited, Ottawa, Canada) and washed again with 
1xPBS. 10mL of cell suspension were then seeded at a concentration of 2x10
5
 cells/mL into a 75cm
2
 
flask. The next day irradiated 3T3 cells were checked under the microscope for confluency and 
morphology and approximately 2x10
5
 W12 20861 or 20863 cells were placed on top. Flasks of 
irradiated feeder cells were freshly prepared as soon as W12 cells grew confluent.  
Special cultivation methods for primary cells and other selected cell lines are described in section 
2.2.5.1. 
2.2.4.3 Counting of cells 
For counting, the respective cell suspension was, if necessary, pre-diluted in 1xPBS and then mixed 
1:1 with Trypan blue solution for live-dead discrimination. Cells were either counted manually with a 
Neubauer counting chamber (0.1mm depth) or counted automatically with the Countess® Automated 
Cell Counter (Invitrogen, Carlsbad, CA, USA). After manual counting with the Neubauer counting 
chamber, the total cell number was calculated using the following formula: 
total cell number =
counted cells
number of large squares
 x dilution factor x chamber factor (10000) 
2.2.4.4 Flow cytometry  
For flow cytometry analysis, a FACS Canto II™ (BD Biosciences, Franklin Lakes, NJ, USA) was 
used provided either by the DKFZ FACS Core Facility or by the Devision of Translational 
Immunology (D015, Philipp Beckhove), DKFZ. The FACS Canto II™ of D015 is equipped with a 
high throughput (HTS) device, which enables automatic processing of samples from a 96-well plate. 
All solutions were applied ice-cold, incubation steps were carried out either on ice or at 4°C and cells 
were kept in 96-well plates or FACS tubes. Typically, between 6x10
4
 to 1x10
6
 cells were used for flow 
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cytometry analysis. Cells were usually washed with FACS buffer (section 2.1.2) once, centrifuged at 
1400rpm for 5min at 4°C and blocked for 15min in 10% FCS in 1xPBS on ice. Subsequently, cells 
were resuspended in FACS buffer containing the appropriate dilutions of primary antibodies (section 
2.1.11.1). After 30 to 60min incubation in the dark at 4°C, cells were washed twice with FACS buffer. 
If necessary, a second incubation step of 30min at 4°C in the dark with FACS buffer containing a 
suitable secondary fluorochrome-conjugated antibody (section 2.1.11.2) was performed. Cells were 
washed twice with FACS buffer and stored on ice in an appropriate volume of FACS buffer for 
immediate analysis by flow cytometry or resuspended in 1% PFA and stored at 4°C until analysis.  
Autofluorescence of cells was determined by acquiring unstained cells. Voltages of lasers were 
adjusted based on single stainings. Gating was performed on living cells and adjusted to the desired 
subpopulations that were identified by distinctive markers. For each sample 10000 events or more 
were recorded in most cases. Final analysis was conducted with FlowJo 6.5 software (TreeStar, 
Ashland, OR, USA).  
Whenever multi-color stainings with more than one fluorochrome were done, compensation needed to 
be performed. Compensation describes the process of determination, calculation and subsequent 
subtraction of spectral overlaps from one fluorescent detector channel in FACS Canto II™ to the 
other. The auto-compensation tool of the BD FACS Diva Software (BD Biosciences, San José, CA, 
USA) calculated and applied the compensation to all acquired samples of one experiment. To 
determine the spectral overlap from one channel to another, additional single color stainings for each 
color used in the experiment were conducted and acquired. For this purpose, beads were coated with 
the same antibodies used for staining of cells. For each antibody, the same concentration as used for 
the cells was diluted in 100µL FACS buffer. One droplet of previously shaken OneComp eBeads 
(eBioscience, San Diego, CA, USA) was added to the solution. Samples were tapped for resuspending 
the antibodies and then incubated in the dark for 20min on ice. After labeling, 1mL FACS buffer was 
added for washing and beads were centrifuged at 4500rpm at 4°C. SNT was discarded and beads were 
resuspended in 200μL FACS buffer. The bead controls were then acquired with the FACS Canto II™ 
for compensation.  
Multi-color stainings 
Multi-color stainings were performed for determining the percentage of B cells in B cell cultures that 
were either generated by immortalizing B cells with EBV or by co-culture of PBMCs with tCD40L-
3T3 NIH feeder cells (section 2.2.5.1). Cells were stained with an antibody against CD19, a B cell 
marker, and antibodies against CD4 and CD8, markers for T cells, to discriminate between these cell 
populations. 
In addition, different protocols for generation of DCs (section 2.2.5.1) were compared and monitored 
by multi-color stainings. To this end, cells were stained on day 0, day 3, and day 8 to follow their 
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development. A panel of antibodies against CD14, CD80, CD83, CD86 and HLA-DR was used to 
discriminate between monocytes, immature Mo-DCs and mature Mo-DCs, displaying the following 
phenotypes: 
monocytes: CD14
+
, CD80
-
, CD83
-
, CD86
+
 and HLA-DR
+
 
immature monocyte-derived (Mo-)DCs: CD14
-
, CD80
+
, CD83
-
, CD86
+
 and HLA-DR
+
 
mature Mo-DCs: CD14
-
, CD80
-
, CD83
+
, CD86
+
 and HLA-DR
+
 
HLA staining 
To estimate the expression level of HLA molecules on cell lines, cells were stained for their respective 
HLA type to be able to isolate high amounts of presented peptides in the subsequent 
immunoprecipitation (section 2.2.3.2). Here, cells were only stained for the known HLA type. In 
addition, PBMCs from buffy coats that were used to generate peptide-specific short-term T cell lines 
(section 2.2.5.1) were also stained with specific antibodies against various HLA supertypes to 
determine their HLA type. In this case, antibodies against all HLA supertypes analyzed in our 
laboratory, HLA-A2, HLA-3, HLA-A11, HLA-A24, HLA-B7 and HLA-B15 were included. For each 
HLA type, a positive control with cells with known HLA type was included as reference. 
Briefly, cells were either detached with trypsin-EDTA or taken from suspensions, washed twice with 
1xPBS, counted and at least 1x10
6
 cells were resuspended in 1mL 10% FCS in 1xPBS for blocking. 
Of this cell suspension 100µL (1x10
5 
cells) were transferred to a well of a 96-well plate which was 
subsequently centrifuged at 1200rpm for 5min at 4°C. Unstained controls and controls for background 
fluorescence of the secondary antibody alone were included if necessary. After discarding the SNT, 
the cells of one well were incubated with 100µL solution of the desired antibody diluted in FACS 
buffer (section 2.1.11.1) for 30 to 60min at 4°C in the dark. In case of unstained controls, cells were 
incubated in FACS buffer without antibody. If a secondary antidody was necessary for detection, cells 
were washed twice with 150 µL/well FACS buffer before 100µL FACS buffer with the fluorochrome-
conjugated secondary antibody (section 2.1.11.2) was added. Cells were incubated for 30min at 4°C in 
the dark. Afterwards, cells were washed twice with 150µL FACS buffer, resuspended in 100µL FACS 
buffer, stored on ice and analyzed with a flow cytometer.  
2.2.4.5 Peripheral blood mononuclear cell  (PBMC) isolation  
Peripheral blood mononuclear cells (PBMCs) were either isolated from fresh blood donations or from 
buffy coats obtained from the DRK through the IKTZ (Heidelberg, Germany) by density gradient 
centrifugation. Prior to PBMC isolation, Ficoll-Paque™ PLUS (GE Healthcare Bio-Sciences, Uppsala, 
Sweden) and ACK lysis buffer (section 2.1.2) were brought to RT.  
First, the blood or buffy coat was diluted 1:1 or 1:10, respectively, in 1xPBS to improve detection of 
cells after centrifugation. In case of fresh blood donations, special Leucosep tubes (Greiner Bio-One, 
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Frieckenhausen) containing a porous barrier were used for gradient separation. 15mL Ficoll-Paque™ 
PLUS were pipetted into each tube and spun down at 1400rpm for 1min at RT. The Ficoll-Paque™ 
PLUS was then located directly under the barrier. 30mL of diluted blood were then poured carefully 
directly on top of the barrier. If PBMCs were isolated from buffy coats, 50mL tubes were filled with 
30mL each of the diluted buffy coat. About 15mL of Ficoll-Paque™ PLUS solution were added 
underneath the diluted buffy coat by using a 10mL glass pipette. To this end, the liquid was aspirated 
to fill the pipette up to the rim. Then the pipette was closed with a thumb and transferred to the 50mL 
tube, where the pipette was carefully placed into the tube to the tip of the bottom. The thumb was 
released to let the ficoll form a layer underneath the diluted buffy coat. As soon as the liquid surfaces 
inside the pipette and the tube were at the same level, the pipette was carefully lifted until its tip 
reached the layer boundary. When the surfaces were balanced again, the pipette was closed with the 
thumb and removed carefully from the tube.  
Every step was conducted carefully not to disturb the layering of the gradient solution and the blood or 
buffy coat, respectively. The tubes containing the layered Ficoll-Paque™ PLUS and diluted blood or 
buffy coat were then centrifuged at 1400rpm for 10min at RT with the centrifuge break turned off to 
prevent disturbing the layers during deceleration. After careful removal of the tubes from the 
centrifuge, a clear layer pattern was observed. The Ficoll-Paque™ PLUS containing most of the 
erythrocytes was located at the bottom of the tube. Clear serum containing soluble blood components 
and small particles was located at the top of the tube. In between those two layers, an opaque layer 
containing the desired PBMCs was located. To isolate this layer, most of the serum, down to 1cm 
above the PBMCs, was aspirated and discarded. The PBMC containing layer was then carefully taken 
up by using a 5mL glass pipette. The cells were collected in 50mL tubes and the volume was filled to 
50mL with 1xPBS. Cells were centrifuged at 1400rpm for 10min at RT. After removing the SNT by 
decanting, the cell pellet was loosened by grinding the tube on the margin of the sterile hood. As the 
cells still included erythrocytes, erythrocyte lysis had to be performed. Depending on the size of the 
pellet, 3 to 5mL of ACK lysis buffer were used to resuspend each cell pellet. The tubes were then 
shaken gently by inverting for 5min. Lysis was stopped by adding 1xPBS up to 50mL into each tube. 
Cells were then washed twice with 1xPBS. If cells were sticking to each other, cell suspensions were 
filtered using a 40μm cell strainer and pooled into a fresh 50mL tube. Eventually, cells were counted 
and stored on ice for subsequent experiments.  
2.2.4.6 Magnetic-activated cell sorting (MACS) 
Magnetic-activated cell sorting (MACS) is a method to separate various cell populations depending on 
their surface molecules (CD molecules). Cells are separated by incubation with magnetic nanoparticles 
coated with antibodies against a particular surface molecule. Cells that express this molecule attach to 
the magnetic nanoparticles and can be separated by a strong magnetic field. Thus, cells can be 
separated positively or negatively with respect to the particular surface molecule. The MACS 
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technology was used to purify CD14
+
 monocytes with CD14
+ 
microbeads (Miltenyi Biotec, Bergisch 
Gladbach) from freshly prepared PBMCs (section 2.2.4.5) and to isolate CD8
+
 T cells with the CD8
+
 T 
Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach) from bulk T cell cultures (section 2.2.5.1). All 
buffers were pre-cooled and cells kept on ice as long as possible. First, cells were counted, adjusted to 
up to 1x10
8
 cells per sample and washed with ice-cold MACS buffer. The procedures were carried out 
according to the manufacturer’s instructions. Afterwards, cell numbers of purified cells were 
determined and adjusted to desired cell numbers in respective media. 
2.2.5 T cell assays 
2.2.5.1 Generation of peptide-specific T cell lines 
Peptide-specific T cell lines were generated in order to show immunogenicity of candidate peptides, 
which were previously identified by competition-based binding assays (section 2.2.3.1). Additionally, 
peptides with confirmed immunogenicity were used to generate peptide-specific T cells that were 
tested for their cytolytic capability. To this end, DCs and B cells were matured and activated, which 
were then peptide-pulsed to serve as antigen-presenting cells (APCs) for stimulation of T cells. 
Different peptides and protocols, discriminating between short-term, semi long-term and long-term, 
were established and used to generate peptide-specific T cell lines. 
Generation of monocyte-derived dendritic cells (Mo-DCs) 
Mature, immunologically competent DCs are the most efficient APCs to stimulate T cells (Steinman, 
1991; Banchereau and Steinman, 1998; Thery and Amigorena, 2001). DCs need to be differentiated, 
matured and activated for this purpose. This is achieved by cultivation with the cytokine IL-4 and the 
growth factor GM-CSF and final maturation with a cocktail of TNFα, IL-1β, IL-6, PGE2 and LPS. 
Matured DCs can then be pulsed with the desired peptide. 
CD14
+
 monocytes were purified by MACS technology (section 2.2.4.6) with magnetic labelling and 
subsequent isolation. Cells were then resuspended at a concentration of 1x10
6
 cells/mL in DC 
medium, supplemented with 500U/mL IL-4 and 1000 U/mL GM-CSF and 2mL seeded into wells of a 
6-well plate. On day 3 and day 6, 500µL DC medium supplemented with IL-4 and GM-CSF, that 
reached a final concentration of 500U/mL and 1000U/mL, respectively, were added per well. 
A cocktail for final maturation of 1000U/mL TNFα (R & D Systems, Minneapolis, MN, USA), 
10ng/mL IL-1β (R & D Systems, Minneapolis, MN, USA), 10ng/mL IL-6 (R & D Systems, 
Minneapolis, MN, USA), 1µM PGE2 (1mg/mL) (Cayman Chemical, Ann Arbor, MI, USA) and 
1µl/mL LPS (5mg/mL, 5x10
4
 EU/mL) (Invivogen, Toulouse, France) was added on day 6 and cells 
were incubated for additional 24 hours. On day 8, mature Mo-DCs showed a unique morphology with 
multiple long thread-like dendrites and were harvested by gentle scraping and pipetting up and down. 
Cells were then stored on ice for subsequent experiments.  
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Differentiation and maturation of CD14
+
 monocytes was followed by flow cytometric analysis as 
described in section 2.2.4.4. (data not shown).  
Generation of CD40-activated B cells 
To generate CD40-B cells from naïve B cells , the following protocol was used. CD40-activated B 
cells (CD40-B cells) have been identified as an alternative source of immuno-stimulatory APCs to 
DCs for cancer immunotherapy studies (Schultze et al., 1997; Schultze et al., 2004; von Bergwelt-
Baildon et al., 2006). Upon stimulation with IL-4 and CD40 ligand, CD40-B cells show a strong 
migratory capacity, an increased expression of HLA and costimulatory molecules and present antigens 
efficiently to T cells (Liebig et al., 2009). 
Preparation of tCD40L NIH/3T3 feeder cells, an adherent murine fibroblast cell line, was always done 
one day before the initial PBMCs were ready or before reculturing of CD40-B cells (see schedule, 
Tab. 13). tCD40L NIH/3T3 feeder cells were never kept in culture for more than six weeks, never 
grown completely confluent und usually split every three days. Cells were harvested as described 
before (2.2.4.2) and adjusted to the desired cell number, which was needed to prepare tCD40L 
NIH/3T3 feeder 6-well plates. Left over tCD40L NIH/3T3 feeder cells were split in an appropriate 
dilution and kept in culture in tCD40L WT medium. tCD40L NIH/3T3 feeder cells for plating were 
irradiated at 98Gy (Gammacell 1000; Atomic Energy of Canada Limited, Ottawa, Canada ) and 
washed twice with 1xPBS and centrifugation at 1400rpm for 5min at RT. Then, 2x10
5
 cells/mL and 
2ml per well in tCD40L NIH3T3 medium were seeded into 6-well plates an incubated o/n at 37°C and 
5% CO2. 
On day 0, PBMCs were obtained as described in 2.2.4.5. Cells were then resuspended in B cell 
medium at 2x10
6
 cells/mL. Cyclosporin A (Sigma, St. Louis, MO, USA) was added at 0.55ng/mL to 
prevent outgrowth of T cells and IL-4 at 50U/mL as growth factor. Cells were kept on ice until the 
tCD40L NIH/3T3 feeder cells plates were ready. Confluency and adherence of tCD40L NIH/3T3 
feeder cells was confirmed and the medium aspirated with a 2mL pipette and the pump system. Now, 
4ml/well of PBMC cell suspension were added carefully at the side of the well and incubated at 37°C 
and 5% CO2. Cells were not disturbed for the first 96hrs. 
For reculturing of PBMCs/CD40-B cells, the schedule shown in Table 13 was followed. Cells were 
harvested by vigorously pipetting up and down with a 5mL pipette. Production of air bubbles was 
avoided. Cells were collected in 50mL tubes, washed with 1xPBS and centrifuged at 1400rpm for 
5min at RT. Now, the same procedure as for the initial culturing of PBMCs was conducted with the 
indicated number of cells.  
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Table 13 I Schedule for culturing of PBMCs/CD40-B cells and preparation of tCD40L plates. 
Day Task Number of cells 
day -1 preparation of tCD40L plates  
day 0 start of co-culture  
day 4 preparation of tCD40L plates  
day 5 reculture of PBMCs 2x10
6
 PBMCs/ml 
day 7 preparation of tCD40L plates  
day 8 reculture of CD40-B cells 1.5x10
6
 PBMCs/ml 
day 11 preparation of tCD40L plates  
day 12 reculture of CD40-B cells 1x10
6
 B cells/ml 
day 14 preparation of tCD40L plates  
day 15 reculture of CD40-B cells 7.5x10
5
 B cells/ml  
day 18 preparation of tCD40L plates  
day 19 reculture of CD40-B cells 1x10
6
 B cells/ml  
day 21 preparation of tCD40L plates  
day 22 
etc. 
reculture of CD40-B cells 7.5x10
5
 B cells/ml  
 
If the viability of CD40-B cells was less than 70%, cells were subjected to Ficoll-Paque™ PLUS 
treatment (section 2.2.4.5) omitting the ACK lysis step, to remove dead cells. In addition, CD40-B 
cells were always ficolled before they were used as APCs. If there were still a lot of tCD40L NIH/3T3 
cells contaminating the CD40-B cell population, a 20min adherence step was performed.  
Quantity of CD19
+
 cells in the culture was monitored regularly between day 8 and 22 by flow 
cytometry (section 2.2.4.4). CD40-B cells should be at least 85% CD19
+
 on day 8 and 95% on day 12. 
This was always achieved (data not shown).  
If not all activated CD40-B cells were used for stimulation of T cells or other experiments, they were 
cryopreserved for later use.  
Generation of the Epstein-Barr Virus (EBV)-transformed B cell line “RiSH” 
Since CD40-B cell were not always available in the amount that was needed for experiments, B cells 
from a regular HLA typed donor were immortalized with EBV to be always accessible for use.  
The protocol used was slightly modified from (Tosato and Cohen, 2007). Briefly, 11mL EBV SNT 
(from B95.8 marmoset cells, titer: 1x10
7
, MOI: 2.5) were added to 6x10
7 
PBMCs (section 2.2.4.5) in 
1ml RPMI with 20% FCS in a 50mL tube and incubated for 2hrs at RT on a roller. Cells were 
centrifuged at 1200rpm for 10mins at 4°C and seeded at 3x10
7
 cells/mL in RPMI with 20% FCS in 
1mL per well into a 24-well plate. In order to prevent outgrowth of T cells and kill regulatory T cells 
that might prevent growth of EBV-B cells in EBV-seropositive donors, medium was supplemented 
with 1mg/mL cyclosporin A (Sigma, St. Louis, MO, USA). Morphology, viability and formation of 
cell clusters were monitored daily. Two days post infection, fresh medium was added and five day 
post infection the first clusters appeared that were then transferred in groups of at least five clusters to 
new wells of the 24-well plate. Transfer of cell clusters was done for four weeks every couple of days, 
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increasing the medium volume slowly from time to time. Cells were thus kept first in 24-well plates, 
then in 6-well plates and finally grown in 25cm
2
 and 75cm
2
 flasks. The purity of the B cell population 
was confirmed by FACS staining (section 2.2.4.4) before cyclosporine A treatment was stopped and 
cells were either used directly for experiments or cryopreserved. During cultivation, the percentage of 
FCS in the medium was slowly reduced from 20 to 10%. EBV SNT was kindly provided by Katharina 
Bernhardt, Division of Pathogenesis of Virus Associated Tumors (F100, Henri-Jacques Delecluse), 
DKFZ. 
Peptide-pulsing of APCs 
To prepare Mo-DCs and B cells for peptide-pulsing, cells needed to be washed with the respective 
serum-free DC or B cell medium, to avoid presentation of FCS peptides later one. Washing was 
performed once with centrifugation at 1400rpm for 5min at RT. DCs were then irradiated at 30Gy and 
B cells at 32Gy. Subsequently, washing was performed three times with centrifugation at 1400rpm for 
5min at RT to remove toxic compounds formed during irradiation. Cells were then resuspended in the 
respective serum-free medium at a concentration of 1x10
6
 cells/mL and transferred to 15mL tubes. 
The desired peptide or the corresponding volume of DMSO for negative controls was added at a 
concentration of 10µg/mL. After peptide addition, cell suspensions were immediately resuspended by 
pipetting up and down with a 1000µL pipette. The cell suspensions incubated with an unscrewed lid at 
37°C and 5% CO2 for 3-4hrs. The tube were tapped gently once every hour. Afterwards, cells were 
washed three times with the respective medium containing serum with centrifugation at 1400rpm for 
5min at RT. After counting, cells were resuspended in the desired medium and stored on ice for 
subsequent experiments. If peptide-pulsed APCs were left over, they were cryopreserved for other 
experiments. 
Peptide-specific short-term T cell lines  
Peptide-specific short-term T cell lines were established to test the immunogenicity of previously 
identified peptide candidates in a high throughput manner. A timeline, displaying the work flow is 
shown in Fig. 15.  
 
Figure 15 I Schematic work flow of generation of peptide-specific short-term T cell lines. PBMCs are seeded on day 0, 
stimulated with peptide and IL-7. IL-2 is added on day 3 and day 7, cells are restimulated on day 10 with peptides and 
ELISpot assays conducted subsequently starting on day 11. 
PBMCs were prepared from buffy coats or blood (section 2.2.4.5) and resuspended at a concentration 
of 1x10
6
 cells/mL in R10 medium that was supplemented with 10ng/mL IL-7 (R & D Systems, 
Minneapolis, MN, USA). In case of buffy coats, 5x10
6
 cells were spared for DNA extraction for HLA 
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typing by PCR (section 2.2.2.2) and 1x10
6
 cells were used for HLA typing by flow cytometry (section 
2.2.4.4). The remaining cells were distributed to 24-well plates in a volume of 1mL/well. Plates were 
incubated at 37°C and 5% CO2 until HLA typing by FACS staining was accomplished. Depending on 
the determined or known HLA types and the number of available cells, HLA-matching peptides and 
controls were added to individual wells. Duplicates were done if possible. Peptides were added at a 
concentration of 10µg/mL. Background controls consisted of non-treated and DMSO-treated (peptide 
diluent) cells, 10µg/mL HLA-specific HIV peptide (only for HLA-A2 and HLA-24) served as 
negative control. Additionally 2µg/mL ConA (Sigma-Aldrich, Steinheim), 5µg/mL PHA (Sigma-
Aldrich, Steinheim) and 2µg/mL CEF-Class I Peptide Pool “Classic” (Cellular Technology Limited, 
Shaker Heights, OH, USA) and/or 10µg/mL HLA-specific EBV peptide were used as positive 
controls. Cells were then incubated at 37°C and 5% CO2. On day 3 and day 7, plates were centrifuged 
at 1400rpm, 500µL medium was carefully removed from each well by holding the plate at an 45° 
angle not to aspirate any cells, collected and frozen at -20°C for other experiments. 1mL R10 medium 
was added for washing per well. This washing step was repeated twice and then 500µL R10 medium 
supplemented with 40U/mL IL-2 (PeproTech, Rocky Hill, NJ, USA) were added to achieve a final 
concentration of 20U/mL IL-2 per well. On day 11, plates were centrifuged at 1400rpm for 5min at 
RT, the medium was carefully removed and cells were washed once with 1mL R10 medium per well. 
Cells were resuspended in 1mL R10 medium and restimulated with the same peptides as on day 0. 
Cells were once more incubated for 18-20hrs at 37°C and 5% CO2. Subsequent steps for IFN 
ELISpot are described in section 2.2.5.3.  
Peptide-specific long-term T cell lines  
Peptide-specific long-term T cell lines for four selected peptides, HPV16 E6/87-95var, HPV16 E6/49-
57, HPV16 E6/49-59 and HPV16 E7/56-65, were established from three HLA-A24 positive healthy 
donors (Fig. 16). Those four peptides were chosen because of a strong binding affinity to HLA-A24 in 
silico (sections 3.1.1, 3.1.3, 3.2), in vitro (sections 3.1.2, 3.2) and because they were shown to be 
immunogenic when screening for long-term T cell memory responses (section 3.4.2, Fig. 30-31).  
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Figure 16 I Schematic work flow of generation of peptide-specific long-term T cell lines. PBMCs are seeded on day 0, 
stimulated with peptide and peptide-pulsed DCs. IL-2 is added five days after each stimulation. Cells are restimulated on day 
7 with peptide-pulsed DCs and on day 14 and 21 with peptide-pulsed activated autologous B cells. On day 26, cells are 
starved and used for co-culture for various subsequent experiments on day 27. 
Seven days prior to PBMC seeding, DCs were differentiated from donor monocytes and used as APCs 
as described above. Matured DCs were peptide-pulsed and plated together with freshly isolated 
PBMCs (section 2.2.4.5) from the same donor. Here, specifically, 1x10
7 
PBMCs and at least 5x10
4
 
peptide-pulsed DCs, to reach a ratio of 1:200, were plated in 2mL T cell medium supplemented with 
10ng/mL IL-7 in one well of a 24-well plate. If possible, a ratio of PBMCs to DCs of 1:50 was 
pipetted. In addition, the respective peptide was also added to the well at a concentration of 10µg/mL. 
On day 5 after stimulation, the plate was centrifuged at 1400rpm for 5min at RT and 1mL SNT was 
aspirated. 1mL T cell medium supplemented with 40U/mL IL-2 was added to reach a final IL-2 
concentration of 20U/mL per well. Seven days after the first stimulation, PBMCs were restimulated 
with fresh peptide-pulsed DCs as before. This time, however, no peptide was added. Again, IL-2 was 
added five days later in the same manner as described before. This scheme was followed until day 26. 
On day 14 and 21, however, restimulation was performed with autologous activated peptide-pulsed B 
cells, which were generated by using the tCD40L/NIH-3T3 system. On day 26, cells were starved o/n 
in plain T cell medium without any cytokine supplements. To this end, cells were washed twice with 
2mL of T cell medium and centrifuged at 1400rpm for 5min at RT before cells were resuspended in 
2ml T cell medium.  
As subsequent assays, IFN ELISpot (section 2.2.5.3) and cytotoxicity assays (section 2.2.5.5) were 
performed, to assess if the established T cell line was functionally active (IFN secretion) and had 
cytolytic activity against cells presenting the cognate peptide.  
Peptide-specific semi long-term T cell lines 
Peptide-specific semi long-term T cell lines were generated for the same purpose as long-term T cell 
lines. Here, only two stimulations with peptide-pulsed DCs were done, and the third and fourth 
stimulation with peptide-pulsed activated B cells were omitted. The IL-2 concentration, however, was 
increased from 20U/mL to 50U/mL and fresh IL-2 was added to the T cells every other day (Fig. 17).  
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Figure 17 I Schematic work flow of generation of peptide-specific semi long-term T cell lines. PBMCs are seeded on day 
0, stimulated with peptide and peptide-pulsed DCs. IL-2 is added every second day. Cells are restimulated on day 7 with 
peptide-pulsed DCs. On day 13, cells are starved and used for cytotoxicity assays on day 14. 
2.2.5.2 T cell receptor sequencing 
T cell receptor (TCR) sequencing of peptide-specific long-term CD8
+
 T cell lines was kindly 
performed by Eliana Ruggiero, Division of Translational Oncology (G100, Christoph von Kalle), 
DKFZ. In short, cells were resuspended in a provided lysis buffer. RNA was extracted, purified and 
cDNA of the TCR α- and β-chain was reverse transcribed. Sequencing on an Illumina machine was 
carried out by using primers attaching to conserved flanking sequences. Thus, the quantity and 
variability of α- and β-chain TCRs in the T cell lines was determined.  
2.2.5.3 Interferon (IFN) ELISpot assays 
The interferon (IFN)γ ELISpot assay is widely used as a general screening method for the 
quantification of antigen-specific CD8
+
 T cell responses. Two different approaches were followed to 
this end. In case of peptide-specific short-term T cell lines, PBMCs were incubated with peptides as 
described above. In case of peptide-specific long-term T cells lines, peptide-pulsed autologous B cells 
served as targets for CD8
+
 T cells.  
IFNγ ELISpot assays were performed, depending on whether short-term or long-term T cell lines were 
used, two days after the last peptide stimulation or seven days after the last stimulation with peptide-
pulsed APCs, respectively (section 2.2.5.1). All steps on the first two days were carried out under 
sterile conditions in a flow hood. On day 1, 96-well MultiScreen®-HA plates (Merck Milipore, Cork, 
Ireland) were coated with 100 μL/well anti-human IFNγ capture antibody (Mabtech, Nacka Strand, 
Sweden) diluted 1:500 in 1xPBS. Plates were wrapped in cling foil and incubated at 4°C o/n. On day 
2, capture antibody was removed by inverting the plate quickly and tapping it afterwards on a paper 
tissue. Plates were washed with 1xPBS three times in the same manner. Plates were then blocked with 
200μL corresponding culture medium for 1-2hrs at 37°C and 5% CO2. Either peptide-specific CD8
+
 T 
cells, bulk T cell cultures or PBMCs (sections 2.2.5.1 and 2.2.4.5) and peptides or peptide-pulsed 
autologous B cells (section 2.2.5.1) were prepared during this incubation time. The blocking medium 
was removed and between 1 - 5x10
5
 cells/well of peptide-specific CD8
+
 T cells, bulk T cell cultures or 
PBMCs were seeded in a volume of 50-100μL. In case of peptide stimulations, 1µL/mL DMSO was 
used as a background control and 10µg/mL HIV peptides as negative control, if applicable for the 
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respective HLA-type. Additionally, 2µg/mL ConA, 5µg/mL PHA and 2µg/mL CEF-Class I Peptide 
Pool “Classic” were used as positive controls. Peptide stimulation was already performed on day 0 and 
10 of short-term T cell line generation (section 2.2.5.1). For co-culture of peptide-specific CD8
+
 T 
cells between 2-4x10
4
 cells/well of peptide-pulsed autologous B cells (section 2.2.5.1) were added in a 
volume of 50µL. 2ng/mL ConA was added to T cells as a positive control, and autologous B cells that 
were peptide-pulsed with a HLA-matching HIV peptide or DMSO were used as negative controls. 
Autologous B cells were also seeded alone as a background control. A typical loading scheme for co-
culture of peptide-specific T cells and peptide pulsed autologous B cells is depicted in Figure 18, it 
was, however, adapted depending on the number of available cells and peptides tested.  
 
Figure 18 I Plate loading scheme of IFN ELISpot. Co-culture wells of T cells with indicated peptide-specificy and 
indicated peptide pulsed-B cells are displayed in blue. Positive control wells with peptide-specific T cells stimulated with 
ConA are shown in green, while wells with peptide-pulsed B cells alone are depicted in yellow. 
Triplicates were done if possible. After incubation for 16-24hrs at 37°C and 5% CO2, cells were 
removed and plates were washed seven times with 0.05% Tween20 in 1xPBS (TPBS). 100µL of 
biotinylated anti-human IFNγ antibody (Mabtech, Nacka Strand, Sweden) diluted 1:1000 in 1xPBS 
were added per well and incubated for 2hrs at RT. After removing the detection antibody, plates were 
washed four times with 1xTPBS. Then, 100µL streptavidin-alkaline phosphatase (Mabtech, Nacka 
Strand, Sweden) diluted 1:1000 in 1xPBS were added per well and incubated for 90min at RT in the 
dark. Plates were subsequently washed four times with 1xTPBS. 100μL/well 1-Step™ NBT/BCIP 
substrate (Thermo Scientific, Rockfort, IL, USA) were added and incubated in the dark. The staining 
reaction was monitored for around 20-30min and stopped by rinsing the plates thoroughly with 
distilled water. Plates were left to dry for at least 2hrs in a flow hood or o/n on the bench. Spots were 
then quantified with an AID ELISpot reader (Autoimmun Diagnostika, Strassberg). 
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2.2.5.4 IL-2 Enzyme Linked Immunosorbent Assay (ELISA)  
IL-2 Enzyme Linked Immunosorbent Assays (ELISAs) were performed with SNT from peptide or 
APC-stimulated T cells (section 2.2.5.1) to test the secretion of this pro-proliferation cytokine.  
On day 1, 96-well Costar™ high binding plates (Thermo Fisher Scientific, Rochester, NY, USA) were 
coated with 100µL/well of 4μg/mL LEAF™ purified anti-human IL-2 capture antibody (BioLegend, 
San Diego, CA, USA) in carbonate coating buffer (pH 9.5, section 2.1.2). The plates were wrapped in 
cling foil and incubated at 4°C o/n. On day 2, capture antibody was removed by inverting the plate 
quickly and tapping it afterwards on a paper tissue. The plate was washed with 0.05% Tween20 in 
1xPBS (TPBS) and blocked with 200μL/well 0.2% gelatine in 1xPBS for 1hr at 37°C and 5% CO2. 
The blocking solution was removed and 100µL sample or standard (recombinant human IL-2 
standard; BioLegend, San Diego, CA, USA) were added per well and incubated o/n at 4°C or for 3hrs 
at RT. The samples were removed and plates washed five times with TPBS. For detection, biotin anti-
human IL-2 antibody (BioLegend, San Diego, CA, USA) was diluted 1:2000 in TPBS, 100µL/well 
were added and incubated for 1-2hrs at RT. Detection antibody solution was removed and the plate 
was washed five times with TPBS. Avidin-Horseradish Peroxidase (HRP) (BioLegend, San Diego, 
CA, USA) was diluted 1:1000 in TPBS and 100µL/well were added and incubated for 30min at RT. In 
the meantime, TMB substrate (BioLegend, San Diego, CA, USA) was prepared and pre-warmed to 
RT. The Avidin-HPR solution was removed and the plate was washed five times again with TPBS. 
100µL/well of TMB substrate was added for color development and the plate was wrapped in 
aluminium foil. After 4 to 30min, the color reaction was stopped with TMB Stop solution (BioLegend, 
San Diego, CA, USA). The optical density (OD) was read for each well with a microplate reader, 
Victor
3
 (Perkin Elmer, Waltham, MA, USA), set to 405nm. 
2.2.5.5 Cytotoxicity assay  
In vitro cytotoxicity assays were performed to assess the cytotoxic capacity of peptide-specific T cells 
by using the standard method based on chromium release. In this assay, target cells are pre-labeled by 
incubation with 
51
Cr. These target cells are then incubated with effector cells, which will lyse the 
target cells. The amount of radioactivity that is released in the SNT, is taken as an indicator of the 
amount of lysis that has occurred. 
Autologous peptide-pulsed B cells were taken as target cells, adjusted to 1x10
6
 cells and were 
centrifuged at 1400rpm for 5min at RT. Target cells were peptide-pulsed with the peptide that was 
used to generate the effector cells for 3hrs as described in section 2.2.5.1. As negative control, 
autologous B cells that were pulsed with HIV HLA-A24 peptide: RYLKDQQLL were used, which 
should not be recognized by HPV-specific T cells. The cell pellet was resuspended in 200μL medium 
and labeled with 100µL of Na2
51
CrO4-solution (5 mCi, 185 MBq, Perkin-Elmer, Waltham, MA, USA) 
for 90min at 37°C and 5% CO2. 
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Peptide-specific T cells, which were generated as describe before (2.2.5.1), were used as effector cells. 
They were adjusted to 2.5x10
6
 cells/mL for a 50:1 effector:target ratio or to less when fewer cells were 
available and were titrated in 1:1 dilution steps into the wells of a round bottom 96-well plate. 
After three washing steps with medium at 1400rpm for 5min at RT, target cells were counted and 
adjusted to 5x10
4
 cells/mL. For co-culture, 100μL of labeled target cells were added to the serial 
dilution of effector cells. A typical loading scheme is depicted in Figure 19. In addition, target cells 
were added to wells to determine spontaneous lysis (assay medium) or maximum lysis (10% Triton-
x100 in medium).  
 
Figure 19 I Plate loading scheme for cytotoxicity assays. Co-culture wells of T cells with indicated peptide specificity and 
indicated peptide pulsed-B cells are displayed in blue. Ratios of effector to target cells are displayed on the left side. 
Maximum lysis control wells with target cells treated with Triton-x100 are shown in green, while control wells for 
spontaneous lysis, target cells in medium, are depicted in yellow. 
Plates were spun down briefly at 300rpm and RT to bring the target and effector cells into close 
proximity. The plates were then incubated for 5hrs at 37°C and 5% CO2. After centrifugation at 
1400rpm for 5min at RT, 100μL of SNT were transferred to LumaPlates (Perkin Elmer, Waltham, 
MA, USA). After drying o/n under the hood, the plates were read with a -counter (TopCount NXT™; 
Perkin Elmer, Waltham, MA, USA). Specific cytotoxicity (lysis) was calculated with the following 
formula: 
% specific lysis =  [
cpm (sample) − cpm (spontaneous lysis)
cpm (maximum lysis) − cpm (spontaneous lysis)
]  x 100 
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3. Results 
To date, three prophylactic vaccines are available that can protect from infection with the major 
cancer-causing HPV types (Harper et al., 2004; Villa et al., 2005; Joura et al., 2015). Still, a 
therapeutic vaccine is desirable that can clear already established infections and thus prevent the 
development of HPV-driven invasive cancer. The overall goal of our group is the development of a 
therapeutic vaccine that elicits T cell-mediated immune responses against HPV16-infected cells. This 
study aimed at the identification of specific T cell epitopes that can elicit CD8
+
 T cell-mediated 
immune responses. 
To this end, the strategy of reverse immunology, first described in 1994, was employed (Celis et al., 
1994). Predictions of potential T cell binding peptides, 8mers to 11mers, derived from HPV16 E6 and 
E7 proteins were calculated using different web-based prediction servers. In silico predictions were 
performed for the representative alleles of the HLA-A3, HLA-A11 and HLA-A24 supertypes, HLA-
A*03:01, HLA-A*11:01 and HLA-A*24:02, respectively (section 3.1.1). These three frequent HLA 
supertypes were selected because together they provide a high population coverage in all ethnic groups 
(Gonzalez-Galarza et al., 2015). Predicted peptides were ranked according to their IC50 or highest 
score. The actual binding affinity of best predicted peptides to the respective HLA molecules was 
tested in competition-based cellular binding assays (section 3.1.2) (Kessler et al., 2003; Kessler et al., 
2004). To identify strongly binding peptides that are not well-predicted in silico, amino acid motifs of 
identified binding and non-binding peptides were created, the HPV16 E6 and E7-derived peptide 
repertoire was scanned for motif-matches in silico and resulting strong-matching tested peptides in 
vitro (section 3.1.3). Moreover, several HPV16 variants exist, that differ in their E6 and E7 protein 
sequences. These sequence differences might change the set of peptides presented on HPV16-
transformed cells. Amino acid exchanges in various HPV16 variants were identified, predictions 
performed for the respective protein sequences and the binding affinities of predicted binders to HLA-
A24 was tested in vitro (section 3.2). To identify HPV16 E6 and E7 peptides that are naturally 
processed and presented on the cell surface of HPV16-transformed cells, HPV16-positive cell lines 
were stained for expression levels of HLA molecules of interest and HLA/peptide complexes were 
isolated from these cell lines via immunoprecipitation (section 3.3). Peptides were eluted for 
subsequent mass spectrometry (MS) analysis. MS analysis is performed by Renata Blatnik, another 
PhD student in our laboratory. Immunogenicity of identified peptides was assessed by establishing T 
cell lines from PBMCs from HLA-matched blood donors (section 3.4). Functional assays such as 
ELISpot assays and cytotoxicity assays were conducted to determine the best vaccine candidates 
(section 3.5). Single steps of the workflow are depicted schematically in Figure 20.  
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Figure 20 I Schematic overview of the experimental set up. The workflow of T cell epitope identification for a therapeutic 
HPV16 E6 and E7 vaccine is depicted. Grey shading indicates cooperation with another PhD project in our laboratory. 
 
3.1 In silico predictions and in vitro binding affinity of HPV16 E6 and E7 peptides 
to HLA-A3, HLA-A11 and HLA-A24 molecules 
In the first part of this study, T cell epitopes from the HPV16 E6 and E7 proteins of the HPV16 
reference sequence (NC_001526) were identified. The E6 and E7 proteins were chosen for epitope 
predictions for multiple reasons. They are constantly expressed in all stages of HPV16-mediated 
carcinogenesis as they are crucial for induction and maintenance of the malignant phenotype. Being 
viral and thus resulting in presentation of foreign viral epitopes on infected cells, these antigens allow 
immunological distinction of infected cells from healthy tissue. Moreover, as HPV is replicated using 
the host’s cellular replication machinery, mutation rates are very low in these viral proteins preventing 
immune escape (Frazer et al., 2011). Since 941 peptides with a length of 8 to 11 amino acids can be 
derived from the HPV E6 and E7 proteins, binding affinities were first predicted in silico to reduce the 
number of peptides to be tested in vitro. Predictions were performed with high throughput in silico 
approaches that estimated potential binding to chosen HLA types. Predicted strong binders were 
further tested experimentally for their actual binding affinity to the HLA types of interest in 
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competition-based cellular binding assays (Kessler et al., 2003; Kessler et al., 2004). The three HLA 
supertypes HLA-A3, HLA-A11 and HLA-A24 were selected because all three together cover a high 
percentage of the world’s population (Gonzalez-Galarza et al., 2015). While HLA-A24 is widely 
spread amongst Asian populations, reaching 58.6% in the Japanese population, up to 37.5% in 
Caucasians harbor HLA-A3 and HLA-A11 alleles.  
3.1.1 T cell epitope predictions reveal numerous potential HLA binding HPV16-derived peptides 
Multiple prediction servers were chosen for T cell epitope predictions to exploit the individual 
strengths of each single server. Servers are based on different algorithms and trained with different 
data sets. A set of six different web-based prediction servers employing ten different algorithms was 
selected (Parker et al., 1994; Rammensee et al., 1999; Nielsen et al., 2003; Peters and Sette, 2005; 
Nielsen et al., 2007; Lundegaard et al., 2008a; Karosiene et al., 2012). To combine all results in a 
sortable excel sheet, the PERL script PeptidePrediction.pl, developed in our laboratory, was applied. 
Complete lists of E6 and E7 peptides that were predicted and tested for HLA-A3, HLA-A11 and 
HLA-A24 binding are displayed in Tables 14 and 15 and Tables 22-25 (Appendix). The results of all 
predictors giving an IC50 value as output were combined to an average IC50 value for each peptide to 
determine overall testing cutoffs. The thresholds for in vitro testing were lowered throughout the 
course of experimental binding affinity assessment, as a final stage where none of the predicted 
peptides was binding anymore, was not reached. Moreover, cutoffs were chosen individually for all 
servers to make sure not to exclude any peptides that were indicated to possibly bind by one individual 
server.  
Of the 941 potential peptides, 69 peptides, 48 for the E6 protein and 21 for the E7 protein, were 
predicted to bind to HLA-A24 with an average IC50 below 7000nM. In case of HLA-A3 and HLA-
A11, the chosen general cutoffs were 5000nM for the average IC50. For HLA-A3, 55 E6 and 16 E7 
peptides were predicted to be binders. In case of HLA-A11, 70 E6 and 19 E7 peptides were predicted 
to bind. For clarity reasons, only HLA-A24 results are shown in Tables 14 and 15. For HLA-A3 and 
HLA-A11, please refer to the Appendix (Tab. 22-25). Tables 14 and 15 display the binding affinities 
for each peptide color-coded according to their predicted and experimental binding strength to HLA-
A24. Not all servers predicted peptides that were actually binding to HLA-A24 and vice versa, not all 
peptides that were in silico predicted to bind, did actually bind experimentally. This applies to many 
peptides that were predicted to be weak or intermediate binders. Of note, no peptides were predicted to 
strongly bind to HLA-A24 by the NetMHC and IEDB servers. In conclusion, none of the servers 
employed showed clear superior results in comparison to the others and thus the average IC50 of 
NetMHC and IEDB servers was selected as one cutoff among individual cutoffs for individual servers 
as indicated in Tables 14 and 15. Highlighted peptides in Italic were not predicted by prediction 
servers, but were added because they were identified as potential binders by the motif analysis 
mentioned above and described below (section 3.1.3). Dashes in the table indicate that prediction of 
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this peptide length was not supported by the respective server and empty cells that the predicted 
binding affinity was above the chosen cutoff which was selected during initial individual predictions 
(40000nM for all NetMHC and IEDB servers).  
Table 14 I Predicted and experimental binding affinities to HLA-A24 for HPV16 E6 peptides. Peptides are sorted by the 
actual binding affinity as determined in the cellular binding assays. Binding affinities are color-coded according to their 
predicted and experimental binding strength. NetMHC and IEDB servers indicate binding affinities as IC50 [nM] and the 
average is displayed in the third column from the left. SYFPEITHI and BIMAS show scores as arbitrary units. Dashes 
indicate that the peptide length was not supported by the respective server and empty cells indicate that the chosen cutoff for 
the individual prediction server was exceeded. Italic highlighting indicates peptides that were determined to be potential 
binders by motif analysis. The code colors dark blue, blue and light blue indicate strong, intermediate and weak binders, 
repectively. Individual recommended (a, b, c) and self-determined (d, e, f) binding affinities: a: strong: < 5µM, intermediate: 5-
15µM, weak: 15-100µM, non: > 100µM; b: strong: < 50nM, weak: 50-500nM, non: > 500nM; c: strong: < 50nM, 
intermediate: 50-500nM, weak: 500-5000nM, non: > 500nM; d: strong: < 50nM, intermediate: 50-500nM, weak: 500-
7000nM, non: > 500nM e: strong: > 22, intermediate: 22-19, weak: 19-15, non: < 15; f: strong: > 240, intermediate: 240-100, 
weak: 100-10, non: < 100; exp: experimental 
 
exp. IC50 NetMHC  NetMHC IEDB IEDB IEDB IEDB IEDB average 
peptide length [µM]ᵃ NetMHCᵇ Panᵇ consᵇ annᶜ smmᶜ arbᶜ smmpmbecᶜ netmhcpanᶜ  IC50ᵈ SYFPEITHIᵉ BIMASᶠ
E6/85-95 11 0,10 782 298,02 912,75 - - - - 1196,26 797,26 - -
E6/49-57 9 0,10 918 260,23 1242,43 918,27 1212,35 1477,97 1379,05 984,56 1049,11 23 240,00
E6/87-95 9 0,12 452 220,05 506,12 452,42 941,67 815,38 955,62 995,27 667,32 20 200,00
E6/49-59 11 0,26 359 187,47 456,69 - - - - 344,70 336,97 - -
E6/66-76 11 0,28 243 215,22 183,04 - - - - 645,63 321,72 - -
E6/82-90 9 0,32 485 176,19 681,52 485,94 944,59 171,73 786,27 482,07 526,66 19 200,00
E6/98-107 10 0,54 641 320,50 1249,17 641,43 1843,39 320,67 966,08 1619,56 950,22 23 360,00
E6/98-108 11 0,77 764 80,69 344,70 - - - - 442,10 407,87 - -
E6/18-26 9 0,83 13649 7391,50 10527,33 13649,07 12695,54 4273,52 10000,34 10757,62 10367,99 13 15,84
E6/60-69 10 1,06 1524 1426,97 2403,86 1524,16 826,25 1845,83 636,62 2607,06 1599,34 13 6,00
E6/67-76 10 1,09 12927 2914,05 6262,79 12927,77 2131,56 26477,50 3084,65 7446,48 9271,47 12 3,30
E6/26-34 9 1,42 9960 6885,20 8950,22 9960,87 5769,79 1095,70 5425,19 7446,48 6936,68 12 -
E6/66-74 9 1,97 2987 4994,68 4129,12 2987,78 2417,63 543,85 3322,73 6829,04 3526,48 20 20,00
E6/82-91 10 1,98 1461 4160,75 4856,71 1461,17 1628,28 8155,47 1199,99 6262,79 3648,27 11 5,00
E6/38-45 8 2,45 356 116,96 273,16 - - - - 743,14 372,31 - -
E6/98-106 9 2,97 6922 1904,71 4288,48 6922,10 3232,16 783,10 2867,38 5869,13 4098,63 21 300,00
E6/51-59 9 3,35 2918 2271,98 1746,99 2918,64 1001,55 1031,70 1285,49 6755,55 2491,24 17 5,00
E6/88-95 8 3,36 9862 4393,89 7092,61 - - - - 8571,13 7479,91 - -
E6/76-83 8 3,36 3094 807,68 2252,76 - - - - 1062,03 1804,12 - -
E6/44-54 11 3,84 6091 3709,41 5382,48 - - - - 7287,08 5617,49 - -
E6/49-58 10 4,30 22795 4425,62 7016,28 22795,33 968,71 403,99 8853,90 9608,41 14 5,00
E6/48-57 10 4,75 26316 24252,68 23192,26 26316,72 4692,18 29425,27 22365,85 12 5,76
E6/76-85 10 4,76 5504 4887,55 6755,55 5504,09 145,37 3597,79 365,53 7054,34 4226,78 11
E6/87-96 10 6,87 8746 15398,63 15373,84 8746,03 193,67 259,91 23699,60 10345,38 12
E6/90-99 10 7,08 16642 2598,01 4062,65 16642,41 2908,53 2089,47 3272,12 6887,88 10 7,20
E6/72-80 9 7,50 3451 3613,62 3167,62 3452,04 2154,86 195,40 1440,51 4989,87 2808,11 16 3,30
E6/35-44 10 8,13 33170 36581,43 31912,64 33170,33 28070,65 34986,78 32981,97 10
E6/76-86 11 10,60 1928 1112,81 2766,91 - - - - 1235,73 1760,86 - -
E6/66-75 10 10,93 30424 23055,24 19932,31 30424,20 1332,71 6586,21 2313,76 33144,32 18401,59 12
E6/50-59 10 11,01 23074 5886,57 10136,12 23074,37 6104,61 1919,25 6959,29 8119,76 10659,25 10
E6/81-90 10 11,98 13783 7388,10 10246,39 13783,08 11149,56 984,55 7561,08 8208,09 9137,98 10
E6/38-47 10 22,28 18572 13666,71 15967,20 18572,52 1649,24 14208,27 3299,59 27875,69 14226,40 13
E6/47-54 8 23,27 6661 7472,81 8342,39 - - - - 10527,33 8250,88 - -
E6/131-139 9 23,93 2617 287,71 1864,16 2617,66 1540,83 186,64 1763,67 598,54 1434,53 6
E6/128-136 9 28,64 28763 36595,66 30232,07 28763,13 - 18872,82 - 39837,46 30510,69 2
E6/75-85 11 32,00 21556 13775,40 16493,98 - - - - 17505,31 17332,67 - -
E6/86-96 11 36,66 30341 33324,12 - - - - 31832,56 - -
E6/38-46 9 46,40 6475 11044,46 12183,00 6475,71 3256,63 535,81 2980,63 27875,69 8853,37 15
E6/128-135 8 46,84 7821 12305,20 7609,38 - - - - 8950,22 9171,45 - -
E6/75-83 9 51,47 11252 2369,46 5470,55 11252,52 9147,96 32534,00 8892,20 4106,84 10628,19 9
E6/127-135 9 55,95 18250 34674,63 22451,54 18250,31 9077,38 35918,49 10174,33 21256,67 11
E6/125-135 11 60,80 17052 17963,69 18882,64 - - - - 18478,42 18094,19 - -
E6/42-52 11 non-binder 4683 1691,82 2707,68 - - - - 6399,79 3870,57 - -
E6/44-52 9 non-binder 4438 3493,93 3869,58 4438,46 2884,43 1062,40 2860,01 9654,43 4087,66 10 2,00
E6/124-132 9 non-binder 4281 6074,72 4551,43 4281,62 1692,30 2665,22 1624,08 7860,43 4128,85 14
E6/76-84 9 non-binder 5695 2363,40 5651,03 5695,84 4421,74 365,41 4927,30 4242,33 4170,26 13
E6/43-52 10 non-binder 8384 1224,53 1824,25 8384,65 1292,96 11225,05 1013,41 5382,48 4841,42 13 3,00
E6/45-54 10 non-binder 10952 12814,39 12790,86 10952,58 713,18 2356,75 520,03 14099,07 8149,86 12
E6/87-94 8 non-binder 9504 4665,36 8758,62 - - - - 11233,42 8540,35 - -
E6/138-146 9 non-binder 13401 5789,73 4989,87 13401,90 5872,85 6220,18 3119,40 16404,99 8649,99 1
E6/90-98 9 non-binder 7752 18535,08 16583,46 7752,90 1765,11 876,04 2961,56 13356,59 8697,84 11
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Table 15 I Predicted and experimental binding affinities to HLA-A24 for HPV16 E7 peptides. Peptides are sorted by the 
actual binding affinity as determined in the cellular binding assays. Binding affinities are color-coded according to their 
predicted and experimental binding strength. NetMHC and IEDB servers indicate binding affinities as IC50 [nM] and the 
average is displayed in the third column from the left. SYFPEITHI and BIMAS show scores as arbitrary units. Dashes 
indicate that the peptide length was not supported by the respective server and empty cells indicate that the chosen cutoff for 
the individual prediction server was exceeded. Italic highlighting indicates peptides that were determined to be potential 
binders by motif analysis. The code colors dark blue, blue and light blue indicate strong, intermediate and weak binders, 
repectively. Individual recommended (a, b, c) and self-determined (d, e, f) binding affinities: a: strong: < 5µM, intermediate: 5-
15µM, weak: 15-100µM, non: > 100µM; b: strong: < 50nM, weak: 50-500nM, non: > 500nM; c: strong: < 50nM, 
intermediate: 50-500nM, weak: 500-5000nM, non: > 500nM; d: strong: < 50nM, intermediate: 50-500nM, weak: 500-
7000nM, non: > 500nM e: strong: > 22, intermediate: 22-19, weak: 19-15, non: < 15; f: strong: > 240, intermediate: 240-100, 
weak: 100-10, non: < 100; exp: experimental 
 
 
3.1.2 Competition-based cellular binding assays verify binding of HPV16 E6 and E7 peptides to 
designated HLA types 
The binding affinity of predicted HLA-binding HPV16 E6 and E7 peptides from the HPV16 reference 
sequence was tested experimentally in competition-based cellular binding assays (Kessler et al., 2003; 
E6/86-95 10 non-binder 12452 8267,63 11355,63 12452,21 3691,83 3474,34 3363,25 15541,08 8824,75 10 4,00
E6/138-147 10 non-binder 15881 10125,40 5126,69 15881,56 1810,69 - 876,51 17888,25 9655,73 0
E6/80-90 11 non-binder 10546 7767,88 10584,44 - - - - 11986,87 10221,30 - -
E6/85-94 10 non-binder 17108 10602,05 13212,86 17108,63 1331,30 - 1212,91 17505,31 11154,44 10 6,00
E6/81-91 11 non-binder 21935 22891,05 21852,38 - - - - 17505,31 21045,94 - -
E6/47-57 11 non-binder 20108 20194,14 20589,91 - - - - 24218,04 21277,52 - -
E6/109-117 9 non-binder 18214 27395,10 24614,30 18214,31 22120,02 13695,08 20203,06 32434,80 22111,33 12 12,00
E6/51-60 10 non-binder 28310 10539,62 10246,39 28310,34 28766,77 - 32185,40 17888,25 22320,97 6
E6/50-60 11 non-binder 32878 19145,63 22573,33 - - - - 23444,56 24510,38 - -
E6/126-135 10 non-binder 33076 18647,54 17410,87 33076,26 27422,18 18082,85 24619,28 11
E6/59-68 10 non-binder 36299 38750,49 34610,27 36299,58 1559,93 2854,29 37739,56 26873,30 0
E6/73-83 11 non-binder 29213 25271,80 27278,95 - - - - 26123,53 26971,82 - -
E6/96-106 11 non-binder 24516 26529,74 23571,74 - - - - 34237,82 27213,82 - -
E6/97-106 10 non-binder 27905 19727,40 20589,91 27905,87 36383,71 36462,87 26123,53 27871,18 10 4,00
E6/11-19 9 non-binder 30651 36931,66 30651,36 32744,67 16 7,92
E6/64-74 11 non-binder 30188 34548,26 27278,95 - - - - 39408,75 32855,99 - -
E6/128-138 11 non-binder 33875 34237,82 - - - - 34056,41 - -
E6/36-46 11 non-binder 33136 35752,13 - - - - 34444,07 - -
E6/65-74 10 non-binder 33112 38780,96 34053,09 33112,06 34764,53 10 4,00
E6/48-58 11 non-binder 33954 31569,21 - - - - 39408,75 34977,32 - -
E6/128-137 10 non-binder 38406 34798,02 38406,26 35060,22 36667,63 1
exp. IC50 NetMHC  NetMHC IEDB IEDB IEDB IEDB IEDB average 
peptide length [µM]ᵃ NetMHCᵇ Panᵇ consᵇ annᶜ smmᶜ arbᶜ smmpmbecᶜ netmhcpanᶜ  IC50ᵈ SYFPEITHIᵉ BIMASᶠ
E7/49-57 9 0,15 1271 142,84 430,30 1271,89 1198,42 443,07 1386,68 525,66 3984,13 10 4,00
E7/56-65 10 0,75 2929 3552,99 6095,65 2929,71 6023,37 2344,86 3845,98 4151,52 8160,61 17 20,00
E7/48-57 10 1,32 11267 9645,45 6719,10 11267,87 1231,09 776,14 933,70 23444,56 1372,49 11
E7/50-57 8 2,28 1510 1087,00 1709,59 - - - - 1183,39 5811,00 - -
E7/51-59 9 6,06 7898 2017,39 2403,86 7898,36 1717,58 335,90 1020,71 5500,22 3599,00 12 10,50
E7/51-58 8 16,51 12750 3501,54 4989,87 - - - - 9245,51 7621,73 - -
E7/67-76 10 34,74 29517 27513,69 23318,07 29517,43 31060,99 28185,44 11 1,50
E7/69-76 8 84,61 8359 10090,02 8806,13 - - - - 14252,45 10376,90 - -
E7/77-87 11 non-binder 9445 3621,79 7903,07 - - - - 6682,85 8210,00 - -
E7/10-20 11 non-binder 6446 5280,10 7054,34 - - - - 12790,86 6913,18 - -
E7/10-19 10 non-binder 16393 8677,53 12584,95 16392,93 504,79 2343,86 21734,48 7892,83 10 9,90
E7/51-60 10 non-binder 22977 10339,78 11479,16 22977,83 2441,57 1745,32 3922,35 15710,15 11233,08 11 0,90
E7/10-18 9 non-binder 10809 21693,29 17130,58 10809,19 3910,09 471,81 4558,84 29425,27 11449,14 10 0,90
E7/22-31 10 non-binder 25185 23251,23 23828,16 25185,83 1738,60 2917,89 29108,61 12351,01 10 6,00
E7/74-82 9 non-binder 24247 21127,54 20926,80 24247,54 22409,06 8321,77 24756,05 25289,19 18745,05 15 0,60
E7/74-83 10 non-binder 33435 14130,72 16493,98 33435,71 25835,18 20063,15 16146,11 18082,85 10062,00 16 0,72
E7/56-66 11 non-binder 20559 20269,23 23067,13 - - - - 25842,40 21415,62 - -
E7/24-33 10 non-binder 26532 35350,60 32787,64 26532,87 885,03 748,67 38150,11 22202,84 10 0,75
E7/24-32 9 non-binder 25058 23098,35 26550,96 25058,49 21161,45 29406,78 30173,54 28795,36 22434,44 10 9,00
E7/82-91 10 non-binder 35937 36804,84 28485,48 35937,71 6989,67 2410,59 37739,56 22998,13 0
E7/61-69 9 non-binder 34954 25374,15 27725,29 34954,43 31060,99 26162,87 0
E7/78-87 10 non-binder 32729 29422,19 27426,93 32730,04 37061,59 27609,62 29745,37 26329,26 12 8,64
E7/67-77 11 non-binder 33264 38900,17 34986,78 - - - - - 30813,77 - -
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Kessler et al., 2004). This assay is based on the competition of the peptide in question with a strongly 
binding, fluorescein-labeled reference peptide for binding to the binding cleft of the HLA molecule on 
B-LCL cells expressing the HLA type of interest. The higher the binding affinity of the test peptide, 
the more the reference peptide is prevented from binding to the HLA molecule, thus resulting in 
decreased fluorescence intensity measured by flow cytometry. By testing a dilution series of the test 
peptide, the concentration needed to inhibit 50% binding of the reference peptide (IC50) could be 
determined. A low IC50  value indicates strong binding affinity. 
In Figure 21, the individual results for HPV16 E6 and E7 peptides binding to HLA-A3, HLA-A11 and 
HLA-A24 are shown. Many binding peptides known from the literature could be confirmed and 
numerous novel binding peptides were identified. HPV16 peptides binding to HLA-A3 and HLA-A11 
displayed strong (< 5µM), intermediate (5-15µM) and weak (15-100µM) binding affinities, while the 
majority of tested peptides for HLA-A24 showed strong binding affinity (< 5µM), which stands in 
contrast to the prediction results of the NetMHC and IEDB servers (Tab. 14 and 25). These predicted 
intermediate or weak binding affinity, if they predicted binding at all.  
For HLA-A3, nine HPV16 E6 and E7 peptides have been previously reported to bind (Kast et al., 
1994; Bourgault Villada et al., 2010). The peptides E6/106-115, E7/89-97, E6/33-41, E6/93-101, 
E6/125-133 and E6/75-83 were identified as binders by Kast and colleagues and E6/59-67 in addition 
by Bourgault and colleagues. E6/54-61, which was shown to bind by Bourgault and colleagues as 
well, did not meet the chosen criteria for testing in this study. A total of 71 peptides were tested for 
HLA-A3 binding. Binding of seven previously identified binders could be confirmed and eleven 
peptides were identified as novel binders (Fig. 21 A). Three peptides displayed strong binding affinity, 
while six peptides showed intermediate and nine peptides showed weak binding. 53 of the tested 
peptides did not bind to HLA-A3.  
In case of HLA-A11 (Fig. 21 B), 70 peptides were tested for their actual binding. Ten reported binding 
peptides (Kast et al., 1994; Bourgault Villada et al., 2010) were confirmed and 23 novel binders were 
found. One previously identified binder, E6/88-97 could not be confirmed and another three peptides, 
E7/7-15, E6/42-52 and E6/54-61 were not included for experimental testing due to the selected cutoff. 
Binding peptides displayed a strong binding affinity in nine cases, intermediate binding for nine and 
weak binding for 15 peptides. 55 tested peptides were not binding to HLA-A11.  
For HLA-A24 (Fig. 21 C and D), a total of 69 peptides were tested for their binding affinity. Eight 
HPV16 peptides have been described to bind in previous studies (Kast et al., 1994; Morishima et al., 
2007; Bourgault Villada et al., 2010). Of those, E6/71-78 was not predicted within the chosen cutoff 
and thus excluded from in vitro testing in this study. While E7/61-69 and E6/44-52 could not be 
confirmed as binders, E6/49-57, E6/87-95, E6/26-34, E6/98-106 and E6/131-139 were identified to 
bind to HLA-A24. 35 peptides could be identified as novel binders. The binding peptides included 26 
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strong binding peptides, comprising the highest number of all binders, and six peptides with 
intermediate binding affinity. Nine peptides were identified as weak binders and 28 peptides classified 
as non-binders.  
 
 
 
 
Figure 21 I Peptide binding affinity to HLA-A3, HLA-A11 and HLA-A24. Binding affinities of predicted peptides 
were tested in competition-based binding assays using B-LCL cells expressing the designated HLA types. Known 
binders are marked in grey. A Binding affinities of peptides binding to HLA-A3. B Binding affinities of peptides binding 
to HLA-A11. C Binding affinities of peptides binding to HLA-A24. D Close up of all HLA-A24 peptides with a binding 
affinity of < 5µM. Dashed lines indicate the ranges of binding affinity: strong (< 5µM), intermediate (5-15µM) and weak 
(15-100µM). Peptides with a binding affinity above 100µM were classified as non-binders and are not shown in this 
figure. Results are plotted as means ± SEM of three independent experiments. 
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3.1.3 Motif analysis identifies additional binding peptides 
In order not to miss any peptide that lies outside the chosen cutoffs but might still bind to the 
designated HLA type, a peptide motif search was performed. To this end, amino acid patterns were 
generated of peptides identified as binders (positive motifs) and as non-binders (negative motifs). 
Peptide motifs generated for HLA-A24 are described as a paradigm for all HLA types investigated in 
this study. 
In Figure 22, positive motif patterns are displayed for peptides with the lengths of 8 to 11 amino acids 
that bind to HLA-A24. All peptides, independent of their length, showed a predominance for tyrosine 
at position 2. Besides this, no clear predominace of other amino acids at designated positions could be 
seen in 8mer peptides. 9mers binding to HLA-A24 showed a predominance of leucine and isoleucin at 
position 9 in the peptide sequences. In 10mer binding peptides, leucine was often present at the last 
two positions of the sequences. In the sequences of 11mer binding peptides, aspartic acid was 
predominant at position 8 and isoleucine was often present at position 9. However, for motif patterns 
of 8mers and 11mers, it has to be considered that the input for motif generation was lower than for 
9mers and 10mers.  
 
Figure 23 I Sequence logos of HPV16 E6 and E7 peptides binding to HLA-A24. Logos were created including all 
experimentally identified binding peptides (n) by using WebLogo 3. Sequence logos were generated separately for each 
peptide length. A The logo for 8mers. B The logo for 9mers. C The logo for 10mers. D The logo for 11mers. The larger an 
amino acid is depicted, the higher its frequency at a given position. The total bit height indicates the amino acid variation at 
one position. Lower bit height indicates less variation. Blue: hydrophilic amino acids, green: neutral amino acids, black: 
hydrophobic amino acids. 
Figure 23 displays the sequence logos of peptides that were identified as non-binders. In case of motifs 
generated for 8mers and 11mers, no clear statement could be deducted due to the limited numbers of 
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identified non-binders. For 9mers, arginine and tyrosine were slightly predominant at position 1 and 2, 
respectively. At position 7 of 9mers, glutamic acid had a slightly higher frequency than other amino 
acids and at position nine leucine and phenylalanine were slightly predominant. Tyrosine was often 
present at position 2 in the sequences of 10mer peptides. However, as all tested peptides were 
originally predicted as binders by the prediction servers, that are based on the tyrosine predominance 
at position 2, being a common residue at this position for HLA-binding, this is likely to result from 
this preselection.  
 
Figure 24 I Sequence logos of HPV16 E6 and E7 peptides not binding to HLA-A24. Logos were created including all 
experimentally identified non-binding peptides (n) by using WebLogo 3. Sequence logos were generated separately for each 
peptide length. A The logo for 8mers. B The logo for 9mers. C The logo for 10mers. D The logo for 11mers. The larger an 
amino acid is depicted, the higher its frequency at a given position. The total bit height indicates the amino acid variation at 
one position. Lower bit height indicates less variation. Blue: hydrophilic amino acids, green: neutral amino acids, black: 
hydrophobic amino acids. 
From the sequence logos, peptide motifs were constructed and applied in a motif search including all 
non-tested HPV16 E6 and E7 peptides using the ExPASy ScanProsite tool. Results were analyzed for 
peptides matching with at least two positive motifs or with one positive and no matching with any 
negative motif. Peptides identified as potential binders by motif analysis are marked in italic in Tables 
14 & 15 and Tables 22-25 (Appendix). For HLA-A3, three peptides were identified by motif search, 
E6/91-101, E6/91-103 and E6/52-61. Motif analysis for HLA-A11 resulted in seven potential 
additional binding peptides, namely E6/ 31-41, E6/65-75, E6/66-75, E7/63-43, E7/41-50, E7/42-50 
and E7/68-75. Since the binding analysis of HLA-A24 had resulted in most novel binders, most strong 
binders and the most peptides suggested through motif analysis, we decided to focus this study on 
HLA-A24 from here on. Furthermore, of the three HLA types initially analyzed, HLA-A24 reached 
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amongst the highest frequencies in various ethnic populations as for example 58.6% in the Japanese 
population or 40.1% in the Chinese population and up to 23.9% in the Caucasion population (Sette and 
Sidney, 1999; Gonzalez-Galarza et al., 2015). For HLA-A24, 26 additional peptides were indicated as 
potential binders through motif analysis. In Figure 24, the results of the competition-based binding 
assays for HLA-A24 motif search-derived peptides are summarized. While one peptide, E6/48-57, 
showed strong HLA-A24 binding properties, two peptides, E6/35-44 and E6/50-59, displayed 
intermediate binding affinity to HLA-A24. Four peptides, E6/75-85, E6/86-96, E6/127-135 and 
E6/125-135 could be identified as weak binders. The remaining 18 peptides did not bind to HLA-A24.  
 
Figure 25 I Peptide binding affinity to HLA-A24 of peptides predicted by motif analysis. Binding affinities of peptides 
predicted by motif analysis were tested in competition-based binding assays using B-LCL cells expressing HLA-A24. 
Dashed lines indicate the ranges of binding affinity: strong (< 5µM), intermediate (5-15µM) and weak (15-100µM). Peptides 
with a binding affinity above 100µM were classified as non-binders and are not shown in this figure. Results are plotted as 
means ± SEM of three independent experiments. 
 
3.1.4 Evaluation of prediction servers 
Throughout the experimental validation of predicted binders and while setting new cutoffs for further 
testing of actual peptide binding (see section 3.1.1 and 3.1.2), it became obvious that not all servers 
were equally good at prediction binding affinities for all peptide lengths and for all three HLA types. 
In order to find the best prediction server for each peptide length and for each HLA type, evaluation of 
the performance of the prediction servers was performed by exploiting the large amount of generated 
experimental binding data in this study. To this end, receiver operating characteristic (ROC) curve 
analysis was performed and the area under the curve (AROC) was calculated, yielding a useful measure 
of prediction quality. The two servers BIMAS and SYFPEITHI were not included for performance 
evaluation due to unclear definition and discrimination of predicted binders and non-binders by the 
developers. 
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In Figure 25, individual ROC curves are shown for predictions of 8mer (A), 9mer (B), 10mer (C) and 
11mer (D) peptides binding to HLA-A24. Corresponding ROC analyses for HLA-A3 and HLA-A11 
are depicted in Figure 36 and Figure 37 in the Appendix. Here, sensitivity represents the proportion of 
experimentally measured binders, which were correctly predicted as binders. This is defined as the 
true positive rate. Experimentally measured non-binders that were incorrectly predicted as binders 
were defined as the false positive rate. Practically, this means that, as shown i.e. in Figure 25 C, if 
NetMHCpan (dark grey) predicts at a given sensitivity of 0.84, 84% of binders are predicted correctly 
as binding. At the same sensitivity, four out of ten peptides that are actual non-binders would be 
predicted as binders. In general, a prediction server that showed a high true positive rate and at this 
sensitivity a low false positive rate could be rated as a good predictor. Thus ROC curves at the upper 
left corner of the graph are favorable. Of note, only four prediction servers, the NetMHC family and 
IEDBpan supported the prediction of 8mers and 11mers.  
 
Figure 26 I Evaluation of prediction server performance for peptide predictions of 8mers, 9mers, 10mers and 11mers 
binding to HLA-A24 by ROC analysis. The rates of true positive predictions are plotted as a function of the rate of false 
positive predictions. A Analysis for 8mers (n=9). B Analysis of 9mers (n=27). C Analysis of 10mers (n=35). D Analysis of 
11mers (n=24). Some curves are slightly overlayed.  
Figure 26 summarizes the ROC analyses for predictions comprising all four peptide lengths combined 
for HLA-A3 (A), HLA-A11 (B) and HLA-A24 (C). Comparing the prediction capabilities of all 
servers combined for all peptide lengths for the three different HLA types, indicated that predictions 
for HLA-A3 (A) are more precise than for HLA-A11 and HLA-A24. This is also reflected by 
calculation of the area under the curve (AROC) (Tab. 16).  
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Figure 27 I Evaluation of prediction server performance for peptide predictions for HLA-A3, HLA-A11 and HLA-
A24 by ROC analysis. The rates of true positive predictions are plotted as a function of the rate of false positive predictions. 
A Analysis for HLA-A3 (n=70). B Analysis for HLA-A11 (n=88). C Analysis for HLA-A24 (n=95). Some curves are 
slightly overlayed. 
In Table 16, the AROC is given for each single ROC curve. The AROC is equal to the probability that a 
prediction server will rank a randomly chosen binding pepide higher than a randomly chosen non-
binding peptide. Thus a higher AROC indicates a higher probability of a prediction server to identify 
true positive binders. Dashes in the table indicate that prediction for the designated peptide length is 
not supported by this predictor. Importantly, it has to be mentioned again, that not all prediction 
servers predict for all peptide lengths. Therefore, the overall (all lengths) performance cannot be 
compared between servers that only include 9mer and 10mers and those that support all lengths. 
Results for the overall performance for servers that do not support predictions for all lengths ar thus 
indicated in brackets in Table 16.  
For HLA-A3, NetMHCpan was identified as the best prediction server for 8mers and 11mers based on 
the experimental data of this study. Moreover, for 11mers, NetMHC and IEDBpan displayed equally 
good prediction performance as NetMHCpan. 9mers could be best predicted by NetMHC, IEDBann 
and IEDBpan. In case of 10mers, NetMHCpan was found to be the best predictor. For prediction of 
8mers binding to HLA-A11, NetMHCcons and IEDBpan showed the best prediction capabilities. For 
9mers and 10mers, NetMHC and IEDBann scored best, and 11mers were best predicted by NetMHC. 
In case of HLA-A24, predictions by NetMHCcons and IEDBpan provided best performance for 
8mers. For 9mers, NetMHCcons showed the best prediction capability and for 10mers NetMHC and 
IEDBann could be determined as the best predictors. NetMHC and NetMHCcons were shown to 
display the best performance for prediction of 11mers for HLA-A24. For all peptides lengths, 
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NetMHC could be determined as the best prediction server for HLA-A3 and for HLA-A11. For HLA-
A24 both NetMHC and NetMHCcons were shown to be best predictors.  
NetMHC and IEDBann are based on the same algorithms and similar training data sets, and therefore 
resulted in similar results for 9mers and 10mers. Taking all peptide lengths into consideration, 
NetMHC showed better performance since IEDBann does not support prediction of 8mers and 
11mers. Additionally, NetMHCcons and IEDBpan do partially use the same training data sets, e.g. for 
predictions for 8mers binding to HLA-A3 and HLA-A24. 
The predictive performance of the prediction servers was also assessed in accordance to criteria 
previously determined by Lin and colleagues (Lin et al., 2008). AROC values above 0.9 indicate 
excellent prediction capability, while values between 0.9 and 0.8 show intermediate prediction 
performance and values under 0.8 indicate poor predictive capability. For HLA-A3, excellent 
prediction performance was achieved by many servers – especially for 9mers and 10mers. For all 
lengths, predictors could be mainly classified as excellent and moderate. In case of HLA-A11, the 
overall prediction capabilities of prediction servers were a bit less accurate than for HLA-A3. Still, 
mostly excellent and moderate prediction performance was shown for prediction servers predicting 
8mers, 9mers and 10mers. However, for 11mers, predictors displayed only moderate prediction 
performance. Some predictors reached the best possible prediction performance of 1.00 for predicting 
11mers binding to HLA-A3 and for predicting 8mer binding to HLA-A11. This results should be 
regarded with caution as the sample size that was used as input in these cases is rather small (Fig. 36 
and 37, Appendix). For HLA-A24, the overall performance of predictors was shown to be worse than 
for HLA-A3 and HLA-A11. This was already expected, as many peptides were experimentally shown 
to be strong binders albeit being predicted mostly as intermediate, weak or non-binding peptides (Tab. 
14 and 15). NetMHC, NetMHCcons and IEDBpan showed moderate prediction performance for some 
lengths, otherwise all predictors displayed poor prediction capabilities for HLA-A24 (Tab. 16).  
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Table 16 I Predictor assessment for classification of binders and non-binders using the AROC. The values indicate 
excellent (AROC > 0.9), moderate (0.8 < AROC < 0.9) and poor (AROC < 0.8) prediction performance as classified by (Lin et al., 
2008). Performance was determined for individual HLA type, for individual length, and for overall (all lengths) performance 
for each HLA type. The best performing predictors for each HLA type and length is indicated in bold. Dashes indicate that 
the peptide length was not supported by the respective server and brackets indicate that the overall (all lengths) performance 
only includes 9mer and 10mers. 
 NetMHC  NetMHC 
pan 
NetMHC 
cons 
IEDB 
ann  
IEDB 
smm 
IEDB 
arb 
IEDB 
smmpmbec 
IEDB 
pan 
HLA-A3 
8mers 
9mers 
10mers 
11mers 
all lengths 
 
0.64 
0.99 
0.95 
1.00 
0.92 
 
0.86 
0.97 
0.96 
1.00 
0.89 
 
0.82 
0.94 
0.95 
0.92 
0.90 
 
- 
0.99 
0.95 
- 
(0.95) 
 
- 
0.82 
0.89 
- 
(0.90) 
 
- 
0.84 
0.68 
- 
(0.88) 
 
- 
0.84 
0.91 
- 
(0.92) 
 
0.82 
0.99 
0.91 
1.00 
0.89 
HLA-A11 
8mers 
9mers 
10mers 
11mers 
all lengths 
 
0.96 
0.96 
0.91 
0.65 
0.89 
 
0.96 
0.92 
0.76 
0.47 
0.80 
 
1.00 
0.94 
0.86 
0.63 
0.86 
 
- 
0.96 
0.91 
- 
(0.69) 
 
- 
0.89 
0.76 
- 
(0.65) 
 
- 
0.89 
0.39 
- 
(0.55) 
 
- 
0.92 
0.80 
- 
(0.65) 
 
1.00 
0.92 
0.76 
0.48 
0.81 
HLA-A24 
8mers 
9mers 
10mers 
11mers 
all lengths 
 
0.75 
0.77 
0.75 
0.84 
0.80 
 
0.63 
0.70 
0.69 
0.74 
0.70 
 
0.88 
0.81 
0.74 
0.84 
0.80 
 
- 
0.77 
0.75 
- 
(0.60) 
 
- 
0.63 
0.58 
- 
(0.52) 
 
- 
0.53 
0.31 
- 
(0.40) 
 
- 
0.63 
0.67 
- 
(0.55) 
 
0.88 
0.77 
0.60 
0.73 
0.70 
 
Overall, these results indicate that not all servers have the same capability to predict for all peptide 
lengths and for all HLA types. This result was already expected and has been partly observed in 
previous studies that evaluated predictor performance for 9mers and 10mers (Lin et al., 2008; 
Gowthaman et al., 2010; Zhang et al., 2011). In these evaluations, IEDBarb showed the least reliable 
prediction performance while NetMHC and NetMHCcons performed best for the given binding data 
input. Hence, the combination of various different prediction servers as employed in this study is of 
great importance if prediction of different lengths and for different HLA types is desired.  
Although the applied prediction servers operated with a generally high accuracy for HLA-A3, these 
results, especially for HLA-A24, indeed indicate a risk of missing potential binding peptides. The 
lowering of individual cutoffs beneath the advised cutoffs by the developer of the prediction servers 
and the use of alternative prediction approaches, such as the motif search (see section 3.1.3), thus 
proved to be beneficial to minimize the loss of potential binding peptides. By combining multiple 
servers and alternative approaches, the probability to find potent HPV16 E6 and E7 derived peptides 
was significantly increased.  
 
3.2 HPV16 variants and their HLA-binding E6 and E7 peptides 
HPV16 includes different variants which are associated with but not restricted to different geographic 
regions (Tu et al., 2006; Tabora et al., 2010). For epitope identification as well as vaccine 
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development, it is important to include these distinct HPV16 variants. HPV16 variants harbored by 26 
cell lines from our cell line collection were characterized. To this end, genomic DNA was isolated and 
the viral genes E6 and E7 were amplified by PCR. PCR products were verified by agarose gel 
electrophoresis (data not shown), sequenced by GATC Biotech and then aligned to the HPV16 
reference sequence (NC_001526), belonging to the HPV16 variant European Prototype 1, to detect 
nucleotide and amino acid exchanges. In parallel, a multiple sequence alignment of 62 HPV16 
sequences already assigned to a specific variant (Burk et al., 2011) was performed (Tab. 26, 
Appendix). HPV16 sequences harbored by the 26 tested cell lines were assigned to a variant based on 
the detected nucleotide exchanges. Table 17 shows the 26 cell lines carrying distinct HPV16 variants 
and their corresponding E6 and E7 amino acid exchanges. Different amino acid exchanges in the E6 
and/or E7 proteins were found in cell lines carrying the same HPV variant sublineage. To be able to 
discriminate between them, the suffix -v1, -v2, -v3 etc. was assigned to the sublineage name.  
Table 17 I HPV16 variants present in cell lines with their amino acid exchanges compared to the HPV16 reference 
sequence. Amino acid position is counted from the first methionine in E6. HLA-A24-positive cell lines are indicated in bold. 
E-1: European Prototype 1, E-2: European Prototype 2, E-A: European (Asian), AA: Asian-American, Af-2: African 2, v: 
variant 
HPV16 
variant  
Amino acid exchanges in E6 and E7 compared to the 
HPV16 reference sequence 
Cell lines harboring the 
variant 
E-1-v1 reference prototype 879, 915, 93VU147T, FK16A, 
Goerke , HPK1A, Marqu 
E-1-v2 E6 L90V C66#3, C66#7, MRI-H-196, 
W12 20861, W12 20863 
E-1-v3 E7 H51N UD-SCC2 
E-1-v4 E6 L90V, E6 E120D, E7 L28F SiHa 
E-2 E6 R17T, E6 L90V CaSki, SCC090, SCC152 
E-A-v1 E6 D32E, E7 N29S SNU 17, SNU 703, SNU 1005 
E-A-v2 E6 D32E, E6 I34R, E7 N29S SNU 1000 
E-A-v3 E6 D32E, E7 N29S, E7 S63F SNU 902 
AA E6 Q21D, E6 H85Y, E6 L90V SCC154, SNU 1299 
Af-2-v1 E6 R17I, E6 Q21D, E6 H85Y, E7 N29S 866 
Af-2-v2 E6 R17I, E6 Q21D, E6 E36Q, E6 A68G, E6 H85Y, E7 
N29S 
UM-SCC-47 
 
A complete list of all cell lines, the exact nucleotide exchanges within the E6 and E7 open reading 
frames (ORFs), also including silent mutations, and the designated HPV16 variant is displayed in 
Table 27 (Appendix). Since transcription of the E6 protein starts at the second methionine of the E6 
ORF (section 2.2.1.1, Tab. 2), the nomenclature for identification of HPV variants does not include the 
first 21 nucleotides or seven amino acids, respectively. For peptide prediction however, the first seven 
amino acids are included nevertheless, resulting in the change of position by seven. As an example, 
the nucleotide exchange T350G results in the amino acid change L83V in HPV variant terms and is 
named L90V in peptide prediction terms. In Table 17 we adhered to the peptide prediction 
nomenclature, while in Table 27 (Appendix) the positions of amino exchanges are shown according to 
the variant nomenclature. In total eighteen and eleven nucleotide exchanges were detected for the E6 
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and E7 ORFs, respectively. These nucleotide exchanges resulted in nine amino acid exchanges for the 
E6 protein and four exchanges for the E7 protein. The remaining nucleotide exchanges were silent.  
Moreover, the HLA types of all HPV16 positive cell lines were determined in order to be able to 
correlate HLA type and potentially presented HPV16 E6 and E7 peptides for subsequent experiments. 
To this end, genomic DNA was extracted from the cell lines of our HPV16-positive cell line collection 
that were not HLA typed before or in cases were literature search resulted in contradicting 
descriptions. HLA genotyping in resolution of four digits was conducted by the DNA subgroup of the 
Department of Transplantation Immunology of the Institute of Immunology at the University of 
Heidelberg and is displayed in Table 27 (Appendix). 
After testing the potential set of HLA-A3-, HLA-A11- and HLA-A24-binding E6 and E7 peptides 
derived from the prototype HPV16 sequence (section 3.1.2), this work was focused on HLA-A24 and 
the effects of amino acid exchanges in the E6 and E7 protein sequences were determined only for this 
HLA molecule. Binding affinities were predicted in silico in the same manner as done initially for the 
HPV16 reference sequence. As depicted in Table 18, peptides were filtered for those with an average 
predicted IC50 below 5000nM.  
Table 18 I HPV16 E6 and E7 variant peptides predicted to bind to HLA-A24. Changes in comparison to the HPV 16 
reference sequence are indictaed in the second and third column for E6 and E7, respectively. Amino acid sequences including 
the change are indicated in bold in the 4th and 5th column. The peptide names include “var “ in the end, indicating that they 
are derived from a HPV16 variant. * No peptides were predicted to bind within a 5000nM average IC50 cutoff for E120D.  
HPV16 
variant  
E6 aa 
changes  
E7 aa 
changes 
Potential HLA-A24 binders 
derived for E6 variants within a 
5000nM average IC50 cutoff  
Potential HLA-A24 binders 
derived for E7 variants within 
a 5000nM average IC50 cutoff 
E-1v2 L90V  SEYRHYCYSV (E6/81-90var), 
EYRHYCYSV (E6/82-90var), 
EYRHYCYSVY (E6/82-91var), 
HYCYSVYGT (E6/85-93var), 
HYCYSVYGTT (E6/85-94var), 
HYCYSVYGTTL (E6/85-95var), 
CYSVYGTT (E6/87-94var), 
CYSVYGTTL (E6/87-95var), 
CYSVYGTTLE (E6/87-96var), 
YSVYGTTL (E6/88-95var), 
VYGTTLEQQ (E6/90-98var), 
VYGTTLEQQY (E6/90-99var)  
 
E-1-v4 L90V, 
E120D 
L28F see E-1v1                                       
* 
TTDLYCYEQF (E7/19-28var) 
TDLYCYEQF (E7/20-28var), 
DTDLYCYEQF (E7/21-28var) 
E-A-v1 D32E  N29S LQTTIHEII (E6/26-34var) LYCYEQFSD (E7/22-30var), 
LYCYEQFSDS (E7/22-31var), 
CYEQFSDSS (E7/24-32var), 
CYEQFSDSSE (E7/24-33var) 
 
Twenty HPV16 variant peptides predicted to bind to HLA-A24 were tested in competition-based 
binding assays (Fig. 28). Seven of these variant peptides were identified as binders. These include 
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three strong binders, E6/87-95var, E6/90-99var and E6/26-34var, and one intermediate binder, E6/82-
90var. E7/21-28var, E6/87-96var and E6/88-95var were ranked as weak binders and the remaining 
thirteen peptides did not bind to HLA-A24. Of note, the respective HPV16 reference-derived peptides 
that were binding as well, scored twice an comparable binding affinity (E6/87-95 and E6/26-34), once 
a slightly lower binding affinity (E6/90-99) and in three cases a higher binding affinity (E6/82-90, 
E6/87-96 and E6/88-95). The counterpart of E7/21-28var was not included in testing due to prediction 
under the chosen cutoff.  
 
Figure 28 I Peptide binding affinity of predicted HPV16 variant peptides to HLA-A24. Binding affinities of predicted 
HPV16 variant peptides were tested in competition-based binding assays using using B-LCL cells expressing HLA-A24. 
Dashed lines indicate the ranges of binding affinity: strong (< 5µM), intermediate (5-15µM) and weak (15-100µM). Peptides 
with a binding affinity above 100µM were classified as non-binders and are not shown in this figure. Results are plotted as 
means ± SEM of three independent experiments. 
 
Table 19 summerizes all in silico predicted binding peptides of this study, including sequences derived 
from the HPV16 E6 and E7 reference sequences and the HPV16 variants, and in vitro tested peptides 
for all three HLA types. In total, 74 were predicted for HLA-A3, 96 for HLA-A11 and 115 peptides 
for HLA-A24, including HPV16 E6 and E7 peptides based on prediction for the HPV16 reference 
type, peptides predicted by motif analysis and HPV16 variants, were predicted. Of those, 18 binders 
could be identified for HLA-A3, 33 for HLA-A11 and 56 for HLA-A24. Those binders can be further 
subdivided into confirmed known binders and novel binders, resulting in seven known binders for 
HLA-A3, ten for HLA-A11 and five for HLA-24. Novel binders comprise eleven for HLA-A3, 23 for 
HLA-A11 and 51 for HLA-A24. 167 tested peptides were found to be non-binders. 
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Table 19 I Predicted and tested HPV16 E6 and E7 peptides and their binding status to their respective HLA type.  
HLA 
supertypes 
possible 
epitopes 
predicted 
peptides 
tested 
peptides 
actual 
binders 
known 
binders 
novel 
binders 
non-
binders 
HLA-A3 all 74 71 18 7 11 53 
HLA-A11 8mers to 96 88 33 10 23 55 
HLA-A24 11mers 115 115 56 5 51 59 
total 941 
+variants 
285 274 107 22 85 167 
 
 
3.3 Immunoprecipitation of HLA/peptide complexes from HPV16-transformed 
cells 
In order to identify naturally processed and presented HPV16 E6 and E7 T cell epitopes on HPV16-
transformed cells, HLA/peptide complexes were isolated. First, HLA expression levels on HPV16-
transformed cells were determined to evaluate the number of cells needed for immunoprecipitation of 
HLA/peptide complexes. After successful immunoprecipitation, peptides were eluted from 
HLA/peptide complexes for subsequent MS analysis. Purity and enrichment of HLA/peptide 
complexes are a prerequisite for MS analysis. 
3.3.1 HLA expression levels 
HLA expression levels were determined for all HLA-A3, HLA-A11 and HLA-A24 positive cell lines 
of our HPV16 positive cell line collection. Cells were stained with corresponding specific HLA 
antibodies and analyzed by flow cytometry. Expression levels were normalized to CaSki HLA-
A*02:01 expression levels, as the cell number needed for immunoprecipitation was initially optimized 
for HLA-A2 and CaSki cells. Results are summarized in Figure 28. For HLA-A3 (A) all cell lines 
showed relatively high HLA expression levels compared to the reference. Expression levels for HLA-
A11 (B) were lower than the reference. The cell line SiHa showed the highest HLA-A24 expression 
level (C), while levels for FKA16A were almost not detectable.  
For HLA-A24, all cell lines were selected for isolation of HLA/peptide complexes and analysis of the 
E6 and E7 epitopes presented. For HLA-A3 and HLA-A11, cell lines with the highest expression 
levels, CaSki, MRI-H196 and 93VU147T (HLA-A3) and SNU 1000 (HLA-A11) were chosen. 
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Figure 29 I HLA expression levels determined for HPV16 positive cell lines. Cells were stained with HLA type specific 
antibodies and the mean fluorescent intensity was analyzed by flow cytometry. Results are normalized to the reference cell 
line’s (CaSki) HLA-A2 expression. A HLA expression levels for HLA-A3-positive cell lines. B HLA expression levels for 
HLA-A11-positive cells. C HLA expression levels for HLA-A24-positive cells. Results are plotted as means ± SEM of three 
independent experiments.  
 
3.3.2 Immunoprecipitation 
Various methods for immunprecipitation (IP) of HLA/peptide complexes were compared and 
optimized. The whole initial optimization procedure was performed with HLA-A2 positive CaSki 
cells, as they are fast growing and eventually were used for MS analysis optimization. Different 
parameters such as antibody concentrations and incubation times were tested and optimized. 
Furthermore, it was assessed whether sonication of cell lysates improved the yield of HLA/peptide 
complex isolation. Moreover, different lysis buffers such as the radioimmunoprecipitation assay 
(RIPA) buffer or a lysis buffer based on Triton-x 100 and NP40, were compared (Alcaraz et al., 1990; 
Riemer et al., 2010). This involved testing of various detergents such as Triton-x 100, NP40, SDS and 
CHAPS. The optimal cell number was determined for each cell line. To this end, cell numbers used in 
each single IP experiment were monitored and cell numbers needed for IP of a novel cell line were 
estimated based on HLA expression levels (Fig. 28). Purity and enrichment of HLA molecules was 
assessed by Coomassie or Oriole staining and Western Blot analysis. Eventually, the IP procedure was 
optimized to the current protocol described in section 2.2.3.2. In brief, 20µL dry sepharose beads were 
coupled with 20µg capture antibody and incubated for two to three hours at room temperature. For 
both, HLA-A2 positive CaSki and HLA-A24 positive SiHa cells, five confluent dishes containing 
approximately 5.5x10
7
 cells were used, cells scraped off and then lysed in 1mL of CHAPS buffer. 
After centrifugation of lysed cells, the remaining cleared lysate was incubated with washed sepharose 
beads coupled with capture antibodies for three hours at 4°C. Susequently, the supernatant (SNT) 
named the‘flow through’ of the beads, fluids from different washing steps and the sepharose beads 
containing the immunoprecipitate were collected for analysis. Figure 29 depicts representative Oriole 
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stained polyacrylamide gels and Western Blots of immunoprecipiated HLA-A24/peptide complexes 
from SiHa cells and HLA/A2 peptide complexes from CaSki cells which served as a reference. 
In the IP fractions for both SiHa (IP SiHa) and CaSki (IP CaSki) cells, a distinct band could be 
detected by Western blot analysis with a pan anti-MHC class I antibody at approximately 44 kDa, 
which is the expected size of the HLA class I α-chain. This verified successful immmunoprecipitation 
of HLA-A24/peptide and HLA-A2/peptide complexes. Enrichment of HLA/peptide complexes was 
achieved for HLA-A24 and HLA-2, as the bands in the IP samples are clearly stronger than the bands 
in the cleared lysate. Some HLA/peptide complexes, however, did not bind to the capture antibodies as 
the 44kDa band was still detectable in the flow through, most probably due to oversaturation. 
Moreover, some HLA/peptide complexes were lost during the first washing steps indicated in the 
lanes of wash 1 and wash 2. No bands were detected in the last washing step, wash 6. Both IP samples 
also includeded other proteins apart from the immunoprecipitated HLA/peptide complexes, as other 
bands than the 44kDa band are detected by Oriole staining and also by Western blot analysis. Since 
peptides had to be eluted anyway from HLA/peptide complexes and purified by size exclusion in 
subsequent steps towards MS analysis, further purification was not nesseccary at this point. Bands at a 
size of 23kDa, that are detectable in the beads and capture antibody control and throughout all samples 
from the whole immmunoprecpitation procedure, represent the light chain of the antibody. This band 
is visible in Oriole stained gels and in the Western blots. On the other hand, the heavy chain of the 
antibody with a size of 50kDa was not detectable with the antibody used for HLA class I detection and 
thus is only visible in Oriole stained gels. The band detected at 100kDa in both IP samples with 
Western blot analysis likely represents antibody heavy chain dimers.  
So far, no peptides defined as potential epitopes in the immunoprecipitated samples could be detected 
by MS analysis. The MS method is currently being optimized and future analysis will reveal whether 
potential peptides are actually presented on the cells transformed by HPV16. 
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Figure 30 I Immunoprecipitation of HLA/peptide complexes from SiHa and CaSki cells. After cell scraping, cells were 
lysed and centrifuged. The cleared lysate (cl. lysate) was incubated with beads coupled to capture antibody for three hours at 
4°C. Subsequently, samples were centrifuged, the supernatant (flow through) collected and beads washed (wash 1-6). As 
controls, uncoupled beads and beads coupled with respective capture antibody, either anti-HLA-A2 or anti-HLA-A24, were 
incubated with buffer instead of cleared lysate in the same manner as IP samples. Controls are always loaded in the first 
lanes. A, C, E Oriole staining of polyacrylamide gels. Prescision Plus Protein™ Unstained Standard (BioRad) was used as a 
marker. B, D, F Western blot analysis of immunoprecipitated HLA-A24 and HLA-A2 performed with an rabbit-anti-human 
MHC class I specific monoclonal antibody (anti-MHC class I). Detection of primary antibody was done with a secondary 
HRP-conjugated goat-anti rabbit antibody and ECL detection. Prescision Plus Protein™ Kaleidoscope (BioRad) was used as 
a marker. Equal protein amounts where loaded in each lane. Arrows indicate HLA class I moleules, either HLA-A24 or 
HLA-A2, heavy chains of antibody (Ab) and light chains of antibody. 
 
3.4 Evaluation of peptide immunogenicity by establishing short-term T cell lines  
In order to assess the immunogenicity of binding peptides, we established peptide-specific short-term 
T cell lines. In order to test the high number of all binding peptides for the HLA types investigated in 
this of the study (Tables 14 and 15 for HLA-A24, Tables 22-25 for HLA-A3 and HLA-A11, and 
section 2.1.12.2 for HLA-A2, HLA-B7 and HLA-B15), a large number of PBMCs was needed. To 
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obtain such a large number, buffy coats of healthy donors were used. Buffy coats are a by product of 
blood donations for erythrocytes and contain concentrated white blood cells. They were easily 
obtained from our local blood bank. Buffy coat donations were HLA typed by FACS staining, which 
provided a fast first test on day 1. For validation, HLA genotyping was performed by PCR. Since 
blood donors are required to be over 18 years in Germany, a contact with a high-risk HPV type can be 
assumed to be likely but not taken for granted (Evander et al., 1995; Woodman et al., 2007). For the 
generation of peptide-specific short-term T cell lines, peripheral blood mononuclear cells (PBMCs) 
were isolated from the buffy coats, stimulated ex vivo with the identified binding HLA-matching 
peptides and kept in culture for twelve days. In this setting, stimulation with HPV16 E6 and E7-
derived peptides is likely to trigger T cell memory responses in individuals, who were previously 
transiently infected by HPV16. IFNγ ELISpot assays were conducted to test peptide immunogenicity.  
3.4.1 HLA typing of buffy coat cells 
The HLA typing results of all twelve buffy coat donors using FACS staining and HLA genotyping 
PCR are displayed in Table 20. The data determined by FACS staining for buffy coats 2 and 6 
suggested, that these donors carry more than two alleles on the A locus. Since this is impossible, 
validation of the HLA types with a more accurate method was required. For validation, HLA 
genotyping with two digits precision was performed with primer sets specific for each probed HLA 
type (Bunce, 2003) (section 2.2.2.2 Tab. 12).  
The false positive results seen in FACS stainings can be explained by cross-reactivity of HLA-A3 with 
the anti-HLA-A11 antibody, according to the product’s data sheet. Thus all buffy coats with HLA-A3 
were also characterized as HLA-A11 positive by FACS. HLA genotyping could, however, confirm 
whether a donor was truly positive for HLA-A11. For buffy coat eight, HLA-A11 could not be 
confirmed by PCR, possibly because the HLA-A11 subtype was not covered by the primer pairs. Here, 
we assumed that the buffy coat was HLA-A11 positive anyway because it was not HLA-A3 positive, 
eliminating the possibility of a cross-reaction with this molecule. 
The false positive results in HLA-A24 FACS stainings may be due to cross-reactivity of the anti-
HLA-A24 antibody with HLA-B27. This cross-reaction was reported by the manufacturer MBL and 
led to 20% false postive results in their studies with samples of Japanese origin. HLA-B27 has an 
allele frequency of 8.5% in the German population (Gonzalez-Galarza et al., 2015) and therefore it is 
possible that the false positive buffy coats were truly positive for HLA-B27. Recognition by the 
antibody was tested positive using a HLA-B27 positive cell line and HLA genotyping confirmed 
which buffy coats were really positive for HLA-A24. The results of HLA-B7 typing by FACS staining 
could not be validated by HLA-B7 specific PCR reactions due to a lack of specific primers for this 
genotype. Determined HLA types for each buffy coat are shaded in grey in Table 20. The prevalence 
of HLA types that were determined for the twelve buffy coat donations in the study, fits quite well to 
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the reported prevalence for HLA types in the German population as indicated in the last row of Table 
20. 
Table 20 I HLA typing for twelve buffy coats by FACS staining and HLA genotyping PCR. Buffy coats were first tested 
for their HLA type by staining with a panel of HLA-specific antibodies and subsequent FACS analysis. The results are shown 
on the left side of the dash. HLA genotyping PCR results are indicated on the right side. Grey highlighting indicates the 
determined HLA types. The prevalence of each HLA type is shown for the German population (Gonzalez-Galarza et al., 
2015). * HLA-B7 primers were not specific for this genotype. 
Buffy coat HLA type: 
HLA-A2 
 
HLA-A3 
 
HLA-A11 
 
HLA-A24 
 
HLA-B7 * 
 
HLA-B15 
1 +/+ -/- +/+ -/- -/ -/- 
2 +/+ +/+ +/- +/- -/ -/- 
3 -/- -/- -/- +/+ -/ -/- 
4 -/- +/+ +/- +/- +/ -/- 
5 -/- -/- -/- +/- +/ -/- 
6 -/- -/- +/+ +/+ +/ -/- 
7 +/+ -/- +/- -/- -/ -/- 
8 -/- +/+ +/- -/- -/ -/- 
9 -/- -/- -/- +/- -/ +/+ 
10 +/+ -/- -/- +/- -/ -/- 
11 +/+ +/+ +/- -/- -/ +/+ 
12 +/+ -/- -/- -/- -/ +/+ 
prevalence in 
this sample 
set (%) 
50 
 
33.3 25 16.7 25 25 
prevalence in 
Germany (%) 
49.9 
 
28.6 10.0 18.1 24.5 15.3 
 
3.4.2 IFN ELISpot assays 
Isolated PBMCs were stimulated with peptides according to their HLA type and cultured for twelve 
days. IFN ELISpot assays were performed. As an example, the results of HLA-A24-restricted 
peptides tested with cells from buffy coat donor 3, are displayed in Figure 30. A peptide-specific T 
cell response was considered positive only when the mean spot number for a given peptide was at least 
twofold higher than the mean spot number of the negative control (DMSO) (upper dashed lines). For 
this donor, five E6 peptides, E6/85-95, E6/66-76, E6/67-76, E6/82-91, and E6/50-59 and two E7 
peptides, E7/56-65, and E7/51-59, could be identified to elicit IFN responses.  
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Figure 31 I Immunogenicity screening of HPV16 E6 and E7 epitopes by IFNγ ELISpot assay. ELISpot analysis of 
peptide-specific IFNγ responses to HPV16 E6 and E7 peptides with cells from a HLA-A24-positive buffy coat (donor 3). 
Light grey indicates controls. DMSO (peptide diluent), no treatment and a HIV HLA-A24-restricted peptide were used as 
negative controls and PHA and an EBV HLA-A24-restricted peptide were used as positive controls. Dark grey shows all 
HPV16 E6 HLA-A24-binding peptides and black all HPV16 E6 HLA-A24-binding peptides that were tested for 
immunogenicity. Results are plotted as means ± SEM of at least three replicates. A peptide-specific T cell response was 
considered positive when the mean spot number for a given peptide was at least twofold higher than the mean spot number of 
the DMSO negative control (lower dashed line). upper dashed line: threshold, bars lined in green: peptides displaying 
positive responses, SFU: spot forming units, n.c.: not countable 
A graphic summary of all immunogenic peptides is displayed in Figure 31. The peptides are sorted by 
their position in the viral proteins E6 (A) and E7 (B) and color-coded for their immunogenicity 
according to how many donors have reacted to the respective peptide. Due to the FACS typing 
difficulties mentioned above, several peptides were tested with non-matching donors. If the assays 
resulted in IFN responses, it can be safely assumed that this was caused by cross-reactive binding of 
the peptide to another HLA type. These results are marked with an asterisk in Figure 31. 
HLA-A2 was the most frequent HLA type amongst all donors and several HLA-A2-restricted peptides 
were shown to be immunogenic in more than three donors. One region (20-30aa) for the E6 protein 
and two regions (10-20aa and 74-92aa) for the E7 protein contained these immunogenic peptides. Also 
for HLA-A3 and HLA-A11, immunogenic regions around 67-78aa and 90-115aa for E6 and at 85-
95aa for E7 could be identified. For the HLA types HLA-A24, HLA-B7 and HLA-B15 further data is 
neccesary to draw clear conclusions. In case of HLA-A24-restricted peptides, various cross-reactions 
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with other HLA types could be observed. One peptide, E6/85-95, was, however, tested to be 
immunogenic in both HLA-A24 positive donors.  
 
Figure 32 I Immunogenicity testing results of HPV16 E6 and E7 peptides in twelve donors. All peptides are sorted by 
their position in the viral protein, E6 (A) and E7 (B), and color coded by the frequency of the IFN responses across different 
donors. Peptides that were tested and did not show immunogenicity are not depicted. 
Several facts complicate the interpretation of this data set. First, even though the peptides were chosen 
because of certain HLA alleles being present, it remains elusive whether the observed responses were 
associated only with these particular HLA molecules or with one of the other HLA molecules present 
on the cells. Testing of immunogenicity in a total of twelve buffy coat donors only gives hints towards 
potential general immunogenicity of a peptide related to a specific HLA type. In order to find 
significant correlations between the peptide and the HLA type, the number of tested donors would 
have to be increased. Moreover, the medical history and especially the HPV status of the donors is 
unknown. Even if T cell memory responses are assumed to occur, due to the high percentage of the 
world population that acquire a transient infection with a high-risk HPV type in their lifetime (Evander 
et al., 1995; Woodman et al., 2007), the immune system of every individual reacts differently. Thus, a 
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peptide might elicit  memory IFN responses in one healthy donor, but not in another, even if both 
individuals carry the same HLA type and have been transiently infected with the same HPV16 variant.  
 
3.5 Functional analysis of peptide candidates using peptide-specific HLA-A24-
positive T cell lines 
To further characterize the potential of peptides to be candidates for a therapeutic HPV16 vaccine, 
various functional assays were performd. IL-2 secretion was assessed in supernatants from peptide-
specific short-term T cell lines. IFNγ secretion and cytolytic activity of peptide-specific long-term T 
cell lines were tested in response to autologous peptide-presenting B cells. Additionally, the clonality 
of peptide- specific T cell lines was assessed by TCR sequencing. Four candidate peptides were 
selected for these experiments based on their binding to HLA-A24 (sections 3.1.2 and 3.2) and the 
immunogenicity screening in short-term peptide-specific T cell lines (section 3.4.2): E6/87-95var, 
E6/49-57, E6/49-59 and E7/56-65. In case of E6/87-95, the variant peptide was chosen to be able to 
test cytolytic activity on the HLA-A24 positive cell line SiHa, which harbors the HPV16 variant 
European Prototype 1 variant 4, with an amino acid exchange of leucine to valine at position 90 in the 
E6 protein. Moreover, these four peptides also showed promising in silico results, indicating at least 
weak binding, when tested for CTL prediction with the prediction server NetCTL (Larsen et al., 2007). 
This prediction server – next to peptide-HLA binding – also takes TAP transport efficiency and 
proteasomal C-terminal cleavage prediction into account. This server was not included in our initial 
predictions as its results are impossible to be combined with other predictive tools. Therefore, we only 
used it for post-hoc assessment of promising candidates.  
Experiments were performed with PBMCs from HLA-A24 positive blood donors. Donor 1 was a 24 
year old male and donors 2 and 3 were 24 and 37 year old females, respectively. No history of 
persistent infection with HPV was known for any donor. Donor characteristics and HLA types are 
given in Table 28 (Appendix).  
3.5.1 IL-2 secretion upon peptide stimulation  
Enzyme Linked Immunosorbent Assays (ELISAs) were performed with supernatants (SNT) from 
peptide-stimulated PBMCs (section 2.2.5.1) to monitor the secretion of the pro-proliferation cytokine 
IL-2. IL-2 secretion was assessed on day 3 and day 7 in peptide-specific short-term T cell lines. To 
this end, SNT was collected before washing and addition of exogenous IL-2.  
Figure 32 shows IL-2 levels of PBMCs from donor 3 stimulated with peptides as indicated, compared 
to the negative control DMSO. IL-2 levels were elevated significantly on day seven in PBMCs 
stimulated with E6/87-95var, E6/49-57 and E7/56-65. Of note, exogenous IL-2 was added on day 3 
after taking the sample. The effect of this exogenous IL-2 on IL-2 levels on day seven can be 
neglected since levels are compared to the negative control, which was treated with the same 
  Results 
119 
 
concentration of exogenous IL-2 and did not show an increase of the measured IL-2 from day 3 to day 
7. At this point, it remained elusive, which cells contained in the PBMC culture specifically produced 
IL-2. It can be assumed, however, that the secreted IL-2 is mainly derived from activated CD4
+
 and 
CD8
+
 T cells (Boyman and Sprent, 2012). Additionally, NKT cells have also been reported to secrete 
IL-2, albeit to a lesser extent (Jiang et al., 2005). 
 
Figure 33 I IL-2 secretion of PBMCs after stimulation with HPV16 E6 and E7 peptides. PBMCs of donor 3 were seeded 
on day 0 and stimulated with peptides and IL-7. IL-2 was added on day 3 and day 7. DMSO was used as negative control and 
ConA and the CEF peptide pool were used as positive controls. IL-2 levels in SNT collected prior to exogenous IL-2 addition 
on day 3 (A) and day 7 (B) were measured by ELISA. Results are plotted as means ± SEM of duplicates. * p < 0.05, ns: not 
significant (unpaired student’s t test) 
 
3.5.2 Clonality of T cell receptors of peptide-specific long-term CD8
+
 T cell lines  
To assess the clonality of CD8
+ 
T cell in peptide-specific T cell lines, the T cell receptor (TCR) α- and 
β-chains were sequenced in collaboration with Eliana Ruggiero of the Division of Translational 
Oncology (G100, Christoph von Kalle), DKFZ. To this end, RNA was extracted from CD8
+
 T cells of 
peptide-specific long-term T cell lines (section 2..2.5.1) and cDNA of the TCR α- and β-chain was 
reverse transcribed. Sequencing on an Illumina machine was carried out by using primers attaching to 
conserved flanking sequences. Of all four peptide-specific T cell lines, results could only be obtained 
for TCR sequencing of E6/49-75-specific CD8
+
 T cells for both the α- and β-chain and for the α-chain 
of E6/87-95var-specific CD8
+
 T cells of donor 3. Different regions of the variable domains of the 
TCRs were analyzed including the variable region (V), the diversity region (D) and the 
complementary determining region 3 (CDR3). CDR3 includes some of the V, all of the D and the 
joining (J) regions. It is the most variable amongst all CDRs and recognizes antigens presented by 
MHC I and MHC II molecules (Murphy, 2007). The findings of CDR3 sequencing are displayed in 
Figure 33. The ten sequences that were retrieved most often for each peptide-specific CD8
+
 T cell line 
are color-coded according to their retrieval frequency, and the respective CDR3 sequences are 
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displayed on the right side. These results indicated high polyclonality of E6/49-75-specific CD8
+
 T 
cells for both chains. However, E6/87-95var-specific CD8
+
 T cells were basically monoclonal for the 
α-chain. Thus, putative E6/49-75-specific CD8+ T cells were not a specific “cell line” and therefore a 
new E6/49-75-specific T cell line was generated for subsequent experiments.  
 
Figure 34 I CDR3 sequencing of peptide-specific CD8+ T cells indicates poly- and monoclonal cultures. The TCRs of 
peptide-specific CD8+ T cell were sequenced after four weeks of culture including four stimulations with antigen-presenting 
cells (APCs) presenting the respective peptide. Retrieval frequencies of CDR3 sequences are presented color-coded on the 
left. The ten sequences that were retrieved most often are shown on the right. The percentages of all other CDR3 sequences 
are indicated. 
Table 21 gives an overview of all sequencing results comprising the numbers of overall TCR 
sequences and V, J and CDR3 sequences. For the E6/87-95var alpha chain, a total of 24,631 TCR 
sequences resulted in 13 sequences for the V region, 14 for the J region and 81 sequences for the 
CDR3 region. Of note, it is not known which α-chain belongs to which β-chain. The method is 
currently still under development and aims at an assignment of these two chains to each other. TCR 
sequencing does not allow to conclude any peptide sequences recognized on binding HLA/peptides 
complexes. 
Table 21 I TCR sequencing of peptide-specific T cell lines. The number of identified TCR sequences, V region sequences, 
J region sequences and CDR3 sequences are shown. 
 E6/49-57 
alpha chain 
E6/49-57 
beta chain 
E6/87-95var  
alpha chain 
TCR sequences 85055 40855 24631 
V 42 43 14 
J 45 13 13 
CDR3 597 2387 81 
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3.5.3 IFN secretion by peptide-specific long-term CD8+ T cells upon co-culture with autologous 
peptide-pulsed B cells  
Additionally to the immunogenicity screening of peptides in peptide-specific short-term T cell lines, 
IFN secretion was monitored in peptide-specific long-term CD8+ T cell lines upon co-culture with 
autologous peptide-pulsed B cells. To this end, eleven long-term peptide-specific T cell lines from the 
three HLA-A*24:02 positive donors were generated (section 2.2.5.1) by four weekly stimulations of 
PBMCs with antigen-presenting cells (APC) pulsed with one of the four candidate peptides described 
above. Subsequently, untouched CD8
+
 T cells were isolated by negative selection using MACS 
technology ( > 95% CD8
+
 T cell purity) as described in section 2.2.4.6. For the IFN ELISpot assay 
1x10
5
 peptide-specific CD8
+
 T cells were co-cultured with 2x10
4
 auotologous B cells presenting the 
respective peptide or control peptides. Figure 34 shows the results of IFN ELISpot assays for co-
culture of E6/87-95var-, E6/49-47-, E6/49-59- and E7/56-65-specific CD8
+
 T cells with their 
respective peptide-presenting B cell targets. CD8
+
 T cell responses were considered positive only 
when the mean spot number was at least twofold higher than the mean spot number of the negative 
control (peptide-specific CD8
+
 T cells co-cultured with DMSO-pulsed B cells). In (A) the spot counts 
for E6/49-57-specific CD8
+
 T cells from donor 2 co-cultured with peptide presenting autologous B 
cells and controls are displayed exemplarily. E6/49-57-specific CD8
+
 T cells exhibited significant 
IFN secretion upon recognizing their cognate peptide. Representative IFN ELISpot wells of data 
shown in (A) are displayed in (B). In (C) the stimulation indices for all tested peptide-specific CD8
+
 T 
cell lines are summerized. The stimulation indices are defined as the ratio between the number of spots 
per 1x10
5
 peptide-specific 
 
CD8
+
 T cells co-cultured with epitope-pulsed B cells and those detected in 
control wells, where peptide-specific CD8
+
 T cells were co-cultured with DMSO-pulsed B cells. 
Positive CD8
+
 T cell responses are indicated by green lines, while red lines mean that the CD8
+
 T cell 
responses were considered negative. All assays were performed in duplicates with the exception of 
cells from donor 1 and E7/56-65-specific CD8
+
 T cells from donor 2, which were only carried out in 
single wells, due to the low numbers of CD8
+
 T cells. E6/87-95var- and E6/49-59-specific CD8
+
 T cell 
lines of donor 1 were shown to be positive for IFN secretion. In case of donor 2, E6/87-95var- and 
E6/49-57-specific CD8
+
 T cell lines showed significant IFN secretion. Positive IFN responses could 
be observed for all four peptide-specific CD8
+
 T cell lines co-cultured with respective peptide-pulsed 
autologous B cells from donor 3. Thus all four tested candidate peptides were capable of inducing 
CTL specific responses in some donors and only one peptide in all three donors. Differences in 
strength of immune reactions between different donors were expected. 
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Figure 35 I IFNγ secretion of peptide-specific CD8+ T cells upon co-culture with autologous B cells presenting the 
respective peptide. ELISpot analysis of peptide-specific CD8+ T cell IFNγ responses to their cognate peptide presented on 
autologous B cell in three HLA-A*24:02 positive donors. Eleven peptide-specific CD8+ T cell lines were generated by 
peptide-specific long-term T cell culture including four stimulations with APCs pulsed with the desired peptide over a time 
period of four weeks. CD8+ T cell responses were considered positive only when the mean spot number was at least twofold 
higher than the mean spot number of the negative control (peptide-specific CD8+ T cells co-cultured with DMSO-pulsed B 
cells). A Spot counts for E6/49-57-specific CD8+ T cells from donor 2 co-cultured with peptide presenting autologous B cells 
and controls. E6/49-57-specific CD8+ T cells stimulated with ConA were used as positive control. Autologous B cells 
(without T cells) pulsed with either DMSO, a HIV HLA-A24-restricted peptide or E6/49-57 are are shown as background 
controls. E6/49-57-specific CD8+ T cells were co-cultured with autologous B cells pulsed with DMSO and a HIV HLA-A24-
restricted peptide as negative controls. Results are plotted as means ±  SEM of duplicates. SFU: spot forming units. B IFNγ 
ELISpot wells corresponding to the results shown in A. C Summary of the results of all eleven peptide-specific CD8+ T cell 
lines co-cultured with respective autologous B cells presenting the cognate peptide. Green lines of bars indicate IFNγ 
reponses that were considered to be positive, while red lines of bars indicate negative results. The stimulation index was 
calculated as the ratio between the number of spots per 1x105 peptide-specific  CD8+ T cells stimulated with autologous B 
cells presenting their cognate peptide and those detected in control wells were peptide-specific CD8+ T cells were co-cultured 
with autologous DMSO-pulsed B cells. Results are plotted as means ±  SEM of dupliactes in all cases, except data from 
donor 1 and the E7/56-65-specific CD+ T cells of donor 2, which are derived from single wells. 
 
3.5.4 Cytotolytic activity of E6/56-65-specific T cells 
Cytotoxicity assays were performed to assess if established peptide-specific T cell lines display 
cytolytic activity against cells presenting their cognate peptide. To this end, semi long-term peptide-
specific T cells were generated by two stimulations of PBMCs of HLA-A24 positive donor 3 with 
peptide-pulsed autologous DCs in an interval of seven days (section 2.2.5.1). On day 13, cells were 
starved from cytokines overnight and on the next day the cytotoxicity assay was conducted. The 
classical chromium release method (section 2.2.5.5) was used as it is still the gold standard for 
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cytotoxicity assays and very sensitive. Autologous peptide-pulsed B cells were taken as target cells 
and labeled with radioactive Na2
51
CrO4-solution. Labeled target cells were then co-cultured with 
peptide-specific T cells and SNTs harvested for analysis after 5 hours. Due to the small population 
size of CD8
+
 T cells (15%) as determined by FACS analysis, bulk T cells were used. Thus it is also 
possible that the cytotoxic effect might have been due to CD4
+
 T cells, as for those a cytolytic 
phenotype has been described (Mumberg et al., 1999; Corthay et al., 2005; Perez-Diez et al., 2007). 
However, as the peptides used to generate the T cell lines were HLA class I-restricted, the majority of 
the observed effects can safely be attributed to CD8
+
 T cells. 
Figure 35 summarizes the result of the cytotoxicity assay. Cytotoxicity, measured as percentage of 
specific lysis of autologous B cells presenting E7/56-65 was ranging between 99% and 40% (upper 
curve with dots). In comparison, no cytotoxicity was detected for target cells presenting the unrelated 
HIV HLA-A24 control peptide (lower curve with squares).  
 
Figure 36 I HPV16 E7/56-65-specific cytolytic activity. Cr51 release cytotoxicity assay with E7/56-65-specific effector T 
cells and autologous B cells presenting either E7/56-65 or the negative control peptide HIV HLA-A24. Target cells were 
labeled with Na2
51CrO4-solution and incubated together with effector cells in indicated ratios for 5hrs. Results are plotted as 
means ± SEM of duplicates. 
These results give a first hint that the E7/56-65 peptide might present a potent HPV16 vaccine 
candidate. However, results need to be reproduced and should be tested with cells from other donors 
and with cancer cells as target cells that naturally present the respective peptides. 
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4. Discussion 
Today, cervical cancer is the third most common cancer worldwide (Schiffman et al., 2007; Scarinci et 
al., 2010). Annualy, approximately half a million women are diagnosed with this form of cancer 
(Ferlay et al., 2012) and more than 90% of cervical cancer cases occur in developing countries (van 
Bogaert, 2013). Human papillomavirus (HPV)16 accounts for the majority of cervical cancer cases 
and is found in approximately 50% of all HPV-induced cervical carcinomas (Munoz et al., 2006). 
Additionally, in the past decade oropharyngeal head and neck squamous cell carcinoma (HNSCC) 
cases have been shown to increase and HPV16 and other high-risk HPVs were reported to be 
associated with HNSCC (Gillison et al., 2000; Howlader et al., 2013; Michaud et al., 2014). The 
identification of HPV as a causative agent for cervical carcinomas (zur Hausen, 1977) has led to the 
development of effective prophylactic vaccines against HPV-mediated malignancies (Lowy et al., 
2008; Joura et al., 2015). These vaccines prevent infections with the most prevalent high-risk HPV 
types but, however, cannot clear persistent HPV infections and thus have no therapeutic effect on 
individuals already infected with HPV (Hildesheim et al., 2007). Moreover, due to the long period 
between infection and tumor development, a large proportion of the global population is already HPV-
infected (Frazer et al., 2011). Especially in developing countries, preventive medical health care such 
as detection of HPV-induced pre-malignant lesions is limited and vaccination with available 
prophylactic vaccines problematic due to socio-cultural factors and high costs of vaccination. Existing 
therapeutic modalities for HPV-induced premalignant lesions and tumors are surgical and can impair 
functions of the affected tissue, leading e.g. to premature births. Thus, there is a great need for novel 
and non-invasive therapeutic treatment options that include therapeutic vaccines (Conesa-Zamora, 
2013).  
Throughout the last decades, immunotherapy with all its tools has evolved as a promising treatment 
approach for various malignant diseases. Recent blockbusters, such as the anti-CTLA-4 antibody 
(Hodi et al., 2010) or CD19-targeting chimeric antigen receptors (CARs) (Grupp et al., 2013) 
eventually raised the awareness of the usefulness of immunotherapy in clinical cancer treatment. Both, 
the development of monoclonal antibodies and engineered T cells took years with steady 
improvements. The same holds true for peptide vaccination, for which the first clinical trial was 
conducted soon after the first tumor antigens were discovered (Hu et al., 1996).  
To date, two main approaches comprise the concept of peptide vaccination, synthetic long peptides 
(SLPs) and synthetic short peptides (SSPs). The overall goal of peptide vaccination is to evoke a 
targeted immune response. To this end, antigen-presenting cells (APCs), mostly dendritic cells (DCs), 
need to present antigens by human leukocyte antigen (HLA) molecules to naïve CD4
+
 and CD8
+
 T 
cells. It is an ongoing discussion in the field of peptide vaccination, which approach, long or short 
synthetic peptides, is more suitable in terms of induction of effective T cell immune responses. SLPs 
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need to be taken up by APCs, processed intracellularly and loaded on HLA molecules for presentation 
of T cell epitopes. They evoke good CD4
+
 T cell responses and in comparison lower CD8
+
 T cell 
responses (Melief and van der Burg, 2008). In case of SSPs, APCs present only precise CD8
+
 T 
epitopes, which can elicit much more specific CD8
+
 T cell responses than SLPs. However, peptide 
vaccination with SSPs has been shown to be less effective in generating long-term memory responses 
and can even lead to tolerance due to presentation of CD8
+
 T cell epitopes by non-professional APCs 
(Bijker et al., 2008). Thus, other components included into the vaccine formulation besides the pure 
peptide(s), such as adjuvants, need to be taken into consideration to determine if short peptides are 
superior to long peptides or the other way around. These issues are addressed in detail in section 4.6.  
Nevertheless, regardless of the length of peptides used for vaccination, it is important to know which 
target epitopes are present on the cancer cell. Therefore, this study focused on the identification of 
HPV16 E6 and E7 CD8
+
 T cell epitopes for the HLA-A3, HLA-A11 and HLA-A24 supertypes. The 
identified epitopes could be potentially used in a therapeutic vaccine setting or for other approaches 
such as immunomonitoring.  
The E6 and E7 oncoproteins of high-risk HPVs present ideal targets for immunotherapeutical 
approaches, as they are foreign to the body, have been shown to be crucial for carcinogenesis and are 
constantly expressed in infected cells (Kanodia et al., 2008; Frazer et al., 2011). Consequently, these 
two oncoproteins are the most frequently targeted HPV antigens for therapeutic vaccine design. 
Pioneering work with HPV16 SLPs was carried out by Cornelis Melief and his team and by other 
groups in Leiden, The Netherlands (Melief and van der Burg, 2008). They have developed therapeutic 
SLP vaccines consisting of overlapping peptides, 27-35 amino acids in length, of the complete 
sequence of HPV16 E6 and E7. These peptides were found to facilitate simultaneous priming of T 
cells against multiple dominant and subdominant CD4
+
 and CD8
+
 T cell epitopes, evoking a broad T 
cell response (Welters et al., 2010). They were thoroughly tested in experimental models, reviewed in 
(Melief and van der Burg, 2008). Partial success could be demonstrated in clinical studies (Kenter et 
al., 2008; Kenter et al., 2009; de Vos van Steenwijk et al., 2012; van Poelgeest et al., 2013; de Vos van 
Steenwijk et al., 2014).  
Rammensee and colleagues from Tübingen, Germany, pursue a slightly different approach for cancer 
immunotherapy. They identify naturally processed and presented HLA-associated peptides directly 
from primary tumor cells. Tumor-associated peptides are then selected by differential gene expression 
analysis and data mining. In the last step, selected candidates are validated from immunogenicity by 
monitoring T cell responses with cells from healthy volunteers (Stevanovic, 2002; Singh-Jasuja et al., 
2004). This approach has led to the development of IMA901, the first therapeutic vaccine for renal cell 
cancer (RCC), which prolonged the survival of patients in a phase II trial in combination with 
chemotherapy (Walter et al., 2012). 
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The work of our laboratory and this study is partly based on a similar approach as employed by 
Rammensee and colleagues. Within the scope of the presented work, potential HPV16 E6 and E7 
CD8
+
 T cell epitopes were investigated. First, potential HLA class I-restricted T cell epitopes for three 
different HLA supertypes were predicted in silico by several prediction servers. In silico predictions 
were refined and eventually the actual binding of the best predicted binders was determind 
experimentally. Subsequently, the immunogenicity of binding peptides was assessed in healthy HLA-
matched donors by screening for memory T cell responses. Furthermore, four promising peptide 
candidates were used to generate peptide-specific long-term T cell lines to further determine their 
potential as vaccine candidates in functional assays. For the direct identification of naturally processed 
and presented HPV16 E6 and E7 CD8
+
 T cell epitopes on HPV16-transformed cells, our group is 
using a highly sensitive mass spectrometry (MS) approach. Identified CD8
+
 T cell epitopes do not 
only represent candidates for peptide vaccines but are also useful for the development of other 
immunotherapies. Validated epitopes can be used for the development of adoptive T cell transfer with 
transgenic T cell receptors (TCRs) or CARs and additionally for immunomonitoring purposes.  
4.1 Identification of HLA-A3, HLA-A11 and HLA-A24-binding HPV16 E6 and 
E7 peptides  
In the past, epitope identification has been carried out mostly by analyzing the specificities of single T 
cell lines or clones. A more recent and widely applied strategy is called the “reverse immunology” 
approach, which involves pre-screening of proteomes by computational algorithms which are followed 
by experimental validation of selected peptides (Celis et al., 1994; Mora et al., 2006; De Groot et al., 
2008; Larsen et al., 2010). This strategy was followed in this study and to this end, a total of ten 
predictors were employed to predict potential HPV16 E6 and E7-derived T cell epitopes that are 
restricted by either HLA-A3, HLA-A11 or HLA-A24 (section 3.1). After adjusting the threshold for 
experimental testing of the predicted peptides throughout the course of experimental testing, 69 
peptides were predicted to bind to HLA-A24. In case of HLA-A3 and HLA-A11, 71 and 79 were 
predicted to bind to the respective HLA type. Many peptides could be verified to bind to the respective 
HLA type by cellular competition-based binding assays (Fig. 21, Tab. 14 and 15, Tab. 22-25, 
Appendix). 18 peptides could be shown to bind to HLA-A3 including seven peptides that were 
previously shown to be binders by other groups (Kast et al., 1994; Bourgault Villada et al., 2010). In 
case of HLA-A11, ten reported binding peptides (Kast et al., 1994; Bourgault Villada et al., 2010) 
could be confirmed and 23 novel binders were found. For HLA-A24, a total of 41 peptides were 
shown to bind including five peptides that have been reported to bind before (Kast et al., 1994; 
Morishima et al., 2007; Bourgault Villada et al., 2010).  
As expected, some of the peptide repertoire binding to HLA-A3 did also bind to HLA-A11 (Fig. 21 A 
and B). This can be explained by great similarities of these two HLA supertypes in terms of their 
binding clefts (Sette and Sidney, 1999). No correlation could be observed, however, comparing 
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peptides binding to HLA-A3 and HLA-A11 with peptides binding to HLA-A24. Peptide sequence 
motifs binding to HLA-A24 are functionally quite distant from peptide sequence motifs binding to 
HLA-A3 or HLA-A11 (Thomsen et al., 2013). This highlights the necessity to define the epitope set 
for each HLA type individually, since a non-binding peptide for one HLA type might be strongly 
binding to another HLA type and vice versa (Paul et al., 2013).  
Due to the magnitude of binding data generated in this study, it was possible to conduct an evaluation 
of the performance of individual prediction servers. The best predictors for each HLA allele in 
combination with either all peptide lengths or single peptide lengths are discussed in section 4.2.  
After using conventional available T cell epitope prediction servers to identify potential HLA-specific 
HPV16 E6 and E7-derived peptides, the prediction approach was expanded to check if any binding 
peptides were missed. To this end, amino acid sequence motifs of all tested peptides that were binding 
(positive motifs) and not binding (negative motifs) to either HLA-A3, HLA-A11 or HLA-A24 were 
generated (section 3.1.3, Fig. 22 and 23). For HLA-A24, amino acid sequence motifs have been 
described with distinct anchor residues at position 2 and at the C-terminus. Tyrosin and phenylalanine 
were reported to be prefered residues at position 2 and phenylalanine, leucine and isoleucine at the C-
terminus of the sequence (Kubo et al., 1994; Maier et al., 1994; Sette and Sidney, 1999). In line with 
these findings, HLA-A24 binding peptides of this study showed tyrosine predominately at position 2 
and leucine and isoleucine at the C-terminal end of the peptide (Fig. 22). Phenylalanine was often 
present at the C-terminus of 8mers and 11mers (Fig 22 A and D). 
Interestingly, tyrosine was also predominant on position 2 of 9mers and 10mers that were not binding. 
This is most likely due to the fact that all tested peptdies were predicted to be binders in the first place 
and all servers are trained with sequences of binding data which often included a tyrosine at position 2. 
Since not all predicted peptides were binding, this indicates that this residue alone is not sufficient for 
peptide binding and other residues are important as well.  
The generated peptide motifs were used to screen non-tested peptides that were predicted with a low 
binding affinity but might bind nevertheless. Peptides with amino acid motifs similar to those of 
identified binding peptides and different to those of non-binding peptides were assumed to possibly 
bind to the respective HLA allele. For HLA-A3 and HLA-A11, three and seven potential peptides 
were identified by this approach, respectively. As HLA-A24 resulted in the highest number of novel 
and strong binders (Fig. 21 D) and is highly prevalent especially in Asian populations (Gonzalez-
Galarza et al., 2015), this study was focused subsequently on this HLA type. For this reason, all 26 
peptides that could be identified as potential binders to HLA-A24 by employing the motif search, were 
tested in vitro for their binding affinity (Fig. 24 and Tab. 14 and 15). Four peptides showed weak 
binding affininity to HLA-A24, two peptides were identified as intermediate binders and one peptide 
as a strong binder. These results indicate that this specific motif search based on known binders and 
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non-binders from the very same protein, is a valid and important supplement to the conventional 
prediction. Even a further decrease of the set cutoff would have failed to identify these peptides, as 
they were predicted badly by most servers, as for example E6/75-85 (Tab. 14). Moreover, in a study 
that determined the HLA-A*11:01-restricted HIV epitome, it was shown that weak binders were 
indeed strongly immunogenic (Yaciuk et al., 2014). Similar observations were made by Rosenberg 
and colleagues when they unraveled which T cell epitopes are actually good targets for a personalized 
treatment with adoptive transfer of tumor infiltrating lymphocytes (TILs) (Robbins et al., 2013). Here, 
only the 16
th
 and 23
rd
 best predicted peptide was acutally shown to be immunogenic (AACR meeting 
on Tumor Immunology and Immunotherapy, Dec 2015, Orlando, FL, USA). This implies that even 
very weak binders should not be omitted when searching for potential immungenicity of CD8
+
 T cell 
epitopes.  
In this study, potential CD8
+
 T cell epitopes were considered only within a length of 8 to 11 amino 
acids. Other studies indicate that not only canonical peptides can be presented by HLA class I 
molecules, but also peptides with non-canonical lengths. MS-profiling by Escobar and colleagues 
revealed N-terminal extended peptide motifs (Escobar et al., 2008). They observed that some peptides 
longer than 11 amino acids represented N-terminal-extended peptides that contained an appropriate 
HLA-B35 peptide motif. In another recent study, the structures of two 15mers bound to HLA-A*02:01 
could be solved and additionally it was shown that both HLA/peptides complexes were successfully 
recognized by T cells (Hassan et al., 2015). Moreover, it was reported that HLA-A*11:01 binds 
peptides containing unusal anchor residues. These epitopes were identified via deep ligand sequencing 
employing MS analysis and could be shown to be immunogenic by IFN ELISpot assays as well 
(Yaciuk et al., 2014). Taken together, this data suggests a paradigm change, indicating that longer 
epitopes can be presented by HLA class I molecules and may play a role in T cell immunity. In 
addition Calis and colleagues were able to demonstrate that the sequence positions 4 to 6 of a 
presented peptide enhance TCR-HLA/peptide interaction and are thus also important for 
immunogenicity (Calis et al., 2013). Since at the beginning of this study and still today, the best 
binding has been attributed to canonical peptides, we decided to focus on 8mers to 11mers. 
Next to the HPV16 reference sequence which belongs to the European Prototype 1, several HPV16 
variants exist, that bear amino acid differences in their protein sequences compared to the HPV16 
reference sequence. As those variants needed to be taken into consideration for potential CD8
+
 T cell 
epitope identification, 26 HPV16-positive cell lines from our cell line collection were tested for their 
HPV16 variant (section 3.2). To this end, genomic DNA was extracted and the viral genes E6 and E7 
were amplified by PCR. The PCR products were sequenced and aligned to the HPV16 reference 
sequence in order to detect nucleotide exchanges. In parallel, a multiple sequence alignment of 62 
HPV sequences already assigned to a specific variant was performed (Tab. 26, Appendix), showing 
the distinct nucleotide exchanges that are specfic for each variant. All 26 cell lines were then assigned 
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to a variant and mutations that resulted in amino acid exchanges were identified (Tab. 16 and Tab. 27, 
Appendix). A total of 13 amino acid exchanges could be detected in the E6 and E7 sequence variants 
present in our cell line collection. Potential binding of HPV16 variant T cell epitopes was predicted to 
HLA-A24 in the same manner as done initially for the HPV16 reference sequence. After setting an 
internal cutoff of 5000nM for binding, a total of 20 variant peptides were tested in vitro for their 
binding to HLA-A24 (Tab. 18). Seven of these variant peptides were shown to be binders (Fig. 27). 
The respective HPV16 reference-derived peptides that were binding as well, scored twice a 
comparable binding affinity, once a slightly lower binding affinity and in three cases a higher binding 
affinity. These observations are attributed to the different strength of binding affinity to the binding 
cleft of the HLA-A24 molecule by the distinct amino acids. Especially if a change occurs at an anchor 
residue position of the peptide sequence or the charge or polarity of the peptide is changed drastically, 
this may lead to stronger binding affinity or could abolish binding completely. The results presented 
here indicate that cells infected with different HPV16 variants likely present different E6 and E7 T cell 
epitopes. Some T cell epitopes might be more immunogenic than others, raising the question whether 
clinical outcomes are different in patients that are infected with different HPV16 variants. It was 
indeed reported, that depending on the patient cohort that was analyzed, different variants were 
correlated with different outcomes (Zehbe et al., 1998; Tu et al., 2006; Xi et al., 2007; Zuna et al., 
2011). However, no clear correlation could be identified for specific HPV16 variants and increased or 
decreased risk of disease progression.  
4.2 Performance evaluation of prediction servers 
After having identified the HPV16 E6 and E7 T cell epitope sets which truly bind either to HLA-A3, 
HLA-A11 or HLA-A24, we decided to exploit the large amount of data that was generated and 
proceeded to assess the performance of the servers used for binding affinity predictions (section 3.1).  
In a first step, the performance of all used prediction servers was roughly estimated step by step in the 
course of setting cutoffs for testing of binding affinity (section 3.1.1). To do so, the binding affinity of 
experimentally tested and predicted binding affinities of each peptide was color-coded according to 
our internal or to the server-specific category of strong, intermediate or weak binders. The cutoffs for 
in vitro testing were elevated throughout the course of experimental binding affinity assessment as a 
final stage where none of the predicted peptides was binding anymore was not reached. Moreover, 
cutoffs were chosen individually for all servers not to exclude any peptides that were indicated to 
possibly bind by only one individual server. Final color-coded lists of all predicted and tested peptides 
are displayed in Tables 14 & 15 and Tables 22-25 (Appendix). Not all peptides that were predicted to 
be binders were actually shown to bind to the respective HLA molecule in vitro. The server 
comparison also revealed that it was important to combine the results of multiple predictors, because 
some binding peptides would have been missed if only the results of individual servers would have 
been considered. For example E6/67-76, a 10mer strongly binding to HLA-A24, was only predicted to 
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be a weak binder by IEDBsmm and IEDBsmmpmbec and not predicted to bind by all other servers. 
Moreover, it has to be noted that not all prediction servers are capable of predicting binding of 8mers 
and 11mers. IEDBann, IEDBsmm, IEDBarb, IEDBsmmpmbec, SYFPEITHI and BIMAS only predict 
9mers and 10mers.  
In a second step, after the experimental testing of binding affinities was finalized, the performance of 
all prediction servers of the NetMHC and IEBD families was evaluated by receiver operating 
characteristic (ROC) analysis and calculation of the area under the curve (AROC) (section 3.1.4). The 
two servers BIMAS and SYFPEITHI were omitted in this evaluation due to unclear definition and 
discrimination of predicted binders and non-binders. A high degree of variability in the prediction 
efficacy for the three different alleles by the same predictors was observed, despite employing the 
same threshold levels. ROC analysis revealed that predictions for peptides binding to HLA-A3 (Fig. 
26 A), if all four peptide lengths were taken into consideration, were more precise than predictions for 
HLA-A11 (Fig. 26 B). Binding predictions to HLA-A24 were shown to be worse than for HLA-A3 
and HLA-A11 (Fig. 26 C). As the performance of a prediction server is depending on training data 
sets, the performance largely depends on the quality of these data sets. For some alleles, the 
availability of published data may be greater than for others (Gowthaman et al., 2010). That leads to 
imbalances in the prediction efficacy among the alleles and could explain why predictions for peptide 
binding to HLA-A3 and HLA-A11 were more accurate than for HLA-A24, as less binding data for the 
latter HLA type is available to train servers.  
A large AROC is correlated to the probability that a prediction server will rank a randomly chosen 
binding pepide higher than a randomly chosen non-binding peptide and thus gives a useful measure of 
prediction quality. Individiual results for each HLA type and each peptide length, as well as for all 
peptide lengths for one HLA type, indicated different predictors to be the respective best choice for 
specific prediction tasks (Tab. 16). Considering all four peptide lengths, NetMHCcons was determined 
to be the best prediction server for HLA-A3 and HLA-A24. NetMHC was identified as the best 
prediction server for HLA-A11. For individual lengths and HLA types, all members of the NetMHC 
family, IEDBann and IEDBpan were ranked to be superior from case to case. For HLA-A3, excellent 
prediction performance was achieved by many prediction servers, especially for 9mers and 10mers 
and overall lengths in accordance to criteria previously determined by (Lin et al., 2008). In case of 
HLA-A11, mostly excellent and moderate prediction performance was shown for prediction servers 
predicting 8mers, 9mers and 10mers. For HLA-A24, the overall performance of predictors was shown 
to be worse than for HLA-A3 and HLA-A11. Here, NetMHC, NetMHCcons and IEDBpan showed 
moderate prediction performance for some lengths, otherwise all predictors displayed poor prediction 
performance. For 11mers binding to HLA-A11 and HLA-24, predictors displayed only moderate and 
mainly poor prediction performance. In summary, IEDBarb showed the least reliable prediction 
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performance while NetMHC and NetMHCcons performed best for the given binding data input in this 
evaluation. 
In the past, assessments of in silico predicton servers have been performed by different groups. In 
general, these groups found, as we did in this study, that some of the predictors were highly accurate 
while others need improvement (Peters et al., 2006; Lin et al., 2008; Gowthaman et al., 2010; Zhang et 
al., 2011). In comparison to our study, predictors were previously only investigated for their prediction 
performance for 9 and 10mers. In these evaluations, mostly an extended set of available prediction 
servers that included partly the same prediction servers as in this study, were used. In line with our 
results (Tab. 16), one study rated NetMHCcons, together with NetMHC and NetMHCpan to be the 
best predictors (Zhang et al., 2011). Gowthaman and collegues reported IEDBann to be the best 
prediction server for HLA-A3. This is in line with our findings, where IEDBann was also amongst the 
best prediction server for 9mers and 10mers. For HLA-A11, NetMHC was rated to be the best 
predictor by us and rated third best, after NetMHCpan and IEDBann, by Gowthaman and colleagues. 
NetMHCcons, that was ranked as the best prediction server for HLA-A24 by us, was not considered 
by Gowthaman and collegues (Gowthaman et al., 2010). They described IEDBarb to be the best 
predictor for this HLA type. In contrast, this server was rated to be the worst predictor for HLA-A24 
amongst the tested prediction servers in our study. This illustrates the importance of evaluation of 
prediction servers with different binding data sets.  
It is important to note that some prediction methods such as the IEDBann method have their own 
limitations as they completetly rely on the training data set. Moreover, matrix-based methods, such as 
IEDBarb, IEDBsmm and IEDBsmmpmbec, depend on independent contributions of amino acids in the 
peptides, therefore ignoring their neighboring residues (Gowthaman et al., 2010). These drawbacks of 
individual prediction serveres need to be taken into consideration when selecting prediction servers to 
be used for a given task. It also has to be noted that some prediction servers are constantly improved 
by the developers and trained with newly available training data sets, as for example the NetMHC 
server family.  
As a single predictor was not shown to be superior for all HLA types and peptides in this study, users 
should select the predictors individually, depending on the desired HLA allele and peptide length to 
get the best possible results.  
4.3 Direct identification of CD8
+ 
T cell epitopes 
In order to identify suitable peptides for the design of a therapeutic vaccine,  natural processing and 
presentation of identified CD8
+ 
T cell epitopes on target cells should be confirmed. Indirect 
confirmation of CTL epitopes is feasible by immunonological methods, such as functional T cell 
assays that detect CD8
+
 T cell specific responses triggered by cells displaying the epitope in question. 
This approach was pursued in this study and the results are discussed in the following sections. 
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However, a direct approach that identifies truly presented CTL epitopes is also desirable. To this end, 
a highly sensitive nano-UPLC-ESI-MS
3
 multiple-reaction monitoring MS approach is being 
established in our laboratory (PhD project of Renata Blatnik) that identifies T cell epitopes presented 
by HLA molecules on HPV16-transformed cells. As a part of this study, sample preparation for 
subsequent MS analysis was established and optimized (section 3.3). First, suitable cell lines for 
immunoprecipitation (IP) of HLA/peptide complexes were determined by screening all HPV16-
positive cell lines of our cell line collection, which were postitive for HLA-A3, HLA-A11 or HLA-
A24, for HLA expression levels (section 3.3.1). 13 different cell lines were tested for their HLA 
expression levels (Fig. 28). For HLA-A3, all cell lines showed relatively high HLA expression levels 
compared to the HLA-A2 expression of the cell line CaSki, which was taken as a reference as it was 
used as the model cell line for optimization of the IP methodology (Fig. 28 A). Expression levels for 
HLA-A11 were lower than the levels of HLA-A2 on CaSki cells (Fig. 28 B). In case of HLA-A24-
positive cell lines, SiHa displayed the highest HLA-A24 expression level, while levels for FKA16A 
were almost not detectable (Fig. 28 C). Consequently, cell lines with the highest HLA expression 
levels, CaSki, MRI-H196 and 93VU147T for HLA-A3 and SNU 1000 for HLA-A11 were selected for 
IP. In case of HLA-A24, all cell lines available, SiHa, SNU 1005, FK16A, W12 20861 and W12 
20863 were selected, as this study became focused on the identification of HLA-A24-restricted CD8
+
 
T cell epitopes.  
Figure 29 (section 3.3.2) displays Oriole protein staining and Western blot analysis of IPs of 
HLA/peptide complexes from SiHa and CaSki cells. Both, HLA-A2/peptide and HLA-A24/peptide 
complexes were successfully immunoprecipitated from cell lines carrying the respective HLA alleles. 
Purification and enrichment of HLA/peptide complexes was successfully achieved as shown by the 
presence of strong bands indicating the HLA class I α-chains at 44kDa in both Oriole stainings (A, C, 
E) and by Western blot analysis (B, D, F). Some HLA/peptide complexes, however, were lost in the 
flow through, which could indicate oversaturation of the capture antibodies. Thus, purity and 
enrichment of HLA/peptide complexes which are a prerequisite for MS analysis could be achieved. 
Since the MS technology is still being optimized, future analysis will reveal which E6 and E7 T cell 
epitopes are presented on the surface of HPV16-positive cells. 
4.4 Immunogenicity of candidate peptides in short-term T cell lines  
As the majority of the adult population has been transiently infected with a high-risk HPV type and 
therefore potentially with HPV16 (Evander et al., 1995; Woodman et al., 2007), buffy coats from 
blood donations of twelve healthy, anonymous donors were used to screen for peptide-specific 
memory T cell responses to determine the immunogenic potential of single peptides (section 3.4). 
Since CD8
+
 T cell epitope screening was conducted without any knowledge of previous infection, this 
raises the possibility that some donors never had contact with HPV16. Additonally, every individual 
displays immune responses with a different strength and therefore one peptide might be considered to 
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be immunogenic in one healthy donor, but not in another, even if both individuals have been 
transiently infected with the same HPV16 type.  
The prerequisite to be able to test the immunogenicity of HLA-specific peptides with anonymous 
blood donations was the successful determination of the donors’ HLA types (section 3.4.1). HLA 
typing was only partly successful with FACS staining for six diefferent HLA supertypes (Tab. 20), as 
it resulted in false positive results in several cases due to cross-reactivity of antibodies. Specifically, 
the anti-HLA-A11 antibody showed cross-reactivity with HLA-A3, while the anti-HLA-A24 antibody 
cross-reacted with HLA-B27. Both cross-reactions were reported in the respective product’s data 
sheet. Thus, we decided to subsequently HLA genotype the buffy coat cells by PCR in two digit 
resolution (Tab. 20). HLA genotyping could successfully confirm HLA-A11 and HLA-A24 positivity. 
However, buffy coats that were tested positive for HLA-B7 by FACS staining could not all be 
validated by PCR, as the used primers did not cover all HLA-B7 subtypes (Tab. 20 and Tab. 12). The 
reported prevalence for HLA types in the German population fits to our HLA typing results, even in 
this small sample of twelve donors.  
IFN ELISpot analysis of peptide-specific short-term T cell lines generated from the buffy coats 
resulted in the identification of several immunogenic HPV16 E6 and E7 peptides (section, 3.4.2, Fig. 
30 and 31). For instance, five peptides were shown to be immunogenic when tested with cells of the 
HLA-A24 positive donor 3 (Fig. 30). As depicted in Figure 31 A and B, multiple immunogenic 
peptides were identified for different HLA types. Peptides were often grouped in certain regions. 
Therefore, it seemed as if E6 and E7 harbor multiple immunogenic stretches within their aa sequence, 
where numerous HLA class I epitopes were located in close proximity. This was also shown for other 
proteins than E6 and E7, such as the well-known tumor antigens HER-2/neu (Disis et al., 2002) or 
NY-ESO-1 (Zeng et al., 2002). Identified immunogenic stretches also represent attractive regions for 
synthetic long peptides (SLPs).  
Some obstacles complicate the interpretation of the obtained data. Even though the peptides were 
chosen because of certain HLA alleles being present, it remains elusive whether the observed T cell 
responses were only associated with these particular HLA molecules or with one of the other HLA 
molecules present on the used cells. Additionally, while immunogenicity of a peptide is confirmed by 
a positive response in one donor, a negative response in one or more donors does not necessarily mean 
that this peptide is not immunogenic. It simply might not be recognized by long-term memory T cells 
of this donor or the evoked immune response might be too low. The sample size of only twelve buffy 
coat donors restricts significance of the results and therefore only gives hints towards general 
immunogenicity of a peptide related to a specific HLA type. One possiblility to ensure that the 
immunogenicity of peptides is indeed HLA-specific, would be to mismatch donors in addition to 
HLA-matched donors and then demonstrate significance stastically. To this end, the group of tested 
donors would need to be increased. Moreover, it has to be taken into consideration that different 
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variants of HPV16 exist and thus the potential peptide repertoire that might have been encountered 
previously can differ in donors that carry the same HLA type but were infected with different variants.  
In conclusion, the obtained data could show immunogenicity of several HLA-A2, HLA-A3, HLA-11, 
HLA-A24, HLA-B7 and HLA-B15-restricted HPV16 E6 and E7 peptides. However, cross-reactions 
with other HLA alleles cannot be excluded.  
4.5 Functional analysis of peptide candidates 
Four HLA-A24-restricted peptides, E6/87-95var, E6/49-57, E6/49-59 and E7/56-65 were selected for 
further functional characterization based on their binding to HLA-A24 (section 3.1.2 and 3.2) and their 
immunogenicity shown in peptide-specific short-term T cell lines (section 3.4.2). To this end, IL-2 
secretion was tested in PBMCs upon peptide stimulation (section 3.5.1). Furthermore, eleven peptide-
specific long-term T cell lines were generated from three different HLA-A24 positive donors, partly 
analyzed for their clonality (section 3.5.2) and co-cultured with autologous B cells pulsed with the 
respective peptide. The T cells were then studied for IFN secretion (section 3.5.3). Peptide-specific 
semi long-term T cell lines were tested for their cytolytic potential (section 3.5.4) in order to validate 
the peptides as CTL epitopes. 
In previous studies, five HLA-A24-restricted CTL epitopes have already been described. These 
include one of the peptides that was also selected in this study to be tested for its potential as a CTL 
epitope, E6/49-57 (Morishima et al., 2007). Moreover, E6/75-83 and E6/91-100 were shown to elicit 
CTL responses in cervical cancer patients (Hara et al., 2005). While E6/75-83 was confirmed to be a 
weak binder in this study (Fig. 21 C and Tab. 14), E6/91-100 was below the cutoff of testing and thus 
not even considered in this study. The peptides E7/61-69 and E7/67-76, which have been described as 
CTL epitopes (Jang et al., 2012), were both tested for their binding affinity. The first one did not bind 
while the second showed weak binding affinity to HLA-A24 (Fig. 21 C and Tab. 15).  
IL-2 secretion detected in the supernatants of PBMCs stimulated with either E6/87-95var, E6/49-57, 
or E7/56-65 on day seven of culture indicated T cell proliferation which was significantly increased in 
comparison to unstimulated PBMCs (Fig. 32 B). As bulk PBMC were used in this experiment, IL-2 
secretion could not be assigned to a specific cell type. IL-2 synthesis by CD8
+
 T cells is comparatively 
weak and the responses of these cells often require help from CD4
+
 T cells  (Boyman and Sprent, 
2012). NKT cells have also been reported to secrete IL-2, however to a lesser extent (Jiang et al., 
2005). However, it can be safely assumed that the secreted IL-2 is mainly derived from activated CD8
+
 
T cells, because HLA class I-restricted peptides were used for stimulation. 
In order to show the clonality of generated peptide-specific long-term T cell lines, TCR sequencing of 
CD8
+ 
 T cells was performed in collaboration with Eliana Ruggiero of the Division of Translational 
Oncology (G100, Christoph von Kalle, DKFZ) for cell lines generated from donor 3. Results could 
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only be obtained for TCR sequencing of E6/49-75-specific CD8
+
 T cells for both the α- and β-chain 
and for the α-chain of E6/87-95var-specific CD8+ T cells (Fig. 32). Monoclonality for the α-chain was 
shown for the E6/87-95var-specific CD8
+
 T cell line. E6/49-75-specific CD8
+
 T cells were polyclonal 
for the α- and β-chain and thus a new T cell line was generated for subsequent assays. So far, the 
technique does not allow to determine which α-chain belongs to which β-chain. The method is 
currently still under development and aims at an assignment of these two chains to each other. 
Moreover, TCR sequencing does not allow to conclude any peptide sequences of the recognized 
HLA/peptide complexes. One step further than testing for clonality would be the determination of 
specificity of CD8
+
 T cells. This could be done by multimer stainings (Altman et al., 1996). As this 
approach requires a specific multimer to be manufactured for each HLA/peptide complex to be tested, 
it was omitted at this stage of this study.  
As another approach to test specific recognition, IFN secretion by peptide-specific long-term CD8+ T 
cells upon co-culture with autologous peptide-pulsed B cells was monitored in ELISpot assays. To this 
end, eleven peptide-specific long-term T cell lines were generated, CD8
+
 T cells isolated and co-
cultured with autologous peptide-pulsed B cells. IFN secretion upon recognition of their cognate 
peptide was shown to be significant in E6/87-95var- and E6/49-59-specific CD8
+
 T cell lines from 
donor 1 (Fig. 34 C). In case of donor 2, E6/87-95var- and E6/49-57-specific CD8
+
 T cell lines showed 
significant IFN secretion, and all four peptide-specific CD8+ T cell lines of donor 3 were shown to be 
significantly positive for IFN in ELISpots (Fig. 34 A, B and C). Hence, all four tested candidate 
peptides were capable of inducing CTL specific responses in some donors. One peptide, E6/87-95var, 
elicited responses in all donors tested, and thus seems to be a very promising candidate to be included 
into a vaccine. To our knowledge all three donors were healthy at the time of blood donation. 
Differences in strength of immune reactions between different donors can be accounted to different 
histories concerning a potential transient infection with HPV16 and due to the different strength of 
immune responses by immune cells varying amongst individuals. 
To find direct evidence for cytotoxic activity of peptide-specific T cells, the potential to actively kill 
autologous B cells pulsed with the respective peptide was analyzed. Cytotoxicity assays were 
successfully performed with  E7/56-65-specific T cells. These cells were able to kill autologous B cell 
that were pulsed with E7/56-65 (Fig. 35). Therefore, these results give a first hint that the E7/56-65 
peptide might present a potent HPV16 vaccine candidate. However, results should be reproduced with 
E7/56-65 specfic T cell lines from other HLA-A24 positive donors. Moreover it would be desirable to 
test the specific cytolytic activity of CD8
+
 T cells by depletion of CD4
+
 T cells and to use HLA-
matched HPV16-transfomed cancer cells as target cells, which naturally present T cell epitopes. The 
latter approach was followed in this study by taking HLA-24 positive SiHa cells as target cells. 
Unfortunately, no reliable results could be produced due to paucity of effector T cells. Besides E7/56-
65-specific T cells, also E6/87-95var-specific T cells were tested for their cytolytic activity. However, 
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cytotoxicity assay results were not consistent with these cells. Cytolytic activity could also be tested 
with other methods for validation. Potential approaches include FACS staining for cytolytic markers 
such as CD107a, perforin and granzyme B (Tschopp et al., 1986; Heusel et al., 1994; Aktas et al., 
2009). Perforin and granzyme B secretion can also be analyzed by ELISpot assays.  
In summary, functional characterization of E6/87-95var-, E6/49-57-, E6/49-59- and E7/56-65-specific 
T cell lines confirmed these peptides as CD8
+
 T cell epitopes and therefore as potential candidates for 
a therapeutic HPV16 vaccine or as targets for immunomonitoring. Especially E7/56-65 was 
determined as a promising candidate as cytolytic activity could be demonstrated with E7/56-65-
specific T cells.  
4.6 Conclusions and future perspectives 
In the present study, potential HPV16 E6 and E7-derived CD8
+
 T cell epitopes restricted by HLA-A3, 
HLA-A11 and HLA-A24 were investigated. Candidate peptides were first identified with diversified 
in silico prediction approaches that determined the potential of peptides to bind to designated HLA 
types. Peptides were subsequently experimentally validated for binding in cellular binding assays. 
After assessment of immunogenicity of candidate peptides, functional assays were performed to 
confirm the potential of these CD8
+
 T cell epitopes as vaccine candidates or for other purposes, such 
as immunomonitoring. 
Several aspects need to be taken into consideration for the development of a synthetic short peptide 
vaccine. These include issues of HLA-restriction of CD8
+
 T cell epitopes, efficacy of immune 
responses and potential tolerance induction (Van de Wall et al., 2014).  
HLA-restriction implicates that only patients which carry matching HLA alleles would benefit from a  
specific epitope single-peptide vaccine. Thus, inclusion of multiple peptides covering several different 
HLA alleles or of a peptide that is not only restricted by a single HLA allele, would be beneficial to a 
broader cohort of patients. The approach of administering multiple synthetic short peptides together is 
already pursued in ongoing peptide vaccination studies. Up to four synthetic short peptides are 
currently used in one dose for treatment of melanoma patients (NIH, NCT01970358 and 
NCT02035956) (Fritsch et al., 2014). It is belived that this number can be increased to up to twenty 
peptides in one dose when adminstered in groups of five at different sides of the body (personal 
communication, Dr. Catherine J.Wu, Harvard Medical School, Cambridge, MA, USA). In the given 
example, the vaccines were developed as a personalized treatment, where all HLA types of the patient 
were determined. A similar approach could be also employed for patients that have HPV16-driven 
malignancies. The patients could be HLA-typed and then vaccinated with a HLA-specific vaccine 
consisting of multiple HLA-restricted synthetic short peptides. This will soon be a valid option, as 
HLA typing costs will decrease. The second option would be to include at least one peptide for every 
HLA supertype to ensure that every vaccinated patient is likely to react with at least one vaccine 
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peptide. Next to the investigation of HLA-A3, HLA-A11 and HLA-A24, our laboratory is currently 
also working other HLA supertypes such as HLA-A2, HLA-B7 and HLA-B15. The combination of 
those six HLA supertypes allows > 95% population coverage (Gonzalez-Galarza et al., 2015). 
Another issue that needs to be considered in case of HPV16 vaccines are the different existing 
variants. As discussed before (section 4.1) several HPV16 variants were identified in our HPV16-
positive cell line collection (Tab. 27) and included into T cell epitope prediction, cellular peptide-
binding assays (section 3.2) and into immunogenicity screening and functional assays (section 3.4 and 
3.5). One of the most promising candidates discovered in this study, E6/87-95var, is indeed derived 
from an European Prototype-1 sequence that carries an exchange from leucine to valine at position 90 
of the E6 protein. Therefore, a potential HPV16 peptide vaccine should include peptides derived from 
the most prevalent HPV16 variants. In terms of a personalized peptide vaccine, the HPV16 variant 
present in lesions or the tumor of a patient could be determined and then a matching vaccine could be 
administered. 
Peptide vaccines including only peptides of CD8
+
 T cell epitopes have been shown to be less effective 
than longer peptides or proteins in creating long-term memory responses and might even lead to 
tolerance, because of presentation by non-professional APCs (Bijker et al., 2007). This is due to 
binding of short peptides to all HLA complexes on the surface of nucleated cells, as they do not 
require processing by APCs. Only properly activated DCs express the necessary costimulatory 
receptors to activate naïve T cells and therefore, exogenously loaded synthetic short peptides have 
been reported to confer tolerance (Toes et al., 1996). Moreover, accumulating data suggest that both 
cytotoxic CD8
+
 T cell and CD4
+
 T helper (TH) cell responses play a pivotal role in the control and 
clearance of HPV infections (Nakagawa et al., 2000; van der Burg et al., 2002; Welters et al., 2003; 
Grabowska et al., 2015). The contribution of CD4
+ 
T cells towards tumor eradication is multifaceted. 
They contribute by supplying help to CTL immune responses and memory T cell responses (Williams 
et al., 2006a; Wiesel and Oxenius, 2012). Moreover, they have been shown to prevent peptide-specific 
tolerance (Shafer-Weaver et al., 2009). CD4
+
 T cells have also been shown to display cytolytic activity 
and can thus directly kill tumor cells by themselves (Mumberg et al., 1999; Corthay et al., 2005; 
Perez-Diez et al., 2007). In HPV-induced lesions, HLA class I surface expression can be reduced as a 
result of HPV immune evasion strategies (Grabowska and Riemer, 2012), therefore exploiting 
cytolytic activitity of CD4
+
 T cells is an important option. HLA class II molecules have been shown to 
be expressed in high-grade cervical lesions and cervical carcinoma (Zhou et al., 2006). Thus the 
inclusion of HLA class II-restricted epitopes, next to CTL epitopes, into a multi-peptide vaccine would 
allow for induction and/or activation of tumor antigen-specific effector CD4
+
 T cells. Together with 
antigen-specific CD8
+
 T cells, those cells could exert more efficient anti-tumor immune responses 
(van Hall and van der Burg, 2012). Different approaches could be followed to this end: one could 
combine HLA class I and HLA class II peptide-epitopes into one vaccine or use CTL epitopes with a 
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CD4
+
 TH epitope in one synthetic long peptide. The elongation of CTL peptides would also contribute 
against the potential tolerizing effect of short peptides and restrict presentation to professional APCs 
(Bijker et al., 2007; Bijker et al., 2008). However, this approach woul bear the risk of generating 
eptitopes that are not presented by tumor cells.  
As synthetic short peptides or peptides in general, even if CD4
+
 TH epitopes are included, are poorly 
immunogenic when administered alone, appropriate immunostimulatory signals are needed for potent 
activation of APCs. To this end, various adjuvants that can activate DCs were tested in our laboratory 
in vitro. The two most promising adjuvants MPLA, a ligand for TLR4, and R848, a ligand for TLR7/8, 
were analyzed in vivo in HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Mice 
were subcutaneously vaccinated with the HLA-A2-restricted E7/11-19 peptide emulsified in 
Montanide ISA51 in association with either MPLA alone, R848 alone, or MPLA and R848 in 
combination. The most immunogenic formulations will be evaluated for anti-tumor efficacy (project 
of Dr. Hadeel Khallouf). The findings of this project could later be translated to the HLA-A24-
restricted peptides that were identified in this study, as a similar HLA-A*24:02 mouse model is 
available (Boucherma et al., 2013).  
A therapeutic HPV16 vaccine consisting of nine E6 and four E7 overlapping SLPs formulated with the 
adjuvant Montanide 51 has been tested in various clinical trials (Kenter et al., 2008; Kenter et al., 
2009; de Vos van Steenwijk et al., 2012; van Poelgeest et al., 2013; de Vos van Steenwijk et al., 
2014). Durable or complete regression could be observed for some VIN3 patients (Kenter et al., 2009), 
no clinical responses, however, were reported in patients with advanced cervical carcinoma (van 
Poelgeest et al., 2013). Despite the latter results, these SLP vaccines were shown to be safe and 
capable of inducing desired T cell responses. Thus, the authors propose therapeutic SLP vaccination in 
combination with other therapies that target regulatory mechanisms and local immunosuppression in 
the tumor microenviroment (Van de Wall et al., 2014). This idea, the combination with other 
therapies, is one of the latest developments in cancer immunotherapy and peptide vaccination seems to 
be an optimal candidate for this purpose (Melero et al., 2014). In the past, cyclophosphamide, which 
leads to depletion of Treg cells, was already successfully combined with peptide vaccination. For 
example, RCC patients showed prolonged survival upon combination of the peptide vaccine IMA901 
and a single dose of cyclophosphamide (Walter et al., 2012). Conventional cancer therapies such as 
chemotherapy, surgery and radiotherapy are also easily combinable with immunotherapies. 
Immunotherapy can especially contribute to eliminate residual disease or to prevent recurrence. In the 
field of therapeutic HPV vaccination, a recent preclinical study has reported the beneficial 
combination of cisplatin and a SLP HPV16 vaccine in mice (van der Sluis et al., 2015). Moreover, 
several clinical studies were performed that combine vaccination with other immunotherapy 
approaches. The sequence optimized gp100 peptide that was developed by Rosenberg and colleagues 
in the 1990s (Rosenberg et al., 1998), was used in combination with high-dose systemic IL-2 
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administration, that showed an improved outcome in an phase III trial with metastatic melanoma 
(Schwartzentruber et al., 2011). Moreover, the gp100 peptide was also tested in combination with 
ipilimumab in a melanoma trial. This combination of immune checkpoint CTLA-4 blockage with the 
peptide vaccine did not lead to superior results in comparison with ipilimumab treatment alone (Hodi 
et al., 2010). For a novel minimal epitope HPV16 vaccine which could include the identified peptides 
of this study, ongoing reseach thus provides numerous ideas of potential combinational therapy 
approaches.  
Next to combinational therapy, another current innovation in the field of cancer vaccination is the 
personalized treatment strategy. This approach is especially challenging, since not only every patient is 
different but also each tumor has its unique set of genomic and epigenomic alterations. The resulting 
antigens are named neoantigens – a newly available class of immunogens based on the personal, 
exquisitely tumor-specific mutations found uniquely in each tumor (Fritsch et al., 2014). Rosenberg 
and colleagues have developed a new method that allows the identification of tumor antigens 
recognized by tumor infiltrating T cells of individual patients. This screening approach involved 
mining whole-exome sequence data to identify mutated proteins expressed in patient tumors, 
subsequent in silico prediction using the prediction server NetMHCpan (Nielsen et al., 2007) to 
identify candidate mutated T cell epitopes and evaluation for recognition by TILs (Robbins et al., 
2013). This approach was extended to a tandem minigene library screening, which successfully 
identified mutated antigens in two melanoma patients and one patient with epithelial cancer. 
Subsequent adoptive TIL therapy with purified T cells against the mutated antigens showed regression 
or prolonged stabilization of disease. (Lu et al., 2014; Tran et al., 2014). Wu and colleagues followed a 
similar approach (Fritsch et al., 2014) and two clinical trials have been initiated to directly test the 
concept of a neoantigen vaccine (NIH, NCT01970358 and NCT02035956). In order to refine the in 
silico peptide predictions in such approaches, it would be worthwhile to extend the use of prediction 
servers by not only using one single one but multiple servers as done in this study.  
In conclusion, the four HPV16 E6 and E7 CD8
+
 T cell epitopes that were identified to be 
immunogenic in this study are promising candidates to be applied as part of a synthetic short peptide 
HPV16 peptide vaccine. Being HLA-A24-restricted, additional minimal epitopes specific for 
additional HLA supertypes would need to be included if this vaccine should be applicable for a wide 
range of patients without the need of prior HLA typing. To improve desired T cell responses upon 
vaccination, the synthetic short peptides need to be administered in a vaccine formulation with 
appropriate CD4
+
 TH epitopes and in context of adjuvants. Moreover, the identified CD8
+
 T cell 
epitopes, that have been shown to be immunogenic, could be employed for immunomonitoring and for 
the development of other immunotherapies. 
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6. Abbreviations  
aa    amino acid 
Ag    antigen 
Ab    antibody 
APC    antigen presenting cell 
AROC    area under the ROC curve 
bp    base pairs 
BSA    bovine serum albumin 
C-terminus   carboxyl-terminus 
°C    degree Celsius 
cDNA    complementary DNA 
CIN    cervical intraepithelial neoplasia 
CMV    cytomegalovirus 
CO2    carbon dioxide 
CTL    cytotoxic T lymphocyte 
Da    Dalton 
DC    dendritic cell 
ddH20    double distilled water 
dNTP    deoxyribonucleoside triphosphate 
DMEM    Dulbecco´s Modified Eagle Medium 
DMSO    dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxynucleoside triphosphate 
ds    double-stranded 
EBV Epstein-Barr virus 
EDTA    ethylenediaminetetraacetic acid 
ELISA    Enzyme Linked Immunosorbent Assay 
ELISpot   Enzyme Linked Immuno Spot 
ER    endoplasmic reticulum 
et al.    et alii, at aliae, et alia 
FACS    fluorescence-activated cell sorting 
FCS    fetal calf serum 
FDA    Food and Drug Administration 
FITC    fluorescein isothiocyanate 
Fig.    figure 
for    forward 
FSC    forward scatter 
Gy    Gray 
hr    hour 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLA    human leukocyte antigen 
HIV    human immunodeficiency virus 
HPV    human papillomavirus 
HNSCC   head and neck squamous cell carcinoma 
HS    human serum 
IC50    half maximal inhibitory concentration 
IFN    interferon 
IL    interleukin 
kb    kilo base pairs 
kDa    kilo Dalton 
LPS    lipopolysaccharide 
M    molarity 
mAb    monoclonal antibody 
Mg     magnesium 
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MHC    major histocompatibility complex 
MFI    mean fluorescent intensity 
min    minute 
mM    millimolar 
mRNA    messenger RNA 
MS    mass spectrometry 
MW  molecular weight 
N-terminus   amino-terminus 
nm    nanometer 
No.    number 
nt    nucleotide 
o/n    overnight 
ORF    open reading frame  
PAGE    polyacrylamide gel electrophoresis 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PFA    paraformaldehyde 
pH    pondus hydrogenii 
PHA    phytohaemagglutinin 
RNA    ribonucleic acid 
RNase    ribonuclease 
rpm    rounds per minute 
ROC    receiver operating characteristic 
RT    room temperature  
sec    second(s) 
SDS    sodium dodecyl sulfate 
SNT    supernatant 
ss    single-stranded 
SCC    squamous cell carcinoma 
SSC    side scatter 
Tab.    table 
Taq    Thermus aquaticus 
TCR    T cell receptor 
temp    temperature 
TGF-β    transforming growth factor beta 
TLR    Toll-like receptor 
TNFα    tumor necrosis factor alpha 
Treg    regulatory T cell 
Tris    Tris(hydroxylmethyl)-aminomethane 
U    unit 
UV    ultraviolet 
UTR    untranslated region 
V    Volt 
VIN    vuval intraepithelial neoplasia 
VLP    virus like particle 
WHO    Word Health Organisation 
WB    Western blot 
w/o    without 
wt    wild type 
x    times, -fold
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7. Appendix 
Table 22 I Predicted and experimental binding affinities to HLA-A3 for HPV16 E6 peptides. Peptides are sorted by the 
actual binding affinity as determined in the cellular binding assays. Binding affinities are color-coded according to their 
predicted and experimental binding strength. NetMHC and IEDB servers indicate binding affinities as IC50 [nM] and the 
average is displayed in the third column from the left. SYFPEITHI and BIMAS show scores as arbitrary units. Dashes 
indicate that the peptide length was not supported by the respective server and empty cells indicate that the chosen cutoff for 
the individual prediction server was exceeded. Italic highlighting indicates peptides that were determined to be potential 
binders by motif analysis. The code colors dark blue, blue and light blue indicate strong, intermediate and weak binders, 
repectively. Individual recommended (a, b, c) and self-determined (d, e, f) binding affinities: a: strong: < 5µM, intermediate: 5-
15µM, weak: 15-100µM, non: > 100µM; b: strong: < 50nM, weak: 50-500nM, non: > 500nM; c, d: strong: < 50nM, 
intermediate: 50-500nM, weak: 500-5000nM, non: > 500nM; e: strong: > 28, intermediate: 28-24, weak: 24-20, non: < 20; f: 
strong: > 40, intermediate: 40-15, weak: 15-5, non: < 5; exp: experimental 
 
 
exp. IC50 NetMHC  NetMHC IEDB IEDB IEDB IEDB IEDB average 
peptide length [µM]ᵃ NetMHCᵇ Panᵇ consᵇ annᶜ smmᶜ arbᶜ smmpmbecᶜ netmhcpanᶜ  IC50ᵈ SYFPEITHIᵉ BIMASᶠ
E6/106-115 10 2,02 41 226,95 247,81 41,36 67,50 7,14 61,13 156,47 106,17 29 45,00
E6/107-115 9 4,67 369 265,28 369,90 394,83 68,51 419,57 233,50 302,94 24 3,00
E6/68-77 10 9,29 192 1928,44 2065,97 192,32 498,02 435,08 645,69 2812,19 1096,21 20 0,30
E6/89-99 11 10,06 180 151,91 129,48 - - - - 257,38 179,69 - -
E6/59-67 9 10,95 472 416,41 472,50 623,06 231,10 676,12 537,16 489,76 28 2,00
E6/75-84 10 11,72 156 1186,57 801,61 156,11 324,35 425,85 261,56 1158,05 558,76 11 0,09
E6/33-41 9 14,69 270 262,48 226,04 270,73 287,34 80,16 322,75 249,16 246,08 23 40,50
E6/92-101 10 17,33 1204 1612,76 2169,05 1204,66 731,56 329,44 799,32 1602,13 1206,61 11 9,00
E6/93-101 9 20,10 315 399,88 315,88 422,99 63,61 520,21 543,00 368,65 13 6,75
E6/129-138 10 21,01 1196 2780,96 2593,00 1196,21 1104,10 602,75 1017,99 1637,18 1516,02 10 0,05
E6/37-46 10 30,56 263 273,59 190,11 263,35 203,86 99,80 240,54 241,20 221,93 21 4,00
E6/68-75 8 34,39 540 358,87 - - - - 384,09 427,65 - -
E6/125-133 9 34,95 3630 6798,29 3472,75 3630,59 2353,77 3408,25 2254,04 7131,08 4084,85 15 0,02
E6/84-91 8 58,09 3308 1139,38 1145,59 - - - - 1145,59 1684,64 - -
E6/75-83 9 61,37 515 1508,88 739,13 515,50 638,82 107,74 561,92 605,05 649,01 17 0,09
E6/8-18 11 64,67 10489 3280,96 4701,59 - - - - 4625,90 5774,36 - -
E6/32-41 10 non-binder 1396 14176,57 12183,00 1396,37 1043,81 1636,43 1064,57 13797,25 5836,75 22 8,10
E6/79-88 10 non-binder 290 387,18 290,89 611,86 737,87 434,00 525,66 468,21 18 5,40
E6/143-151 9 non-binder 1106 569,75 1106,78 636,84 536,52 962,03 704,01 803,13 10 4,00
E6/113-122 10 non-binder 4435 3642,54 5743,49 4435,20 1838,79 2130,07 3568,73 3416,85 3651,33 15 0,90
E6/58-67 10 non-binder 2933 4442,73 7208,66 2933,61 2025,29 9580,25 2450,65 7054,34 4828,57 17 0,60
E6/89-97 9 non-binder 6110 3827,94 4062,65 6110,91 8139,51 351,81 7649,44 7446,48 5462,34 20 0,30
E6/139-148 10 non-binder 4519 12100,85 12517,05 4519,88 3554,74 1149,95 4200,95 12653,21 6901,95 7 0,20
E6/142-151 10 non-binder 1179 8307,51 6978,43 1179,31 1579,16 2652,43 1455,73 9047,59 4047,40 14 0,06
E6/144-153 10 non-binder 802 2598,42 3745,99 802,87 645,64 1009,96 927,35 3685,69 1777,24 8 0,00
E6/34-41 8 non-binder 890 645,94 605,05 - - - - 330,10 617,77 - -
E6/37-47 11 non-binder 438 553,77 - - - - 446,91 479,56 - -
E6/94-101 8 non-binder 1621 1083,36 1103,02 - - - - 759,40 1141,69 - -
E6/79-86 8 non-binder 625 876,57 797,29 - - - - 855,38 788,56 - -
E6/73-83 11 non-binder 3039 1474,46 1709,59 - - - - 1097,07 1830,03 - -
E6/143-153 11 non-binder 2095 937,27 989,90 - - - - 1145,59 1291,94 - -
E6/122-129 8 non-binder 1018 1962,79 1501,43 - - - - 1347,45 1457,42 - -
E6/129-136 8 non-binder 3383 3240,86 3099,81 - - - - 1785,20 2877,22 - -
E6/75-85 11 non-binder 4743 4742,80 2889,29 - - - - 2496,64 3717,93 - -
E6/48-55 8 non-binder 1279 3485,82 2510,18 - - - - 2579,01 2463,50 - -
E6/72-79 8 non-binder 1304 1830,91 1445,63 - - - - 2607,06 1796,90 - -
E6/144-151 8 non-binder 2840 1955,47 2607,06 - - - - 2607,06 2502,40 - -
E6/144-154 11 non-binder 1774 1804,62 2277,27 - - - - 2751,98 2151,97 - -
E6/29-39 11 non-binder 5068 2509,08 2430,01 - - - - 2751,98 3189,77 - -
E6/105-115 11 non-binder 3259 4248,75 3491,59 - - - - 3066,45 3516,45 - -
E6/81-91 11 non-binder 5663 4106,89 2443,19 - - - - 4196,68 4102,44 - -
E6/43-52 10 non-binder 25750 25316,84 20589,91 25750,01 14125,77 15501,17 25289,19 21760,41 21 27,00
E6/44-52 9 non-binder 20826 28515,92 22818,90 20826,74 24218,04 23441,12 20 18,00
E6/134-142 9 non-binder 7073 7947,14 7169,76 7073,45 4326,94 9135,07 3656,74 7945,94 6791,00 20 0,60
E6/68-76 9 non-binder 19386 19172,91 17985,29 19386,32 18709,61 1400,54 18176,88 19295,70 16689,16 22 0,40
E6/52-61 10 non-binder 12813 5963,81 6755,55 12813,99 10303,64 10169,68 5620,54 9205,74 13 0,40
E6/116-124 9 non-binder 20579 34734,94 27131,77 20579,11 4757,86 34237,82 23670,08 20 0,30
E6/67-75 9 non-binder 11316 7262,05 5805,97 11316,13 5024,17 646,45 5845,77 6610,93 6728,43 10 0,30
E6/89-98 10 non-binder 9136 9659,52 9146,01 9136,42 1253,81 2951,06 13648,77 7847,37 20 0,23
E6/70-79 10 non-binder 10487 19563,23 13947,35 10487,43 336,97 1743,07 670,51 20589,91 9728,18 13 0,18
E6/74-83 10 non-binder 8274 17006,16 18279,56 8274,43 2583,73 6050,70 1981,89 13356,59 9475,88 9 0,03
E6/38-46 9 non-binder 11173 16412,45 9195,62 11173,30 5396,69 513,86 5189,70 18279,56 9666,77 7 0,01
E6/53-62 10 non-binder 1563 5092,70 6062,77 1563,50 1998,50 1226,80 1959,75 5932,98 3175,00 15 0,01
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Table 23 I Predicted and experimental binding affinities to HLA-A3 for HPV16 E7 peptides. Peptides are sorted by the 
actual binding affinity as determined in the cellular binding assays. Binding affinities are color-coded according to their 
predicted and experimental binding strength. NetMHC and IEDB servers indicate binding affinities as IC50 [nM] and the 
average is displayed in the third column from the left. SYFPEITHI and BIMAS show scores as arbitrary units. Dashes 
indicate that the peptide length was not supported by the respective server and empty cells indicate that the chosen cutoff for 
the individual prediction server was exceeded. Italic highlighting indicates peptides that were determined to be potential 
binders by motif analysis. The code colors dark blue, blue and light blue indicate strong, intermediate and weak binders, 
repectively. Individual recommended (a, b, c) and self-determined (d, e, f) binding affinities: a: strong: < 5µM, intermediate: 5-
15µM, weak: 15-100µM, non: > 100µM; b: strong: < 50nM, weak: 50-500nM, non: > 500nM; c, d: strong: < 50nM, 
intermediate: 50-500nM, weak: 500-5000nM, non: > 500nM; e: strong: > 28, intermediate: 28-24, weak: 24-20, non: < 20; f: 
strong: > 40, intermediate: 40-15, weak: 15-5, non: < 5; exp: experimental 
 
 
Table 24 I Predicted and experimental binding affinities to HLA-A11 for HPV16 E6 peptides. Peptides are sorted by the 
actual binding affinity as determined in the cellular binding assays. Binding affinities are color-coded according to their 
predicted and experimental binding strength. NetMHC and IEDB servers indicate binding affinities as IC50 [nM] and 
theaverage is displayed in the third column from the left. SYFPEITHI and BIMAS show scores as arbitrary units. Dashes 
indicate that the peptide length was not supported by the respective server and empty cells indicate that the chosen cutoff for 
the individual prediction server was exceeded. Italic highlighting indicates peptides that were determined to be potential 
binders by motif analysis. The code colors dark blue, blue and light blue indicate strong, intermediate and weak binders, 
repectively. Individual recommended (a, b, c) and self-determined (d, e, f) binding affinities: a: strong: < 5µM, intermediate: 5-
15µM, weak: 15-100µM, non: > 100µM; b: strong: < 50nM, weak: 50-500nM, non: > 500nM; c, d: strong: < 50nM, 
intermediate: 50-500nM, weak: 500-5000nM, non: > 500nM; e: strong: > 22, intermediate: 22-19, weak: 19-15, non: < 15; f: 
strong: > 6, intermediate: 6-4, weak: 4-0.4, non: < 0.4; exp: experimental 
 
E6/144-152 9 non-binder 20362 21299,45 21500,59 20362,93 30300,51 510,49 23586,76 25017,04 20367,47 5 0,00
E6/52-62 11 non-binder 6243 2392,09 2889,29 - - - - 2264,98 3447,34 - -
E6/43-50 8 non-binder 6273 4147,55 4174,04 - - - - 4727,10 4830,42 - -
E6/91-101 11 not tested - - - - - - - 14722,66 14722,66 - -
E6/93-103 11 not tested - - - - - - - 29745,37 29745,37 - -
exp. IC50 NetMHC  NetMHC IEDB IEDB IEDB IEDB IEDB average 
peptide length [µM]ᵃ NetMHCᵇ Panᵇ consᵇ annᶜ smmᶜ arbᶜ smmpmbecᶜ netmhcpanᶜ  IC50ᵈ SYFPEITHIᵉ BIMASᶠ
E7/88-97 10 2,22 62 133,49 62,91 87,26 64,11 75,34 100,41 83,65 19 1,80
E7/89-97 9 3,16 36 65,03 40,03 36,28 39,74 9,86 44,80 58,45 41,28 21 2,00
E7/87-97 11 6,32 2796 1049,93 1610,82 - - - - 953,12 1602,47 - -
E7/52-60 9 15,84 3679 3049,31 2737,14 3679,87 1434,87 46,98 1128,23 2722,37 2309,72 13 0,06
E7/53-60 8 17,88 487 252,83 222,40 - - - - 249,16 302,85 - -
E7/50-60 11 28,96 1070 930,26 582,56 - - - - 659,75 810,64 - -
E7/63-73 11 non-binder 2006 861,66 979,25 - - - - 837,07 1170,99 - -
E7/51-60 10 non-binder 6879 999,09 984,56 6879,10 739,80 600,69 707,95 554,88 2293,13 11 0,40
E7/68-77 10 non-binder 7694 1190,51 1654,99 7694,16 7128,74 7941,86 1469,28 4967,65 20 0,40
E7/77-84 8 non-binder 11355 2852,50 4909,54 - - - - 4382,30 5874,83 - -
E7/63-71 9 non-binder 14702 9471,40 8119,76 14702,13 4011,61 1354,36 3837,88 10191,11 8298,78 18 0,00
E7/85-93 9 non-binder 17045 8957,97 9295,66 17045,71 5608,92 1939,76 4616,44 9346,08 9231,94 16 0,05
E7/19-27 9 non-binder 14706 12456,79 9396,78 14706,74 11798,37 1130,34 11925,05 19088,05 11901,01 11 0,00
E7/55-63 9 non-binder 22433 18782,24 16583,46 22433,09 9020,44 364,83 8466,23 16404,99 14311,03 11 0,00
E7/18-26 9 non-binder 22248 21121,82 19611,42 22248,42 16096,73 1003,08 19681,74 24481,50 18311,59 12 0,00
E7/71-80 10 non-binder 30342 14322,65 9865,62 30342,51 5997,96 - 34043,30 16583,46 20213,93 16 0,00
E7/31-40 10 non-binder 36295 35559,24 36295,07 36049,77 17 0,00
E7/18-25 8 non-binder 4701 6228,96 6062,77 - - - - 5997,52 5747,56 - -
E7/69-77 9 not tested 6693 5265,77 5869,13 6693,85 2238,76 1625,60 2293,64 7131,08 4726,35 10 0,12
E7/36-43 8 not tested 30697 38565,12 - - - - 34631,06 - -
E7/42-50 9 not tested 25939 33504,88 25939,19 19863,93 26311,75 5 0,00
E7/68-75 8 not tested 25613 27753,19 23192,26 - - - - 31398,89 26989,33 - -
E7/41-50 10 not tested 37421 37132,00 37420,98 37324,66 1 0,00
exp. IC50 NetMHC  NetMHC IEDB IEDB IEDB IEDB IEDB average 
peptide length [µM]ᵃ NetMHCᵇ Panᵇ consᵇ annᶜ smmᶜ arbᶜ smmpmbecᶜ netmhcpanᶜ  IC50ᵈ SYFPEITHIᵉ BIMASᶠ
E6/106-115 10 1,36 162 269,21 214,14 162,29 136,93 141,45 122,15 146,63 169,35 17 0,60
E6/52-62 11 2,67 697 207,33 350,34 - - - - 216,47 367,78 - -
E6/93-101 9 3,99 13 12,85 13,45 18,99 5,79 23,70 11,91 14,24 21 3,00
E6/9-18 10 4,06 4381 5330,69 5590,22 4381,30 1072,84 4102,43 2000,83 3975,68 3854,37 11 0,60
E6/92-101 10 4,19 33 38,54 41,12 33,29 35,94 4,85 35,97 61,70 35,55 23 6,00
E6/68-77 10 4,80 553 716,37 492,62 553,46 586,96 718,05 710,85 810,33 642,70 15 0,01
E6/33-41 9 4,98 28 70,84 29,25 28,26 69,85 35,47 71,48 48,11 47,66 18 1,20
E6/107-115 9 5,21 2376 488,95 1017,05 2376,57 813,86 47,11 658,10 427,98 1025,70 16 0,40
E6/94-101 8 6,03 471 253,84 314,41 - - - - 277,63 329,22 - -
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E6/32-41 10 6,80 241 1935,47 1164,33 241,09 252,54 136,24 188,70 1946,61 763,25 18 0,36
E6/34-41 8 8,34 337 406,29 311,03 - - - - 238,60 323,23 - -
E6/68-75 8 9,72 35 49,15 27,56 - - - - 30,21 35,48 - -
E6/68-78 11 11,51 4129 7887,81 5900,97 - - - - 7446,48 6341,07 - -
E6/67-75 9 12,64 2496 1056,96 1255,95 2496,66 778,33 55,93 826,29 953,12 1239,91 12 0,30
E6/105-115 11 14,75 6791 3538,34 4778,52 - - - - 3454,02 4640,47 - -
E6/59-67 9 18,78 288 314,32 279,13 288,41 388,74 260,66 424,89 396,76 330,11 10 0,04
E6/48-55 8 27,75 98 253,51 165,16 - - - - 159,89 169,14 - -
E6/37-46 10 36,49 407 73,66 407,58 272,27 383,80 353,86 51,34 278,50 24 1,60
E6/91-101 11 43,48 5502 3009,38 4651,00 - - - - 4830,50 4498,22 - -
E6/53-62 10 47,68 3076 2576,04 4551,43 3076,75 3578,01 3060,57 3182,41 3066,45 3270,96 18 0,04
E6/68-76 9 48,82 11564 16297,43 13648,77 11564,68 3300,57 317,03 3581,45 16946,23 9652,52 19 0,04
E6/79-88 10 48,83 400 268,76 208,42 400,07 725,63 433,32 525,14 384,09 418,18 6 0,02
E6/144-154 11 54,36 637 264,36 425,67 - - - - 466,68 448,43 - -
E6/69-79 11 58,43 9918 7208,82 6434,51 - - - - 3766,31 6831,91 - -
E6/89-99 11 64,75 521 497,78 585,72 - - - - 659,75 566,06 - -
E6/80-88 9 65,36 1681 3848,74 4174,04 1681,37 2408,44 3199,22 2166,99 4727,10 2985,86 10 0,00
E6/139-148 10 82,74 6496 1308,96 2469,77 6496,13 3084,13 4590,76 2944,84 1904,94 3661,94 18 0,20
E6/37-47 11 non-binder 505 192,50 289,91 - - - - 137,41 281,21 - -
E6/144-151 8 non-binder 422 253,28 324,79 - - - - 461,65 365,43 - -
E6/144-153 10 non-binder 481 488,27 1011,56 481,63 549,10 881,39 936,25 883,60 714,10 18 0,00
E6/75-84 10 non-binder 1089 702,01 1067,79 1089,97 824,95 1580,65 821,98 912,75 1011,14 9 0,24
E6/29-39 11 non-binder 1071 1186,02 1017,05 - - - - 1073,58 1086,91 - -
E6/72-79 8 non-binder 1922 932,32 958,29 - - - - 963,49 1194,02 - -
E6/8-18 11 non-binder 1596 1032,98 1067,79 - - - - 1209,27 1226,51 - -
E6/143-151 9 non-binder 2474 350,56 700,21 2474,40 1184,39 1472,28 2136,48 492,62 1410,62 14 0,08
E6/79-86 8 non-binder 1692 1000,90 1501,43 - - - - 1654,99 1462,33 - -
E6/113-122 10 non-binder 3304 1705,71 2510,18 3304,32 911,52 1270,13 1784,73 1501,43 2036,50 13 0,60
E6/143-153 11 non-binder 5384 704,49 1854,10 - - - - 932,72 2218,83 0 -
E6/77-84 8 non-binder 4477 1289,30 2403,86 - - - - 2216,49 2596,66 - -
E6/75-83 9 non-binder 5128 4394,98 5182,46 5128,19 1926,12 533,51 2270,04 2443,19 3375,81 3 0,01
E6/122-129 8 non-binder 5791 2564,73 3646,02 - - - - 2781,92 3695,92 - -
E6/84-91 8 non-binder 8998 2588,75 5044,15 - - - - 3033,45 4916,09 - -
E6/38-46 9 non-binder 8266 6396,26 5774,65 8266,38 1908,89 409,42 2588,80 6903,33 5064,22 14 0,16
E6/81-91 11 non-binder 8103 4421,13 4936,17 - - - - 3529,57 5247,47 - -
E6/58-67 10 non-binder 4404 3309,07 5295,83 4404,78 2635,19 14072,03 3429,32 4526,88 5259,64 6 0,01
E6/92-99 8 non-binder 7104 4033,48 5620,54 - - - - 4429,97 5297,00 - -
E6/129-136 8 non-binder 11469 3887,26 6610,93 - - - - 4106,84 6518,51 - -
E6/28-36 9 non-binder 11296 9443,97 4727,10 11296,68 1765,21 390,99 3029,02 15044,73 7124,21 18 0,00
E6/89-97 9 non-binder 9881 6574,05 5238,84 9881,33 5600,87 992,73 5513,92 13356,59 7129,92 15 0,00
E6/73-83 11 non-binder 15003 4493,70 8032,38 - - - - 4382,30 7977,84 - -
E6/70-79 10 non-binder 13842 13324,55 8853,90 13842,41 440,77 2042,62 760,54 11479,16 8073,24 11 0,04
E6/75-85 11 non-binder 13502 7981,50 9972,95 - - - - 7131,08 9646,88 - -
E6/129-138 10 non-binder 13372 4436,52 7818,02 13372,06 16548,24 17666,36 19967,66 4478,16 12207,38 9 0,04
E6/64-72 9 non-binder 17607 15901,68 15457,23 17607,61 9264,62 533,00 8441,33 19932,31 13093,10 14 0,12
E6/48-56 9 non-binder 17492 21324,51 16673,41 17492,35 3192,61 714,36 3153,46 28485,48 13566,02 14 0,00
E6/101-109 9 non-binder 21637 16001,61 16316,49 21637,34 2904,36 1874,55 2891,90 25842,40 13638,21 13 0,36
E6/88-97 10 non-binder 22481 11223,96 12249,09 22481,32 5992,45 11213,93 19505,61 15021,05 16 0,00
E6/29-37 9 non-binder 24187 21596,42 15541,08 24187,40 6275,95 1118,56 4949,49 27875,69 15716,45 14 0,00
E6/28-37 10 non-binder 30761 15625,01 10699,58 30761,66 4304,45 3250,97 21269,21 16667,41 17 0,00
E6/140-148 9 non-binder 21145 13694,63 15290,89 21145,42 30041,50 552,60 21296,52 10757,62 16740,52 8 0,00
E6/144-152 9 non-binder 23240 19612,34 19295,70 23240,87 14560,43 1017,81 15983,85 23957,42 17613,55 10 0,00
E6/134-142 9 non-binder 24314 11254,35 13872,10 24314,92 23048,16 28377,77 19392,44 14722,66 19912,05 15 0,08
E6/71-79 9 non-binder 22417 29957,47 22818,90 22417,68 18089,75 218,84 12892,88 33144,32 20244,61 11 0,01
E6/145-153 9 non-binder 24229 19723,50 20149,14 24229,18 37241,87 1030,74 30689,30 22209,93 22437,83 11 0,00
E6/27-36 10 non-binder 28156 22669,63 18780,76 28155,93 6162,05 26553,41 28178,94 22665,24 17 0,00
E6/81-89 9 non-binder 25002 32280,41 27575,71 25002,43 29460,31 1493,11 13228,82 27575,71 22702,31 3 0,00
E6/116-124 9 non-binder 28702 32709,34 28178,94 28702,82 5008,77 33144,32 26074,37 15 0,00
E6/18-25 8 non-binder 29754 32976,28 29425,27 - - - - 36931,66 32271,80 - -
E6/63-73 11 non-binder 29590 35176,57 - - - - - 32383,29 - -
E6/52-61 10 non-binder 3972 3617,43 4242,33 3972,80 1876,44 2167,22 2264,98 3159,03 6 0,01
E6/65-75 11 not tested 10642 9950,92 9447,76 - - - - 13212,86 10813,38 - -
E6/31-41 11 not tested 12779 24988,00 6330,92 - - - - 6682,85 7996,18 - -
E6/66-75 10 not tested 24988 24839,38 9447,76 24988,09 5440,22 7380,68 23444,56 18451,97 14 0,04
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Table 25 I Predicted and experimental binding affinities to HLA-A11 for HPV16 E7 peptides. Peptides are sorted by the 
actual binding affinity as determined in the cellular binding assays. Binding affinities are color-coded according to their 
predicted and experimental binding strength. NetMHC and IEDB servers indicate binding affinities as IC50 [nM] and 
theaverage is displayed in the third column from the left. SYFPEITHI and BIMAS show scores as arbitrary units. Dashes 
indicate that the peptide length was not supported by the respective server and empty cells indicate that the chosen cutoff for 
the individual prediction server was exceeded. Italic highlighting indicates peptides that were determined to be potential 
binders by motif analysis. The code colors dark blue, blue and light blue indicate strong, intermediate and weak binders, 
repectively. Individual recommended (a, b, c) and self-determined (d, e, f) binding affinities: a: strong: < 5µM, intermediate: 5-
15µM, weak: 15-100µM, non: > 100µM; b: strong: < 50nM, weak: 50-500nM, non: > 500nM; c, d: strong: < 50nM, 
intermediate: 50-500nM, weak: 500-5000nM, non: > 500nM; e: strong: > 22, intermediate: 22-19, weak: 19-15, non: < 15; f: 
strong: > 6, intermediate: 6-4, weak: 4-0.4, non: < 0.4; exp: experimental 
 
 
 
exp. IC50 NetMHC  NetMHC IEDB IEDB IEDB IEDB IEDB average 
peptide length [µM]ᵃ NetMHCᵇ Panᵇ consᵇ annᶜ smmᶜ arbᶜ smmpmbecᶜ netmhcpanᶜ  IC50ᵈ SYFPEITHIᵉ BIMASᶠ
E7/88-97 10 2,22 62 133,49 62,91 87,26 64,11 75,34 100,41 83,65 19 1,80
E7/89-97 9 3,16 36 65,03 40,03 36,28 39,74 9,86 44,80 58,45 41,28 21 2,00
E7/87-97 11 6,32 2796 1049,93 1610,82 - - - - 953,12 1602,47 - -
E7/52-60 9 15,84 3679 3049,31 2737,14 3679,87 1434,87 46,98 1128,23 2722,37 2309,72 13 0,06
E7/53-60 8 17,88 487 252,83 222,40 - - - - 249,16 302,85 - -
E7/50-60 11 28,96 1070 930,26 582,56 - - - - 659,75 810,64 - -
E7/63-73 11 non-binder 2006 861,66 979,25 - - - - 837,07 1170,99 - -
E7/51-60 10 non-binder 6879 999,09 984,56 6879,10 739,80 600,69 707,95 554,88 2293,13 11 0,40
E7/68-77 10 non-binder 7694 1190,51 1654,99 7694,16 7128,74 7941,86 1469,28 4967,65 20 0,40
E7/77-84 8 non-binder 11355 2852,50 4909,54 - - - - 4382,30 5874,83 - -
E7/63-71 9 non-binder 14702 9471,40 8119,76 14702,13 4011,61 1354,36 3837,88 10191,11 8298,78 18 0,00
E7/85-93 9 non-binder 17045 8957,97 9295,66 17045,71 5608,92 1939,76 4616,44 9346,08 9231,94 16 0,05
E7/19-27 9 non-binder 14706 12456,79 9396,78 14706,74 11798,37 1130,34 11925,05 19088,05 11901,01 11 0,00
E7/55-63 9 non-binder 22433 18782,24 16583,46 22433,09 9020,44 364,83 8466,23 16404,99 14311,03 11 0,00
E7/18-26 9 non-binder 22248 21121,82 19611,42 22248,42 16096,73 1003,08 19681,74 24481,50 18311,59 12 0,00
E7/71-80 10 non-binder 30342 14322,65 9865,62 30342,51 5997,96 - 34043,30 16583,46 20213,93 16 0,00
E7/31-40 10 non-binder 36295 35559,24 36295,07 36049,77 17 0,00
E7/18-25 8 non-binder 4701 6228,96 6062,77 - - - - 5997,52 5747,56 - -
E7/69-77 9 not tested 6693 5265,77 5869,13 6693,85 2238,76 1625,60 2293,64 7131,08 4726,35 10 0,12
E7/36-43 8 not tested 30697 38565,12 - - - - 34631,06 - -
E7/42-50 9 not tested 25939 33504,88 25939,19 19863,93 26311,75 5 0,00
E7/68-75 8 not tested 25613 27753,19 23192,26 - - - - 31398,89 26989,33 - -
E7/41-50 10 not tested 37421 37132,00 37420,98 37324,66 1 0,00
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Figure 37 I Evaluation of prediction server performance for peptide predictions of 8mers, 9mers, 10mers and 11mers 
binding to HLA-A3 by ROC analysis. The rates of true positive predictions are plotted as a function of the rate of false 
positive predictions. A Analysis for 8mers (n=13). B Analysis of 9mers (n=20). C Analysis of 10mers (n=24). D Analysis of 
11mers (n=14). Some curves are slightly overlayed. 
 
Figure 38 I Evaluation of prediction server performance for peptide predictions of 8mers, 9mers, 10mers and 11mers 
binding to HLA-A11 by ROC analysis. The rates of true positive predictions are plotted as a function of the rate of false 
positive predictions. A Analysis for 8mers (n=16). B Analysis of 9mers (n=30). C Analysis of 10mers (n=24). D Analysis of 
11mers (n=18). Some curves are slightly overlayed. 
 
  
 
Lineage Isolate # NCBI# Nucleotide exchanges in the E6 open reading frame 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nucleotide exchanges in the E7 open reading frame Resulting amino acid exchanges 
Position of change 83 109 131 132 143 145 146 162 176 178 233 286 289 335 350 403 433 457 532 618 647 732 789 795 843 846 E6 E7 
E-1 HPV16Ref NC_001526 A T A G C G T A G T G T A C T A G T A A A T T T T T     
                                                              
E-1 AS411b HQ644236 - - - - - - - - - - - - - - - - - - - - - - - - - -     
E-1 Qv02234b HQ644259 - - - - - - - - - - - - - - - - - - - - - - - - - -     
E-1 Qv11074b HQ644267 - - - - - - - - - - - - - - - - - - - - - - - - - -     
E-1 Qv11687b HQ644268 - - - - - - - - - - - - - - G - - - - - - - - - - - L83V   
E-1 Qv13956b HQ644271 - - - - - - - - A - - - - - G - - - - - - - - - - - D25N, L83V   
E-1 Qv15521b AY686581 - - - - - - - - - - - - - - - - - - - - - - - - - -     
E-1 Qv16936b AY686580 - - - - - - - - - - - - - - G - - - - - - - - - - - L83V   
E-1 Qv17286b HQ644272 - - - - - - - - - - - - - - - - - - - - - - - - - -     
E-1 Qv17722b AY686584 - - - - - - - - - - - - - - - - - c - - - - - - - -     
E-1 Qv18158b AY686583 - - - - - - - - A - - - - - G - - - - - - - - - - - D25N, L83V   
E-1 Qv19110b HQ644274 - - - - - - - - - - - - - - - - - - - - - - - - - -     
E-1 Qv24723b HQ644280 - - - - - - - - - - - - - - G - - - - - - - - - - - L83V   
E-1 Qv25054b HQ644282 - - - - - - - - - - - - - - G - - - - - - - - - - - L83V   
E-1 Qv25086b HQ644283 - - - - - - - - - - - - - - G - - - - - - - - - - - L83V   
E-1 Qv28131b HQ644284 - - - - - - - - - - - - - - - - - - - - - - - - - -     
E-1 Qv33501b HQ644286 - - - - - - - - - - - - - - G - - - - - - - - - - - L83V   
E-1 Qv35943b HQ644287 - - - - - - G - - - - - - - - - - - - - - - - - - - L15V   
E-1 Z032b HQ644297 - - - - - - - - - - - - - - - - - - - - - - - - - -     
                                                              
E-2 W0122 AF536179 - - G - - - - - - - - - - - G - - - - - - - - - - - R10T, L83V   
                                                              
E-A AS097b HQ644234 - - - - - - - - - G - - - - - - - - - - G - - - c c D25E N29S 
E-A AS310b HQ644235 - - - - - - - - - G - - - - - - - - - - G - - - - c D25E N29S 
E-A IN/Qv151168b HQ644248 - - - - - - - G - G - - - - - - - - - - G - - - - c Q20R, D25E N29S 
E-A INJP0168b HQ644251 - - - - - - - G - G - - - - - - - - - - G - - - - c Q20R, D25E N29S 
E-A Qv02706b HQ644261 - - - - - - - - - G - - - - - - - - - - G - - - - c D25E N29S 
E-A W0724b AF534061 - - - - - - - - - G - - - - - - - - - - G - - - - c D25E N29S 
                                                              
Af-1 BF215b HQ644238 C - - C G T - - - - - a g T - - - - - - - - c g - - M(-6)L, R10T, Q14D, H78Y   
Af-1 BF325b HQ644240 C - - C G T - - - - - a g T - - - - - - - - c g - - M(-6)L, R10T, Q14D, H78Y   
Af-1 R872b AF472508 C - - C G T - - - - - a g T - - - - - g - - c g - - M(-6)L, R10T, Q14D, H78Y   
Af-1 Rw768b HQ644290 C - - C G T - - - - - a g T - - - - - - - - c g - - M(-6)L, R10T, Q14D, H78Y   
Af-1 Rw918b HQ644293 C - - C G T - - - - - a g T - - - - - - - - c g - - M(-6)L, R10T, Q14D, H78Y   
Af-1 W0236b AF536180 C - - C G T - - - - - a g T - - - - - - - - c g - - M(-6)L, R10T, Q14D, H78Y   
Af-1 Z016b HQ644296 C - - C G T - - - - - a g T - - - - - - - - c g - - M(-6)L, R10T, Q14D, H78Y   
Af-1 Z109b HQ644298 - - G - G T - - - - - a g T - - - - - - G - c g - -  R10T, Q14D, H78Y N29S 
Af-1 Z122b HQ644299 C - - C G T - - - - - a g T - - - - - - - - c g - - M(-6)L, R10T, Q14D, H78Y   
                                                              
Af-2 BF039b HQ644237 - c - T G T - - - - - a g T - g - - - - G - c g - - R10I,Q14D,H78Y N29S 
Af-2 BF236b HQ644239 - c - T G T - - - - - a g T - g - - - - G - c g - - R10I,Q14D,H78Y N29S 
Af-2 IN221688b HQ644249 - c - T G T - - - - - a g T - g - - - - G - c g - - R10I,Q14D,H78Y N29S 
Af-2 IN272098b HQ644250 - c - T G T - - - - - a g T - g - - - - G - c g - - R10I,Q14D,H78Y N29S 
Af-2 R460b AF472509 - c - T G T - - - - - a g T - g - - - - G - c g - - R10I,Q14D,H78Y N29S 
Af-2 Rw851b HQ644291 - c - T G T - - - - - a g T - g - - - - G - c g - - R10I,Q14D,H78Y N29S 
Af-2 Rw862b HQ644292 - c - T G T - - - - - a g T - g - - - - G - c g - - R10I,Q14D,H78Y N29S 
                                                              
NA1 Qv00512 HQ644257 - - - - - T - - - - - a g T G - - - - - - - c g - - Q14H, H78Y, L83V   
                                                              
AA1 IN000078b HQ644247 - - - - - T - - - - A a g T G - - - g - - c c g - - Q14H, D44N, H78Y, L83V   
AA1 Qv00079b HQ644253 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Qv00346b HQ644255 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Qv00995b AF402678 - - - - - T - - - - - a g T G - a - g - - c c g - - Q14H, H78Y, L83V   
AA1 Qv04917b HQ644265 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Qv13040b HQ644269 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Qv21730b HQ644276 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Qv23856b HQ644278 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Qv33364b HQ644285 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Rw649b HQ644288 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA1 Rw677b HQ644289 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
                                                              
AA2 Qv00124b HQ644254 - - - - - T - - - - - a g T G - - - - - - c c g - - Q14H, H78Y, L83V   
AA2 Qv13791b HQ644270 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA2 Qv15321b AY686579 - - - - - T - - - - - a g T G - - - g - - c c g - - Q14H, H78Y, L83V   
AA2 Qv15351b AY686582 - - - - - T - - - - - a g T G - - - - - - c c g - - Q14H, H78Y, L83V   
AA2 Qv19067b HQ644273 - - - - - T - - - - - a g T G - - - - - - c c g - - Q14H, H78Y, L83V   
AA2 Qv22478b HQ644277 - - - - - T - - - - - a g T G - - - - - - c c g - - Q14H, H78Y, L83V   
AA2 Qv23890b HQ644279 - - - - - T - - - - - a g T G - - - - - - c c g - - Q14H, H78Y, L83V   
AA2 Qv24898b HQ644281 - - - - - T - - - - - a g T G - - - - - - c c g - - Q14H, H78Y, L83V   
1
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Table 26 I Classification of 62 HPV16 whole genome sequences to distinct HPV16 variants. HPV16 sequences were 
kindly provided by Robert D. Burk (Burk et al., 2011). The right column indicates the variant lineage (E: European, Af-1: 
African-1, Af-2: African-2, AA: Asian American) and the sublineages where applicable (E-1: European Prototype 1, E-2: 
European Prototype 2, E-A: European Asian; NA-1: North American-1, AA1: Asian-American-1, AA2: Asian-American-2). 
The isolate numbers were generated by Robert D. Burk. The prefix indicates the location the sample was obtained from: AS: 
Taiwan, BK: Burkina Faso, IN/INJP: Thailand, Qv: Costa Rica, R: USA (HAPI study), Rw: Rwanda, W: USA (WIHS 
study), Z: Zambia. The b after the number refers to the whole genome sequence being available.  
The first 1000bp of the HPV16 sequences were analyzed in this multiple sequence alignment. Exchanges within the E6 and 
the E7 ORF (nucleotides 83-559 and 562-858, respectively) with regard to the HPV16 reference sequence (HPV16Ref, 
NC_001526) are displayed. The first row displays exchanges in position counted from the first nucleotide in the reference 
sequence. The second row indicates the nucleotide of the reference sequence (HPV16Ref) at the given position. Dashes (-) 
within the table indicate no exchange. Lowercase letters refer to silent mutations whereas capital letters indicate non-
synonymous mutations. Resulting amino acid exchanges for E6 and E7 are listed in the last two columns, respectively. The 
positions of change are counted from the first amino acid in the actual protein, i.e. the second methionine in the coding 
sequence of E6 (encoded by nucleotides 104-106) and the first methionine in the coding sequence of E7 (encoded by 
nucleotides 562-564). Shading in the same light color (lineage assignment, isolate number and NCBI number) states that 
sequences are identical within the E6 and E7 ORF. Exchanges distinguishing a variant from the others are shaded yellow. 
Those shared between two variants (light orange) and those shared among all non-European variants (dark orange) are 
indicated. The T350G exchange (blue) does not correlate with a specific variant as it is present in some European and all 
Asian variants.  
Table 27 I Cell lines with their HLA type and designated HPV16 variant including nucleotide and amino acid 
exchanges in comparison to the HPV16 reference sequence. The first column indicates the cell line, the second its HLA 
types, the third the identified HPV16 variant and the last two columns nucleotide exchanges in the E6 and E7 open reading 
frame (ORF), respectively. Resulting amino acid changes are included in (). “New” states that this amino acid change was not 
included in the 62 sequences supplied from Robert D. Burk (Burk et al., 2011). n.a.: not applicable, sil: silent mutation, XX: 
new allele 
Cell line HLA type HPV16 
variant 
exchanges  
within E6 ORF  
exchanges 
within E7 ORF 
HPV16Ref  European 
Prototype 1 
  
CaSki A*02:01, A*03:01; 
B*07:02, B*37:01; 
C07, - 
European 
Prototype 2 
A131G (R10T), 
T350G (L83V)  
- 
SiHa A*24:02, - ; 
B*40:02, - ; C03, -  
European 
Prototype 1 
T350G (L83V), 
A442C (E113D, new)  
A645C (new, 
L28F) 
Marqu A*02:01,  -; 
B*27:02, -;C*02:02 
,- 
European 
Prototype 1 
- n.a. 
SNU 703 A*02:01, A*02:06; 
B*35:01, B*40:06 
European 
(Asian) 
T178G (D25E)  A647G (N29S), 
T846C (sil) 
SNU 902 A*01:01, A*11:01; 
B*07:05, B*35:01 
European 
(Asian) 
T178G (D25E) A647G (N29S), 
C749T (new, 
S63F), T846C 
(sil) 
SNU 1299 A*02:01, A*33:03; 
B*27:05, B*44:03 
Asian-American G145T (Q14D), 
T286A (sil), A289G 
(sil), C335T (H78Y), 
T350G (L83V), 
A532G (sil) 
T732C, T789C, 
T795G, all: sil 
SCC090 A*02:01, A*03:01; 
B*44:03, B*51:01 
European 
Prototype 2 
A131G (R10T), 
T350G (L83V)  
- 
SCC152 A*02:01, A*03:01; 
B*44:03, B*51:01 
European 
Prototype 2 
A131G (R10T), 
T350G (L83V)  
- 
SCC154 A*25:01, -; 
B*44:02, B*44:03 
Asian-American G145T (Q14D), 
T286A (sil), A288G 
(sil), C335T (H78Y), 
T350G (L83V), 
A532G (sil) 
T732C, T789C, 
T795G, all: sil 
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93VU147T A*03:01, -; 
B*07:02, - 
European 
Prototype 1 
- - 
UM-SCC-47 A*01:01, A*23:01; 
B*37:01, B*45:01 
African-2 T109C (sil), G132T 
(R10I), C143G 
(Q14D), G145T, 
G188C (new, E29Q), 
C285G (new, A61G), 
T286A (sil), A289G 
(sil), C335T (H78Y), 
A403G (sil) 
A647G (N29S), 
T789C (sil), 
T795G (sil) 
UD-SCC2  A*25:01,-; B*18N  European 
Prototype 1 
- C712A (new, 
H51N) 
C66#3 A*02:01, A*30:02; 
B*18:01, B*35:03 
European 
Prototype 1 
C256T (sil,new), 
T350G (L83V) 
- 
C66#7 A*02:01, A*30:02; 
B*18:01, B*35:03 
European 
Prototype 1 
C265T (sil, new), 
T350G (L83V) 
- 
FK16A A*01:01, A*24:02; 
B*07:02, B*0801 
European 
Prototype 1 
- - 
HPK 1A  A*02:01, A*03:01; 
B*40:01,B*55:01 
European 
Prototype 1 
- - 
MRI-H-196 A*02:XX, 
A*03:01; B*07:02 
,B*51:01 
European 
Prototype 1 
T350G (L83V)  - 
SNU 1000 A*02:01, A*11:01; 
B*40:02, - 
European 
(Asian) 
T178G (D25E), 
T183G (I27R) 
A647G (N29S), 
T846C (sil) 
W12 20861 A*11:01, A*24:02; 
B*15:01, B*51:01 
European 
Prototype 1 
C256T (sil,new), 
T350G (L83V) 
- 
W12 20863 A*11:01, A*24:02; 
B*15:01, B*51:01 
European 
Prototype 1 
C256T (sil,new), 
T350G (L83V) 
- 
SNU 1005 A*24:02, - ; 
B*52:01, - 
European 
(Asian) 
T178G (D25E)  A647G (N29S), 
T846C (sil) 
Goerke A*01:01, - ; 
B*37:01 
European 
Prototype 1 
- - 
879 A*02:01, A*31:01; 
B*39:XX, B*40:01 
European 
Prototype 1 
- - 
866 A*02:01, A*68:01; 
B*15:01, B*27:05 
African-2 T109C (sil), G132T 
(R10I), C143G 
(Q14D in combi), 
G145T (Q14D in 
combi), T256A 
(sil),T286A (sil), 
A289G (sil), C335T 
(H78Y), A403G (sil) 
A647G (N29S), 
C765T (new, sil), 
T789C (sil), 
T795G (sil) 
915 A*03:01, - ; 
B*14:XX, -  
European 
Prototype 1 
- - 
SNU 17 A*02:06, - , 
B*48:01, - 
European 
(Asian) 
T178G (D25E)  A647G (N29S), 
T828C (new,sil), 
T846C (sil) 
 
Table 28 I Blood donor characteristics and HLA types. Questions marks indicate HLA types that are not known. * HLA 
typing was available only for two digits. 
Donor gender age  HLA class I HLA class II 
1* male 24 A*23, A*24; B*18, B*44; ? DRB1*04, DRB1*07; ? 
2 female  24 A*24:02, ?  ? 
3 female  37 A*24:02, A*26:02; B*35:03, B*51:08; 
?, ? 
DRB1*04:08, DRB1*13:01; 
DQB1*03:04, DQB1*06:03; 
DRB3*02:02, DRB4*01; DPB1*09:02, 
DRB1*15:01 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
